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Abstract 
This thesis  concerns synthesis, magnetic and mesogenic properties of 
novel iron(II) complexes based on 2,6-bis(pyrazol-1-yl)pyridine derivatives, 
with  short and long alkyl chains on the pyrazolyl or pyridyl rings. 
Chapter 1 is an introduction to the spin crossover and liquid crystal 
phenomena. Using significant literature examples, it outlines: their discovery 
and physical origin; the interplay between spin crossover and long alkyl 
chains; the factors that affect spin crossover; and progress towards their 
practical application. 
Chapter 2 describes a family of 2,6-bis(pyrazol-1-yl)pyridine derivatives with 
no long alkyl chain substituents, and explores the effect of small structural 
differences on their spin crossover. 
Chapter 3 presents two series of 2,6-bis(pyrazol-1-yl)pyridine derivatives 
with long alkyl chains bound to the pyridyl ring, and investigates the effect of 
the alkyl chain length on spin crossover and phase transitions in their iron(II) 
complexes. 
Chapter 4 discusses four series of 2,6-bis(pyrazol-1-yl)pyridine derivatives 
with long alkyl chains on the pyrazolyl rings. Mono- and disubstituted 
examples bearing saturated and unsaturated substituents are included. An 
unusual spin crossover exhibited by some of the complexes is described. 
Chapter 5 details some asymmetric 2,6-bis(pyrazol-1-yl)pyridine and 
isomeric 2-(1H-pyrazol-1-yl)-6-(triazolyl)pyridine derivatives. It includes a 
study of a coordination polymer formed from one of these ligands, using 
crystallography and magnetic measurements. 
Chapter 6 is an account of all the synthetic procedures used in this work, 
the standard characterisation of the new products, and the instrumentation 
used for the analyses.   
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Introduction  
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1.1 Spin crossover phenomenon 
1.1.1 Introduction to the SCO effect 
Since its discovery in 1931 by Cambi et al.,1,2 spin crossover (SCO) has 
received much interest and has been extensively researched (Fig. 1.1).3  
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Fig. 1.1 Number of research articles containing concept “spin crossover” per 
each year from 1970 till 2018, according to SciFinder3 
An abrupt drop in the magnetic susceptibility of certain Fe(III) complexes 
upon cooling was initially explained by a change in the bond type from 
covalent to ionic,4 but Orgel first suggested the correct explanation.5,6 
According to the Crystal Field Theory, formation of the coordinate bond 
between the ligand and the metal ion breaks the degeneracy of the d-
orbitals.7 Strong-field ligands (e.g. CO) produce a bigger gap between the d-
orbitals, and therefore favours the low spin (LS) state, while weak-field 
ligands (e.g. I-) produce low splitting energy and high spin (HS) complexes. 
The gap between the d orbitals is called the splitting energy (Δ), or “10Dq”.8 
The splitting energy depends on both the ligand and the metal ion. When Δ 
is between 10,000 cm-1 and 23,000 cm-1, the metal complex may switch 
between high and low spin or, in other words, undergo SCO. SCO is 
impossible outside of this splitting energy range.6 
In an octahedral ligand field the t2g orbitals are non-bonding, while the eg 
orbitals are anti-bonding and therefore higher in energy (Fig. 1.2). Because 
of this, the same metal complex in the HS and LS states has different metal-
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ligand bond lengths, and therefore different splitting energies, with ΔLS/ΔHS 
≈ 1.75. As LS metal complexes have a larger gap between the t2g and eg 
orbitals, they also absorb light at higher frequencies.9 Iron(II) complexes 
have different electric conductivity in HS and LS, which is usually lower in 
HS state.10 
 
Fig. 1.2 Low Spin to High Spin transition of Fe2+ ion in octahedral ligand field 
Usually SCO is induced by changing the temperature, but it can also be 
caused by pressure changes, application of light, a magnetic field or X-
rays.11 Bidentate SCO complexes are very common, and tri-, tetra-12 and 
polydentates are also quite common, but SCO complexes with solely 
monodentate13 ligands are rarer.14 This thesis is focused on derivatives of 
2,6-bis(pyrazol-1-yl)pyridine, or bpp, which is a very popular tridentate ligand 
core for spin crossover, and is related to terpyridine, or tpy (Fig. 1.3).  
 
Fig. 1.3 Chemical structures of some tridentate ligand cores mentioned in 
this chapter: bpp - 2,6-bis(pyrazol-1-yl)pyridine, try - 2,2';6',2"-terpyridine, 
and dpt - 2,4-dipyrazolyl-1,3,5-triazine 
1.1.2 Metal ions that can undergo SCO 
SCO is known only for complexes of five metals (Fig. 1.4): Fe2+, Fe3+, Co2+, 
Co3+, Mn2+, Mn3+, Cr2+, and Ni2+.15-17  
 
Fig. 1.4 The five elements that can form homonuclear SCO complexes 
For example, Zhang et al. obtained Mn3+ SCO complexes with axially-
compressed octahedral geometry, heavy counterions and T1/2 at ca 220 K. 
The originally used Mn2+ was oxidized to Mn3+ during complex formation.18 
The same author also obtained another series of Mn3+ SCO complexes in a 
axially-compressed octahedral geometry with more abrupt switching.19 
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Boskovic et al. obtained terpyridine-based SCO coordinational polymers with 
Co2+.20 Larkworthy et al. obtained a Cr2+ SCO complex that switches abruptly 
at ca 170 K.21 Homma and Ishida obtained Ni2+ complexes, which exhibit 
gradual SCO with T1/2 around 170 K.22 
In the literature there are also examples of heteronuclear SCO complexes. 
They may even contain metal centres that cannot undergo SCO. For 
example, Bousseksou et al. obtained [Fe1−xZnx(Htrz)2(trz)](BF4) SCO 
complexes that combine Fe2+ and Zn2+ ions. Replacing SCO-active Fe2+ 
centres with inactive Zn2+ ions led to lowering of the T1/2 and broadening of 
the switching temperature range due to loss of cooperativity. The materials 
with Fe centres, and the ones with some Fe centres replaced by Zn atoms 
were isostructural in most cases.10 There are examples of SCO complexes 
that combine ions of the same metal in different oxidation states, both of 
which undergo the switching; such compounds are called mixed-valence 
complexes. For example, Oshio et al. obtained a tetranuclear SCO complex, 
containing both Fe2+ and Fe3+.23 The other metal in a heteronuclear SCO 
complex can be also introduced via the counterion, for example, a SCO 
complex obtained by same author contains Fe2+ and Ni2+, where Ni is a part 
of the counterion.24 
Most studied are Fe2+ SCO complexes – about 90% of the reported SCO 
complexes contain Fe2+.6 The first SCO Fe2+ complex was reported by Konig 
and Madeja in 1966.25 In its low-spin state Fe2+ is completely diamagnetic, 
and in the high-spin state it is paramagnetic (Fig. 1.2), which makes it easier 
to detect its SCO.26 The transition between these states is usually 
accompanied by a strong colour change. The complexes with Fe2+ in the 
low-spin state are strongly coloured but, on changing to the high-spin state, 
they usually become pale or colourless.27 SCO is also accompanied by 
changes to ligand-metal bond lengths. When changing from LS to HS, the 
ligand-metal bond length in Fe2+ complexes increases by ca 10%.28 The Fe-
N bond length in bbp ligands (Fig. 1.3) is typically ca. 1.9 Å for LS, and ca 
2.2 Å for HS.29 SCO can occur in metal complexes with more than one metal 
centre. SCO is known for di-, tri-, tetra-, penta-, hexa-, and octanuclear Fe2+ 
complexes.30 
1.1.3 Types of SCO switching 
The percentage of the molecules that are HS and LS at a given temperature 
can be measured by different techniques (see below), but the most useful 
and widely-used are magnetic moment vs temperature graphs, obtained by 
SQUID magnetometer for solid state SCO, and by Evans method NMR for 
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solutions. The path that the SCO follows can be very different: gradual, 
abrupt, with hysteresis, with multiple steps, or incomplete (Fig. 1.5).31 
In solution SCO is always gradual, and often incomplete inside the liquid 
range of the solvent (Fig. 1.5 – A and E). In the solid state SCO can be 
either gradual, as in solution, or abrupt. Abrupt SCO, which is required for 
practical application, can be achieved in materials with stronger 
cooperativity.31 The greater the structural difference between the HS and LS 
states a compound has, the more abrupt SCO it undergoes.32  
Some SCO curves can show hysteresis (Fig. 1.5 - C), and in rare cases 
SCO can occur in multiple steps (Fig. 1.5 - D). For example, a mixed-metal 
SCO complex [Fe(bpp)2]2+[Ni(mnt)2]2·MeNO2 undergoes a SCO with three 
additional steps.23 A helical supramolecular iron(II) SCO complex obtained 
by Hannon et al. underwent a two-step switching, but only for the perchlorate 
salt. The salts with other counterions exhibited a regular one-step SCO.33 
 
Fig. 1.5 Types of SCO in solid state: A – gradual, B – abrupt, C – with 
hysteresis, D – with steps, E – incomplete30 
1.1.4 Influence of the lattice solvent and counterion on SCO 
Even a small change in the ligand geometry can dramatically affect the spin 
state of its metal complexes. For example, Halcrow et al. obtained a series 
of 2,4-dipyrazolyl-1,3,5-triazine derivatives (Fig. 1.3), and their Fe2+ 
complexes. Unlike many other similar tridentate ligands, which all form SCO 
complexes with Fe2+, the iron complexes with this ligand series all were HS. 
This fact can be explained by a subtle change in the ligand’s geometry which 
narrowed the chelate bite angle by ca 1o. This increased the distance 
between the chelating nitrogens and the d-orbitals of the iron centre, which 
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lowered the ligand field and the splitting energy, that made the HS state 
more energetically favourable.34 The strong effect of the ligand geometry 
distortions on spin crossover should be taken into account when designing 
SCO materials with specific properties for practical applications.35 
Weak intermolecular interactions, such as π–π stacking, play a key role in 
cooperativity of an SCO behaviour.36,37 For example, Vela et al. has shown 
that iron(II) complex of a bpp derivative can undergo an abrupt spin 
crossover at ca 170 K when there is one acetone in the crystal lattice, 
whereas having two propylene carbonate molecules per one iron complex 
molecule makes it stay LS above 300 K. Also, they have shown using DFT, 
that solvent-solvent interactions promote the LS state by forming propylene 
carbonate dimers.38 The temperature at which an iron complex exhibits SCO 
can change by as much as a 100 K from having a different solvent in the 
lattice.39 An example of a pronounced effect of the lattice solvent on SCO 
was observed in Chapter 2 of this thesis (Fig. 2.28 and 2.31).  
Real et al. studied Co(II) 4-terpyridone complexes with [BF4]-, [SiF6]2-, NCS-, 
I-, [PF6]-, [NO3]- as counterion, all of which were crystallized from methanol. 
Co(II) complexes with [PF6]-, [SiF6]2- were HS, NCS, I- were LS, and [BF4]-, 
[SiF6]2-, [NO3]- exhibited SCO with T1/2 from 100 to 400 K, therefore the 
counterion can dramatically affect spin crossover in solid state.27,40 Hannon 
et al. showed that SCO in the same helical Fe2+ complex is strongly 
influenced by the counterion.34 Brooker et al. in their review article showed 
many examples of SCO in polynuclear iron(II) complexes that heavily 
depends on both the lattice solvent and the counterion.29 Song et al. showed 
that a Mn3+ complex that they obtained undergoes SCO with a T1/2 ca 230 K 
higher when with [Ni(mnt)2]2- as a counterion, than with ClO4-.18 Brooker et 
al. obtained seven diiron(II) complexes that vary only by the counterion, 
which showed that the counterion dramatically affects the lattice packing and 
the SCO behaviour.41 A series of Co(ɪɪ) complexes with a lipophilic 
counterion, obtained by Hayami et al., all showed very gradual SCO 
switching.42 
1.1.5 The LIESST effect 
Light-Induced Excited-State Spin Trapping, or LIESST, was first observed in 
mid-eighties.2 Many SCO compounds can be switched from LS into a 
metastable HS state by irradiating with the light of the frequency that 
matches the charge transfer absorption energy. In such case system 
crosses from the singlet LS to a pentet HS state; and the metal complex may 
remain in that metastable HS state almost indefinitely,30 as long as it is kept 
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at cryogenic temperatures.43 LS molecules can be switched to a metastable 
HS state with a green light laser irradiation at ca 514 nm,44 and the reverse 
switching, from HS to LS, can be achieved with red light laser irradiation at 
ca 820 nm.44,45 As was shown by Hauser et al., the HS to LS LIESST effect 
can also be achieved by red light irradiation at ca 980 nm.46,47  
Oshio et al. achieved a controlled stepwise switching of the two iron centres 
in a tetranuclear mix-valence iron SCO complex (Fig. 1.6) using different 
frequency lasers.33  
 
Fig. 1.6 Photo-switchable system obtained by Oshio et al. 
1.1.6 Detection methods for SCO 
SCO can be detected in solution by Evans method NMR, paramagnetic 1H 
NMR and UV-VIS spectroscopy. In the solid state SCO can be detected 
using crystallography, by measuring the metal-ligand bond length and other 
distortion parameters;48 by comparing PXRD patterns taken at different 
temperatures; by detecting the SCO transition with DSC; by Mössbauer 
spectroscopy; by UV-VIS spectroscopy;31 and, most importantly, by 
measuring the magnetic susceptibility.  
Magnetic susceptibility (χ) is a physical unit which describes quantitatively 
the interaction between the studied material and magnetic field. In this 
regard all materials can be divided into three categories: diamagnetic, 
paramagnetic and ferromagnetic. Diamagnetic substances when put into an 
external magnetic field produce a very weak internal magnetic field, which 
opposes the applied magnetic field. For diamagnetic materials the magnetic 
susceptibility is negative. Paramagnetic substances produce an internal 
magnetic field in the same direction and proportional to the applied field. 
Ferromagnetic substances produce very strong magnetic field, often a few 
times stronger than the original one, pointing the same direction as the 
original magnetic field. This ferromagnetic field is retained when the external 
magnetic field is removed.49  
The oldest technique used for the magnetic susceptibility measurement is 
the Gouy method:  the sample is weighed on a very sensitive balance in the 
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presence and absence of a magnetic field. The difference in the two 
measurements is used in the equation to calculate the magnetic 
susceptibility.50 Later the Evans balance, an improved version of the Gouy 
method, was developed, which allows to samples as small as 50 mg to be 
studied.51 The most modern and precise technique for magnetic 
susceptibility measurement is using Superconducting Quantum Interference 
Device, or SQUID. During the SQUID measurement the sample is moved up 
and down in the pick-up coil, which is connected to a Josephson Junction, 
that consists of two superconductors, separated by a thin insulator. Because 
of the quantum tunnelling effect, the electrons may pass through the 
insulator. Even a small change in the magnetic flux through the pick-up coil 
affects the phase difference between the two superconducting coils, which 
affects the voltage through the Josephson Junctions. This voltage is than 
amplified and measured by a voltmetre. Therefore, a SQUID can convert 
magnetic flux into an electric voltage. The main use of SQUIDs is for 
biological studies and for diagnostic in medicine.28  
The magnetic moment (μ) is not measured directly, but is calculated from the 
magnetic susceptibility using the equation μef = 2.828(χAT)1/2, where μef is 
the magnetic susceptibility in Bohr Magnetons, χA is the molar magnetic 
susceptibility with diamagnetic correlations, and T is the temperature in K.51 
Even if the sample stays HS below 50 K, XT value may decrease at such 
low temperatures due to zero-field splitting.52 
1.1.7 Possible applications for SCO 
SCO compounds may potentially be used in molecular electronics, displays 
manufacturing and data storage.53 SCO occurs in nanoseconds in individual 
molecules, and switching both from HS to LS and from HS to LS can be 
induced by application of light. This two features make SCO compounds 
promising materials for information storage.15,54 Also, understanding 
interactions between a ligand and metal ion is important for bioinorganic 
chemistry and for base-metal catalysis.55 For example, mononuclear 
iron(IV)-oxo non-heme enzymes which are common in nature, particularly in 
plant organisms, always contain a HS iron, although the reason for this 
remains unclear, as similar to them biomimetic enzymes with the iron in LS 
showed comparable activity.56 Spin crossover has also been detected in 
natural systems, in a number of heme derivatives, where it can play an 
important role in controlling biological fuctions.31,57 
Study of SCO may help development of single molecule magnets, and 
different types of functional materials, such as superconducting ceramics.58 
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Liquid crystals with SCO properties, just like any other metal-containing 
liquid crystals, can align in a much weaker magnetic field much stronger 
than ordinary diamagnetic liquid crystals.59 To have practical application a 
SCO complex must have the following qualities: a room-temperature working 
range, full reversibility, low addressing power, and chemical stability.53 
Because SCO is associated with molecular volume change, it could be used 
for development for molecular machines.60 Bousseksou et al. achieved a 
tuneable actuation on microscopic scale, using thermal SCO in a bilayer 
cantilever of a PMMA/[Fe(trz)(Htrz)2](BF4) composite deposited on the 
surface of polymer doped with Ag nanoparticles (PMMA stands for 
poly(methyl methacrylate)).61 Besides thermal switching, the same results 
were achieved using modulated current. In both cases the prototype device 
showed repeatable and tunable actuation with both large displacements 
(several mm) and large force (several mN).62 
1.2 Liquid crystals 
1.2.1 Liquid crystal phase overview 
Liquid Crystals (LCs), or mesogens, are materials that in a certain 
temperature range can exhibit both the properties of liquids, such as 
molecular mobility and fluidity, and the properties of crystalline state; namely 
optical and electrical anisotropy. A substance can stay in a liquid crystalline 
state only in acertain temperature range - between its melting and clearing 
points.63 Liquid crystals were discovered in 1888 by observing the melting of 
cholesteryl benzoate, which has two melting points: at 145.5˚C it melts into a 
cloudy liquid, with crystals seen under microscope, and 178.5˚C it turns into 
transparent liquid. Liquid crystals can be thermotropic and lyotropic. 
Thermotropic liquid crystals exist in a certain temperature range between the 
solid and liquid state, while lyotropic liquid crystals can exist in a certain 
range of concentration of the amphiphilic molecules in a solvent.63  
Nowadays LCs are broadly researched, and they find application mostly in 
the LCD screen industry, as the optical properties of some LC systems 
depend on a magnetic field. Also, LCs are used in many other, more niche 
areas, such as elastomer actuators, liquid crystal functionalized polymers, 
and nanoparticle organization using liquid crystals.64 LCs can be used in 
sensors,45 and in biosensors.65 
A molecule is likely to exhibit liquid crystalline behavior if it: has an 
anisotropic shape, for example if it is elongated,66 has a rigid core and 
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several long flexible groups such as alkyl chains, has strongly polarizable 
groups62, and contains flat substituents, such as benzene rings.66 A purely 
inorganic lyotropic mesogen has been reported, which contains the 
extended cluster anion Mo3Se3-.67 
1.2.2 Intermediate LC phases 
As a substance with liquid crystalline properties goes from liquid to solid 
state, it passes through many intermediate phases, called mesophases. The 
most important of them are: Isotropic (liquid) → nematic→ cholesteric→ 
smectic→ crystalline state (solid) (Fig. 1.7 and 1.8).68 
 
Fig. 1.7 Schematic representation of the main mesophases of rod-like 
molecules 
 
Fig. 1.8 Schematic representation of the main mesophases of disc-like 
molecules 
Molecules in liquid crystalline substances are oriented the same way – 
parallel to the axis, called the director. In the liquid state the molecules are 
oriented randomly. The average value of the angle between the molecules in 
liquid crystal and the director is called theta (θ). It can be used to calculate 
the order parameter S, using the formula: S = 0.5∙<3∙cos2(θ-1)>, where the 
wedge brackets denote the average value. A perfect crystal would have an 
order parameter equal to 1.68 
The liquid crystalline state is common for molecules of anisotropic shape. 
The most common molecular shapes for formation of liquid crystals are rod-
shaped and disk-shaped (Fig. 1.9).69  
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Fig. 1.9 Calamitic (rod-like) liquid crystal molecule structure and its physical 
model (left) vs discotic (disc-like) liquid crystal and its physical model (right)67  
The nematic liquid crystal phase is the least ordered mesophase. In nematic 
phases molecules have no positional order but tend to point in the same 
direction, along the director. The word “nematic” came from the Greek word 
“νήμα”, which means “thread”. In nematic phase the molecules are oriented 
along the director in long “threads”, which however are not ordered with 
respect to each other. 
In a smectic mesophase molecules maintain the orientational order of 
nematics, but besides this they align themselves in layers or planes. The 
word smectic came from the Latin word "smecticus", which means “soap”. 
Most compounds have more than one smectic mesophase.68 There are 
known twelve different smectic phases.  
The cholesteric (also called chiral nematic) liquid crystal phase usually 
consists of chiral molecules, which, due to presence of both enantiomers, 
can’t pack close to each other, and therefore align at a slight angle to each 
other. This leads to formation of a structure, which can be described as a 
stack of very thin two-dimensional layers, each of which has order as in 
nematic phase, and the director of each new layer in the stack is slightly 
turned, forming a continuous helical pattern. 
The columnar mesophase can be formed only by disk-like molecules. It is 
formed by stacking the discotic molecules into columns. Different 
arrangements of the molecules within the columns, and the arrangement of 
the columns with respect of each other lead to additional mesophases.69  
To study phase transitions in liquid crystals, Differential Scanning 
Calorimetry, or DSC, is often used. The solid to LC (crystalline to smectic 
phase) and LC to liquid (nematic to isotropic) transitions are much more 
distinct than the transitions between the LC mesophases (smectic to 
nematic) (Fig. 1.10).69 
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Fig. 1.10 Differential Scanning Calorimetry of octyloxy-cyanobiphenyl at the 
1oC/min rate69 
1.2.3 Langmuir-Blodgett films 
A Langmuir film is an organized monolayer of amphiphilic molecules that 
forms at a liquid/gas interface. These molecules can spontaneously orient 
themselves at a liquid/gas interface with the hydrophilic head pointing 
towards the aqueous phase, and hydrophobic tails oriented towards the air 
or a hydrophobic phase.70 
A Langmuir film deposited on a solid substrate is called a Langmuir-Blodgett 
film. Pressure is applied using a moveable barrier in a Langmuir trough to 
increase the two-dimensional film concentration and obtain a highly ordered 
two-dimensional film. This film may be prepared also from a mix of different 
amphiphilic molecules. Multiple layers of Langmuir-Blodgett films can be 
deposited on a surface by repeating the cycle.70 
1.3 Spin-crossover liquid crystals 
Metallomesogens are broadly researched and are interesting because they 
may combine the properties associated with metal atoms, such as 
magnetism, conductivity, bright colour and dichroism, with the properties of 
mesogens, e.g. order, easy processability, fluidity, etc.71 The use of 
metallomesogens in LC displays is hindrance by the fact that they often have 
high viscosity and conductivity, which increases the magnetic field strength 
required to switch their orientation and therefore optical properties.72 
However, they may be used in spatial light modulators, and in information 
storage and transfer devices.73  
Maeda et al. obtained a series of nine Fe2+ complexes, which combine SCO 
and the LIESST effect, and five of which also form a LC phase (Fig. 1.11).52 
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The complexes were studied by SQUID, Mossbauer spectra, DSC, X-ray 
powder diffraction (PXRD) and optical polarized microscopy using the hot-
stage experiment. The temperature range of the mesophase formation 
obtained by DSC and PXRD corresponded to each other. The compounds 
that do not exhibit mesophase transition (n = 6, 8, 10, 22) exhibit SCO at 
lower temperatures than the ones that form liquid crystals (n = 12, 14, 16, 
18, 20) (Fig. 1.11).52 
 
Fig. 1.11 Chemical structure of 4-hexadecyloxy-N-(2-pyridinylmethylene) -
benzenamine [Fe(bzimpy)2(NCS)2]  
The same researcher also obtained another iron(II) complex series that 
combines liquid crystalline and spin-crossover properties. Both of these 
ligands (Fig. 1.12) form complexes that have liquid crystalline properties, 
however only complex of ligand A exhibits spin crossover.59 
  
Fig. 1.12 Chemical structures of the bzimpy derivatives ligands: A – 2,6-
bis(benzimidazol-2’-yl)-4-hexadecyloxypyridine, and B – 2,6-bis(N-
hexadecylbenzimidazol-2’-yl)pyridine 
Hayami et al. obtained three similar iron(II) complexes, but with branched 
long alkyl chain substituents. The iron complex with one branched alkyl 
chain exhibited a gradual SCO, while the one with three branched alkyl 
chains showed an abrupt switching, caused by a crystal-mesophase 
transition which coincided with the SCO and increased the cooperativity.74 
Based on this it may be concluded that the branched alkyl chain iron 
complexes are more inclined towards cooperative effects between metal 
complexes and linear long alkyl chains.  
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Real et al. obtained a series of tripod ligands with short and long alkyl 
chains, and their Fe2+ complexes (Fig. 1.13), which exhibit thermal SCO and 
form a smectic LC phase. The long alkyl chain complexes switch more 
gradually than the short alkyl chain ones; and in a form of a thin film they 
showed more gradual SCO than in solid state. The compounds A and B 
showed similar SCO behaviour, with compounds B having more abrupt 
switching (Fig. 1.13), while the compound C remained HS.75  
 
Fig. 1.13 Structures of the tripod iron complexes obtained by Real et al. 
Aida et al. obtained a series of Fe2+ long alkyl chain triazole 1D coordination 
polymers which all undergo SCO. Abrupt switching was achieved for the 
twelve- and sixteen-carbon chain complexes, because their mesophase 
transitions coincide with the SCO (Fig. 1.14).76 
 
Fig. 1.14 Series of SCO coordination polymers, obtained by Aida et al.  
Kurth et al obtained a Fe2+ coordination polymer, and introduced long alkyl 
chains into it using dihexadecyl phosphate as an amphiphilic counterion (Fig. 
1.15). The phase transition caused distortion around the metal iron and a 
decrease in the splitting energy between the d-orbitals, which induced a 
reversible transition from LS to HS state. The obtained compound was 
successfully deposited as a Langmuir-Blodgett multilayer, which is good for 
its potential practical application.77  
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Fig. 1.15 Coordination polymer with long alkyl chain counterions 
Usually, when a phase transition coincides with SCO, the switching 
becomes more abrupt. However, there are some exceptions. For example, 
Gutlich et al. obtained a few series of Fe2+ complexes with different 
substituents, counterions, and lattice solvent contents (Fig. 1.16). Four of 
them showed a mesophase formation at the same temperature range with 
SCO, without significantly affecting the SCO transition, which is very 
unusual. These four compounds include: all three of the different alkyl chain 
lengths iron complexes with Cl- counterion, and the eighteen carbon chain 
compound with the F- counterion, each containing 3.5 lattice water 
molecules. Noteworthy is the strong effect of the lattice solvent content on 
the SCO in these compounds, as the same compounds with 3.5, 0.5, and no 
water molecules showed completely different magnetic behaviour.78 
 
Fig. 1.16 Long alkyl chain SCO complexes, obtained by Gutlich et al. 
1.4 Spin-crossover metal complexes bearing alkyl chains 
Weber et al. obtained iron(II) complexes that differ only by the alkyl chain 
length (Fig. 1.17 - A). All of them showed the same SCO behaviour in 
solution, but in the solid state their SQUID curves looked significantly 
different: the eight-carbon chain ligand showed abrupt switching with a 4 K 
hysteresis and T1/2 at ca 182 K, the twelve-carbon one showed a gradual, 
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stepwise and incomplete SCO, while the sixteen-carbon iron complexes 
showed a full switching with a ca 23 K hysteresis and the T1/2 of 222 and 245 
K.79 Therefore the alkyl chain length affects the cooperativity and packing.79 
The same author obtained a series of short alkyl chain iron(II) complexes 
with a similar ligand (Fig. 1.17). These didn’t show a lipid-bilayer-like 
packing, which means that eight carbon chains in this case were are too 
short to induce that arrangement. All of them showed a gradual SCO, 
comparable to the switching in the solution, which may be explained by low 
cooperativity due to missing lipid-bilayer-like packing.80 
  
Fig. 1.17 SCO complexes with alkyl chains, obtained by Weber et al. 
Introducing long alkyl chains into SCO complexes, besides increasing their 
cooperativity, can help to deposit them on a surface as a thin film. For 
example, Brooker et al. obtained a sixteen-carbon chain Fe2+ complex that 
exhibits SCO around room temperature and can form Langmuir–Blodgett 
film at an air–water interface. This is good for its potential practical 
opplication in devices that can operate at room temperature without need for 
additional heating or cooling (Fig. 1.18).81 
 
Fig. 1.18 A N4-hexadecyl-3,5-di(2-pyridyl)-4H1,2,4-triazole 
Weber et al. also investigated the effect of the long alkyl chains on 
cooperativity for bipyridines. The magnetic measurements and crystal 
structures of the three Fe2+ SCO complexes with different length of alkyl 
chain spacers showed the correlation between the alkyl chain length, the 
system’s flexibility, and consequently the cooperativity (Fig. 1.19).82   
A B 
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Fig. 1.19 The influence of the bridging ligand on the SCO properties of Fe2+ 
1D coordination polymers 
Clerac et al. obtained an long alkyl chain Fe2+ complex with interesting 
properties, such as a wide abrupt hysteresis at room temperature, and 
formation of an additional ordered HS-LS phase upon cooling, which causes 
an additional small hysteresis loop on the magnetic susceptibility curve (Fig. 
1.20). This transition arises from the symmetry breaking from monoclinic into 
orthorhombic space group. The bent geometry of this SCO complex causes 
a strain near the iron centre. When it undergoes SCO transition, the 
distortion in the core are magnified by the long alkyl chains, which causes 
huge deformation of the crystal packing and symmetry breaking. This is the 
first example in the literature, of magnetic tristability caused by coincidence 
of SCO and symmetry breaking.83 
  
Fig. 1.20 Magnetic tristability observed by Clerac et al.   
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Albrecht et al. obtained a series of Fe3+ complexes with alkyl chains (Fig. 
1.21). Unlike the other members of this series, the iron complex with 
eighteen carbon chain showed an unusually abrupt SCO in solution, which 
can be explained by its self-assembly in solution. This quite abrupt SCO can 
be easily observed by eye or UV-VIS spectroscopy, as when the compound 
is HS the solution is red, and it is dark-blue when the molecules switch to 
LS.84 
 
Fig. 1.21 SCO series obtained by Albrecht at al. 
Another interesting area of research that often involves long alkyl chain 
ligands is dendrimers. Dendrimers are materials with densely packed 
regularly branched substituents. They usually have a good solubility for such 
large structures, which makes them promomising materials for obtaining 
soluble SCO polymers.62 Gutlich et al. obtained a series of Fe2+ dendrimeres 
(Fig. 1.22 – A1, A2),85 and Schluter et al. obtained similar, even more 
branched iron complexes (Fig. 1.22 – B1, B2).85 The compounds A1 and B1 
shown SCO switching at ca 200 K, while the compounds with long alkyl 
chains A2 and B2 shown incomplete switching above 300 K.85,86,87 
 
Fig. 1.22 Dendrimeres reported by: A – Gutlich,85 B – Aida, Schluter86 
Long alkyl chains may be introduced to a SCO complex not only via the 
ligand, but also through the counterion. For exaple, Hayami et al. obtained a 
series of long alkyl chain Co2+ complexes with a lipophilic glutamate 
counterion (Fig. 1.23), which all exhibited a very gradual SCO switching.42 
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Fig. 1.23 SCO Co2+ complex with a lipophilic glutamate counterion 
It may be concluded from many of the literature examples, that the presence 
of long alkyl chains may increase the cooperativity due to the lipid-bilayer-
like packing,80 and therefore make SCO more abrupt in a solid state. 
However, in some cases introducing long alkyl chain can make the switching 
incomplete and more gradual.79 Symmetry breaking83 and mesophase 
transitions83 that coincide with SCO make it more abrupt, but in some rare 
cases they can coincide without affecting each other.78  SCO in solution is 
normally very gradual, but in rare cases the presence of long alkyl chains 
can induce self-assembly of the dissolved molecules, and therefore make 
the switching much more abrupt.84 
1.5 Project aims 
Since the discovery of SCO in 1931,1,2 many different metal centres and 
ligand SCO systems were obtained and studied.48 Lately, the multifunctional 
materials which combine SCO with other functions were receiving much 
attention in the literature.88 This includes nanoparticles,89 chiral 
molecules,90,91 liquid crystals,92 thin films or gels,93 which can undergo SCO. 
Development of these materials is an important step towards practical 
application of spin-crossover materials.78 
The aim of this project is to obtain series of long alkyl chain Fe2+ complexes 
based on a well-established spin-crossover backbone 2,6-bis(pyrazol-1-
yl)pyridine or bpp (Fig. 1.3), functionalized with long alkyl chains at various 
positions, and to study the influence of the alkyl chain position and length on 
the SCO transition. Comparison of the switching in solution and in solid 
together with crystal structure analysis can reveal the effect of the alkyl 
chains on the cooperativity, packing and SCO.80 If some of the compounds 
exhibit a mesophase formation, the interplay between the phase transition 
and spin crossover may also be studied.52   
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Chapter 2 
Bis(pyrazol-1-yl)pyridine derivatives with no long alkyl 
chains, and their iron(II) complexes 
  
- 30 - 
2.1  Introduction 
This chapter contains information about novel ligands based on 2,6-
bis(pyrazol-1-yl)pyridine bpp (Fig. 2.1), and their iron(II) complexes, which 
have no long alkyl chains, and therefore are unlikely to form liquid crystals. 
However, they are interesting in respect of the effect of ligand structure on 
spin crossover, and the effect of the alkyl chain length, when compared with 
the corresponding iron(II) complexes from Chapter 3.  
 
Fig. 2.1. The list of the ligands, discussed in Chapter 2. The bpp core is 
highlighted in blue 
2.2  Ligand synthesis 
The first two steps of the synthesis below afforded L2, which then was used 
as a precursor for the seven ligands with no long alkyl chains (Fig. 2.1), 
discussed below in this chapter, as well as for a poorly soluble ligand L7, for 
which no iron complexes were obtained, and for two novel ligands series, 
L11C and L12C, with different alkyl chain lengths, which are discussed in 
Chapter 3.   
2.2.1 L1 - 2,6-dibromo pyridine-4-carboxylic acid 
 
Fig. 2.2. Synthesis of 2,6-dibromo pyridine-4-carboxylic acid 
The first step of this synthesis (Fig. 2.2) was performed according to a 
procedure reported by Beierlein et al.1. Some quantity of insoluble glass-like 
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impurity formed during this reaction, which was separated piece by piece 
using tweezers. It appears that if the reaction mixture is heated quickly, the 
amount of the above-mentioned by-product is reduced.   
2.2.2 L2 - 2,6-di(1H-pyrazole-1’-yl)pyridine-4-carboxylic acid 
 
Fig. 2.3. Synthesis of 2,6-di(1H-pyrazole-1’-yl)pyridine-4-carboxylic acid 
L2 was obtained according to the procedure, reported by Cook et al.2 (Fig. 
2.3). This compound is soluble in water at alkali pH, but precipitates when 
the solution is acidified. When obtaining L2 from the solution, a two forms of 
it, with slightly different 1H NMR shifts were collected: A and B (Fig. 2.4). If 
sufficiently acidified, the form A turns into form B. 
 
 
 
Fig. 2.4. Comparison of 1H NMRs of the two forms of 2,6-di(1H-pyrazole-1’-
yl)pyridine-4-carboxylic acid, measured in DMSO-D6 
The transition between the A and the B forms was tracked by 1H NMR only, 
and 13C NMR has been collected only for the form B. As a quite low pH, 
around pH 3, is required to convert the form A into B, the two forms must 
differ from each other by the protonation of the COOH group rather than by 
L2-A 
L2-B 
L2-A+HCl 
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the protonation of the pyridyl nitrogen. Therefore, the form A must have a 
formula bpp-COO-, and form B shall be bpp-COOH. 
2.2.3 L3, L4 - 3,4-dimethoxyphenyl (2,6-di-1H-pyrazole-1-
yl)pyridine-4-carboxylate, and 4-methoxyphenyl (2,6-di-1H-
pyrazole-1-yl)pyridine-4-carboxylate 
 
Fig. 2.5. Synthesis of L3 and L4 
All attempts to analyse the intermediate acyl chloride were unsuccessful, as  
it hydrolyses readily.  
Out of the two esterification methods3 that were tested: using thionyl 
chloride, and using DCC as a coupling agent, the second reaction is faster 
and more convenient (Fig. 2.9). However it is important to use fresh DCC, 
and to store DCC in a fridge, otherwise the synthesis may fail. 
2.2.4 L5, L6 - 3,4-dihydroxyphenyl (2,6-di-1H-pyrazole-1-
yl)pyridine-4-carboxylate, and 4-hydroxyphenyl (2,6-di-1H-
pyrazole-1-yl)pyridine-4-carboxylate 
 
Fig. 2.6. Synthesis of L5 and L6 
Ligands L3 and L4 were demethylated using boron tribromide,2 which turned 
them into L5 and L6 correspondingly (Fig. 2.6). This reaction yielded a 
mixture of two precipitates - a white and a red one, which were filtered off 
from the reaction mixture and physically separated. Each precipitate was 
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separately washed with water, dried on the filter, and then washed with DCM 
and recrystallized from acetone. After this purification both the red and the 
white precipitates turned into greyish-white powders, which were confirmed 
to be the same compound by 1H NMR.  
2.2.5 L7 - 1,4-Bis[2,6-di(1H-pyrazole-1’-yl)pyridine-4-
carboxylate]benzene 
 
Fig. 2.7. Synthesis of L7 
Attempts to attach a long alkyl chain to L6 led to formation of the ligand L7 
(Fig 2.7). The product was very poorly soluble in any of the common 
solvents, so only 1H NMR (Fig. 2.8) and a crystal structure (Fig. 2.15) were 
collected for this ligand.  
 
 
Fig. 2.8 1H NMR of L7 in DMSO-D6: full view and an expansion 
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2.2.6 L8, L9, L10 - 3,4-dimethoxy benzyl(2,6-di-1H-pyrazole-1-
yl)pyridine-4-carboxylate, 4-methoxy benzyl(2,6-di-1H-
pyrazole-1-yl)pyridine-4-carboxylate, and benzyl(2,6-di-1H-
pyrazole-1-yl)pyridine-4-carboxylate 
 
Fig. 2.9. Synthesis of L8, L9, L10 
3,4-Dimethoxy benzyl(2,6-di-1H-pyrazole-1-yl)pyridine-4-carboxylate L8, 4-
methoxy benzyl(2,6-di-1H-pyrazole-1-yl)pyridine-4-carboxylate L9, and 
benzyl(2,6-di-1H-pyrazole-1-yl)pyridine-4-carboxylate L10 were all 
synthesized using the same esterification reaction protocol, during which the 
coupling agent, N,N'-dicyclohexylcarbodiimide (DCC) turns into 
dicyclohexylurea  (DCU). The latter is notoriously hard to remove. DCU is 
much more soluble in cold MeCN than the ligands, and it was possible to 
obtain a clean ligand L8 by recrystallization from MeCN, however L9 and 
L10 required column chromatography for complete purification.  
2.3  Iron(II) complex synthesis 
L1 is not suitable for forming spin crossover iron complexes, the iron(II) 
complex of L2 has been reported before2, and L7 was too insoluble to carry 
out the complexation reaction. For all the other listed above ligands, iron(II) 
complexes were obtained and studied (Fig. 2.10).  
It is known that the structure of the ligand, the counterion4 and the lattice 
solvent5 affect spin crossover in solid state, and as trying all of the possible 
combinations of counterion and crystallization solvent for each ligand would 
be too much work, the BF4-  was used as a counterion throughout this thesis. 
Keeping the same solvent for crystallization with each different ligand was 
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more difficult, as different ligands have different solubilities, and sometimes 
growing single crystals for XRD might take many tries to succeed. In 
general, the lattice solvent was either MeCN or acetone for ligands with no 
long alkyl chains, and a DCE-acetone mixture for the ligands with long alkyl 
chains.
 
Fig. 2.10 General scheme for obtaining iron(II) complexes in Chapter 2 
2.4  XRD 
2.4.1 Crystal structures of the ligands 
L2, L3, L4, L5, and L6 
In this ligand series crystal structures were obtained for each ligand, except 
L5, despite multiple attempts to obtain crystallographic quality crystals of it. 
All ligands in this series crystallized with no lattice solvent. 
L2 molecules stack on top of each other, and form hydrogen bonding 
between the COOH hydrogen and the N5 nitrogen of the molecule from the 
neighbouring stack. The second molecule, mentioned above, in turn, bonds 
with its COOH hydrogen of the molecule directly above the first molecule. 
This means that, rather than forming the clusters of two molecules, hydrogen 
bonded to each other reciprocally, this ligand forms long polymeric hydrogen 
bonded structures, which connect parallel stacks together (Fig 2.11). 
In L4 packing, both bpp and phenyl rings pile in parallel stacks (Fig. 2.12), 
while L3 and L6 pack, so the bpp parts of the molecules stack parallel to 
each other, with every other bpp turned at ca 96o for L6 (Fig. 2.14) and ca 
109o for L3 (Fig. 2.13). In this case every other phenyl ring sticks in different 
direction, so they do not overlap.  
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Fig. 2.11 Crystal structure of L2 and its packing diagram from the view, 
parallel to the [010] vector  
  
Fig. 2.12 Crystal structure of L3 and its packing diagram from the view, 
parallel to the [010] vector 
 
Fig. 2.13 Crystal structure of L4 and its packing diagram from the view, 
parallel to the [010] vector 
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L6 forms a hydrogen bond between the Ph-OH hydrogen and the N5 from 
the neighbouring molecule, and the ligand molecules are connected with 
hydrogen bonding in long zig-zag threads. L3, L4, L5 and L6, all crystallized 
with one ligand molecule per asymmetric unit, e.g. Z’ = 1. 
 
Fig. 2.14 Crystal structure of L6 and its packing diagram from the view, 
parallel to the [010] vector 
L7 
Poorly soluble needle crystals of the ligand L7, that formed from the reaction 
mixture, were of diffraction quality, which allowed to collect the crystal 
structure from one of them (Fig 2.15). The molecules of L7 pack in the 
lattice, so the the bpp fragments of the molecules stack on top each other, 
same as the phenyl rings (Fig 2.15). For L7 there is half a molecule in the 
asymmetric unit, i.e. Z’ = 0.5. 
 
Fig. 2.15 Crystal structure of the ligand L7 and its packing diagram from the 
view, parallel to the vector [001] 
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L8, L9, L10 
The crystals of the ligands L8, L9, and L10 were collected at the Diamond 
Light Source. L8∙0.5MeCN has two ligand molecules and one MeCN 
molecule per asymmetric unit, while L9 (Fig. 2.17) has one and L10 (Fig. 
2.18) has two ligand molecules per asymmetric unit, and no lattice solvent.  
The molecules of L8∙0.5MeCN  are packed the way that the phenyl rings are 
facing each other, but not forming π- π stacking, and MeCN molecules are 
located in the gaps between them (Fig. 2.16). The molecules of L10 are 
packed more tightly than L8, probably because L10 has no methoxy groups 
and lattice solvent. 
 
Fig. 2.16 Crystal structure of L8∙0.5MeCN and its packing diagram from the 
view, parallel to the [100] vector 
 
Fig. 2.17 Crystal structure of L9 and its packing diagram from the view, 
parallel to the [010] vector 
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Fig. 2.18 Crystal structure of L10 and its packing diagram from the view, 
parallel to the [100] vector 
2.4.2 Crystal structures of iron complexes 
[Fe(L3)2][BF4]2, [Fe(L4)2][BF4]2, [Fe(L5)2][BF4]2, [Fe(L6)2][BF4]2, 
 [Fe(L3)2][BF4]2, [Fe(L4)2][BF4]2, [Fe(L5)2][BF4]2, and [Fe(L6)2][BF4]2 were 
the first series of iron(II) complexes obtained during my PhD project, and 
because of that they were tested more for different crystallization solvents 
and techniques, which resulted in many different solvates, many of which 
were collected at few different temperatures to track the spin crossover 
process. This series has many crystal structures, and for convenience, they 
are all summarized in the table below (Table 2.1). 
Crystallographic quality crystals of [Fe(L3)2][BF4]2 were grown from three 
different solvents: acetone, MeCN, and MeNO2. The crystals   grown from 
acetone, contained in the asymmetric unit one iron complex molecule, two 
conteranions, one acetone, and two diethyl ether molecules. The structure 
grown from MeCN, had 2 MeCN and 3 water molecules and one iron 
complex molecule per asymmetric unit. A crystal structure for this compound 
was also collected at 300K, and the molecule remained LS at that 
temperature, but only one molecule of MeCN per iron complex molecule 
remained in the lattice. The crystals of [Fe(L3)2][BF4]2 grown from MeNO2 
formed two polymorphs: the red crystals, and a small fraction of yellow 
crystals. The red polymorph was LS at 120K, so the crystal was heated to 
290K, but it remained LS at this temperature. A crystal structure of the 
yellow polymorph was also collected, which showed that the iron(II) centre is 
HS in this molecule even at 120K. The two polymorphs, despite being grown 
from the same solvent and both having two MeNO2 molecules per one iron 
complex molecule, have different colours, different unit cell parameters 
(Table 2.2), and completely different magnetic behaviour with temperature: 
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the red polymorph remains LS, even when heated to 290K, and the yellow 
polymorph stays HS even when cooled to 120K. Besides this, in the yellow 
polymorph molecules pack, so the iron complex molecules are located 
directly behind each other, while in the red polymorph every other molecule 
is shifted, which forms two co-parallel but offset  rows (Fig. 2.19).  
Table 2.1 XRD structures, collected for different solvates of [Fe(L3)2][BF4]2, 
[Fe(L4)2][BF4]2, [Fe(L5)2][BF4]2, [Fe(L6)2][BF4]2, [Fe(L8)2][BF4]2, [Fe(L9)2] 
[BF4]2, and [Fe(L10)2][BF4]2  
* The highlighted solvates were also measured with the SQUID magnetometer 
Ligand Crystallization solvent Iron Complex formula 
Per 
asym. 
unit 
Meas. at 
T, K 
L3 
Acetone [Fe(L3)2][BF4]2∙Me2CO∙2Et2O 1 120 
MeCN [Fe(L3)2][BF4]2∙2MeCN∙3H2O 1 120, 300 
MeNO2 red polymorph* [Fe(L3)2][BF4]2∙2MeNO2 1 120, 290 
MeNO2 yellow polymorph [Fe(L3)2][BF4]2∙2MeNO2 1 120 
L4 
Acetone* [Fe(L4)2][BF4]2 1 120, 293 
MeNO2 [Fe(L4)2][BF4]2 1 120 
L5 Acetone* [Fe(L5)2][BF4]2 2 120 
L6 
Acetone [Fe(L6)2][BF4]2∙Me2CO 1 120 
MeCN [Fe(L6)2][BF4]2∙MeCN 2 120 
MeCN [Fe(L6)2][BF4]2 1 121 
MeNO2* [Fe(L6)2][BF4]2∙0.5H2O 2 
100, 250, 
360 
L8 
MeCN [Fe(L8)2][BF4]2∙0.25MeCN 2 150 
Acetone* [Fe(L8)2][BF4]2∙Me2CO∙0.25H2O 2 120 
L9 
MeCN* [Fe(L9)2][BF4]2∙1.5MeCN 2 150 
Acetone* [Fe(L9)2][BF4]2∙0.5Me2CO 2 120 
L10 
MeCN* [Fe(L10)2][BF4]2∙1.5MeCN 2 150 
Acetone* [Fe(L10)2][BF4]2∙2/3Me2CO 3 120 
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Table 2.2 Comparison of the unit cells for the two polymorphs of 
[Fe(L3)2][BF4]2∙2MeNO2 
[Fe(L3)2][BF4]2∙2MeNO2 polymorphs 
Red Yellow 
Temperature/K  120.1(4)  
Crystal system  triclinic  
Space group  P-1  
a/Å  8.32214(15)  
b/Å  12.8301(2)  
c/Å  23.1768(6)  
α/°  88.1141(17)  
β/°  80.2771(19)  
γ/°  89.5667(14)  
Volume/Å3  2437.80(9)  
Z 2 
 
Temperature/K  120.0(3)  
Crystal system  triclinic  
Space group  P-1  
a/Å  11.3589(9)  
b/Å  13.2662(13)  
c/Å  17.5527(14)  
α/°  67.653(8)  
β/°  80.169(7)  
γ/°  78.448(8)  
Volume/Å3  2383.7(4)  
Z  2  
 
 
 
  Fig. 2.19 Packing for the [Fe(L3)2][BF4]2∙2MeNO2: red polymorph (left) and 
the yellow polymorph (right)  
[Fe(L4)2][BF4]2 was crystallized from acetone and MeNO2, and in both cases 
the unit cell was the same (Table 2.3), so a complete dataset was collected 
only for the sample obtained from acetone (Fig. 2.12). There was no solvent 
in the crystal lattice, and as the iron was LS at 120K, another structure of the 
same iron complex was collected, this time at 293K, but at this temperature 
the iron centre remained LS.    
There are no hydrogen bonding or π- π interactions in the crystal lattice of 
[Fe(L4)2][BF4]2, and the phenyl rings align, so they are not parallel to each 
other (Fig. 2.20). 
For [Fe(L5)2][BF4]2 a crystal structure was collected only for the crystals 
grown from acetone. There was no solvent in the crystal lattice, and two iron 
complex molecules in the asymmetric unit. In the lattice there are hydrogen 
bonds between the para-OH hydrogen and the meta-OH oxygen from the 
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neighboring molecule, as well as between the para-OH hydrogen and BF4 
fluorine (Fig. 2.21).  
Table 2.3 Comparison of the unit cells for [Fe(L4)2][BF4]2 grown from 
different solvents 
[Fe(L4)2][BF4]2 
Acetone MeNO2 
Temperature/K  120.0(3)  
Crystal system  monoclinic  
Space group  I2/a  
a/Å  27.5349(8)  
b/Å  8.3035(2)  
c/Å  35.3908(7)  
α/°  90  
β/°  99.537(2)  
γ/°  90  
Volume/Å3  7979.8(3)  
 
Temperature/K  119.99(10) 
Crystal system  monoclinic  
Space group  I2/a  
a/Å  27.453(7) 
b/Å  8.294(3) 
c/Å  35.428(14) 
α/°  90  
β/°  99.38(3)  
γ/°  90  
Volume/Å3  7959(5) 
 
 
 
Fig. 2.20 Crystal structure of [Fe(L4)2][BF4]2 at 120K, and its packing 
diagram from the view, parallel to the [010] vector 
[Fe(L6)2][BF4]2 was crystallized from acetone, MeCN, and MeNO2. The 
crystals grown from acetone contained in the asymmetric unit one acetone 
and one iron complex molecule. For the crystals grown from MeCN there 
were two different crystal structures collected: one with no solvent in the 
lattice, and the other with two MeCN and two iron complex molecules in the 
asymmetric unit. The two structures had different unit cell parameters, but 
were both LS at 120K. 
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The crystals grown from MeNO2 had one water molecule in the lattice per 
two iron complex molecules. The same crystal has been remeasured at 
100K, 250K, and 360K, and the water molecule remained in the lattice at 
100K and at 250K at full occupancy, but at 360K there was no solvent in the 
lattice. This water molecule was connected with two hydrogen bonds: water 
hydrogen to BF4 fluorine, and water hydrogen to O3C oxygen. Besides this, 
there were other hydrogen bonds present: O3D hydrogen to O3C oxygen, 
and O3A hydrogen to F3 fluorine (Fig. 2.22). 
The change in the average Fe-N bond length of [Fe(L6)2][BF4]2∙0.5H2O when 
heated is too large to explain it by thermal expansion. Further investigation 
of this change and linking it with spin crossover can be found in the 
subchapter “Distortion parameters” below. 
 
Fig. 2.21 Crystal structure of [Fe(L5)2][BF4]2 at 120K, and its packing 
diagram from the view, parallel to the [100] vector 
 
Fig. 2.22 Crystal structure of [Fe(L6)2][BF4]2∙0.5H2O at 250K, and its packing 
diagram from the view, parallel to the [100] vector 
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 [Fe(L8)2][BF4]2, [Fe(L9)2][BF4]2, and [Fe(L10)2][BF4]2 
 It was relatively easy to obtain good quality crystals of the iron complexes 
[Fe(L8)2][BF4]2, [Fe(L9)2][BF4]2, and [Fe(L10)2][BF4]2, so crystal structures 
were collected for all three iron complexes, for crystals grown from MeCN, 
and from acetone – 6 structures in total. The [Fe(L8)2][BF4]2 crystals grown 
from acetone and MeCN have the same unit cell, while for the other two, 
[Fe(L9)2][BF4]2 and [Fe(L10)2][BF4]2, different solvents resulted in a different 
unit cell (Table 2.4). In all three cases the crystal structures of the MeCN 
solvates had much better quality, than crystals grown from acetone, and 
therefore the crystal structures of MeCN solvates will be discussed below. 
[Fe(L8)2][BF4]2∙0.25MeCN has one half occupancy MeCN molecule per 2 
iron complex molecules in the asymmetric unit (Fig. 2.23), while 
[Fe(L9)2][BF4]2∙1.5MeCN  and [Fe(L10)2][BF4]2∙1.5MeCN  have three. In 
[Fe(L9)2][BF4]2∙1.5MeCN, the MeCN molecules are located in the lattice in 
groups of two, packed head-to-tail (Fig. 2.24), while in 
[Fe(L8)2][BF4]2∙0.25MeCN and [Fe(L10)2][BF4]2 ∙1.5MeCN  they are packed 
differently – further from each other, and in a less organized fashion. 
[Fe(L8)2][BF4]2∙0.25MeCN  and [Fe(L9)2][BF4]2∙1.5MeCN  had no π- π 
stacking between the phenyl rings, as they were located too far from each 
other and were tilted from being parallel to each other. 
[Fe(L10)2][BF4]2∙1.5MeCN  also had no π - π stacking, and the phenyl rings 
are much further from each other than in previous two cases, but the 
packing in general seems to be more tight and aligned (Fig. 2.25), which 
may explain the good cooperativity that causes abrupt spin crossover (Fig. 
2.28). 
   
Fig. 2.23 Crystal structure of [Fe(L8)2][BF4]2∙0.25MeCN, and its packing 
diagram from the view, parallel to the [100] vector 
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Table 2.4 Comparison of the unit cells of [Fe(L8)2][BF4]2, [Fe(L9)2][BF4]2, 
and [Fe(L10)2][BF4]2 
 Acetone MeCN 
[Fe(L8)2][BF4]2  
Crystal system  orthorhombic  
Space group  Pna21  
a/Å  16.1790(10)  
b/Å  21.1621(11)  
c/Å  28.8196(8)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  9867.3(8)  
Z  8  
 
Crystal system  orthorhombic  
Space group  Pna21  
a/Å  16.1146(5)  
b/Å  21.2398(8)  
c/Å  28.5755(10)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  9780.6(6)  
Z  8  
 
[Fe(L9)2][BF4]2 Crystal system  orthorhombic  
Space group  Pca21  
a/Å  20.7502(16)  
b/Å  15.444(3)  
c/Å  28.842(7)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  9243(3)  
Z  8  
 
  Crystal system  monoclinic  
  Space group  P21/c  
  a/Å  27.4401(4)  
  b/Å  16.5615(3)  
  c/Å  20.5281(2)  
  α/°  90  
  β/°  100.2570(10)  
  γ/°  90  
  Volume/Å3  9179.9(2)  
  Z  8  
 
[Fe(L10)2][BF4]2 Crystal system  monoclinic  
Space group  P21/c  
a/Å  14.6653(5)  
b/Å  46.894(2)  
c/Å  20.7067(6)  
α/°  90  
β/°  105.985(3)  
γ/°  90  
Volume/Å3  13689.7(9)  
Z  12  
 
Crystal system  triclinic  
Space group  P-1  
a/Å  13.8965(6)  
b/Å  17.0836(7)  
c/Å  20.8001(7)  
α/°  95.020(3)  
β/°  102.703(3)  
γ/°  113.133(4)  
Volume/Å3  4345.8(3)  
Z  4  
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Fig. 2.24 Crystal structure of [Fe(L9)2][BF4]2∙1.5MeCN, and its packing 
diagram from the view, parallel to the [010] vector 
 
Fig. 2.25 Crystal structure of [Fe(L10)2][BF4]2∙1.5MeCN, and its packing 
diagram from the view, parallel to the [100] vector 
2.5  SQUID 
2.5.1 [Fe(L3)2][BF4]2, [Fe(L4)2][BF4]2, [Fe(L5)2][BF4]2, and [Fe(L6)2][BF4]2      
The magnetic behaviours of [Fe(L3)2][BF4]2∙2MeNO2, [Fe(L4)2][BF4]2, 
[Fe(L5)2][BF4]2, and [Fe(L6)2][BF4]2∙0.5H2O were very similar to each other: 
they all remained LS between 5 and 300K, but started SCO at further 
heating, with T1/2 beyond the measurement limit of the instrument, which is 
about 350K.  
As the lattice solvent can affect the spin crossover in solid state,5 it would be 
useful to measure magnetic a SQUID curve for each solvate. However there 
was no possibility to measure all of them, due to the limited instrument time, 
and only one solvate of each ligand has been measured. However, for many 
- 47 - 
solvates crystal structures were collected at multiple temperatures, which 
also allows us to judge their spin-crossover behaviour (Table 2.1). 
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Fig. 2.26  Variable temperature magnetic susceptibility of [Fe(L3)2][BF4]2 
∙2MeNO2 yellow polymorph, and [Fe(L4)2][BF4]2 
As was mentioned above, [Fe(L3)2][BF4]2∙2MeNO2 formed two polymorphs: 
the red and the yellow. The yellow polymorph stayed HS even at 120K, as 
can be seen from its crystal structure. The red polymorph, on the other hand, 
had a potential to switch from LS to HS when heated. The SQUID magnetic 
susceptibility measurements has shown that the red polymorph of 
[Fe(L3)2][BF4]2∙2MeNO2 does partially switch to HS when heated to 350K, 
and goes back to LS after cooling to about 240K, however almost all sample 
is LS already below 300K. The T1/2 lies beyond the measurement limit of this 
instrument of ca 350K (Fig. 2.26). [Fe(L4)2][BF4]2 is the [Fe(L4)2][BF4]2 
crystallized from acetone, and as mentioned above, it has no lattice solvent, 
has shown similar magnetic behaviour to [Fe(L3)2][BF4]2∙2MeNO2, but 
needed a slightly higher temperature to start switching to HS (Fig. 2.26).  
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Fig. 2.27  Variable temperature magnetic susceptibility of [Fe(L5)2][BF4]2 
and [Fe(L6)2][BF4]2∙0.5H2O 
[Fe(L5)2][BF4]2 likely consists of two phases: ca 14% of the fully HS part, and 
ca 86% of the LS phase, that undergoes very gradual SCO above 300K (Fig. 
2.27). As the powder pattern of the bulk sample corresponds with the 
simulated from the crystal structure of the pure LS [Fe(L5)2][BF4]2 (Fig. 2.32), 
it can be concluded that the HS fraction in the SQUID sample of 
[Fe(L5)2][BF4]2 must either be not crystalline, or be a hydrate, that formed by 
absorbing the moisture from the air before the SQUID was measured. 
[Fe(L6)2][BF4]2∙0.5H2O reached xT about 0.69 cm3⋅mol/K, which is about 
20% of the sample being HS at 350 K, and returned to fully LS after cooling 
to 275K (Fig. 2.27).  
2.5.2 [Fe(L8)2][BF4]2, [Fe(L9)2][BF4]2, and [Fe(L10)2][BF4]2 
For [Fe(L8)2][BF4]2, [Fe(L9)2][BF4]2, and [Fe(L10)2][BF4]2, the single crystals 
were grown from both acetone and MeCN, and magnetic susceptibility was 
measured by SQUID for all of them. 
[Fe(L8)2][BF4]2∙Me2CO∙0.25H2O has shown gradual spin crossover with 
hysteresis, [Fe(L9)2][BF4]2 ∙0.5Me2CO shown similar magnetic behaviour, but 
with smaller, hardly noticeable, hysteresis, and finally [Fe(L10)2][BF4]2 
∙2/3Me2CO magnetic susceptibility vs temperature curve turned out to be the 
most promising – it showed an abrupt spin crossover from ca 233 to 300K, 
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with a small hysteresis with T1/2 at 269K upon heating and T1/2 at 278K upon 
cooling (Fig. 2.28). 
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∙Me2CO∙0.25H2O, [Fe(L9)2][BF4]2∙0.5Me2CO, and [Fe(L10)2][BF4]2∙2/3Me2CO 
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Fig. 2.29  Variable temperature magnetic susceptibility of 
[Fe(L9)2][BF4]2∙1.5MeCN  
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[Fe(L8)2][BF4]2 ∙0.25MeCN, despite having the same unit cell (Table 2.4) as 
the acetone solvate [Fe(L8)2][BF4]2∙Me2CO∙0.25H2O (Fig. 2.28), displayed 
different magnetic behaviour and remained low spin from 0 to 370 K (Fig. 
2.29). [Fe(L9)2][BF4]2∙1.5MeCN, had a small hysteresis only during the first 
cycle, but upon second heating, the χT curve started following the cooling 
curve exactly. The T1/2 was ca 343K on heating, and 365K upon cooling, and 
heating 2 (Fig. 2.29). [Fe(L10)2][BF4]2∙1.5MeCN underwent a nice, abrupt 
SCO, similar to [Fe(L10)2][BF4]2 ∙2/3Me2CO, but at higher temperature, with 
T1/2 ca 363K upon cooling, and 358K upon heating (Fig. 2.30). There is 
almost a 100oC difference in T1/2 for [Fe(L10)2][BF4]2 just because of the 
lattice solvent being MeCN or acetone. After undergoing two heating-cooling 
cycles, the [Fe(L10)2][BF4]2∙1.5MeCN sample didn’t decompose and 
followed exactly the same line on the magnetic susceptibility graph (Fig. 
2.30). 
0 50 100 150 200 250 300 350
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
x
T
, 
c
m
3
·K
/m
o
l
T, K
 Cooling 1
 Heating 1
 Cooling 2
 Heating 2
 [Fe(L10)
2
][BF
4
]
2
·1.5MeCN
12
3
4
 
Fig. 2.30  Variable temperature magnetic susceptibility of 
[Fe(L10)2][BF4]2∙1.5MeCN  
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2.6 Distortion parameters for the XRD crystal structures 
2.6.1 Introduction to distortion parameters 
 
 
Fig. 2.31 Typical for crystal structures of bpp derivatives iron(II) complexes 
labelling of the Fe and N atoms at the bpp core, used in the distortion 
parameters calculations, and the angles used for distortion parameters 
calculation 
The atoms in the crystal structures were all consistantly labeled  as shown 
on the Fig. 2.31. The distortion parameters were calculated using the 
methods, described by Cook et al.6 θ is the dihedral angle between the least 
squares planes of the two ligands, and it is usually ca 86.0-87.8o for HS, and 
ca 87.2-89.4o for LS bpp complexes.7 Φ is the N3A-Fe1-N3B angle, which is 
usually around 167.8-169.5o for HS bpp complexes, and ca 174.3-174.5o for 
LS7. α is the average of the four angles: N3B-Fe-N5B, N3B-Fe-N2B, N3A-
Fe-N5A, and N3A-Fe-N2A, that for HS bpp iron complexes is between 73o 
and 74o, and 79.0-80.4o for LS7. Σ measures the local angular distortions 
from octahedral geometry, and is calculated by this formula: Σ =
 ∑ |90 − 𝛽|12𝑖=1 , where βi
 are the 12 cis-N–Fe–N angles at the metal centre, 
and is usually 144-149o for HS, and 80-96o for LS.7 Besides these, one more 
distortion parameter has been calculated – Voct, which is the volume of the 
octahedron, that has the vertices in the nitrogen atoms, that coordinate to 
the iron: N1A, N3A, N5A, N1B, N3B, N5B. Voct is ca 9.4 Å3 for fully LS 
samples, and ca 12.4 Å3 for fully HS ones. Some distortion paramters are 
higher for LS state structures, and some for HS ones (Table 2.5). The 
distortion parameters of some crystal structures can diviate frome the typical 
values, for example, most distorted known iron complex has θ = 59.84(3)◦ 
and Φ = 154.52(14)7, which indicate HS state, but are far off from the typical 
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value range. The results of the distortion parameters calculations are 
summarized in the tables below (Tables 2.6-2.12). 
Table 2.5 Typical values of the distortion parameters for iron(II) complexes 
of bpp derivatives6,7 
Distortion 
parameters 
LS HS 
Perfect 
octahedron 
α 79.0-80.4* 73-74 90 
Σ 80-96 144-149 0 
Φ 174.3-174.5 167.8-169.5 180 
θ 87.2-89.4 86.0-87.8 90 
Voct 9.4 12.4 n/a 
* The higher values for each distortion parameter are highlighted in grey 
2.6.2 Distortion parameters for the structures, for which SQUID 
has been measured 
For the [Fe(L3)2][BF4]2, [Fe(L4)2][BF4]2,  [Fe(L5)2][BF4]2,  and [Fe(L6)2][BF4]2 
the distortion parameters were calculated for those solvates, for which 
SQUID data were measured (Table 2.1), in order to compare the results 
derived from both techniques. 
For [Fe(L3)2][BF4]2∙2MeNO2 it can be seen, that the average Fe-N bond 
length almost didn’t change upon heating from 120K to 290K, as well as all 
the other distortion parameters (Table 2.8), which means that at 290K the 
iron centre is still LS, which agrees with the SQUID data (Fig. 2.31).  
When heated from 120K to 293K, [Fe(L4)2][BF4]2 has shown a small 
decrease in the average Fe-N bond length, as well as in Φ (Table 2.8), 
which is rather unusual, and as this change is within the margin of error, it 
may be explained by an error of the bond length and angles determination, 
so we may conclude that the sample remained LS, and this result 
corresponds with the SQUID (Fig. 2.31). 
The [Fe(L5)2][BF4]2 has two iron complex molecules in the asymmetric unit, 
which have slightly different distortion parameters, however both are LS 
(Table 2.9). There are no variable temperature crystal structures for this iron 
complex, but we know from SQUID that it remained LS up until 300K (Fig. 
2.28).  
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Table 2.6 Percentage of [Fe(L6)2][BF4]2∙0.5H2O switched to HS at different 
temperatures, based on average Fe-N bond length 
 Average Fe-N bond length in Å, [Fe(L6)2][BF4]2∙0.5H2O 
Fully HS 
Fe* 
100K 250K 360K 
Fe1 Fe2 Fe1 Fe2 Fe1 Fe2 
1.942 1.947 1.948 1.951 2.006 1.986 
Average 1.945 1.950 1.996 2.177 
% HS** 0.0 2.2 22.2 100 
* The reference fully HS distortion parameters were taken from the crystal 
structure of the yellow HS polymorph of [Fe(L3)2][BF4]2∙2MeNO2, which 
corresponds with the previously reported data for HS iron(II) complexes with 
bpp derivatives 6 
** The percentage of the HS fraction in the sample was calculated by the 
formula: %HS = 
𝑋𝑇−𝑋𝐿𝑆
𝑋𝐻𝑆−𝑋𝐿𝑆
∙100%, where X is the parameter, which is used to 
calculate %HS, either Fe-N bond length or Voct, XT its value at the 
temperature T, and XHS and XLS are its values in a fully HS sample and fully 
LS sample correspondingly.  
For [Fe(L6)2][BF4]2∙0.5H2O there were crystal structures collected at three 
different temperatures. The mean Fe-N bond lengths for each temperature 
was averaged between the two molecules in the unit cell, and then these 
values were compared to the fully LS and full HS values. It was assumed 
that the sample is fully LS at 100K, as may be also seen from its SQUID, 
and the fully HS values were taken from the [Fe(L3)2][BF4]2∙2MeNO2 sample 
that is HS at low temperatures (Table 2.12), and these data are consistent 
with the values for HS iron complexes in the paper by Cook et al.6 It turned 
out that the sample reached 2.2% HS at 250K, and 22.2% HS at 360K 
(Table 2.6), which is consistent with the SQUID data, which showed xT 
0.688 cm3⋅K/mol, i.e. 20% HS at 350K (Fig 2.28). The same calculations 
based on the volume of the coordination octahedron gave very close values 
of the HS fraction percentage for each temperature (Table 2.7). 
Table 2.7 Percentage of [Fe(L6)2][BF4]2∙0.5H2O switched to HS at different 
temperatures, based on the volume of the coordination octahedron 
 
Average Voct in Å3, for [Fe(L6)2][BF4]2∙0.5H2O 
Fully HS 
Fe* 
100K 250K 360K 
Fe1 Fe2 Fe1 Fe2 Fe1 Fe2 
9.442 9.541 9.537 9.599 10.345 9.951 
Average 9.492 9.568 10.148 12.369 
% HS** 0.0 2.7 22.8 100.0 
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Table 2.8 The distortion parameters of [Fe(L3)2][BF4]2∙2MeNO2 and 
[Fe(L4)2][BF4]2 
 [Fe(L3)2][BF4]2∙2MeNO2 [Fe(L4)2][BF4]2 
120K 290K 120K 293K 
Fe1-N1A, Å 1.9832(18) 1.967(2) 1.979(3) 1.981(2) 
Fe1-N1B, Å 1.9641(17) 1.951(2) 1.972(3) 1.969(2) 
Fe1-N3A, Å 1.8908(16) 1.8914(18) 1.893(2) 1.892(2) 
Fe1-N3B, Å 1.8908(16) 1.8914(18) 1.895(2) 1.896(2) 
Fe1-N5A, Å 1.9491(18) 1.967(2) 1.952(3) 1.952(2) 
Fe1-N5B, Å 1.965(17) 1.984(2) 1.964(3) 1.964(2) 
Average, Å 1.94 1.94 1.94 1.94 
α, o 80.34(7) 80.29(8) 80.35(11) 80.35(9) 
Σ, o 84.52(7) 85.21(8) 86.05(11) 86.13(9) 
Φ, o 174.36(7) 174.81(8) 174.83(11) 174.76(10) 
θ, o 89.044 89.232 90.204 89.664 
Voct, Å3 9.438 9.461 9.460 9.463 
Table 2.9 The distortion parameters of the [Fe(L5)2][BF4]2 and 
[Fe(L6)2][BF4]2∙0.5H2O 
 [Fe(L5)2][BF4]2  [Fe(L6)2][BF4]2∙0.5H2O 
120K 100K 
molecule 1* molecule 2  molecule 1 molecule 2 
Fe1-N1A, Å 1.990(4) 1.975(4) 1.996(4) 1.967(3) 
Fe1-N1B, Å 1.971(4) 1.968(4) 1.955(4) 1.956(3) 
Fe1-N3A, Å 1.895(3) 1.888(3) 1.889(3) 1.893(3) 
Fe1-N3B, Å 1.896(3) 1.898(3) 1.895(3) 1.888(4) 
Fe1-N5A, Å 1.956(4) 1.967(4) 1.952(3) 1.987(3) 
Fe1-N5B, Å 1.965(4) 1.965(4) 1.963(4) 1.991(3) 
Average, Å 1.94 1.94 1.94 1.95 
α, o 80.31(15) 80.26(15) 80.02(15) 80.22(14) 
Σ, o 89.06(15) 84.44(15) 86.68(15) 84.97(14) 
Φ, o 177.00(15) 178.07(14) 175.18(14) 176.58(14) 
θ, o 87.765 88.680 88.622 90.873 
Voct, Å3 9.519 9.500 9.442 9.541 
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Table 2.10 The distortion parameters of [Fe(L6)2][BF4]2∙0.5H2O 
 [Fe(L6)2][BF4]2∙0.5H2O 
250K 360K 
molecule 1 molecule 2 molecule 1 molecule 2 
Fe1-N1A, Å 1.957(4) 1.982(4) 2.054(7) 1.998(7) 
Fe1-N1B, Å 1.971(4) 1.965(4) 2.027(8) 2.033(8) 
Fe1-N3A, Å 1.901(4) 1.897(3) 1.961(6) 1.925(8) 
Fe1-N3B, Å 1.901(4) 1.898(3) 1.967(7) 1.951(8) 
Fe1-N5A, Å 1.996(4) 1.979(4) 2.004(7) 1.993(8) 
Fe1-N5B, Å 1.964(4) 1.985(4) 2.022(7) 2.014(10) 
Average, Å 1.95 1.95 2.01 1.99 
α, o 79.89(16.25) 80.17(14) 98.45(3) 78.08(3.75) 
Σ, o 88.0(2) 79.97(14) 98.0(3) 105.0(3) 
Φ, o 175.66(16) 177.24(14) 177.5(3) 173.4(3) 
θ, o 89.056 90.735 90.596 88.876 
Voct, Å3 9.537 9.599 10.345 9.951 
At 150K [Fe(L9)2][BF4]2∙1.5MeCN and [Fe(L10)2][BF4]2∙1.5MeCN remained 
LS, judging by their distortion parameters (Table 2.11), which is in 
agreement with the SQUID magnetic measurement results (Fig. 2.29 and 
2.31). 
Table 2.11 The distortion parameters of the crystal structures [Fe(L8)2][BF4]2 
∙0.5MeCN, [Fe(L9)2][BF4]2∙1.5MeCN, and [Fe(L10)2][BF4]2∙1.5MeCN 
 
[Fe(L8)2][BF4]2∙
1
2
MeCN  [Fe(L9)2][BF4]2∙1.5MeCN [Fe(L10)2][BF4]2∙1.5MeCN 
150K 150K 150K 
mol. 1 mol. 2 mol. 1 mol. 2 mol. 1 mol. 2 
Fe1-N1A 1.969(7) 1.981(8) 1.967(3) 1.966(3) 1.962(3) 1.953(3) 
Fe1-N1B 1.954(8) 1.984(9) 1.976(3) 1.964(3) 1.956(3) 1.962(3) 
Fe1-N3A 1.886(6) 1.889(7) 1.895(3) 1.891(3) 1.892(2) 1.891(2) 
Fe1-N3B 1.886(7) 1.909(7) 1.890(3) 1.895(3) 1.893(2) 1.893(2) 
Fe1-N5A 1.886(7) 1.961(8) 1.970(3) 1.977(3) 1.965(3) 1.953(3) 
Fe1-N5B 1.886(7) 1.960(9) 1.965(3) 1.994(3) 1.956(3) 1.970(3) 
Average 1.91 1.95 1.95 1.95 1.94 1.94 
α 80.4(3) 80.5(3) 80.32(12) 80.13(12) 80.31(11) 80.33(11) 
Σ 84.3(3) 82.1(3) 83.92(13) 90.49(12) 84.24(11) 83.88(11) 
Φ 176.6(3) 173.6(3) 176.39(13) 175.92(12) 175.98(11) 178.44(11) 
θ 88.518 89.174 90.267 87.104 88.727 91.562 
Voct, Å3 9.459 9.486 9.499 9.534 9.399 9.406 
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2.6.3 Distortion parameters for the structures, for which SQUID 
has not been measured 
Since time on the SQUID magnetometer was limited, magnetic data were 
measured only for one solvate of each iron complex. There are structures of 
some solvates, for which the crystal structures were collected at different 
temperatures in order to track spin crossover, but which were not measured 
with SQUID: [Fe(L3)2][BF4]2∙2MeCN∙3H2O and the yellow polymorph of 
[Fe(L3)2][BF4]2∙2MeNO2. It can be seen from the distortion parameters 
(Table 2.12), that the yellow polymorph of [Fe(L3)2][BF4]2∙2MeNO2 is very 
different from the LS molecules, and must be fully HS, as its average Fe-N 
bond length corresponds with the previously reported values for HS FeII 
complexes of bpp derivatives6,7. [Fe(L3)2][BF4]2∙2MeCN∙3H2O seems to 
remain LS when heated from 120 K to 300 K, which is similar to the 
behaviour of the MeNO2 solvate of the same iron complex (Fig. 2.31). 
Table 2.12 The distortion parameters of the crystal structures of 
[Fe(L3)2][BF4]2∙2MeCN∙3H2O, and [Fe(L3)2][BF4]2∙2MeNO2 yellow polymorph 
 [Fe(L3)2][BF4]2∙2MeCN∙3H2O [Fe(L3)2][BF4]2∙2MeNO2 
120K 150K 
120K, yellow 
polymorph 
Fe1-N1A, Å 1.973(3) 1.957(8) 2.205(4) 
Fe1-N1B, Å 1.971(3) 1.971(7) 2.203(4) 
Fe1-N3A, Å 1.894(3) 1.88(6) 2.157(4) 
Fe1-N3B, Å 1.897(3) 1.889(6) 2.144(3) 
Fe1-N5A, Å 1.98(3) 1.961(7) 2.153(4) 
Fe1-N5B, Å 1.976(3) 1.976(7) 2.200(4) 
Average, Å 1.95 1.94 2.18 
α, o 80.37(12) 80.15(3) 73.1(13) 
Σ, o 85.24(12) 85.6(3) 158.76(13) 
Φ, o 175.32(12) 176.7(3) 166.33(13) 
θ, o 92.928 91.962 82.384 
Voct, Å3 89.23 88.99 91.02 
2.7 Powder Patterns 
2.7.1 [Fe(L3)2][BF4]2, [Fe(L4)2][BF4]2, [Fe(L5)2][BF4]2, and [Fe(L6)2][BF4]2      
The diffraction patterns were collected for the powders of 
[Fe(L3)2][BF4]2∙2MeNO2, [Fe(L4)2][BF4]2, [Fe(L5)2][BF4]2, and [Fe(L6)2][BF4]2 
∙Me2CO, and plotted along with the powder patterns, simulated from the 
crystal structures for comparison (Fig. 2.32). The collected and simulated 
patterns roughly match each other, and all the powders are crystalline, 
[Fe(L3)2][BF4]2∙2MeNO2 and [Fe(L4)2][BF4]2 are much more crystalline than 
[Fe(L5)2][BF4]2 and [Fe(L6)2][BF4]2∙Me2CO. 
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Fig. 2.32  Collected and simulated powder patterns of [Fe(L3)2][BF4]2 
∙2MeNO2, [Fe(L4)2][BF4]2, [Fe(L5)2][BF4]2, and [Fe(L6)2][BF4]2∙Me2CO 
2.7.2 [Fe(L7)2][BF4]2, [Fe(L8)2][BF4]2, and [Fe(L9)2][BF4]2      
For [Fe(L7)2][BF4]2, [Fe(L8)2][BF4]2, and [Fe(L9)2][BF4]2, the powder patterns 
were collected for both, the crystals grown from acetone and from MeCN. 
For the MeCN solvates, the powder patterns, which were simulated from the 
single crystal diffraction are quite different from the obtained from the 
powders (Fig. 2.33). The powders of [Fe(L8)2][BF4]2∙0.25MeCN, 
[Fe(L9)2][BF4]2∙1.5MeCN, and [Fe(L10)2][BF4]2∙1.5MeCN were obtained from 
nice, big single crystals, so they must be clean and highly crystalline. The 
difference may be explained by the lattice solvent, which each of these 
structures has. The MeCN may be lost during the grinding of the crystals into 
powder. 
For the acetone solvates, the simulated and obtained powder patterns were 
similar to each other for [Fe(L8)2][BF4]2∙Me2CO∙0.25H2O, but for [Fe(L9)2] 
[BF4]2∙0.5Me2CO and [Fe(L10)2][BF4]2∙2 3⁄ Me2CO they are quite different, 
which may be explained by the loss of the lattice solvent (Fig. 2.34). 
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Fig. 2.33 Collected and simulated powder patterns of [Fe(L8)2][BF4]2 
∙0.25MeCN, [Fe(L9)2][BF4]2∙1.5MeCN, and [Fe(L10)2][BF4]2∙1.5MeCN 
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Fig. 2.34 Collected and simulated powder patterns of [Fe(L8)2][BF4]2 
∙Me2CO∙0.25H2O, [Fe(L9)2][BF4]2∙0.5Me2CO, and [Fe(L10)2][BF4]2∙2/3Me2CO 
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2.8 Evans method NMR  
Spin crossover in solution for [Fe(L3)2][BF4]2, [Fe(L4)2][BF4]2, [Fe(L5)2] 
[BF4]2, and [Fe(L6)2][BF4]2 was studied by Evans method NMR in MeCN-D3. 
As expected, spin crossover in solution was much more gradual than in the 
solid state, as in solution the cooperativity decreases due to break up of the 
intermolecular interactions. All the iron complexes showed quite similar 
behaviour in solution. The T1/2 was determined by measuring the 
temperature at which the sample reached 1.75 cm3⋅K/mol, half the magnetic 
susceptibility of the full HS state. The results are shown in the table on the 
graph (Fig. 2.35).  
There were no Evans method NMRs collected for the [Fe(L8)2][BF4]2, 
[Fe(L9)2][BF4]2, and [Fe(L10)2][BF4]2, as the variable temperature NMR 
probe at the School of Chemistry was broken. Quite likely they would look 
similar to the previous four samples, because changing the substituent at the 
ester bond seems to have a very weak effect on the magnetic behaviour in 
solutions for this series (Fig. 2.35). 
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Fig. 2.35  Evans method NMR spectra of  [Fe(L3)2][BF4]2, [Fe(L4)2][BF4]2, 
[Fe(L5)2][BF4]2, and [Fe(L6)2][BF4]2, measured in MeCN-D3 
2.9 Paramagnetic NMR  
Paramagnetic NMR spectra were measured for each iron complex in this 
chapter. The spectra in the [Fe(L3)2][BF4]2, [Fe(L4)2][BF4]2, [Fe(L5)2][BF4]2, 
and [Fe(L6)2][BF4]2 series looked all almost identical, with two peaks close to 
each other, at around 40.5 and 39.6 ppm, a peak near 26.3 ppm, and a peak 
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at around 23.1 ppm, which all integrate in 1:1 ratio (Fig. 2.36). On expansion 
of the 0 to 7 ppm area the diamagnetically shifted peaks from the ligand are 
observed: 7.08 Ph H2, 3.88 (Ph H7), as well as the MeCN peak at 1.94. 
For the [Fe(L8)2][BF4]2, [Fe(L9)2][BF4]2, and [Fe(L10)2][BF4]2 series, the 
paramagnetic NMRs were also almost identical between each other, but a 
bit less shifted downfield comparing to the previous series (Fig. 2.37), which 
means that at 300K in solution the fraction of the sample that is HS for 
[Fe(L8)2][BF4]2, [Fe(L9)2][BF4]2, and [Fe(L10)2][BF4]2 iron complexes is lower 
than for [Fe(L3)2][BF4]2, [Fe(L4)2][BF4]2, [Fe(L5)2][BF4]2, and [Fe(L6)2][BF4]2. 
In the diamagnetic region of the [Fe(L8)2][BF4]2 spectrum were observed 
peaks from MeCN at 1.94, from acetone at 2.08, diamagnetically shifted  
peaks from the ligand at 5.86 Ph7, 2.86 Ph8,9, as well as a big TMS peak, 
because the solvent that was used for Evans method NMRs was prepared 
for Evans method NMR, and therefore contained TMS.  
 
Fig. 2.36  Paramagnetic NMR of [Fe(L3)2][BF4]2, measured in MeCN-D3 
 
Fig. 2.37 Paramagnetic NMR of [Fe(L8)2][BF4]2, measured in MeCN-D3 
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2.10 Conclusions for Chapter 2 
In this chapter are discussed the seven novel bpp carboxylate phenyl or 
benzyl ester ligands and their iron(II) complexes. Most of the iron complexes 
shown similar spin-crossover behaviour: they stayed low-spin below about 
300K, and upon heating above this temperature exhibited gradual spin 
crossover, similarly to the previously reported iron complexes of bpp 
carboxylate esters.8,9,10,11 The exception is [Fe(L10)2][BF4]2∙2/3Me2CO, which 
exhibited abrupt SCO around 270K with a 9 K hysteresis. Also, noteworthy 
are the two polymorphs of [Fe(L3)2][BF4]2∙2MeNO2, which despite having the 
same counterion and lattice solvent, show completely different SCO 
behaviour: the yellow polymorph stayed HS above 120K, and the red 
polymorph exhibited typical for this series gradual SCO above 300K. 
Studying the polymorphism in SCO systems is important for understanding 
the contribution of structural factors to SCO.12,13 For this iron complexes 
family the separate crystallization of weakly distorted low-spin and strongly 
distorted high-spin polymorphs has only been observed once before, by 
Haryono et. al.14 
All the phenyl ester ligands in this chapter have one ligand molecule per 
asymmetric unit, while the benzyl ester ligands, except L9, have two. The 
same tendency was observed for their iron complexes: all the iron 
complexes from the phenyl series have Z’ = 1, except for [Fe(L5)2][BF4]2, 
which has two; and for all the benzyl series iron complexes Z’ = 2, except 
one solvate, [Fe(L10)2][BF4]2∙2/3Me2CO, with Z’ = 3 (Table 2.1). This 
consistent pattern may be explained by the additional flexibility of benzyl 
comparing to phenyl substituent, due to the presents of the methylene 
group, which allows it to bend into different positions and therefore distort 
the symmetry. The iron complexes of these more flexible benzyl derivatives 
seems to have better cooperativity, as they showed more abrupt spin 
crossover (Fig. 2.28).15 The percentage of HS molecules calculated from the 
crystal structures’ distortion parameters matched the magnetic behaviour 
observed by SQUID. 
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Chapter 3 
Pyridine-substituted bis(pyrazol-1-yl)pyridine derivatives 
with long alkyl chains, and their iron(II) complexes 
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3.1  Introduction 
The aim of this PhD project is to obtain novel iron(II) complexes, which can 
both undergo spin crossover and form liquid crystalline phases. To achieve 
this, bpp, a core that is well-studied for spin crossover, was attached to the 
substituent groups that are likely to induce liquid crystallinity: long alkyl 
chains, phenyl rings and strongly polarizable groups. This chapter is about 
the bpp derivatives with substituents attached to the pyridine ring (Fig. 3.1), 
and their iron(II) complexes. 
  
Fig. 3.1. The ligands, discussed in Chapter 3 
3.2  Ligands synthesis 
L2, the precursor for the synthesis of L11Cx and L13Cx ligand series, was 
obtained through a two-step synthesis described in Chapter 2.2.2. 
3.2.1 L11Cx - alkyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylates 
 
Fig. 3.2. Synthesis of L11C6, L11C12, L11C14, L11C16, and L11C18 
Alkyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylates were synthesized using 
DCC as a coupling agent (Fig. 3.2), as described by Vermonden et al.1 
During this reaction DCC turns into DCU, which is notoriously hard to 
remove. A few consecutive recrystallizations from boiling MeCN, during 
which the DCU stayed in the solution and the target product crystallized out, 
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allowed pure L11C12-L11C18 to be obtained, but for the less hydrophobic 
shorter alkyl chain ligand L11C6, column chromatography was required. A 
crystal structure of a DCC intermediate was unintentionally collected (Fig. 
3.12). 1H NMR spectra of all the L11Cx ligands look very similar to each 
other, and differ by the integration of the 1.25 ppm peak, which comes from 
the overlapping of the C4 – Cn-1 alkyl chain hydrogens (Fig. 3.3). The 
labelling scheme for each chapter may be seen in the Chapter 6. The 13C 
NMR spectra of this series also look almost the same, and differ just by the 
C4 – Cn-1 carbon peaks: for L11C6 and L11C12 the peak from each carbon 
can be clearly seen, and for longer alkyl chains, the peaks from all the 
carbons past 12 start overlapping (Fig. 3.4). For example, L11C14 has only 
12 alkyl carbon NMR peaks, and the signal at 29.8 ppm is much more 
intense, because the two missing peaks overlapped with it (Fig. 3.4).  
 
Fig. 3.3. 1H NMR of L11C14 in CDCl3, typical for all L11Cx ligands 
 
 
Fig. 3.4. 13C NMR of L11C14 in CDCl3: full view and an expansion 
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2.2.4 L12Cx - 4-alkyloxyphenols 
 
Fig. 3.5 Synthesis of L12C6, L12C12, L12C14, L12C16, and L12C18 
 
 
Fig. 3.6. 1H NMR of L12C14 in CDCl3, typical for all L12Cx ligands 
 
 
Fig. 3.7. 13C NMR of L12C14 in CDCl3: full view and an expansion 
The L12CxM intermediate ligand series was obtained, so then they may be 
attached to L2 to get the target L13Cx ligands. The synthesis of L12Cx was 
performed by the procedure reported by Borisov et al.2 The target 
monosubstituted product was separated from the disubstituted product by 
extracting it with acetone. 1H NMR spectra of all the ligands in these series 
differ from each other by the integration of the 1.27 ppm peak, depending on 
the number of carbons in the alkyl chain (Fig. 3.6). For the 13C NMR, up to 
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12 alkyl chain carbons’ peaks were observed, and if there were more than 
12 alkyl carbons, still only 12 peaks were observed, because the signals 
started to overlap (Fig. 3.7). As the result of obtaining the L12CxM ligands, 
the disubstituted by-products L12CxD were also isolated, and proven by 
analyses to be pure compounds (Chapter 6.3), but no practical use was 
found for them in this research. 
2.2.5 L13Cx - 4-(alkyl)phenyl 2,6-di-1H-pyrazol-1-ylisonicotinates 
 
     
Fig. 3.8 Synthesis of  4-(alkyl)phenyl 2,6-di-1H-pyrazol-1-ylisonicotinates 
The original plan was to attach a long alkyl chain to the L5 and L6 ligands 
(Fig. 3.8). However, this synthesis led to destruction of the ester bond and 
formation of an unexpected product L7 (Fig. 2.7). To avoid this, another 
strategy was used to obtain the L13Cx ligands (Fig. 3.8).  
As for the previous series in this chapter, 1H NMR spectra of the L13Cx  
ligands differed from each other only by the integration of the 1.27 ppm alkyl 
peak (Fig. 3.9), and their 13C NMR alkyl peaks start overlapping after there 
more than 11 of them (Fig. 3.10).  
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Fig. 3.9. 1H NMR of L13C14 in CDCl3, typical for all L13Cx ligands 
 
 
 
Fig. 3.10. 13C NMR of L13C14 in CDCl3: full view and an expansion 
3.3  Iron(II) complex synthesis 
 
Fig. 3.11. General scheme for obtaining iron(II) complexes in Chapter 3 
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As the ligands in this chapter are quite hydrophobic, the usual solvents that 
are used for growing single crystals of iron complexes (MeCN, MeNO2 and 
acetone) would not work in this case. Also, the antisolvents that are normally 
used for growing crystals by slow diffusion – diethyl ether or diisopropyl 
ether, would dissolve the iron complex and not induce the precipitation. After 
some trials, the best results were obtained in the following solvent system: 
the long alkyl chain ligand was dissolved in dichloroethane (DCE), 
Fe(BF4)2·6H2O in acetone, and pentane was used as an antisolvent (Fig. 
3.11). For more details and general procedure for growing single crystals for 
crystallography, please see the used techniques in the Experimental chapter 
(Chapter 6.1.2). 
3.4  Crystal structures 
Table 3.1 Crystal structures from Chapter 3  
Formula Per asym. 
unit 
Formula Per asym. 
unit 
L11C12 1 [Fe(L11C6)2][BF4]·2H2O 1 
L11C14 1 [Fe(L13C6)2][BF4]·H2O 1 
L12C12M 2 [Fe(L13C14)2][BF4] ·2MeCN 1 
L12C14M 2 [Fe(L13C16)2][BF4]·H2O 1 
L13C12 1 DCC intermediate 1 
L13C14 1   
In this chapter, the crystal structures were collected for at least one member 
of each ligand family, except for L12CxD ligands that have two long alkyl 
chains that disfavours single crystals formation, and also for each iron 
complex series (Table 3.1). None of the ligands had any solvent in their 
lattice, but all the iron complexes had some lattice solvent, usually water. 
Perhaps the non-polar long alkyl chains can hinder the escaping of the water 
molecules and trap them near the polar part of the iron complex molecule. 
Attempts were made to collect crystal structures for every ligand in this 
chapter, however data were successfully collected only for the ligands with 
twelve and fourteen carbon alkyl chains, which indicates that this chain 
length is optimal for crystallization of ligands, with six carbon being too short 
to form a strong bilayer, and sixteen and eighteen carbon chains being too 
long, bringing distortion into the crystal structure. In total for this chapter 
there were collected seven ligand and four iron complex crystal structures. 
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3.4.1 Crystal structures of the ligands 
L11Cx 
Crystals of L11C6 did not diffract well, but among them there was a needle 
crystal that gave an unexpected structure of DCC intermediate (Fig. 3.12). 
Apparently L2, that was used as a starting material for obtaining L11C6, 
contained a trace of the monosubstituted product with one bromine atom not 
being replaced with a pyrazole ring. This compound formed an intermediate 
with DCC, which was then supposed to react with the long alkyl chain 
alcohol and emit DCU. However, instead it  crystallized from the mixture at 
the intermediate stage. The molecules of the DCC intermediate pack in 
head-to-tail stacks, connected by hydrogen bonds between the N-H 
hydrogen and NC=O oxygen of the neighbouring molecule (Fig. 3.12). 
The bpp fragments of the L11C12 molecules pack on top of each other in 
stacks, and the alkyl chains from the neighbouring stacks interdigitate. The 
molecules in the adjacent stacks are related by 21 symmetry, so their alkyl 
chains point at different directions, which forms a V-shaped array (Fig. 3.13). 
A crystal structure of L11C14 also has been collected. Its unit cell was very 
similar to L11C12 (Table 3.2). 
 
 
Fig. 3.12. Chemical formula, crystal structure, and packing diagram from the 
view, parallel to the [010] vector, for the DCC intermediate 
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Fig. 3.13. Crystal structure of L11C12 and its packing diagram from the 
view, parallel to the [010] vector 
L12Cx  
For the L12Cx series a crystal structures of L12C12M and L12C14M were 
collected, which have very similar unit cells (Table 3.2). There are two 
molecules of L12C12M in the unit cell. The phenyl rings are connected in 
parallel sheets by the hydrogen bonds between the OH hydrogen and the 
OH oxygen of the adjacent molecules (Fig. 3.13). The disubstituted products 
were hard to crystallize, so no crystal structures of them were collected.  
 
Fig. 3.14. Crystal structure of L12C12M and its packing diagram from the 
view, parallel to the [010] vector 
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Table 3.2 Unit cells of L11C12, L11C14, L12C12M and L12C14M 
 L11C12 L11C14 L12C12M L12C14M 
Space group P212121 P212121 P-1 P-1 
a/Å 4.8180(4) 4.8622(4) 5.4266(2) 5.4604(11) 
b/Å 8.9611(5) 8.9415(12) 7.2027(2) 7.2025(14) 
c/Å 53.627(3) 57.636(6) 42.2414(14) 46.898(5) 
α/° 90.00 90 88.093(3) 91.733(14) 
β/° 90.00 90 86.332(3) 90.505(14) 
γ/° 90.00 90 89.637(3) 90.417(16) 
Volume/Å3 2315.3(3) 2505.8(5) 1646.75(9) 1843.5(6) 
Z’ 1 1 2 2 
L13Cx 
L13C12 and L13C14 had similar unit cells (Table 3.3) and the same packing 
of the molecules in the lattice. While L11C12 ligand molecules are almost 
planar, in L13C12 the bpp part of the molecule and the alkyl chain are in 
almost perpendicular planes, because of the additional flexibility added by 
the phenyl ring. L13C12 forms V-shaped arrays, similarly to L11C12, but at 
a more obtuse angle (Fig. 3.15). 
 
Fig. 3.15. Crystal structure of L13C12 and its packing diagram from the 
view, parallel to the [001] vector 
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Table 3.3 Unit cells of L13C12M and L13C14M  
 L13C12 L13C14 
Space group P21/n P21/n 
a/Å 4.09650(10) 4.12350(10) 
b/Å 64.3183(13) 68.6353(8) 
c/Å 10.3525(2) 10.32150(10) 
α/° 90 90 
β/° 96.694(2) 96.8220(10) 
γ/° 90 90 
Volume/Å3 2709.08(10) 2900.48(8) 
Z’ 1 1 
3.4.2 Crystal structures of iron complexes 
 [Fe(L11Cx)2][BF4]2 
The iron complexes from the [Fe(L11Cx)2][BF4] series were very hard to 
crystallize, and a low quality crystal structure was collected only for 
[Fe(L11C6)2][BF4]2 ·2H2O. The molecules in this structure pack, so the 
counterions, the bpp parts of the molecules, and the lattice water molecules 
are located closely together in one layer, while the alkyl chains interdigitate 
with each other and form another layer, with much more free space inside it 
(Fig. 3.16). 
 
Fig. 3.16. Crystal structure of [Fe(L11C6)2][BF4]·2H2O and its packing 
diagram from the view, parallel to the [001] vector 
[Fe(L13Cx)2][BF4]2 
[Fe(L13Cx)2][BF4]2 formed crystals more readily than [Fe(L11Cx)2] [BF4]2, so 
crystal structures were collected for [Fe(L13C6)2][BF4]2·H2O, [Fe(L13C14)2] 
[BF4]2·2MeCN, and [Fe(L13C16)2][BF4]2·H2O. The crystals of [Fe(L13C14)2] 
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[BF4]2·2MeCN were grown in a NMR tube by slow evaporation from MeCN-
D3, and collected at the Diamond Light Source. The other two were grown 
by the conventional method of slow pentane diffusion. Unlike the ligands, 
iron complexes were reluctant to form crystals during slow evaporation, and 
usually decomposed, forming the ligand and Fe(BF4)2, so this was the only 
successful attempt out of many. Despite having long alkyl chains that may 
hinder crystal formation, [Fe(L13C16)2][BF4]2·H2O crystallized reproducibly 
and relatively easily, while shorter-chained [Fe(L13C6)2][BF4]2·H2O was 
crystallized only after multiple attempts. All three crystal structures of this 
series adopt triclinic space group P-1, but have different unit cell parameters 
(Table 3.4).  
Table 3.4 Unit cells of [Fe(L11C6)2] [BF4]2·2H2O, [Fe(L13C6)2][BF4]2·H2O, 
[Fe(L13C14)2][BF4]2·2MeCN, and [Fe(L13C16)2][BF4]2·H2O 
 
[Fe(L11C6)2] 
[BF4]2·2H2O 
[Fe(L13C6)2] 
[BF4]2·H2O 
[Fe(L13C14)2] 
[BF4]2·2MeCN 
[Fe(L13C16)2] 
[BF4]2·H2O 
Space group P21/c P-1 P-1 P-1 
a/Å 17.925(3) 10.3105(8) 14.31590(10) 13.2899(3) 
b/Å 15.1997(15) 15.1489(10) 15.21930(10) 13.6465(4) 
c/Å 20.4944(16) 16.7306(8) 16.7869(2) 19.4605(6) 
α/° 90 89.136(5) 84.0090(10) 98.865(2) 
β/° 101.974(12) 77.066(6) 89.7180(10) 91.201(2) 
γ/° 90 82.387(6) 72.7220(10) 98.421(2) 
Volume/Å3 5462.2(12) 2524.2(3) 3472.07(6) 3446.19(17) 
Z’ 1 1 1 1 
 
Fig. 3.17. Crystal structure of [Fe(L13C6)2][BF4]·H2O and its packing 
diagram from the view, parallel to the [100] vector 
Each of the crystal structures in this series had a lattice solvent. Water 
molecules formed hydrogen bonds between the H2O hydrogen and BF4 
fluorine in both [Fe(L13C6)2][BF4]2·H2O (Fig. 3.17) and [Fe(L13C16)2][BF4]2 
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·H2O (Fig. 3.18), while MeCN molecules didn’t form any hydrogen bonds in 
the crystal structure of [Fe(L13C14)2][BF4]2·2MeCN (Fig. 3.19). All three 
complexes were low spin, and it seems the hydrogen bonds in the lattice 
solvents didn’t affect the iron centres substantially, as they were located too 
far from each other. There were no π- π interactions found in any of the 
three crystal structures.  
 
Fig. 3.18. Crystal structure of [Fe(L13C14)2][BF4]·2MeCN and its packing 
diagram from the view, parallel to the [100] vector 
 
Fig. 3.19. Crystal structure of [Fe(L13C16)2][BF4]·H2O and its packing 
diagram from the view, parallel to the [010] vector 
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3.5  Distortion parameters 
As can be seen from the distortion parameters, all the crystal structures of 
iron complexes in this chapter were LS (Table 3.5), which corresponds with 
their SQUID measurements at the given temperatures (Fig. 3.20, 3.23). 
Table 3.5 The distortion parameters for the crystal structures of 
[Fe(L11C6)2][BF4]·2H2O, [Fe(L13C6)2][BF4]·H2O, [Fe(L13C14)2][BF4]·2MeCN, and 
[Fe(L13C16)2][BF4]·H2O 
 [Fe(L11C6)2] 
[BF4]·2H2O 
[Fe(L13C6)2] 
[BF4]·H2O 
[Fe(L13C14)2] 
[BF4] ·2MeCN 
[Fe(L13C16)2] 
[BF4]·H2O 
120 K 120 K 293 K 120 K 
Fe1-N1A, Å 
1.967(15) 1.970(4) 1.9538(10) 1.9688(17) 
Fe1-N1B, Å 1.950(15) 1.974(3) 1.9694(11) 1.9591(16) 
Fe1-N3A, Å 1.884(13) 1.898(3) 1.8911(10) 1.8852(16) 
Fe1-N3B, Å 1.892(14) 1.896(3) 1.8986(10) 1.8839(16) 
Fe1-N5A, Å 1.981(13) 1.965(3) 1.9837(10) 1.9561(17) 
Fe1-N5B, Å 1.967(13) 1.957(4) 1.9765(11) 1.9548(16) 
Average, Å 1.94 1.94 1.95 1.94 
α, o 80.05(6) 80.29(14) 80.10(4) 80.47(7) 
Σ, o 86.7(6) 84.26(14) 87.45(4) 82.66(7) 
Φ, o 178.5(6) 178.05(14) 175.39(4) 176.98(7) 
θ, o 90.307 91.266 87.196 91.245 
Voct, Å3 9.436 9.499 9.503 9.374 
3.6  SQUID 
3.6.1 [Fe(L11Cx)2][BF4]2 
All of the [Fe(L11Cx)2][BF4]2 series members showed similar magnetic 
behaviour – they remained fully LS up to ca 340 K, but show a gradual 
switching above that temperature (Fig. 3.20), with a slight hysteresis for 
[Fe(L11C14)2][BF4]2 (Fig. 3.21). Heating [Fe(L11C18)2][BF4]2  to 170oC 
causes annealing, which makes some fraction of the sample permanently 
switch to HS (Fig. 3.22). Annealing was confirmed to take place for other 
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iron complexes in this series by DSC (Fig. 3.35) and powder patterns (Fig. 
3.1). 
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Fig. 3.20 Variable temperature magnetic susceptibility of 
[Fe(L11C6)2][BF4]2·2H2O, [Fe(L11C12)2][BF4]2·0.25Me2CO, and 
[Fe(L11C16)2][BF4]2   
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Fig. 3.21 Variable temperature magnetic susceptibility of 
[Fe(L11C14)2][BF4]2, showing hysteresis 
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Fig. 3.22 Variable temperature magnetic susceptibility of 
[Fe(L11C18)2][BF4]2: annealed at 170oC vs the fresh sample  
3.5.2 [Fe(L13Cx)2][BF4]2 
The magnetic behaviour of the [Fe(L13Cx)2][BF4]2 iron complexes was not 
as uniform as the one of [Fe(L11Cx)2][BF4]2. Their powder patterns shown 
the same trend: similar powder patterns for all the [Fe(L11Cx)2][BF4]2 series, 
and different powder patterns for each alkyl chain length [Fe(L13Cx)2][BF4]2 
iron complexes (Chapter 3.9). [Fe(L13C6)2][BF4]2·H2O and [Fe(L13C18)2] 
[BF4]2·1.6H2O remained LS from 5 to 350 K (Fig. 3.23). [Fe(L13C14)2][BF4]2 
·2MeCN showed some slight and gradual changes in the magnetic moment 
with temperature (Fig. 3.23). [Fe(L13C12)2][BF4]2 showed some significant 
decrease in the magnetic moment upon cooling below 225 K, which may be 
explained by gradual spin crossover (Fig 3.23 purple and green dots). 
Another sample of the same iron complex has been measured, this time for 
three cycles (Fig 3.23 red, blue and magenta dots). Both times the magnetic 
moment followed roughly the same path, and the second heating cycle 
followed exactly the cooling cycle. This means that the SQUID 
measurements of [Fe(L13C12)2][BF4]2 are reproducible, and showed gradual 
spin crossover with no hysteresis, probably in two steps with T1/2 at around 
240 and 340K. 
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A sample of [Fe(L13C16)2][BF4]2·1.6H2O was heated in the 170oC oil bath 
for a few minutes and allowed to cool to room temperature, after which 
measured at a SQUID magnetometer. The annealing changed the magnetic 
behaviour of the sample, so the main fraction of the sample remained HS 
from 5 to 370 K (Fig. 3.24). 
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Fig. 3.23 Variable temperature magnetic susceptibility of [Fe(L13C6)2] 
[BF4]2·H2O, [Fe(L13C14)2][BF4]2·H2O, [Fe(L13C18)2][BF4]2·1.4H2O, and the 
two measurements of [Fe(L13C12)2][BF4]2 
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Fig. 3.24 Variable temperature magnetic susceptibility of 
[Fe(L13C16)2][BF4]2·1.6H2O: annealed at 170oC vs the fresh sample  
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3.7  DSC and TGA 
3.7.1 Ligands 
L11Cx 
The DSC graphs of all the ligands in L11Cx series were pretty similar, with 
one peak on the first heating cycle, which corresponds with its manually 
measured melting point (see Chapter 6 for more details). The second 
heating cycle resembles the first one, but with the melting peak shifted down 
for about one degree (Fig. 3.25, 3.26). Unlike the other ligands in this series, 
L11C18 shows one additional peak on the second heating cycle, ca 8 
degrees below the main peak (Fig. 3.27). On the cooling cycle, the peak 
from the freezing back was observed on all the L11Cx series DSCs. In every 
case it was substantially below the melting point. This may be explained by 
the fact that forming crystals from liquid takes longer time than melting, 
which may cause a delay. The heating cycles were performed at 10oC per 
minute, and the cooling cycle was performed at 5oC per minute speed. 
Further details about DSC measurements can be seen at Chapter 6.1.4.  
The TGA analyses of the L11Cx ligands all looked similar, with no signs of 
solvent loss. Decomposition started at 165-225oC depending on the alkyl 
chain length, with longer-chain ligands being more stable (Fig. 3.28). 
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Fig. 3.25. DSC of L11C6 
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Fig. 3.26. DSC of L11C14 
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Fig. 3.27. DSC of L11C18 
0 50 100 150 200 250 300 350 400
0
20
40
60
80
100
W
e
ig
h
t 
(%
)
Temperature (°C)
 L11C6
 L11C12
 L11C14
 L11C16
 L11C18
 
Fig. 3.28. TGA of L11C6, L11C12, L11C14, L11C16, and L11C18 
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L13Cx 
The DSC analyses of L13Cx ligands were very similar to L11Cx series, but 
the peaks were sharper, and the peaks on the cooling mode were less 
downshifted. For the L13Cx ligands, only  one peak was observed on each 
cycle, which corresponds with the melting points of the ligands, except 
L13C12, which on its cooling mode had some splitting of the main peak with 
1.7oC difference between the two subpeaks, and one additional broad and 
very small peak at 108.7oC.  
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Fig. 3.29. DSC of L13C6, which is typical for the L13Cx series  
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Fig. 3.30. DSC of L13C12, not similar to the other L13Cx ligands 
For the TGAs of L13Cx series, unlike the L11Cx ligands, there was no direct 
correlation between the alkyl chain length and the temperature at which the 
ligand starts to decompose (Fig. 3.31). There were no signs of solvent loss 
on the TGAs. 
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Fig. 3.31. TGA of L13C6, L13C12, L13C14, L13C16, and L13C18 
3.7.2 Iron(II) complexes 
The DSCs of the iron complexes had broader and less clear peaks, 
compared to the ligands. Some of the iron complexes shown peaks at the 
first heating cycle, and no peaks on the remaining two cycles, which means 
some irreversible changes happened in the sample upon heating to that 
temperature. In cases when this annealing was occurring, a fresh sample of 
the same compound was measured again at a lower maximum temperature 
to avoid the annealing. The annealing of the [Fe(L11Cx)2][BF4]2 and 
[Fe(L13Cx)2][BF4]2 series of iron complexes was studied also by SQUID, 
DSC, VT photographs and by powder patterns. 
[Fe(L11Cx)2][BF4]2 
TGAs of some of the [Fe(L11Cx)2][BF4]2 iron complexes showed presence 
of lattice solvent, and there are a few techniques that can help to identify 
them: TGA, DSC, microanalysis (which can be found in Chapter 6.3.4), and 
XRD. Sometimes these methods suggested different lattice solvents, so all 
the results were summarized all together in one table to compare them 
easily (Table 3.4).  
[Fe(L11C16)2][BF4]2 was first measured by DSC from 0 to 250oC (Fig. 3.35), 
up to the same temperature for which the ligands were measured. Because 
some irreversible changes were observed, the same compound was re-
measured with heating until 175oC, and annealing happened again. Running 
- 85 - 
a DSC from 0 to 110oC lead to absence of annealing, with the peaks on the 
heating 1 and heating 2 cycles matching each other (Fig. 3.36). There were 
two peaks on the cooling cycle, and one peak on each of the heating cycles 
at  ca 92.5oC, or 366K, which may come from an SCO transition, as this 
temperature matches its expected T1/2 (Fig. 3.20). The doubled peak on the 
cooling cycle does not come from a LC phase formation, as on the photos it 
may be seen that at that temperature the sample remains solid (Fig. 3.46). 
Therefore the origin of the second peak remains unknown. As the DSC 
showed no peaks from the solvent loss (Fig. 3.36), the TGA showed 
insignificant mass loss at 100oC (Fig. 3.38), and CHN showed no lattice 
solvent, the sample is likely to have no lattice solvent (Table 3.6). 
Table 3.6 Assigning lattice solvents to [Fe(L11Cx)2][BF4]2 based on TGA, 
CHN and XRD 
# of 
carbons 
Mr, Da Suspected 
lattice solvent 
Solv, 
Mr, Da 
Solvent loss, % 
CHN XRD Theo-
retical 
Obs. at 
1000C 
C6 908.24 2H2O 36 3.81 3.68 0 2H2O 
C12 1076.55 0.25Me2CO 14.52 1.33 1.09 0 - 
C14 1132.66 -* 0* 0.00 0.5 0 - 
C16 1188.77 - 0 0.00 0.24 0 - 
C18 1244.87 - 0 0.00 0.53 3H2O - 
* - -  no measurement taken; 0 - no lattice solvent found 
The DSC of [Fe(L11C6)2][BF4]2 was featureless (Fig. 3.32), which may be 
explained by its gradual SCO (Fig. 3.20), that produced a very broad and 
weak DSC peak. The crystal structure of this iron complex (Fig. 3.16) and its 
TGA (Fig. 3.38) suggest presence of two lattice water molecules, while the 
CHN shows no solvent (Table 3.4), which may be explained by escape of 
the lattice solvent during preparation of the CHN sample. Thus the final 
formula of this iron complex must be [Fe(L11C6)2][BF4]2·2H2O. 
For [Fe(L11C12)2][BF4]2 there were two peaks on each cycle: at ca 44oC and 
63oC, i.e. 317 and 336 K (Fig. 3.33). The second peak corresponds with T1/2 
of this iron complex (Fig. 3.20), while the first peaks on each heating cycle 
may come from escaping of the lattice solvent, which based on TGA and the 
escaping temperature from DSC must be 0.25Me2CO. 
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The DSCs of both [Fe(L11C14)2][BF4]2 and [Fe(L11C18)2][BF4]2 had one 
peak on each cycle, which corresponded with their spin crossover T1/2 of ca 
350K or 77oC (Fig. 3.21), and at 95oC, i.e. 368 K (Fig. 3.37) respectively. 
Their TGAs suggest no lattice solvent present (Fig. 3.38). 
The TGAs of the [Fe(L11Cx)2][BF4]2 iron complexes all looked similar, with a 
rapid drop in the mass at ca 300oC (Fig. 3.38). This means that the 
annealing, which happened to the iron complexes in this series between 
100oC and 170oC, didn’t cause a significant mass loss, but was likely 
associated with the alkyl chain orientation changes.  
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Fig. 3.32. DSC of [Fe(L11C6)2][BF4]2·2H2O
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 Fig. 3.33. DSC of [Fe(L11C12)2][BF4]2·0.25Me2CO 
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Fig. 3.34. DSC of [Fe(L11C14)2][BF4]2 
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Fig. 3.35. DSC of [Fe(L11C16)2][BF4]2, showing annealing 
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Fig. 3.36. DSC of [Fe(L11C16)2][BF4]2  
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Fig. 3.37. DSC of [Fe(L11C18)2][BF4]2  
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Fig. 3.38. TGA of [Fe(L11C6)2][BF4]2·2H2O, [Fe(L11C12)2][BF4]2·0.25Me2CO, 
[Fe(L11C14)2][BF4]2, [Fe(L11C16)2][BF4]2, and [Fe(L11C18)2][BF4]2 
[Fe(L13Cx)2][BF4]2 
On the TGA graphs of the [Fe(L13Cx)2][BF4]2 iron complexes we see that all 
of them undergo a rapid mass loss upon heating beyond ca 250oC (Fig. 
3.44). Also, all of them except  [Fe(L13C12)2][BF4]2, had a 1.37 – 2.15% 
mass loss at 100oC, which corresponds with the loss of lattice water (Table 
3.7). For [Fe(L13C6)2][BF4]2·H2O and [Fe(L13C16)2][BF4]2·H2O there are 
also crystal structures available, showing lattice water molecules (Fig. 3.17, 
3.19). The DCE molecules found in [Fe(L13C6)2][BF4]2 and [Fe(L13C12)2] 
[BF4]2 by CHN can probably escape with time and be replaced by 
atmospheric water, which explains their DSC and TGA results. 
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Table 3.7 Assigning lattice solvents to [Fe(L13Cx)2][BF4]2 based on TGA, 
CHN and XRD 
# of 
carbons 
Mr, Da 
Suspected 
lattice 
solvent 
Solv. 
Mr, Da 
Solvent loss, % 
CHN XRD Theo-
retical 
Obs. at 
1000C 
C6 
1092.43 
H2O 18 1.62 1.61 DCE H2O 
C12 1260.74 -* 0 0.00 0.24 0.5DCE - 
C14 1316.85 H2O 18 1.35 1.37 0* - 
C16 1372.96 1.6 H2O 28.8 2.05 2.15 0 H2O 
C18 1429.06 1.4 H2O 25.2 1.73 1.72 0 - 
*  -  - no measurement taken; 0 - no lattice solvent found 
On the DSC graph of [Fe(L13C6)2][BF4]2·H2O there were no peaks observed 
on any of the three cycles, except two very small peaks during the first 
heating cycle, first of which is at 53oC, which is close to 56oC, the boiling 
point of acetone, and the second peak at 89.1oC may appear due to the loss 
of water (Fig. 3.39). This corresponds with the SQUID results (Fig. 3.23), 
which showed that the sample remained LS, which allows to make a 
conclusion that T1/2 for this iron complex must lie beyond 180oC or 453 K.  
The crystals of [Fe(L13C14)2][BF4]2·2MeCN were grown from MeCN-D3 
solution, and used only to collect the crystal structure, while the 
[Fe(L13C14)2][BF4]2·H2O sample was grown from acetone-DCE mixture, and 
was used for all the other measurements.  
[Fe(L13C14)2][BF4]2·H2O, [Fe(L13C16)2][BF4]2·1.6H2O, and [Fe(L13C18)2] 
[BF4]2·1.4H2O showed similar behaviour: there were two peaks on the first 
heating cycle, and no peaks on the consecutive ones. Unlike on the 
[Fe(L11Cx)2][BF4]2 graphs, for [Fe(L13Cx)2][BF4]2 the peaks were appearing 
at much higher temperatures, which made it impossible to lower the 
measurement temperature in order to avoid annealing. The first peaks on 
each of these graphs (Fig. 3.41, 3.42, 3.43) correspond with the loss of the 
lattice solvent, and the second peaks at 141.9oC, 134.8oC,  and 126.0oC for 
the C12, C14 and C18 iron complexes respectively, most likely comes from 
a spin crossover transition, which matches with the observed SQUID curves, 
which show that the samples remained LS until the upper limit of the 
magnetometer of ca 360 K or 87oC (Fig. 3.23, 3.24). On the DSC graph for 
[Fe(L13C14)2][BF4]2·H2O the line is not horizontal, as in other DSC graphs, 
but is significantly tilted above ca 70oC. This process is observed on the both 
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heating cycles,  and it indicates a very gradual release of thermal energy 
(Fig. 3.41). It may come from the increase in the entropy due to the long 
alkyl chains order loss. The other iron complexes from this series didn’t 
show this behaviour at such low temperatures. A significant loss in 
crystallinity of [Fe(L13C14)2][BF4]2·H2O already at 100oC, that did not 
happen to any other iron complex in this chapter, was also observed in the 
powder pattern (Fig. 3.44). 
[Fe(L13C12)2][BF4]2 stands out of this series, because unlike the others, this 
iron complex showed only one peak on its DSC graph, at ca 126oC or 399 K 
(Fig. 3.40), and also shown some switching on its SQUID curve (Fig. 3.23). 
This SQUID measurement was repeated, and twice the same result was 
obtained (Fig. 3.23), which means that probably this iron complex switches 
in two steps: firstly gradually at ca 250K or -23oC, which is below the DSC 
measurement, and secondly at ca 399 K or 126oC. 
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Fig. 3.39. DSC of [Fe(L13C6)2][BF4]2·H2O  
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Fig. 3.40. DSC of [Fe(L13C12)2][BF4]2 
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Fig. 3.41. DSC of [Fe(L13C14)2][BF4]2·H2O 
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Fig. 3.42. DSC of [Fe(L13C16)2][BF4]2·1.6H2O 
0 20 40 60 80 100 120 140 160
-3
-2
-1
0
1
2
H
e
a
t 
F
lo
w
 (
W
/g
)
Temperature (°C)
 Heating 1
 Cooling 1
 Heating 2
[Fe(L13C18)
2
][BF
4
]
2
·1.4H
2
O
53.7
o
C
79.3
o
C 90.9
o
C 126.0
o
C
43.9
o
C 61.1
o
C
 
Fig. 3.43. DSC of [Fe(L13C18)2][BF4]2·1.4H2O 
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Fig. 3.44. TGA of [Fe(L13C6)2][BF4]2·H2O, [Fe(L13C12)2][BF4]2, 
[Fe(L13C14)2][BF4]2·H2O, [Fe(L13C16)2][BF4]2·1.6H2O, and 
[Fe(L13C18)2][BF4]2·1.4H2O 
3.8  VT photographs 
[Fe(L11C12)2][BF4]2·0.25Me2CO, [Fe(L13C14)2][BF4]2·H2O, [Fe(L13C16)2] 
[BF4]2·1.6H2O, and [Fe(L13C18)2][BF4]2·1.4H2O show doubled DSC peaks, 
which most likely come from the lattice solvent, and [Fe(L11C16)2][BF4]2 
shows a doubled peak of an unknown origin, so some of these cases may 
be signs of mesophase formation. Therefore, all the iron complexes from this 
chapter were tested for phase transitions by heating it on an oil bath and 
observing the colour and the consistency change by taking a photo every 
20oC from room temperature to 170oC. Neither the [Fe(L11Cx)2][BF4]2 (Fig. 
3.45), nor [Fe(L13Cx)2][BF4]2 (Fig. 3.46) iron complex series shown any sign 
of melting, although some colour changes from red to orange were 
observed, which indicates spin crossover on heating. 
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Fig. 3.45. Changes in appearance of [Fe(L13Cx)2][BF4]2 iron complexes series with heating from room temperature to 170oC 
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Fig. 3.46. Changes in appearance of [Fe(L11Cx)2][BF4]2 iron complexes series with heating from room temperature to 170oC 
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3.9  Powder patterns 
3.9.1 Ligands 
Powder patterns were collected for all the ligands in this chapter: L11Cx, 
L12CxM, L12CxD, and L13Cx, but only the powder patterns of the ligand 
series that are interesting for this research are discussed below, as they can 
form iron complexes: L11Cx and L13Cx. Available crystal structures were 
used to simulate powder patterns to compare them with the experimental 
data.  
L11Cx 
The ligands from the L11Cx series have similar powder patterns, with peaks 
at similar angles, but differing intensity proportions between them (Fig. 3.47). 
The L11C6 sample was not very crystalline, but the observed peaks match 
the most intense peaks in the powder patterns of other ligands in this series. 
Data from L11C12 and L11C14 were an excellent match for their simulated 
powder patterns, showing those compounds are phase pure (Fig. 3.47). 
5 10 15 20 25 30 35 40
0
50
100
150
200
L11C6
L11C12
L11C12-simulated
L11C14-simulated
L11C14
L11C18
C
o
u
n
ts
2 Theta (deg.)
L11C16
 
Fig. 3.47. Collected and simulated powder patterns of L11Cx ligands 
The L13Cx series was more crystalline than L11Cx, and the powder 
patterns of all those ligands look similar to each other (Fig. 3.48). Again, the 
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powder patterns of L13C12 and L13C14 agree well with their simulated 
patterns (Fig. 3.48). 
L13Cx 
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Fig. 3.48. Collected and simulated powder patterns of L13Cx ligands 
3.9.2 Iron(II) complexes 
DSC analyses for the [Fe(L11Cx)2][BF4]2 and [Fe(L13Cx)2][BF4]2 iron 
complex series shown some irreversible changes after heating to 
temperature between 100oC and 170oC. This effect was studied also by 
powder diffraction by comparing analyses collected at different 
temperatures: at room temperature, 100oC, and 170oC. A sample was 
heated to the corresponding temperature in a vial on an oil bath, kept at this 
temperature for about a minute, allowed to cool to room temperature, and 
then immediately measured. The same sample was reheated again, and 
used for all three measures. Collection of one powder pattern takes about 
half an hour, which hinder collecting analyses from more temperatures. 
[Fe(L11Cx)2][BF4]2 
The simulated powder pattern of [Fe(L11C6)2][BF4]2·2H2O matches that 
obtained at room temperature (Fig. 3.49). The sample slightly lost its 
crystallinity upon heating to 100oC, as the peaks became weaker, while 
heating to 170oC led to annealing and almost complete loss of crystallinity 
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(Fig. 4.43). All the other samples in this series - [Fe(L11C12)2][BF4]2 
·0.25Me2CO, [Fe(L11C14)2][BF4]2, and [Fe(L11C16)2][BF4]2 and 
[Fe(L11C18)2][BF4]2, behaved similarly: heating to 100oC had almost no 
effect on their powder patterns, and heating to 170oC caused annealing (Fig. 
3.49). The C12, C14 and C16 iron complexes after heating to 170oC 
underwent annealing with the main peaks remaining visible, while the C6 
and C18 ones almost lost their crystallinity. 
[Fe(L13Cx)2][BF4]2 
The annealing effect for [Fe(L13Cx)2][BF4]2 (Fig. 3.50) was not as 
pronounced as for [Fe(L11Cx)2][BF4]2 (Fig. 4.43). Also, the powder patterns 
of [Fe(L13Cx)2][BF4]2 iron complexes were much less similar to each other, 
than [Fe(L11Cx)2][BF4]2 (Fig. 3.49, 3.50, and 3.51), which agrees with the 
obtained SQUID data, which show much more uniform behaviour for 
[Fe(L11Cx)2][BF4]2 (Fig. 3.20, 3.21 and 3.22), than for [Fe(L13Cx)2][BF4]2 
(Fig. 3.23 and 3.24), and with the unit cells of the collected crystal structures 
(Table 3.3). 
Upon heating to 100oC, significant changes were observed only for the C14 
iron complex. These results match its DSC measurements, which show 
some changes after heating above 70oC (Fig. 3.47). The C18 iron complex 
also showed some annealing upon heating to 100oC (Fig. 3.51). This 
behaviour was not observed in the DSCs of any of the other iron complexes 
in this chapter. Heating to 170oC caused no significant loss in crystallinity for 
[Fe(L13C6)2][BF4]2·H2O and DSC of [Fe(L13C12)2][BF4]2, a strong annealing 
by DSC of [Fe(L13C14)2][BF4]2·H2O and [Fe(L13C18)2][BF4]2 ·1.4H2O, and a 
very strong annealing [Fe(L13C16)2][BF4]2·1.6H2O (Fig. 3.50), which 
corresponds with the DSC results for these iron complexes: likely SCO 
above 180oC which didn’t allow us to judge about the reversibility of the 
changes in [Fe(L13C6)2][BF4]2·H2O after heating (Fig. 3.39), no annealing 
observed for  [Fe(L13C12)2][BF4]2 (Fig. 3.40), and irreversible changes upon 
heating for [Fe(L13C14)2][BF4]2·H2O, [Fe(L13C16)2][BF4]2 ·1.6H2O, and 
[Fe(L13C18)2] [BF4]2·1.4H2O (Fig. 3.47, 3.48, and 3.49 correspondingly). 
Even though [Fe(L13C6)2][BF4]2·H2O had low crystallinity, the observed 
peaks matched its simulated pattern (Fig. 3.50). The powder patterns of 
[Fe(L13C14)2][BF4]2·H2O don’t quite match the pattern simulated from the 
crystal structure of [Fe(L13C14)2][BF4]2·2MeCN, which means that the lattice 
solvent affected the unit cell in this case. For [Fe(L13C16)2][BF4]2 ·1.6H2O 
the obtained powder pattern matched the simulation for [Fe(L13C16)2][BF4]2 
·H2O. 
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Fig. 3.49. Powder patterns of [Fe(L11C6)2][BF4]2·2H2O, [Fe(L11C12)2][BF4]2·0.25Me2CO, [Fe(L11C14)2][BF4]2, and 
[Fe(L11C16)2][BF4]2, collected at room temperature, 100oC, 170oC, and, where available, simulated powder patterns  
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Fig. 3.50. Powder patterns of [Fe(L13C6)2][BF4]2·H2O, [Fe(L13C12)2][BF4]2, [Fe(L131C14)2][BF4]2·H2O, and 
[Fe(L13C16)2][BF4]2·1.6H2O, collected at room temperature, 100oC, 170oC, and, where available, simulated powder patterns  
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Fig. 3.51. Powder patterns of [Fe(L11C18)2][BF4]2, and [Fe(L13C18)2][BF4]2·1.4H2O collected at room temperature, 100oC, and 170oC 
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3.10  Magnetic properties in solution 
Evans method NMR 
Magnetic properties in solution were studied by Evans method NMR in 
MeCN-D3, and by paramagnetic NMR. Evans method NMR data were 
collected for one member of each iron complex series: for 
[Fe(L11C16)2][BF4]2 and [Fe(L13C16)2][BF4]2. Their solubility in MeCN-D3 
was not sufficient, and so the measurements failed due to a low 
concentration of the long alkyl sample, therefore series of  Evans method 
NMRs were taken in MeCN-D3:CDCl3 1:1 mixture in order to achieve a 
better solubility of ca 5.2 mg of the iron complex per 5 ml of solvent mixture, 
and to be able to measure at a high enough temperature below the boiling 
point. Both iron complexes show similar magnetic behaviour in solution (Fig. 
3.52), which shows gradual switching with T1/2 at ca 290K for both. That is 
similar to the Evans method results for the iron complexes in the previous 
chapter (Chapter 2, Fig. 2.35).  
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Fig. 3.52. Evans method NMRs of [Fe(L11C16)2][BF4]2 and [Fe(L13C16)2] 
[BF4]2, measured in MeCN-D3:CDCl3 1:1 mixture 
Paramagnetic NMR 
Paramagnetic NMR spectra of for [Fe(L11Cx)2][BF4]2 all looked very similar. 
A typical NMR can be seen below (Fig. 3.53). The solubility of 
[Fe(L11C16)2][BF4]2 in MeCN-D3 was enough to run paramagnetic NMR, 
but for Evans method NMR a MeCN-D3:CDCl3 1:1 mixture had to be used in 
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order to achieve acceptable solubility, as the Evans method NMR run in pure 
MeCN-D3 has failed. A paramagnetic NMR of [Fe(L11C18)2][BF4]2 was also 
measured in CDCl3 and in this case no paramagnetically shifted peaks were 
observed. 
 
Fig. 3.53. Paramagnetic NMR of [Fe(L11C16)2][BF4]2, measured in MeCN-
D3, typical for [Fe(L11Cx)2][BF4]2 series 
The [Fe(L13Cx)2][BF4]2 iron complexes were all measured in MeCN-D3, and 
all their spectra looked almost the same (Fig. 3.54). Two unexpected extra 
peaks were observed at ca 66.19 and 63.23 ppm for the spectra measured 
in MeCN-D3, so the iron complexes were re-measured in a 1:1 MeCN-
D3:CDCl3 mixture, which resulted in spectra with no additional peaks. These 
also all looked almost identical (Fig. 3.55), except for [Fe(L13C12)2][BF4]2, 
whose paramagnetically shifted peaks were about 1-2 ppm  shifted upfield, 
comparing to the other [Fe(L13Cx)2][BF4]2  iron complexes (Fig. 3.56). This 
difference cannot be corrected by referencing a different peak as a solvent, 
as each peak is shifted differently. Measurements in pure CDCl3 were also 
done for the [Fe(L13C12)2][BF4]2, [Fe(L13C14)2][BF4]2, and [Fe(L13C18)2] 
[BF4]2, and in each case no paramagnetically shifted peaks were observed. 
 
Fig. 3.54. Paramagnetic 1H NMR of [Fe(L13C16)2][BF4]2, measured in 
MeCN-D3, typical for [Fe(L11Cx)2][BF4]2 series 
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Fig. 3.55 Paramagnetic 1H NMR of [Fe(L13C16)2][BF4]2, measured in 
MeCN-D3:CDCl3 1:1 mixture, typical for [Fe(L13Cx)2][BF4]2 series 
 
Fig. 3.56. Paramagnetic 1H NMR of [Fe(L13C12)2][BF4]2, measured in 
MeCN-D3:CDCl3 1:1 mixture 
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3.11  Conclusions 
Two series of 2,6-bis(pyrazol-1-yl)pyridine-4-carboxylate esters with six, 
twelve, fourteen, sixteen and eighteen carbon chains were obtained, along 
with some intermediate ligands3. As the long alkyl chain ligands are 
nonpolar, a non-typical solvent system was used to obtain their iron 
complexes: a DCE-acetone mixture as a solvent, with pentane as an 
antisolvent. Despite their being hard to crystallize as single crystals, three 
crystal structures were collected for the iron complexes of 4-(alkyl)phenyl 
carboxylates [Fe(L13Cx)2][BF4]2, and one for the iron complex of alkyl 
carboxylate [Fe(L11C6)2][BF4]2·2H2O. Crystal structures were also obtained 
for some intermediate and long alkyl chain ligands. 
In solution, judging by Evans method NMR4,5, both series of iron complexes 
shown typical gradual spin-crossover, similar to the iron complexes of non-
long-alkyl-chain 2,6-bis(pyrazol-1-yl)pyridine-4-carboxylate esters from 
Chapter 2,6 with T1/2 at ca 290 K. The paramagnetic NMR spectra were 
almost identical for [Fe(L11Cx)2][BF4]2 iron complexes, and 
[Fe(L13Cx)2][BF4]2 iron complexes, showing four paramagnetically shifted 
peaks, which means that at 300K a significant fraction of these samples is 
HS. Based on these data it may be concluded, that the presence of long 
alkyl chains doesn’t affect SCO in solution significantly for bpp esters. 
In the solid state all the [Fe(L11Cx)2][BF4]2 iron complexes began switching 
to HS above 340oC, sometimes with a small hysteresis. [Fe(L13Cx)2][BF4]2 
remained LS below the instrument’s upper limit of 350 K, except for 
[Fe(L13C12)2][BF4]2, which shown gradual switching above 225 K. This SCO 
behaviour is similar to the iron complexes from the Chapter 2, and to other 
previously reported [Fe(bpp)2]2+ derivatives with carboxy substituents on the 
pyridine ring.7,8,9 The results of the distortion parameter analysis from the 
available crystal structures corresponded to the SQUID results. Heating 
[Fe(L11C18)2][BF4]2 and [Fe(L13C16)2][BF4]2·1.6H2O to 170oC caused 
annealing, with part of the sample becoming trapped in HS. The annealing 
effect was observed by powder diffraction and DSC, which revealed that 
annealing happens between 100oC and 170oC.  The observed annealing 
may be explained by change in conformation of the long alkyl chains upon 
heating, which then freeze back in more disordered orientations, causing the 
changes to be irreversible. This behaviour is common for organic soft 
materials, and it is similar to a glass transition.10,11  
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The [Fe(L11Cx)2][BF4]2 series was isostructural by powder diffraction, while 
[Fe(L13Cx)2][BF4]2 showed different structures and magnetic behaviour. On 
the DSC graphs SCO peaks, and sometimes lattice solvent loss peaks, were 
observed for the iron complexes, and only the melting peaks for the ligands. 
[Fe(L11C16)2][BF4]2 shown an unexpected doubling of the SCO peak on the 
cooling cycle. The TGAs showed decomposition after 200oC for L11Cx, 
300oC for L13Cx, and 250oC, with small mass loss for escaping lattice 
solvent where applicable, for all the iron complexes in this chapter. All the 
[Fe(L13Cx)2][BF4]2 iron complexes except [Fe(L13C12)2][BF4]2 had water as 
lattice solvent, while all the [Fe(L11Cx)2][BF4]2 iron complexes, except 
[Fe(L13C6)2][BF4]2·H2O and [Fe(L13C12)2][BF4]2, had no lattice solvent. The 
lattice water can escape at around 340 K.12,13,14,15 Each of the iron 
complexes in this chapter was heated from room temperature to 170oC, and 
their photographs were taken every 20oC, which showed no mesophase 
formation or melting for any of them, only the colour change from red to 
orange due to spin crossover. Loss of crystallinity and changes in spin 
behaviour on heating, which is not related to melting or mesophase 
formation, has been reported previously.16-22 
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Chapter 4 
Pyrazole-substituted bis(pyrazol-1-yl)pyridine derivatives 
with long alkyl chains, and their iron(II) complexes 
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4.1 Introduction 
In this chapter 1,4-bis[2,6-di(1H-pyrazole-1’-yl)pyridine derivatives with long 
alkyl chains at the 4-pyrazolyl position were obtained and studied, along with 
their iron(II) complexes. During these syntheses some intermediate ligands 
were obtained, and their iron(II) complexes with no long alkyl chains were 
also prepared and studied in cases when they were new (Fig. 4.1). 
 
Fig. 4.1 The list of ligands discussed in Chapter 4 
4.2 Ligands synthesis 
4.2.1 L14, L15, L16 – the precursors 
In order to obtain pyrazole-substituted bpps with long alkyl chains, first 
mono- and di- iodo bpps substituted at the pyrazolyl C4 position were 
obtained in large quantities, at about a 10 g scale. The di-iodo bpp L15 was 
obtained in a single step (Fig. 4.2). This ligand has been reported before,1 
while the mono-iodo bpp L16 is a novel compound. The L16 synthesis 
required a two-step procedure with a column chromatography separation 
(Fig. 4.3, 4.4). The intermediate ligand in the L16 synthesis, 2-fluoro-6-(1H-
pyrazol-1-yl)pyridine L14 (Fig. 4.3) was used also in other syntheses of 
various asymmetric ligands, which are discussed in Chapter 5. L14, besides 
being analysed by 1H NMR and 13C NMR like all the other ligands, was also 
studied by 19F NMR, and this spectrum had only one peak as expected, at -
68.27 ppm (Fig. 4.6). The 13C NMR of L14 has an interesting feature – the 
peaks  from certain carbon atoms are doubled, due to coupling with the 
fluorine atom (Fig. 4.5). More details on the assignment of these peaks may 
be found in Chapter 6.4.1. 
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Fig. 4.2 Synthesis of 2,6-bis(4-iodo-1H-pyrazol-1-yl)pyridine L15 
 
Fig. 4.3 Synthesis of 2-fluoro-6-(1H-pyrazol-1-yl)pyridine L14 
 
Fig. 4.4 Synthesis of 2-(3-iodo-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine 
L16 
 
Fig. 4.5 13C NMR of L14 2-fluoro-6-(1H-pyrazol-1-yl)pyridine, measured in 
CDCl3, showing doubling of certain peaks 
 
Fig. 4.6 19F NMR of L14 2-fluoro-6-(1H-pyrazol-1-yl)pyridine, measured in 
CDCl3 
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4.2.2 L17CxM – unsaturated mono-substituted ligands 
2-(4-Alk-1-yn-1-yl-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridines L17CxM 
were obtained using a procedure described in the literature2 with some 
modifications (Fig. 4.7). The alkyne was added to the degassed reaction 
mixture, and the reaction was carried out under nitrogen at 80oC with 
monitoring by TLC, and took ca 2 days to complete. The initial purification 
was done by filtering the reaction mixture, as the palladium and copper 
catalysts are mostly insoluble in dioxane. The trimethylamine and excess 
alkyne were mostly removed under vacuum, together with the solvent. 
Recrystallization from boiling MeCN in all four cases afforded clean 
products, with yields 34-48%. 
  
Fig. 4.7 Synthesis of L17CxM ligands 
The 1H NMR spectra of L17CxM ligands looked almost identical, and 
differed only in the integration of the 1.26 ppm peak (Fig. 4.8). The closely 
spaced peaks at 7.75 – 7.92 ppm were assigned using COSY NMR and 
NMRDB4 spectra simulation - see Chapter 6.4 for the assignment of each 
NMR peak. The 13C NMR spectra also looked almost identical, and for each 
ligand in this series there were twelve alkyne chain carbon NMR peaks 
present. For ligands with alkyne chains, longer than twelve carbon atoms, no 
additional peaks were observed. Instead the intensity of the peak at ca 29.8 
ppm would increase, due to overlapping of the signals (Fig. 4.9). The carbon 
NMR peaks were assigned using HMQC NMR, except for the alkyne chain 
C5 – Cn-1 carbons, which were coupling with to same 1.26 ppm 1H NMR 
peak. Therefore these seven signals were reported with no assignment to 
specific carbon atoms. 
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Fig. 4.8 1H NMR of L17C14M with expansion, measured in CDCl3, typical for 
L17CxM ligands series 
 
Fig. 4.9 13C NMR of L17C14M with expansion, measured in CDCl3, typical 
for L17CxM ligand series  
4.2.3 L17CxD – unsaturated di-substituted ligands 
 
Fig. 4.10 Synthesis of L17CxD ligands 
The L17CxD ligands were obtained using the same procedure as mentioned 
above for L17CxM. For the L17C12D synthesis the product mixture had to 
be separated by column chromatography and as well as the target 
disubstituted product at 62% yield, the monosubstituted product was also 
separated. About 9% of the starting material L15 was converted into the 
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monosubstituted product. The starting material L15 was proven to be clean 
by  1H (Fig. 4.11) and 13C NMR, and MS (Chapter 6.4). Therefore there must 
have been a side reaction, which caused substitution of one iodine by 
hydrogen (Fig. 4.10). The orange particles of the palladium catalyst passed 
through the column in small quantities and contaminated both the mono- and 
disubstituted fractions, which were additionally purified by recrystallization 
from ethyl acetate, so clean white crystalline powders of L17C12D and 
L17C12M were obtained. The consecutive ligands, L17C14D and L17C16D, 
were purified by multiple recrystallizations from ethyl acetate, which yielded 
clean white crystalline powders.  
  
Fig. 4.11 1H NMR of L15, measured in CDCl3 
 
Fig. 4.12 1H NMR of L17C14D in CDCl3, typical for L17CxD ligand series 
1H NMR spectra of all three L17CxD ligands looked almost identical, and 
differ in the integration of the 1.27 ppm peak. The alkyne peaks appeared to 
have integrations slightly higher than expected, which is to be expected for 
taller peaks (Fig. 4.12). 13C NMR L17CxD ligands also looked almost 
identical, and similarly as for the L17CxM series, since only twelve alkyne 
chain carbon peaks were observed for each ligand. With the increase of the 
alkyne chain length beyond twelve carbons, the peaks from the additional 
carbon atoms overlapped, so the peak at ca 29.8 ppm would increase for the 
longer-chained ligands (Fig. 4.13).   
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Fig. 4.13 13C NMR of L17C14D with expansion, measured in CDCl3, typical 
for L17CxD ligand series 
4.2.4 L18CxM – saturated mono-substituted ligands 
 
Fig. 4.14 Synthesis of L18CxM ligands 
2-(4-Alk-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridines L18CxM were 
obtained using a procedure described in the literature2 with some 
modifications (Fig. 4.14) - see Chapter 6.4.5 for the full procedure, which 
gave the target products at 91 – 94% yields. 
1H and 13C NMR spectra of all four L18CxM ligands looked identical. 1H 
NMR spectra of L18CxM (Fig. 4.15) looked similar to the unsaturated 
ligands L17CxM (Fig. 4.7). The most affected by the saturation are the PzA 
hydrogen atoms. The signals from the alkyne chain Ak H3, H4, and H5 next 
to the triple bond hydrogens closely match alkyl chain Ak H1, H2, and H3 
signals next to the pyrazole ring. The rest of the peaks were not significantly 
affected by the saturation. Although there is a 8.59 ppm peak present in both 
cases, it belongs to different hydrogen atoms and has different multiplicity 
(Table 4.1). The Py H3 and H5 signals are doublets of doublets, because in 
the aromatic system they couple not only with the immediate neighbour Py 
H4, but also with each other (Table 4.1). Some ambiguity remained about 
the Py H3 and H5 peaks, which were assigned using online NMR simulation 
NMRDB.3 
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Table 4.1 1H NMR spectra comparison for L17C14M and L18C14M   
Assignment L17C14M L18C14M Diff. 
 
PzA H5 8.59 s 8.32 s -0.27 
PzB H5 8.55 dd 8.59 d 0.04 
Py H4 7.92 t 7.90 t -0.02 
Py H3 7.87 dd 7.80 dd -0.07 
Py H5 7.82 dd 7.82 d 0 
PzB H3 7.76 d 7.76 d 0 
PzA H3 7.75 s 7.59 s -0.16 
PzB H4 6.49 dd 6.49 dd 0 
Ak H3/ H1 2.41 t 2.55 t 0.14 
Ak H4/ H2 1.61 p 1.64 p 0.03 
Ak H5/ H3 1.45 p 1.35 h -0.10 
Ak H6-13/4-13 1.26 s 1.26 s 0 
Ak H14 0.87 t 0.88 t 0.01 
 
 
Fig. 4.15 1H NMR of L18C14M with expansions, measured in CDCl3, typical 
for L18CxM series  
13C NMR spectra of L18CxM (Fig. 4.16) were assigned using HMQC NMR. 
The assignments of the pairs of similar 13C environments Py C3, Py C5,  and 
Py C2, Py C6, were done by the best judgement from the mainly overlapping 
HMQC spots, as the NMRDB simulation was unable to distinguish them.  
It can be seen from comparison of 13C NMR spectra of the unsaturated 
L17C14 and saturated L18C14 ligands, that most affected by the saturation 
of the triple bond were the Ak C1, C2, and C3 atoms, and the neighbouring 
PzA C4. The other two carbons on the PzA ring, Pz C3 and C5 were also 
affected, while all the other atoms had almost the same chemical shifts for 
both structures (Table 4.2, and see Table 4.1 for the labelling scheme). On 
the 13C NMR of the L18CxM series there were 10 alkyl chain peaks 
observed for each ligand, and the signals from the carbon atoms above this 
number were overlapping with each other at ca 29.8 ppm, increasing the 
intensity of that peak (Fig. 4.16). For the unsaturated ligands this 
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overlapping of the peaks occured after 12 carbons in the alkyne chain (Fig. 
4.9).  
 
 
Fig. 4.16 13C NMR of L18C14M with expansion, measured in CDCl3, typical 
for L18CxM series 
Table 4.2 13C NMR spectra comparison for L17C14M and L18C14M   
Assign. L17C14M L18C14M Diff. Assign. L17C14M L18C14M Diff. 
Py C2 150.23 150.33 0.1 PzB C4 108.19 108.00 -0.19 
Py C6 149.64 150.14 0.5 Ak C1 106.60 24.4 -82.2 
PzA C3 144.71 142.76 -1.95 Ak C2 92.77 30.83 -61.94 
PzB C3 142.6 142.45 -0.15 PzA C4 70.85 124.64 53.79 
Py C4 141.58 141.39 -0.19 Ak C4 28.88 n/a n/a 
PzA C5 129.11 124.88 -4.23 Ak C3 19.66 29.5 9.84 
PzB C5 127.13 127.17 0.04 Ak C5-13 7 pks 5 pks n/a 
Py C3 109.77 109.15 -0.62 Ak C14 14.25 14.26 0.01 
Py C5 109.48 108.97 -0.51     
4.2.5 L18CxD – saturated di-substituted ligands 
  
Fig. 4.18 Synthesis of L18CxD ligands 
2-(4-Alk-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridines L18CxD were 
obtained using the same procedure as for L18CxM ligands (Fig. 4.18), which 
resulted in lower yields than for L18CxM series: 61 – 91%. The disubstituted 
ligands L18CxD are more lipophilic than the monosubstituted L18CxM, 
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therefore less soluble in ethyl acetate, which makes them harder to separate 
from the catalyst, which resulted in lower yields.  
 
 
Fig. 4.19 1H NMR of L18C14D with expansions, measured in CDCl3, typical 
for L18CxD series  
 
Fig. 4.20 13C NMR of L18C14D with expansion, measured in CDCl3, typical 
for L18CxD series 
As for the previous ligand series, the 1H and 13C NMR spectra of the 
L18CxM ligands look almost identical. The 1H NMR spectrum (Fig. 4.19) 
was assigned using COSY NMR. Each 13C NMR in L18CxD series has 11 
alkyl carbon peaks, and the signals from the rest of the alkyl carbons 
overlapped with each other, which made the peak at ca 29.8 ppm 
significantly taller (Fig. 4.20). 
4.3 Iron(II) complex synthesis 
Iron(II) complexes were obtained for all the ligands in this chapter, except for 
L14, which is not likely to form a SCO iron complex, and L15, whose iron 
complex has already been reported.1 
The iron complex of L16 was obtained by dissolving both the ligand and the 
iron salt in MeCN, and using iPr2O as antisolvent. For the unsaturated 
ligands L17CxM and L17CxD, DCM was used to dissolve the ligand and the 
iron salt, with iPr2O as an antisolvent, and for the saturated ligands L18CxM 
and  L18CxD, dichloroethane DCE was used to dissolve the ligand, acetone 
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was used to dissolve Fe[BF4]2, with pentane as an antisolvent (Fig. 4.21). 
Different solvent systems were used for different series, because the ligands 
had different solubilities, and it was hard to tune the system to give 
crystalline iron complex samples. Most of the obtained iron complexes were 
yellow plate microcrystals, with only [Fe(L16)2][BF4], [Fe(L17C12M)2][BF4]2, 
[Fe(L17C14M)2][BF4]2, [Fe(L17C16D)2][BF4]2 having a darker  brown-orange 
colouration, which suggest that most of the iron complexes of pyrazole-
substituted bpp in solid state are HS at room temperature. 
 
Fig. 4.21 General scheme for obtaining iron(II) complexes in Chapter 4  
4.4 XRD Crystal Structures 
4.4.1 Ligand crystal structures 
Precursor ligands: L14, L15, L16 
Crystal structures were collected for all three precursor ligands: L14, L15, 
and L16. L14 initially was obtained by column chromatography as a clear oil, 
but after ca a week it started crystallization, and soon most of the sample 
transformed into large transparent prismatic crystals. L15 readily formed 
transparent needle crystals, while for L16 it was hard to obtain diffraction-
quality crystals, so its XRD structure was collected at the Diamond Light 
Source. 
L15 forms double layers of ligand molecules, with aromatic rings facing each 
other, and I atoms pointing out, with a quite long distance between iodine 
atoms i.e. between the two bilayers (Fig. 4.23). The molecules in the 
horizontal rows, adjacent to each other from the pyrazole rings, are not in 
one plane, and face each other at ca 90o angle, forming wedge-like grooves. 
The packing of L16 is similar to the one of L15, but the bilayers are located 
closer together, because this time there is only one iodine atom per ligand 
molecule, so they can fit into the empty space, without repulsion by other 
iodine atoms (Fig. 4.24). L14 molecules are arranged in the lattice even 
more closely together than L16. The L14 packing consists of pairs of 
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molecules, facing each other with the pyridyl nitrogen and fluorine atom (Fig. 
4.22), and these two molecules are in two planes, tilted at 67.5o angle 
relative each other. There were no hydrogen bonding or π-π interactions 
found in any of these three structures. 
 
 
Fig. 4.22 Crystal structure of L14 and its packing diagram from the view, 
parallel to the [100] vector 
 
 
Fig. 4.23 Crystal structure of L15 and its packing diagram from the view, 
parallel to the [010] vector 
 
 
Fig. 4.24 Crystal structure of L16 and its packing diagram from the view, 
parallel to the [010] vector 
Unsaturated ligands: L17CxM and L17CxD 
For the unsaturated long alkyne chain ligands the crystal structures were 
collected for L17C12D, L17C16D, and L17C12M. All of them had two 
molecules per unit cell (Z = 2), and one molecule per asymmetric unit (Z’ = 
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1). For all the unsaturated ligands there was no interdigitation between the 
long alkyl chains. 
The crystal structure of L17C16D was obtained from a crystal, which was 
accidently grown during the attempt to obtain a mixed-ligand iron(II) complex 
between L17C16D and bpp. The unit cell parameters of L17C12D and 
L17C16D looked very similar (Table 4.3), and their molecules packed in the 
unit cell in the same way – the long alkyne chains are facing each other, and 
the bpp core of the molecules are stacked parallel to each other in layers 
(Fig. 4.25 and 4.26).  
L17C12M had different unit cell parameters from the previous two structures 
(Table 4.3). The long alkyl chains are facing each other, forming bilayers 
(Fig. 4.27). At the edge of two bilayers, the two stacks of the aromatic part of 
the molecules are located close to each other. They are related by 21 
symmetry, so the unsubstituted pyrazolyl rings can fit into the gaps between 
pyrazolyl rings in the adjacent stacks, which allows them to pack closely 
(Fig. 4.27). 
Table 4.3 Unit cells of L17C12D, L17C16D, L17C12M, L18C12M, and 
L18C14M 
 L17C12D L17C16D L17C12M L18C12M L18C14M 
Temp., K 133.20(17) 150.00(10) 293(2) 293(2) 119.97(15) 
Cr. sys. monoclinic monoclinic monoclinic triclinic triclinic 
Space gr. Pc Pc P21 P-1 P-1 
a, Å 5.45900(10) 5.4576(3) 5.3944(2) 5.38900(10) 5.4094(4) 
b, Å 5.45440(10) 5.4477(3) 5.4384(2) 10.17380(10) 10.1832(6) 
c, Å 52.5779(10) 65.309(2) 35.4153(14) 19.2473(3) 20.8390(15) 
α, ° 90 90 90 95.5290(10) 87.346(5) 
β, ° 91.576(2) 89.041(4) 90.989(3) 94.4050(10) 83.903(6) 
γ, ° 90 90 90 90.2580(10) 89.881(5) 
V, Å3 1564.94(5) 1941.45(16) 1038.82(7) 1047.18(3) 1140.19(14) 
Z 2 2 2 2 2 
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Fig. 4.25 Crystal structure of L17C12D and its packing diagram from the 
view, parallel to the [010] vector 
 
 
Fig. 4.26 Crystal structure of L17C16D and its packing diagram from the 
view, parallel to the [010] vector 
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Fig. 4.27 Crystal structure of L17C12M and its packing diagram from the 
view, parallel to the [010] vector 
Saturated ligands: L18CxM and L18CxD 
 
 
Fig. 4.28 Crystal structure of L18C12M and its packing diagram from the 
view, parallel to the [100] vector 
The saturated ligands were harder to crystallize than the unsaturated ones, 
so the crystal structures were collected only for L18C12M and L18C14M. 
Saturated disubstituted ligands L18CxD were particularly reluctant to form 
crystals. For both L18C12M and L18C14M there were two molecules in the 
unit cell, and one in the asymmetric unit, i.e. Z = 2, and Z’ = 1. All the 
available crystal structures of saturated ligands shown interdigitation of long 
alkyl chains, while all the unsaturated ligands had none. L18C12M and 
L18C14M have similar unit cell parameters (Table 4.3), and similar packing 
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of molecules in their unit cells (Fig. 4.28 and 4.29). Both of them form 
bilayers, where the molecules from the opposite sides of the bilayer are 
related by 21 symmetry. Because there is no rigid triple bond, the saturated 
ligands pack more tightly than the unsaturated ones. As for the saturated 
ligands the aromatic part of the molecule lies at a different angle to the alkyl 
chain, so both the pyrazolyl and pyridyl rings from the adjacent bilayers 
come close together (Fig. 4.28 and 4.29). There were no π-π interactions or 
hydrogen bonding found for the crystal structures of the ligands in this 
chapter, and also none of them contained lattice solvent.  
 
 
Fig. 4.29 Crystal structure of L18C14M and its packing diagram from the 
view, parallel to the [100] vector 
4.4.2 Iron complex crystal structures 
Iron complexes of precursor ligands: 
The iron complexes of L16 were surprisingly hard to crystallize. A crystal 
structure of [Fe(L16)2][BF4]2 was collected, but it was substantially 
disordered and hard to solve, although the main molecular backbone can 
still be seen. A crystal structure with another counterion, 
[Fe(L16)2][ClO4]2·2MeCN was also disordered, but finally solved (Fig. 4.30). 
All analyses were still collected for [Fe(L16)2][BF4]2 for consistency reasons, 
as all the iron complexes in this thesis had this counterion, and 
[Fe(L16)2][BF4]2 is a good quality crystalline sample. For [Fe(L16)2][ClO4]2 
there were found: a weak hydrogen bond between a ClO4- oxygen and  
unsubstituted pyridyl hydrogen H3, and no π-π interactions (Fig. 4.30). It 
crystallized in P-1 space group, with Z = 2 and Z’ = 1. 
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Fig. 4.30 Crystal structure of [Fe(L16)2][ClO4]2·2MeCN, collected at 120K, 
and its packing diagram from the view, parallel to the [010] vector 
Iron complexes of long alkyl chain ligands: Fe(L17C18M)2][BF4]2, 
[Fe(L18C12M)2][BF4]2, [Fe(L18C16M)2][BF4]2, and [Fe(L18C18M)2][BF4]2 
Out of all long alkyl chain iron complexes from this chapter, the iron 
complexes of monosubstituted saturated ligands L18CxM formed diffraction-
quality crystals most readily, so the crystal structures were collected for three 
iron complexes from this series: [Fe(L18C12M)2][BF4]2, 
[Fe(L18C16M)2][BF4]2, and [Fe(L18C18M)2][BF4]2. Thanks to Diamond Light 
Source and efforts of Izar Capel an additional crystal structure was obtained 
from a small single crystal of the unsaturated iron complex 
[Fe(L17C18M)2][BF4]2. All four iron complexes, from which the crystal 
structures were collected, were obtained from DCE/acetone mixtures by slow 
pentane diffusion. All of them were pale-yellow plate crystals, and none of 
them contained lattice solvent. All four of these iron complexes had similar a 
and b unit cell dimensions (Table 4.4). All the saturated long alkyl chain iron 
complexes pack in the same way, forming bilayers of interdigitating long alkyl 
chains of molecules, which are related by 21 crystallographic symmetry. They 
only differ in the distance between the stacks of the aromatic parts of the 
molecules, which increases for longer alkyl chains (Fig. 4.32, 4.33, and 4.34).  
The [Fe(L17C18M)2][BF4]2 molecules pack with interdigitation of the long alkyl 
chains (Fig. 4.31). At the same time, L17C12M, a ligand from the same 
series, had no interdigitation (Fig. 4.27). 
All long alkyl chain iron complexes in this chapter pack with four molecules in 
the unit cell, and two molecules per asymmetric unit: Z = 4 and Z’ = 2 (Table 
4.4). No π-π interactions or hydrogen bonding were found for them. 
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Fig. 4.31 Crystal structure of [Fe(L17C18M)2][BF4]2, and its packing diagram 
from the view, parallel to the [010] vector 
 
 
Fig. 4.32 Crystal structure of [Fe(L18C12M)2][BF4]2, and its packing diagram 
from the view, parallel to the [010] vector 
  
Fig. 4.33 Crystal structure of [Fe(L18C16M)2][BF4]2, collected at 120K, and 
its packing diagram from the view, parallel to the [010] vector 
 
 
Fig. 4.34 Crystal structure of [Fe(L18C18M)2][BF4]2, and its packing diagram 
from the view, parallel to the [010] vector 
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Table 4.4 Unit cells of [Fe(L17C18M)2][BF4]2, [Fe(L18C12M)2][BF4]2, 
[Fe(L18C16M)2][BF4]2, and [Fe(L18C18M)2][BF4]2 
 [Fe(L17 
C18M)2] 
[BF4]2 
[Fe(L18 
C12M)2] 
[BF4]2 
[Fe(L18C16M)2][BF4]2 
[Fe(L18 
C18M)2] 
[BF4]2 
Temp., K 293(2) 293(2) 119.99(16) 150.00(10) 293(2) 
Cr. sys. triclinic triclinic triclinic triclinic triclinic 
Space gr. P-1 P-1 P-1 P-1 P-1 
a, Å 10.6801(2) 10.8827(4) 10.8707(15) 10.9510(14) 10.9192(5) 
b, Å 15.2720(2) 15.2657(5) 15.1781(18) 15.0831(18) 15.1344(5) 
c, Å 36.8778(5) 30.1249(11) 34.644(4) 34.713(4) 36.7856(17) 
α, ° 95.9150(10) 97.199(3) 83.813(10) 83.845(10) 84.117(4) 
β, ° 98.8820(10) 97.707(3) 82.791(10) 82.536(10) 85.034(4) 
γ, ° 89.9730(10) 90.123(3) 89.934(10) 89.868(10) 89.951(3) 
V, Å3 5910.51(16) 4919.5(3) 5637.5(12) 5652.1(12) 6024.1(4) 
Z 4 4 4 4 4 
4.5 Distortion parameters 
For all the long alkyl chain iron complexes in this chapter the volumes of the 
FeNx octahedra around the iron atoms were around 12.40 Å3, which means 
that they were HS at the temperatures at which the crystal structures were 
collected (Table 4.5). It was unnecessary to calculate all the distortion 
parameters for them, except for [Fe(L18C16M)2][BF4]2, which seemed to 
have some fraction of LS molecules in the sample (Table 4.5). Comparison 
of the distortion parameters for [Fe(L18C16M)2][BF4]2 shows that there are 
more LS molecules in that sample at 150K than at 120K, which is unusual 
(Table 4.6). This effect may be explained by thermal spin trapping4. 
Crystallographic data of the di-iodo bpp iron complex [Fe(L16)2][BF4]2 were 
of a  poor quality, but even for an incompletely solved structure it can be 
seen that the molecule is HS at 120 K (Table 4.5). The other structure of the 
same iron complex, but with a different counterion, [Fe(L16)2][ClO4]2 
·2MeCN, was also disordered, but solved. The molecule was modelled with 
two intertwining molecule positions: A and B (Fig. 4.30). The distortion 
parameters from the two positions of the molecule were quite different from 
each other (Table 4.5), which may be explained by the disorder in the 
structure, but the average octahedral volume of 9.443 Å3, along with the rest 
of the distortion parameters, clearly indicates that the structure is LS. The 
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typical values of the distortion parameters for the high and low spin states 
can be found in the Table 2.5. 
Table 4.5 Distortion parameters of the iron complexes from Chapter 4 
 
T, K 
 
Voct, Å3 
    
[Fe(L18C12M)2][BF4]2 293 
Fe1 12.440 
12.394 
Fe2 12.348 
[Fe(L18C16M)2][BF4]2 
120 
Fe1 11.938 
11.807 
Fe2 11.675 
150 
Fe1 11.494 
11.477 
Fe2 11.459 
[Fe(L18C18M)2][BF4]2 293 
Fe1 12.145 
12.144 
Fe2 12.142 
[Fe(L17C18M)2][BF4]2 293 
Fe1 12.447 
12.454 
Fe2 12.460 
[Fe(L16)2][ClO4]2·2MeCN 120.15 
Fe1A 9.191 
9.433 
Fe1B 9.674 
[Fe(L16)2][BF4]2 133.07 
Fe1 12.128 
11.770 Fe2 11.811 
Fe3 11.370 
Table 4.6 The distortion parameters for the crystal structures of 
[Fe(L16)2][ClO4]2·2MeCN and [Fe(L18C16M)2][BF4]2 
 
[Fe(L16)2][ClO4]2 
·2MeCN 
[Fe(L18C16M)2][BF4]2 
120.15 K 120 K 150 K 
mol. A mol. B mol. 1 mol. 2 mol. 1 mol. 2 
Fe1-N1A 1.971(14) 1.953(14) 2.108(17) 2.130(20) 2.104(14) 2.112(18) 
Fe1-N1B 1.949(15) 1.988(14) 2.205(15) 2.158(15) 2.139(14) 2.112(14) 
Fe1-N3A 1.875(14) 1.915(14) 2.078(14) 2.076(17) 2.058(10) 2.069(12) 
Fe1-N3B 1.899(14) 1.872(13) 2.084(14) 2.140(16) 2.040(10) 2.068(10) 
Fe1-N5A 1.866(17) 2.051(18) 2.214(19) 2.158(14) 2.119(10) 2.112(11) 
Fe1-N5B 1.996(15) 1.94(14) 2.213(13) 2.129(15) 2.145(11) 2.11(8) 
Average 1.93 1.95 2.15 2.13 2.10 2.10 
α 79.5(6) 80.93(6) 73.4(7) 73.7(7) 75.2(4) 75.0(4) 
Σ 93.0(6) 78.2(6) 159.3(7) 157.8(7) 137.0(4) 137.4(4) 
Φ 179.0(6) 176.3(6) 171.9(6) 171.4(8) 173.8(4) 174.3(4) 
θ 92.336 90.881 87.273 86.120 88.194 87.907 
Voct, Å3 9.191 9.674 11.938 11.675 11.494 11.459 
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4.6 Powder diffraction 
4.6.1 Ligands 
The powder patterns of the unsaturated monosubstituted ligands L17CxM 
roughly match each other. The pattern simulated from the only crystal 
structure collected from this series, L17C12M, also matches the collected 
powder pattern for that compound (Fig. 4.34). Similarly, for the unsaturated 
disubstituted ligands L17CxD, the powder patterns of a different alkyl chain 
length were similar to each other. The patterns, simulated from the crystal 
structures of L17C12D and L17C16D, matched the obtained powder 
patterns, but in the both cases the peaks at 15-30o were much more intense 
on the simulated powder patterns (Fig. 4.35). That probably arises from 
preferred orientation of the polycrystalline sample. 
The saturated monosubstituted ligands L18CxM can be divided into two 
groups of ligands with similar powder patterns: L18C12M and L18C14M in 
the first group, and L18C16M and L18C18M in the second (Fig. 4.36). The 
simulated powder patterns of L18C12M and L18C14M matched the 
obtained ones. The powder patterns  of saturated disubstituted ligands 
L18CxD were quite similar and with intense peaks, which shows good 
crystallinity of the samples (Fig. 4.37).   
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Fig. 4.34 Collected and simulated powder patterns of L17CxM ligands 
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Fig. 4.35 Collected and simulated powder patterns of L17CxD ligands 
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Fig. 4.36 Collected and simulated powder patterns of L18CxM ligands 
5 10 15 20 25 30 35 40
0
50
100
150
200
250
300
L18C16D
L18C14D
C
ou
nt
s
2 Theta (deg.)
 L14C12D
 L14C14D
 L14C16D
L18C12D
  
Fig. 4.37 Collected and simulated powder patterns of L18CxD ligands 
4.6.2 Iron complexes 
[Fe(L18C16M)2][BF4]2 and [Fe(L18C16M)2][ClO4]2 both had broad and noisy 
peaks on their powder patterns, which means they were not very crystalline 
(Fig. 4.38). The crystal structures of these two salts were disordered, and 
the powder patterns simulated from them poorly match the obtained powder 
patterns (Fig. 4.38). From these results it may be concluded that asymmetric 
ligands with heavy atoms like iodine and their iron complexes are reluctant 
to form crystals. 
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Fig. 4.38 Powder pattern of [Fe(L18C16M)2][BF4]2 
All of the [Fe(L17CxM)2][BF4]2 iron complexes had two intense peaks near 
10o, but otherwise their powder patterns looked different, which suggests 
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that they had different unit cells. There was only one crystal structure 
collected for this series, [Fe(L17C18M)2][BF4]2. For this structure the 
collected powder pattern matches the simulated one, but it also has an extra 
peak at ca 7o, which could mean that the sample had some additional 
crystalline phase in the sample. Out of this series, the powder pattern of 
[Fe(L17C16M)2][BF4]2 looks the most crystalline, and has the most intense 
peaks. The collected powder pattern of [Fe(L17C16M)2][BF4]2 also matches 
the simulated one for Fe(L17C18M)2][BF4]2 very well. The peaks on both 
patterns appear in roughly the same places, but with different intensities 
(Fig. 4.39), which suggests that this two iron complexes must have very 
similar unit cells, with Fe(L17C16M)2][BF4]2 being phase pure, and 
Fe(L17C18M)2][BF4]2 having some other crystalline phase in the sample. 
Fe(L17C12M)2][BF4]2  and Fe(L17C14M)2][BF4]2  both have a broad peak at 
ca 18o, which must mean that both samples had some amorphous powder 
fraction (Fig. 4.39). 
The powder patterns of [Fe(L17C12D)2][BF4]2 and [Fe(L17C14D)2][BF4]2 
look similar, while the powder pattern of [Fe(L17C16D)2][BF4]2 had some 
features different from them (Fig. 4.40). There are no simulated powder 
patterns for this series to compare the measured patterns to. 
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Fig. 4.39 Collected and simulated powder patterns of [Fe(L17CxM)2][BF4]2 
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Fig. 4.40 Powder patterns of [Fe(L17CxD)2][BF4]2 
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The most crystal structures among all the iron complexes series in this 
chapter were collected for [Fe(L18CxM)2][BF4]2 series, and all the simulated 
patterns matched the measured ones (Fig. 4.41). The powder pattern of 
[Fe(L18C18M)2][BF4]2 and [Fe(L17C18M)2][BF4]2 resemble each other, 
which should be expected, as they have similar unit cell parameters (Table 
4.4). The powder patterns of [Fe(L18C14M)2][BF4]2, [Fe(L18C16M)2][BF4]2, 
and [Fe(L18C18M)2][BF4]2 look very similar, while the pattern of 
[Fe(L18C12M)2][BF4]2 stands out of this group (Fig. 4.41), which is also true 
for its unit cell parameters (Table. 4.4). 
The powder patterns of the [Fe(L18CxD)2][BF4]2 iron complexes are all 
similar to each other, and show a good crystallinity of the samples (Fig. 
4.42). 
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 Fig. 4.41 Powder patterns of [Fe(L18CxM)2][BF4]2: fresh samples, annealed 
at 170oC, and simulated from crystal structures 
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Fig. 4.42 Powder patterns of [Fe(L18CxD)2][BF4]2 
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4.7 SQUID 
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Fig. 4.43 SQUID magnetic susceptibility measurements for [Fe(L17C12M)2] 
[BF4], [Fe(L17C14M)2][BF4], and[Fe(L17C16M)2][BF4] 
Variable temperature magnetic susceptibilities were measured only for a 
cooling cycle for [Fe(L17C12M)2][BF4]2, [Fe(L17C14M)2][BF4]2, and 
[Fe(L17C16M)2][BF4]2 (Fig. 4.43), and for three cycles for [Fe(L17C18M)2] 
[BF4]2 (Fig. 4.44).  [Fe(L17C12M)2][BF4]2 shows rather gradual SCO with HS 
traping of some fraction of the sample. As the χT didn’t go below ca 1.2 
cm3·K/mol, it may be concluded that about 1.2/3.5 = 34% of the sample are 
trapped in HS. Therefore the T1/2 shall be reached not at 1.75 cm3·K/mol, but 
at 1.2 + (3.5 - 1.2)/2 = 2.35 cm3·K/mol, which corresponds with 253 K. 
[Fe(L17C14M)2][BF4]2 had much more gradual switching (Fig. 4.43), which 
makes it hard to determine its T1/2 precisely, but from the DSC data for this 
compound it can be seen that its T1/2 lays at about 24oC or 297 K (Fig. 4.65). 
[Fe(L17C16M)2][BF4]2 remained HS  between 300 K and 50 K (Fig. 4.43). 
[Fe(L17C18M)2][BF4]2 shown a very gradual SCO with HS trapping of about 
50% of the sample, as the SQUID curve reached only the χT of 1.75 
cm3·K/mol before undergoing zero-field splitting (Fig. 4.44). The T1/2 
therefore should be measured at 1.75 + (3.5 - 1.75) = 2.625 cm3·K/mol, 
which corresponds with 239 K or -34oC, which is too low to see the 
corresponding peak on the DSC (Fig. 4.66). 
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Fig. 4.44 SQUID magnetic susceptibility measurements for 
[Fe(L17C18M)2][BF4]2 
[Fe(L17CxD)2][BF4]2  
All the iron complexes from the [Fe(L17CxD)2][BF4]2 series shown similar 
magnetic behaviour, and remained HS from 300 K to 50 K with a decrease 
in the magnetic moment below 50 K due to zero-field splitting (Fig. 4.45). 
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Fig. 4.45 SQUID magnetic susceptibility measurements for 
[Fe(L17CxD)2][BF4]2 iron complexes series 
- 144 - 
[Fe(L18CxM)2][BF4]2  
Out of all iron complexes in this chapter, the [Fe(L18CxM)2][BF4]2 series 
formed crystallographic quality crystals the most readily. Besides this, they 
show some interesting SCO behaviour, so each compound from this series 
was measured over a few thermal cycles in the SQUID. All of them shown 
quite abrupt SCO with T1/2 at ca 155-160 K. Because of this, unlike the other 
iron complexes, [Fe(L18CxM)2][BF4]2 series were also studied by Evans 
method NMR (Section 4.10) and variable temperature images (Section 4.9). 
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Fig. 4.46 SQUID magnetic susceptibility measurements for 
[Fe(L18C12M)2][BF4]2 
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Fig. 4.47 SQUID magnetic susceptibility measurements for 
[Fe(L18C14M)2][BF4]2 and [Fe(L18C18M)2][BF4]2 
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Fig. 4.48 SQUID magnetic susceptibility measurements for 
[Fe(L17C16M)2][BF4]2  
[Fe(L18C12M)2][BF4]2 shows incomplete and gradual SCO between 125 and 
250 K, with only ca 2/7 of the sample completely switching, as the magnetic 
moment only reached 2.5 cm3·K/mol (Fig. 4.46). There was no significant 
hysteresis observed, but heating the sample to 370 K or 97oC seems to 
decrease the number of the molecules trapped in the HS state, as the 
magnetic moment on both the cooling and the heating cycles 3 and 4, 
decreased by 0.15 cm3·K/mol over the 50-150 K temperature range. 
[Fe(L18C14M)2][BF4]2 shown similar magnetic behaviour: it also underwent 
an incomplete SCO only until ca 2.5 cm3·K/mol, but this time the switching 
was more abrupt, from ca 127 to ca 170 K, and with about 16o hysteresis 
(Fig. 4.47).  [Fe(L18C16M)2][BF4]2 reached the magnetic moment of only 
1.75 cm3·K/mol upon cooling, which indicates that about half of the sample 
was trapped in the HS state. However upon heating, during cycle 2, the 
system gained enough energy to switch to the LS state, the magnetic 
moment started to decrease with the increase of the temperature, which is 
unusual (Fig. 4.48). This effect was also observed by comparing the crystal 
structures of [Fe(L18C16M)2][BF4]2, collected at 120 K and 150 K, which 
shown that the distortion parameters indicate the crystal being more LS at 
150 K than at 120 K (Table 4.6). After the first two cycles the HS trapping 
became less pronounced, so cycle 3 reached lower χT values than cycle 1 
(Fig. 4.48). [Fe(L18C18M)2][BF4]2 shows quite abrupt SCO from ca 138 K to 
ca 208 K, with about 14 K hysteresis. SCO for this sample seems to occur in 
two steps: from 138 to ca 208 K, and from ca 350 K and beyond 370 K (Fig. 
4.47). The amount of the sample trapped in HS for this compound was 
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around 1/7 of the sample, as the magnetic moment didn’t go below 0.5 
cm3·K/mol, except for below 25 K due to zero-field splitting (Fig. 4.47). 
Heating the sample to 370 K seems to have no effect on the amount of the 
HS-trapped fraction, as each cycle followed the same path. Thus, all of the 
[Fe(L18CxM)2][BF4]2 iron complexes shown similar magnetic behaviour, with 
HS trapping to a different extent.  
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Fig. 4.49 SQUID magnetic susceptibility measurements for 
[Fe(L18C12D)2][BF4]2  
0 50 100 150 200 250 300 350
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
xT
, 
cm
3
·K
/m
o
l
T, K
 Heating 1
 Cooling 1
 Heating 2
 Cooling 2
 Heating 3
 Cooling 3
 Heating 4
 Cooling 4
[Fe(L18C14D)
2
][BF
4
]
2
1
2
3
4
5
6
7
8
 
Fig. 4.50 SQUID magnetic susceptibility measurements for 
[Fe(L18C14D)2][BF4]2 
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The [Fe(L18CxD)2][BF4]2 series shows interesting SCO magnetic behaviour, 
and some of these iron complexes were measured over multiple cycles in 
the SQUID. After the first two cycles, and heating to 370 K, 
[Fe(L18C12D)2][BF4]2 underwent some irreversible changes which increased 
the HS fraction of the sample (Fig. 4.49), and as at 5 K its magnetic moment 
is 0.5 cm3·K/mol, the HS trapped fraction must be ca 1/7 of the whole 
sample. Additional heating and cooling cycles didn’t cause any further HS 
trapping, as cycle 3, 5, and 6 follow the same path. There was a small 
hysteresis observed after annealing, between cycles 4 and 5 (Fig. 4.49). 
This was not the case for [Fe(L18C14D)2][BF4]2, which shows a change in 
the HS trapped fraction after each heating to 370 K (Fig. 4.50). 
[Fe(L18C16D)2][BF4]2 behaved differently from the previous two samples, 
and remained LS from 0 K to 248 K, after which it started a gradual SCO, 
which reached only the magnetic moment of 0.50 cm3·K/mol at 350 K (Fig. 
4.51), which means that its T1/2 must lie far beyond the upper limit of the 
SQUID. 
[Fe(L16)2][BF4]2  
[Fe(L16)2][BF4]2 shows a gradual SCO upon cooling (Fig. 4.51), which 
corresponds with its crystal structure data, which indicated that at 133 K the 
sample is mostly HS (Table 4.5). 
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Fig. 4.51 SQUID magnetic susceptibility measurements for 
[Fe(L18C16D)2][BF4]2 and [Fe(L16)2][BF4]2 
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4.8 DSC 
4.8.1 Ligands 
L17CxM 
The DSC of each L17CxM ligand had a peak that corresponds with its 
melting point. However, L17C16M and L17C18M had a small additional 
peak at about 20oC below the main peak on the first cooling cycle (Fig. 
4.52). The DSC of L17C14M didn’t have that additional peak, and also was 
missing the peak on the cooling cycle, likely because it lays below 0oC. 
L17C12M shows different DSC behaviour from the other members of this 
series, as it underwent some irreversible changes after heating to 175oC, so 
there were no peaks observed after the first heating cycle (Fig. 4.53). 
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Fig. 4.52 DSC of L17C16M, typical for the L17CxM series 
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Fig. 4.53 DSC of L17C12M, different from the other L17CxM ligands 
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The ligands from the L17CxM series show the onset of mass loss by TGA 
above about 220oC, with the ligands with longer alkyl chains being more 
temperature resistant (Fig. 4.54). 
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Fig. 4.54 TGA of the L17CxM ligand series 
L17CxD 
The DSCs of L17C14D and L17C16D all show the same features: a peak on 
each cycle, that corresponds with the ligand’s melting point, and with the 
doubling of this peak on the cooling cycle, with 0.8-1.3o difference between 
the two parts of the peak (Fig. 4.55). L17C12D had the same features, but 
with no doubling of the peak on the cooling cycle. All the ligands from the 
L17CxD series start decomposing by TGA above 270oC, with the longer 
alkyl chain ligands being more thermally stable (Fig. 4.56). 
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Fig. 4.55 DSC of the L17C14D, typical for the L17CxD series 
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Fig. 4.56 TGA of the L17CxD ligand series 
L18CxM 
The DSCs of L18C14M, L18C16M, and L18C18M looked similar, showing 
only the one peak on each cycle, which corresponds with the melting point 
(Fig. 4.58), while L18C12M had some additional peak on the cooling cycle 
(Fig. 4.57). 
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Fig. 4.57 DSC of L18C12M, different from the other L18CxM ligands 
In the TGA all the L18CxM  ligands behaved similarly, with mass loss 
starting above ca 220oC, with a direct correlation between the alkyl chain 
length and the thermal stability of the ligand (Fig. 4.59). 
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Fig. 4.58 DSC of L18C14M, typical for the L18CxM series 
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Fig. 4.59 TGA of the L18CxM ligand series 
L18CxD 
The DSCs of L18CxD ligands looked similar, showing a peak for melting of 
the ligand on each cycle. L18C12D and L18C14D also had a doubling of the 
peak on the cooling cycle, with a 9o and 3o difference between the peak 
parts correspondingly (Fig. 4.60), while L18C16D didn’t have this feature on 
the cooling cycle. Also, there was annealing observed for L18C12D, when 
the sample was heated to 250oC, so after the first heating cycle there were 
no significant peaks observed on the consecutive cycles (Fig. 4.61), which is 
consistent with its TGA (Fig. 4.62). Please note, that for the L11Cx and 
L13Cx ligands from the previous chapter there was no annealing observed 
for the ligands upon heating to 250oC, only for the iron complexes (Chapter 
3.7.1). The TGA shows that the L18C12D ligands are stable below about 
170oC. Interestingly, unlike for the other ligand series, this one doesn’t have 
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a direct correlation between the alkyl chain length and the ligand thermal 
stability (Fig. 4.62). 
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Fig. 4.60 DSC of L18C12D, typical for the L18CxD series 
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Fig. 4.61 DSC of L18C12D showing annealing upon heating above 250oC 
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Fig. 4.62 TGA of the L18CxD ligand series 
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4.8.2 Iron complexes 
[Fe(L17CxM)2][BF4]2 
For [Fe(L17C12M)2][BF4]2 there were no DSC peaks observed on any of the 
cycles (Fig. 4.63), which may be explained by the fact that its T1/2 lays at ca 
253 K or -20oC, below the measurement range of this DSC (Fig. 4.43). 
[Fe(L17C14M)2][BF4]2 had one peak on each DSC cycle, which probably 
comes from the SCO transition (Fig. 4.43), which therefore had T1/2 at ca 
24oC or 297oC (Fig. 4.64).  
The DSC of Fe(L17C16M)2][BF4]2 also had one peak on each cycle (Fig. 
4.65), but at ca 60 K higher than [Fe(L17C14M)2][BF4]2. On the other hand, 
the DSC peaks of [Fe(L17C18M)2][BF4]2 appeared just at ca 2 K higher than 
for [Fe(L17C16M)2][BF4]2. It appears that [Fe(L17C16M)2][BF4]2 and 
[Fe(L17C18M)2][BF4]2 are different from the previous two iron complexes. 
This suggestion can be also supported with the fact that they are 
isostructural (Table 4.43). As the SQUID graphs show that 
[Fe(L17C16M)2][BF4]2 remained HS (Fig. 4.43), and [Fe(L17C16M)2][BF4]2 
underwent an extremely gradual SCO with T1/2 at ca -34oC (Fig. 4.44), the 
observed DSC couldn’t come from a SCO transition. These peaks also did 
not come from melting of the corresponding ligands, which may be formed 
during decomposition of the iron complexes, as these ligands melt at 
significantly lower temperatures (Chapter 6.4.2). The observed DSC peaks 
may be caused by phase transitions. 
On the TGA of [Fe(L17C18M)2][BF4]2 there is some mass loss between 70oC 
and 120oC, which reached 5.2% at 120oC (Fig. 4.67), which corresponds 
with the loss of 3.5 water molecules per mole of the iron complex, and on its 
DSC there is a small broad peak at ca 120oC on the first heating cycle (Fig. 
4.66), which probably comes from the same process. In the crystal structure 
of  [Fe(L17C18M)2][BF4]2, however, there was no lattice solvent present (Fig. 
4.31). As the TGA was collected soon after obtaining the iron complex, and 
the crystal structure was collected about 3 months later, the lattice solvent 
might just evaporate from the sample. The rest of the compounds from this 
series were not losing any mass until about 225oC (Fig. 4.67). 
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Fig. 4.63 DSC of [Fe(L17C12M)2][BF4]2 
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Fig. 4.64 DSC of [Fe(L17C14M)2][BF4]2 
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Fig. 4.65 DSC of [Fe(L17C16M)2][BF4]2 
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Fig. 4.66 DSC of [Fe(L17C18M)2][BF4]2 
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Fig. 4.67 TGA of the [Fe(L17CxM)2][BF4]2 series iron complexes 
[Fe(L17CxD)2][BF4]2 
Unlike other iron complexes series, [Fe(L17CxD)2][BF4]2 turned noticeably 
paler with time. The strongest effect was observed for [Fe(L17C12D)2][BF4]2. 
All three [Fe(L17CxD)2][BF4]2 iron complexes had one peak on each DSC 
cycle: [Fe(L17C12D)2][BF4]2 at ca 81oC or 354 K (Fig. 4.68), [Fe(L17C14D)2] 
[BF4]2 at ca 62oC or 335 K (Fig. 4.69), and [Fe(L17C16D)2][BF4]2 at ca 95oC 
or 368 K. However, on their SQUID magnetic measurements there were no 
sign of SCO transition, as all three iron complexes remained HS (Fig. 4.45), 
therefore the observed DSC peaks must come from some other transitions. 
These iron complexes decompose at 265-280oC without melting, therefore 
the DSC peaks cannot come from melting of the sample. The melting points 
of the corresponding ligands: 80.9oC for L17C12D, 84.9–85.5oC for 
L17C14D, and 89.4–89.7oC for L17C16D (Chapter 6.4), closely match the 
observed peaks for these iron complexes, except [Fe(L17C14D)2][BF4]2.  
- 156 - 
Therefore, it may be concluded, that most likely all the [Fe(L17CxD)2][BF4]2 
iron complexes were HS, but were not stable, and partially decomposed 
when stored. The formed ligand fraction gave a peak on the DSC. On the 
powder patterns of these iron complexes (Fig. 4.40) there are no significant 
peaks that may correspond with the ligands (Fig. 4.35), therefore the formed 
ligand fraction is either non-crystalline or very small. 
 [Fe(L17C12D)2][BF4]2 and [Fe(L17C14D)2] ][BF4]2 also had some additional 
very broad and small peaks solely on the first heating cycle, which must 
come from escaping lattice solvent. This mass loss is also visible on the 
TGA for these two iron complexes (Fig. 4.71), and [Fe(L17C16D)2][BF4]2 
didn’t have any signs of the lattice solvent loss neither on TGA, nor on DSC 
(Fig. 4.70). 
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Fig. 4.68 DSC of [Fe(L17C12D)2][BF4]2 
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Fig. 4.69 DSC of [Fe(L17C14D)2][BF4]2 
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Fig. 4.70 DSC of [Fe(L17C16D)2][BF4]2 
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Fig. 4.71 TGA of the [Fe(L17CxD)2][BF4]2 series iron complexes 
[Fe(L18CxM)2][BF4]2 
Each iron complex from the [Fe(L18CxM)2][BF4]2 series has one peak on 
each DSC cycle (Fig. 4.72, 4.73, 4.74, and 4.75). These peaks cannot come 
from the SCO transition, as all the [Fe(L18CxM)2][BF4]2 iron complexes 
underwent SCO with T1/2 at ca 160 K or -113oC (Fig. 4.47), which is below 
the minimum measurement temperature for the DSC machine of  ca 200 K. 
They are also very different from the melting points of the corresponding 
ligands (Fig. 4.58), and therefore these DSC peaks must come from some 
other phase transitions, which take place for all the iron complexes in this 
series, and the temperature of this transition is higher for longer alkyl chain 
compounds. This transition might be a rearrangement of the long alkyl 
chains’ position. [Fe(L17C16M)2][BF4]2 and [Fe(L17C18M)2][BF4]2 are both 
isostructural with [Fe(L18C18M)2][BF4]2, and unlike other iron complexes in 
the [Fe(L17CxM)2][BF4]2 series, they also show the DSC peaks, which may 
be explained by the long alkyl chains rearrangement (Fig. 4.65 and 4.66). 
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Fig. 4.72 DSC of [Fe(L18C12M)2][BF4]2 
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Fig. 4.73 DSC of [Fe(L18C14M)2][BF4]2 
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Fig. 4.74 DSC of [Fe(L18C16M)2][BF4]2 
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Fig. 4.75 DSC of [Fe(L18C18M)2][BF4]2 
On the first heating cycle DSCs of [Fe(L18C12M)2][BF4]2 (Fig. 4.72) and 
[Fe(L18C14M)2][BF4]2 (Fig. 4.73) there are some broad and small peaks 
present, which must come from loss of the lattice solvent, probably water. 
For the same compounds there is some mass loss observed by TGA at ca 
70oC and 94oC (Fig. 4.76).  
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Fig. 4.76 TGA of the [Fe(L18CxM)2][BF4]2 series iron complexes 
 [Fe(L18CxD)2][BF4]2 
All three  [Fe(L18CxD)2][BF4]2 iron complexes had similar behaviour on 
DSC: one peak on the first heating cycle, and two peaks on the consecutive 
cycles (Fig. 4.77, 4.78, and 4.79). This behaviour correspond with their 
SQUID curves. [Fe(L18C12D)2][BF4]2 had one peak at 75oC (Fig. 4.77) or 
348 K, which corresponds with its first two SQUID cycles (Fig. 4.49). Then 
some irreversible changes happen to the sample upon heating above 370 K, 
and the sample starts switching at a lower temperature on all the 
- 160 - 
consecutive cycles. The same effect can be observed for 
[Fe(L18C14D)2][BF4]2 (Fig. 4.78), which corresponds with the changes on its 
SQUID graph (Fig. 4.50). The same process can be observed on the DSC of 
[Fe(L18C16D)2][BF4]2, but its first peak appears at a higher temperature, ca 
84oC or 357, which is above the measured SQUID values for this sample. 
However, it can be seen that the sample was starting switching to HS above 
ca 275 K, which shall reach its T1/2 at ca 357 K (Fig. 4.51), judging by its 
DSC (Fig. 4.79) and comparing it to the other iron complexes from this 
series. In the TGA [Fe(L18C12D)2][BF4]2 lost ca 1.5% mass at 67oC, which 
must come from a lattice solvent, [Fe(L18C14D)2][BF4]2 lost ca 3% at 195oC, 
and finally all the iron complexes from this series started rapid mass loss at 
ca 275oC (Fig. 4.80). 
0 20 40 60 80 100 120 140 160
-2
-1
0
1
74.9°C
65.2°C50.6°C
41.0°C 48.7°C
H
e
a
t 
F
lo
w
 (
W
/g
)
Temperature (°C)
 Heating 1
 Cooling 1
 Heating 2
[Fe(L18C12D)
2
][BF
4
]
2
 
Fig. 4.77 DSC of [Fe(L18C12D)2][BF4]2 
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Fig. 4.78 DSC of [Fe(L18C14D)2][BF4]2 
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Fig. 4.79 DSC of [Fe(L18C16D)2][BF4]2 
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Fig. 4.80 TGA of the [Fe(L18CxD)2][BF4]2 series iron complexes 
4.9 VT images 
The iron complexes from the [Fe(L18CxM)2][BF4]2 series were heated in an 
oil bath, and photographed every 20 K, in order to track any phase changes, 
or a colour change, associated with spin crossover (Fig. 4.81). The same 
experiment was performed for different iron complexes in Chapter 3.8. All 
the [Fe(L18CxM)2][BF4]2 iron complexes were pale-yellow plate crystals, and 
didn’t show any phase change all the way up to 170oC. Heating to 170oC 
also didn’t do any noticeable change to their powder patterns (Fig. 4.40). 
Between 140o and 160oC them all changed their colour to a darker yellow 
(Fig. 4.81).  
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Fig. 4.81 The photographs of [(L18CxM)2Fe][BF4]2 iron complexes, as they are being heated from room temperature to 170oC 
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4.10 Evans method NMR 
Evans method NMR was measured only for one iron complex from this 
chapter, for [Fe(L18C16M)2][BF4]2. As expected, in solution it undergoes 
gradual SCO (Fig. 4.82). Unlike the pyridyl-substituted iron complexes from 
the previous chapters, which were undergoing SCO in solution with T1/2 at ca 
300K (Fig. 2.35 and 3.46), the pyrazolyl-substituted iron complex shows 
SCO with T1/2 at 255K. Therefore it may be expected that the pyrazolyl-
substituted bpp iron(II) complexes should also be HS at lower temperatures 
in solid state, as observed. 
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Fig. 4.82 Evans method NMR of [Fe(L18C16M)2][BF4]2, measured in 
Me2CO-D6 
4.11 Paramagnetic NMR 
Iron complexes of precursor ligands 
As expected, the paramagnetic NMR spectra of [Fe(L16)2][BF4]2 and 
[Fe(L16)2][ClO4]2 looked identical (Fig. 4.83). The samples had poor 
solubility in chloroform, so the analyses were run in MeCN-D3. The 
paramagnetically shifted peaks were assigned, and the full peaks 
assignment can be found in Chapter 6.4.6. The peaks that are closest to the 
iron centre are most shifted downfield. The least shifted peak, which is 
located at 1.1 ppm, belongs to the Py H4 hydrogen, the 57.8 ppm peak 
comes from the PzB H4 hydrogen, and the remaining peaks are assigned in 
pairs of barely distinguishable signals (Chapter 6.4.6). This peaks 
assignment is consistent with the results, obtained for similar bpp iron(II) 
complexes by L. Kershaw Cook in his PhD thesis5.  
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Fig. 4.83 Paramagnetic NMR of [Fe(L16)2][BF4]2, with extension, identical to 
[Fe(L16)2][ClO4]2, collected in MeCN-D3 
[Fe(L17CxM)2][BF4]2 
The iron complexes from the [Fe(L17CxM)2][BF4]2 series were both soluble 
in MeCN-D3 and in CDCl3, and the spectra collected in each of the solvents 
looked very similar, with slightly different chemical shift values. All the 
paramagnetic NMR spectra within the series looked identical (Fig. 4.84), and 
very similar to the spectrum of the asymmetric iron complex [Fe(L16)2][BF4]2 
(Fig. 4.83). 
 
 
Fig. 4.84 Paramagnetic NMR of [Fe(L17C12M)2][BF4]2, with extension, 
typical for [Fe(L17CxM)2][BF4]2 series, collected in CDCl3 
[Fe(L17CxD)2][BF4]2 
The [Fe(L17CxD)2][BF4]2 iron complexes had poor solubility in MeCN-D3, 
and their spectra were measured in a CDCl3/MeCN-D3 1:1 mixture. All of 
them looked identical, having four paramagnetically shifted peaks with 
2:2:2:1 ratio (Fig. 4.85). 
- 165 - 
  
Fig. 4.85 Paramagnetic NMR of [Fe(L17C14D)2][BF4]2, with extension, 
typical for [Fe(L17CxD)2][BF4]2 series, collected in CDCl3/MeCN-D3 1:1 
mixture 
[Fe(L18CxM)2][BF4]2 
The paramagnetic NMR spectra of [Fe(L18CxM)2][BF4]2 series were 
measured in MeCN-D3. All the paramagnetic spectra for this series looked 
identical, except for two weak additional peaks at 66.48 and 41.05 ppm, 
which integrated at 0.1-0.2 hydrogens, and were observed for 
[Fe(L18C14M)2][BF4]2 and [Fe(L18C16M)2][BF4]2, but not for 
[Fe(L18C12M)2][BF4]2. The paramagnetic spectra of this series and other 
asymmetric iron complexes resemble each other (Fig. 4.84), however for 
[Fe(L18CxM)2][BF4]2 some peaks were overlapping (Fig. 4.86). For example, 
the peak at 54.6 ppm must come from overlapping of either PzA H3 or PzB 
H3 signal with the PzB H4 peak. The [Fe(L18CxM)2][BF4]2 paramagnetic 
NMR spectra were assigned by comparing them with the spectra of the other 
asymmetric iron complexes, and by taking into account the peaks’ 
integrations (Chapter 6.4.6).  
 
Fig. 4.86 Paramagnetic NMR of [Fe(L18C14M)2][BF4]2, with extension, 
typical for [Fe(L18CxM)2][BF4]2 series, collected in MeCN-D3  
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[Fe(L18CxD)2][BF4]2 
The paramagnetic NMR spectra of the [Fe(L18CxD)2][BF4]2 iron complexes 
were recorded in MeCN-D3. As for the [Fe(L17CxD)2][BF4]2 series, there 
were four paramagnetically shifted peaks, which integrate at a 2:2:2:1 ratio 
(Fig. 4.87), but are slightly less shifted downfield. 
 
Fig. 4.87 Paramagnetic NMR of [Fe(L18C14D)2][BF4]2, with extension, 
typical for [Fe(L18CxD)2][BF4]2 series, collected in MeCN-D3  
4.12 Conclusions 
Pyrazolyl-substituted 1,4-bis[2,6-di(1H-pyrazole-1’-yl)pyridine derivative 
ligands and their iron complexes were obtained, analysed, and discussed in 
this chapter. All the long alkyl chain ligands, and some of the precursor 
ligands with no long alkyl chains from this chapter are novel. There were four 
series of long alkyl chain ligands obtained: unsaturated monosubstituted 
L17CxM, unsaturated disubstituted L17CxD, saturated monosubstituted 
L18CxM, and saturated disubstituted L18CxD, with the twelve, fourteen, and 
sixteen-carbon chain ligands in each. The eighteen-carbon chain ligands 
were obtained only for L17CxM and L18CxM series. 
All these iron complexes either remained HS from 300 to 3 K, or shown spin 
crossover. The [Fe(L17CxM)2][BF4]2 iron complexes with twelve and 
fourteen carbon chains underwent a gradual SCO, with a part of the sample 
remaining HS, and this spin transition produced a peak on DSC. The iron 
complexes with sixteen and eighteen carbon chains were isostructural, and 
both underwent some possible phase transitions, which can be seen on their 
DSCs. The [Fe(L17CxD)2][BF4]2 series iron complexes all remained HS, 
while the [Fe(L18CxM)2][BF4]2 iron complexes underwent an interesting 
SCO switching with HS trapping and release, which caused unusual 
decrease of the magnetic moment upon heating. The same effect was 
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observed by Weihermüller for long alkyl chain ester iron complexes,6 and to 
a smaller extent by Lee for iron complexes with branched long alkyl chains.7 
This effect was more pronounced for longer alkyl chain iron complexes, and 
was also tracked by XRD. The [Fe(L18CxD)2][BF4]2 series underwent SCO 
with annealing after the first heating cycle on SQUID, and the same effect 
was also observed on its DSC.  
Besides being isostructural, [Fe(L17C18M)2][BF4]2 and [Fe(L18C18M)2] 
[BF4]2 undergo different SCO: [Fe(L17C18M)2][BF4]2 switches very 
gradually, with T1/2 at ca 360 K, and no hysteresis, while 
[Fe(L18C18M)2][BF4]2 undergoes a two-step SCO, with a quite abrupt SCO 
with T1/2 at ca 150 K, and an about 14 K hysteresis, along with a more 
gradual second step switching at ca 350 K.  
In the solution the pyrazolyl-substituted iron complexes shown switching at 
ca 225 K, which is around 65 K lower than the pyridyl-substituted iron 
complexes from Chapters 2 and 3.  
  
- 168 - 
List of References 
1. Pritchard, R.; Lazar, H.; Barrett, S.A.; Kilner, C.A.; Asthana, S.; 
Carbonera, C.; Letard, J.F. and Halcrow, M.A. Thermal and light-
induced spin-transitions in iron(II) complexes of 2,6-bis(4-
halopyrazolyl)pyridines: the influence of polymorphism on a spin-
crossover compound. Dalton Trans. 2009, 6656-6666. 
2. Basak, S.; Hui, P.; Boodida, S. and Chandrasekar, R. Micropatterning 
of Metallopolymers: Syntheses of Back-to-Back Coupled Octylated 
2,6-Bis(pyrazolyl)pyridine Ligands and Their Solution-Processable 
Coordination Polymers. J. Org. Chem. 2012, 77, 3620-3626. 
3. NMR prediction tool online. http://www.nmrdb.org 
4. Buchen, T.; Gütlich, P.;  Sugiyarto, K. H.;  Goodwin, and H. A. High‐
Spin → Low‐Spin Relaxation in [Fe(bpp)2](CF3SO3)2·H2O after 
LIESST and Thermal Spin‐State Trapping—Dynamics of Spin 
Transition Versus Dynamics of Phase Transition. Chem. Eur. J. 1996, 
2, 1134-1138. 
5. Kershaw Cook, L. J. Crystal Engineering and Bifunctionality in Spin-
Crossover Materials. PhD Thesis. University of Leeds. 2014. 
6. Weihermüller, J.; Schlamp, S.; Dittrich, B. and Weber, B. Kinetic 
Trapping Effects in Amphiphilic Iron(II) Spin Crossover Compounds. 
Inorg. Chem. 2019, 58, 1278−1289. 
7. Lee, Y.H.; Ohta, A.; Yamamoto, Y.; Komatsu, Y.; Kato, K.; Shimizu, 
T.; Shinoda, H.; Hayami, S. Iron(II) spin crossover complexes with 
branched long alkyl chain. Polyhedron. 2011, 30, 3001-3005. 
- 169 - 
Chapter 5 
Asymmetric ligands with no long alkyl chains, and their 
iron(II) complexes  
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5.1  Introduction 
In the previous chapter a series of asymmetric ligands was obtained: L16, 
L17CxM, and L18CxM (Fig. 4.1). Some of their Fe2+ complexes showed 
interesting SCO behaviour, such as thermal HS trapping, and many of them 
also readily formed crystallography quality single crystals. Therefore, 
research in this direction was continued, and attempts were made to obtain 
other asymmetric ligands. The starting material for these syntheses, 2-
fluoro-6-(1H-pyrazol-1-yl)pyridine L14, was obtained  previously in Chapter 
4.2.1 (Fig. 4.3). 
 Chandrasekar et al. obtained three novel asymmetric ligands and their Fe2+ 
complexes, one of which shown an interesting SCO behaviour, with the 
switching around room temperature and a ca 10 K hysteresis (Fig. 5.1).1 
Similar novel asymmetric ligands with pyrazole and triazole rings were 
obtained and discussed in this chapter (Fig. 5.2). 
 
 
Fig. 5.1 An asymmetric ligand, obtained by Chandrasekar et al., and its 
magnetic behaviour1 
 
 
Fig. 5.2  List of the ligands discussed in Chapter 5 
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5.2 Ligand synthesis 
L19 – Two isomers of 2-(1H-pyrazol-1-yl)-6-(1H -1,2,3-triazol-1-
yl)pyridine 
The reaction between 2-fluoro-6-(1H-pyrazol-1-yl)pyridine L14 and 1H-1,2,3-
triazole yielded the asymmetric ligand L19 2-(1H-pyrazol-1-yl)-6-(1H -1,2,3-
triazol-1-yl)pyridine. The synthesis was carried out at 80oC while being 
monitored by TLC, and was complete after 3 days (Fig. 5.3).  
  
Fig. 5.3 Synthesis of 2-(1H-pyrazol-1-yl)-6-(1H -1,2,3-triazol-1-yl)pyridine 
L19 
 
 
Fig. 5.4 1H NMR of the L19-A and L19-B 1:1 mixture with expansion, 
measured in CDCl3. The peaks from L19-B are highlighted in yellow. 
Unfortunately 1H-1,2,3-triazole can undergo isomerization to 2H-1,2,3-
triazole, which gave a 1:1 mixture of two isomers L19-A and L19-B (Fig. 
5.3). In some cases it is possible to avoid isomerisation. For example, Wang 
et al. shown that it is possible to achieve selective N-2-substitution using 
direct alkylation without protecting groups for some 1,2,3-triazole derivatives, 
such as 4,5-dibromo-, 4-bromo-5-trimethylsilyl-, and 4,5-bis(trimethylsilyl)-
1,2,3-triazoles.2 Some of these derivatives might be used in the future work 
instead of plain 1,2,3-triazole, to avoid obtaining a mixture of isomers. 
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 The 1H NMR peaks were assigned to each isomer using COSY 2D NMR 
and NMRDB.3 The mass spectrum showed only a presence of [L+H+] and 
[L+Na+] ions, as the two isomers have the same molecular weight. This 
proves that a 1:1 mixture of two pure isomers was obtained. 
It was not possible to separate the two isomers by chromatography, as their 
rf values were very similar in hexane/ethylacetate or in DCM/MeOH eluent 
mixtures. Two recrystallizations from hexane/CHCl3 1:1 mixture afforded a 
1:3 mixture of isomers, with isomer A being more soluble. The process was 
monitored by integration of the 1H NMR peaks. The further recrystallizations 
were not performed. 
L20 – 2-(1H-pyrazol-1-yl)-6-(1H -1,2,4-triazol-1-yl)pyridine 
To avoid obtaining a mixture of isomers another, similar ligand was 
synthesized, but this time with 1H-1,2,4-triazole (Fig. 5.5) as there is no 
difference between the two isomers 1H-1,2,4-triazole and 2H-1,2,4-triazole.  
 
Fig. 5.5 Synthesis of 2-(1H-pyrazol-1-yl)-6-(1H -1,2,4-triazol-1-yl)pyridine 
L20 
 
Fig. 5.6 1H NMR of L20 with expansion, measured in CDCl3 
 
Fig. 5.7 13C NMR of L20 with expansion, measured in CDCl3 
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The 1H NMR of L20 contained hexane, CHCl3, and TMS peaks. The Pz H3 
peak at 7.78 ppm almost overlaps with the Py H4 signal at 7.77 ppm (Fig. 
5.6). The peaks were assigned based on their multiplicity, chemical shifts, 
COSY NMR, and a NMRDB simulation.3 The ambiguity between the Py C3 
and C5, and Py C2 and C6 peaks in the 13C NMR spectrum of L20 (Fig. 5.7) 
was resolved using an NMRDB3 simulation. 
L21 – 2-(4-(Ethylcarboxy)pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine 
Although a similar symmetrical ligand, 2,6-di[4-(ethylcarboxy)pyrazol-1-
yl]pyridine, has been reported before by Halcrow et al.,4 the asymmetric bpp 
derivative with (ethylcarboxy)pyrazol-1-yl ligand hasn’t been reported in the 
literature.5 It was obtained using the same procedure as for the other ligands 
from this series (Fig. 5.8). However the yield for L21 was significantly lower, 
ca 53%. This may be because this ligand has a better solubility in hexane, 
so more of it was lost during the purification process. 
 
Fig. 5.8 Synthesis of 2-(4-(ethylcarboxy)pyrazol-1-yl)-6-(1H-pyrazol-1-
yl)pyridine L21 
The 1H NMR peaks were assigned based on their multiplicity and using 
COSY NMR. The three pyridyl peaks have very similar chemical shifts (Fig. 
5.9 - expansion).  
 
Fig. 5.9  1H NMR of L21 with expansion, measured in CDCl3. The pyridine 
ring spiting signals are highlighted with dots for clarity: Py H4 – red, Py H3 – 
blue, Py H5 – black. 
The Py H4 peak (see Fig. 5.8 for the labelling) couples with two other signals 
and is doublet of doublets at 7.96 ppm. One of its splitting peaks overlaps 
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with the Py H3 signal, which is a doublet at 7.93 ppm. The Py H5 peak is 
also a doublet, at 7.78 ppm. The Py H4 and Py H3 peaks undergo a strong 
roofing towards each other. 
The 13C NMR for L21 (Fig. 5.10) was assigned using HMQC NMR. The 
ambiguities between the Py C2 and C6, and Py C3 and C5 assignments 
were resolved using a NMRDB3 simulation. 
 
Fig. 5.10  13C NMR of L21, measured in CDCl3 
5.3 Iron complex synthesis 
[Fe(L21)2][BF4]2 
[Fe(L21)2][BF4]2 was obtained by a standard procedure for obtaining iron 
complexes, using acetone as a solvent, and diethyl ether as an antisolvent 
(Fig. 5.11). The crystallization from a concentrated solution yielded an oil 
precipitate, while more dilute solutions formed dark-yellow needle crystals 
which, however, were not big enough for crystallographic data collection. 
 
Fig. 5.11 Synthesis of [Fe(L21)2][BF4]2  
[Fe(L20)2][Fe(L20)2(H2O)2][BF4]4·MeNO2·H2O 
The attempts to obtain an iron(II) complex with L20 led to formation of a 
coordination polymer [Fe(L20)2][Fe(L20)2(H2O)2][BF4]4·MeNO2·H2O (Fig. 
5.12). Crystallization from MeCN led to a powder, while using MeNO2 as a 
solvent led to formation of diffraction-quality crystals. Attempts to obtain an 
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iron complex with a NCS- as a counterion, instead of BF4-, were 
unsuccessful. Therefore BF4- as a counterion, MeNO2 as a solvent, and 
iPr2O as an antisolvent was found to be the best system for obtaining iron 
complexes of L20 as single crystals. Formation of the abovementioned 
coordination polymer is reproducible, and was repeated twice. More details 
on its structure can be found in the crystallography section of this chapter. 
 
Fig. 5.12 The structure of the coordination polymer [Fe(L20)2][Fe(L20)2 
(H2O)2][BF4]4·MeNO2·H2O 
5.4 Paramagnetic NMR 
[Fe(L21)2][BF4]2 
Paramagnetic NMR of [Fe(L21)2][BF4]2 was very similar to the one for 
[Fe(L16)2][BF4]2 from the previous chapter (Chapter 4.11). The peak 
assignment can be seen in Chapter 6.5.5. The further the peak is located 
from the iron centre, the less shifted upfield its signal appears, with the least 
shifted Py H4 signal appearing at 1.11 ppm (Fig. 5.13 extension). All the 
paramagnetically shifterd peaks integrate at 1:1 ratio. The ambiguity 
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between some pairs of peaks, such as PzA H3 and PzB H3, hasn’t been 
resolved.  
 
 
Fig. 5.13 Paramagnetic 1H NMR of [Fe(L21)2][BF4]2 with extension, 
measured in MeCN-D3 
5.5 XRD crystal structures and distortion parameters 
Ligands 
Both asymmetric triazole ligands readily crystallized as white needles, and 
their crystal structures were collected (Fig. 5.14 and 5.15). For L19 only a 
crystal structure of one isomer was collected. 
  
Fig. 5.14 Crystal structure of L19, and its packing diagram from the view, 
parallel to the [100] vector 
 
 
Fig. 5.15 Crystal structure of L20, and its packing diagram from the view, 
parallel to the [010] vector 
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The two ligands pack very differently: the L19 molecules in the lattice are 
related by a 4-fold symmetry, while the L20 – by a 2-fold symmetry. They 
have very different unit cell parameters, but similar unit cell volumes (Table 
5.1). 
Table 5.1 Unit cells of L19 and L20 
 L19 L20 
Temperature/K 120.00(13) 150.01(10) 
Crystal system monoclinic monoclinic 
Space group Cc P21/c 
a/Å 4.54380(10) 12.5794(9) 
b/Å 25.9740(7) 3.8549(3) 
c/Å 8.5078(2) 20.4981(14) 
α/° 90 90 
β/° 99.788(3) 103.628(7) 
γ/° 90 90 
Volume/Å3 989.48(4) 966.01(12) 
Z 4 4 
Iron complexes 
[Fe(L20)2][Fe(L20)2(H2O)2][BF4]4·MeNO2·H2O 
The synthesis of coordination polymer [Fe(L20)2][Fe(L20)2(H2O)2][BF4]4 
·MeNO2·H2O is reproducible, and it was repeated twice. The product forms 
clusters of orangy-yellow prismatic crystals. A crystal structure from the first 
batch was collected at 150 K, and then a crystal from the second batch was 
used to obtain a series of complete crystal structure at different 
temperatures. For convenience, these five crystal structures will be referred 
as S1-S5 further in the text (Table 5.2).  
Table 5.2 Solvent content in crystal structures of [Fe(L20)2][Fe(L20)2(H2O)2] 
[BF4]4·MeNO2·nH2O at different temperatures based on crystal structures 
Code Batch Temp. Formula* Solvent content** 
S1 1 150 K C41H41B4F16Fe2N25O5 [Fe1L2][Fe2L2(H2O)2][BF4]4·MeNO2·H2O 
 S2 2 150 K C41H43B4F16Fe2N25O6 [Fe1L2][ Fe2L2(H2O)2][BF4]4·MeNO2·2H2O 
S3 2 200 K C41H43B4F16Fe2N25O6 [Fe1L2][ Fe2L2(H2O)2][BF4]4·MeNO2·2H2O 
S4 2 250 K C41H41B4F16Fe2N25O5 [Fe1L2][ Fe2L2(H2O)2][BF4]4·MeNO2·H2O 
S5 2 290 K C41H41B4F16Fe2N25O5 [Fe1L2][ Fe2L2(H2O)2][BF4]4·MeNO2·H2O 
* The formula is calculated for one segment of the coordination polymer 
chain, which contains two asymmetric units. 
** L = L20 
The formulae in the Table 5.2 were calculated for a segment of the 
coordination polymer chain, spanning two asymmetric units, because that is 
the smallest segment that allows to obtain a whole number of each atom. 
There is some ambiguity for the structures S1, S4 and S5, whether they 
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actually have one less lattice water molecule than the rest of the structures, 
or maybe they just appear to have half occupancy due to distortions in the 
structure.  
 
Fig. 5.16 Asymmetric unit of coordination polymer S2 with labelling 
The coordination polymer forms long parallel strains with a repeating pattern 
of two different iron centres: Fe1, which coordinates to N1, N3, and N5; and 
Fe2, which coordinates to N6A, N6B, and the two water molecules (Fig. 
5.16).  
 
Fig. 5.17 Fragment of the crystal structure of coordination polymer S2, from 
the view parallel to the [010] vector. Counterions and lattice solvents are 
omitted for clarity. 
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Interestingly, the nitrogens on the triazole and pyrazole rings around Fe1 are 
pointing towards the iron centre, which is typical for iron complexes, while 
the ligand molecules around the Fe2 centre resemble the triazole and 
pyrazole rings orientation of a free ligand (Fig. 5.17).  
In the crystal structures S1-S5 there are two water molecules coordinating to 
the Fe2 centre, and also one lattice solvent water molecule for S1 and S5, or 
two lattice solvent water molecules for S2-S4. All of structures S1-S5 contain 
one MeNO2 molecule per a segment (Table 5.2). 
All five crystal structures had similar unit cell parameters (Table 5.3). The 
structures S1 and S2 were collected at the same temperature, but still have 
slightly different cell parameters, which may suggest that they do have 
different number of lattice water molecules. 
Table 5.3 Unit cell parameters for five crystal structures of [Fe(L20)2] 
[Fe(L20)2(H2O)2][BF4]4·MeNO2 ·nH2O  
 
S1 S2 S3 S4 S5 
Temperature/K 150.00(10) 150.01(10) 200.00(10) 250.00(10) 289.97(10) 
Crystal system monoclinic monoclinic monoclinic monoclinic monoclinic 
Space group C2/c C2/c C2/c C2/c C2/c 
a/Å 19.9215(6) 19.9190(3) 19.9235(5) 19.9189(6) 19.9010(5) 
b/Å 15.5378(5) 15.3887(3) 15.5984(5) 15.8603(5) 15.9683(4) 
c/Å 18.5292(6) 18.5909(3) 18.6533(4) 18.7484(4) 18.7282(6) 
α/° 90 90 90 90 90 
β/° 101.222(3) 101.152(2) 100.512(2) 99.528(2) 99.397(3) 
γ/° 90 90 90 90 90 
Volume/Å3 5625.8(3) 5591.02(17) 5699.7(3) 5841.3(3) 5871.7(3) 
Z 4 4 4 4 4 
Z' 0.5 0.5 0.5 0.5 0.5 
Distortion Parameters 
Based on the octahedral volume it may be concluded that the Fe2 centre 
remains HS from 150 to 290 K, while the Fe1 centre undergoes SCO (Table 
5.4). For bpp iron(II) complexes Voct is ca 12.4 Å3 for HS, and ca 9.4 Å3 for LS 
(Chapter 2.51). Based on these values the percentage of HS molecules in 
the crystal at a given temperature was estimated (Table 5.4). Slightly 
different octahedral volume values should be expected for the Fe2 centre, 
which coordinates to two water molecules.  
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Table 5.4 Comparison of the octahedral volumes around the two iron 
centres in crystal structures of [Fe(L20)2][Fe(L20)2 (H2O)2][BF4]4·MeNO2·H2O 
at different temperatures  
  S1 S2 S3 S4 S5 
Temperature, K 150 150 200 250 290 
Voct Fe1, Å3 10.102 9.764 10.502 12.109 12.236 
Voct Fe2, Å3 13.624 13.695 13.707 13.656 13.653 
% HS Fe1 23 12 37 90 95 
The same structures were analysed regarding the Fe-N bond lengths. The 
average Fe-N for Fe1 centre is expected to be 2.177 Å in HS, and 1.941 Å in 
LS (Chapter 2.51). Based on these expected values the percentage of HS 
molecules in the crystal at each temperature was estimated (Table 5.5), 
which roughly matched the results obtained by comparing the octahedral 
volumes (Fig. 5.4). 
Table 5.5 Comparison of Fe-N bond lengths for the two iron centres in 
crystal structures of [Fe(L20)2][Fe(L20)2(H2O)2][BF4]4·MeNO2·H2O at 
different temperatures  
 
S1 S2 S3 S4 S5 
T, K 150 150 200 250 290 
Fe1-N1, Å 2.001(5) 1.977(3) 2.022(4) 2.137(6) 2.148(4) 
Fe1-N3, Å 1.922(5) 1.900(3) 1.964(4) 2.077(6) 2.100(4) 
Fe1-N5, Å 2.042(4) 2.016(3) 2.086(3) 2.200(4) 2.208(3) 
Average 1.99 1.96 2.02 2.14 2.15 
%HS 20 10 35 83 89 
Fe2-O1, Å 2.096(4) 2.104(2) 2.102(3) 2.111(4) 2.112(3) 
Fe2-N6A, Å 2.231(4) 2.234(2) 2.227(3) 2.218(4) 2.212(3) 
Fe2-N6C, Å 2.186(4) 2.187(2) 2.191(3) 2.192(4) 2.193(3) 
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5.6 SQUID 
[Fe(L20)2][Fe(L20)2(H2O)2][BF4]4·MeNO2·H2O 
SQUID magnetic measurements for [Fe(L20)2][Fe(L20)2(H2O)2][BF4]4 
·MeNO2·H2O obtained from the first batch, the one that yielded the crystal 
structure S1,  shown a gradual switching between 50 and 300 K, with no 
hysteresis (Fig. 5.18). 
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Fig. 5.18 SQUID magnetic susceptibility measurements a the coordination 
polymer [Fe(L20)2][Fe(L20)2(H2O)2][BF4]4·MeNO2·H2O 
The magnetic moment changes from ca 3 to 4.9 cm3·K/mol, which may 
mean that ca 15% of molecules in the Fe2 centre were switching from HS to 
LS below 150K, but remained fully HS above ca 150 K; and the Fe1 centre 
didn’t switch fully to HS at 300 K. Based on the distortion parameters, at 290 
K the Fe2 is expected to be fully HS, and the  Fe1 shall be ca 90% HS, 
which would predict a magnetic moment of ca 6.65 cm3·K/mol, and not 4.9 
cm3·K/mol, as was measured by SQUID. This difference may be explained 
by the fact that the variable temperature crystal structures were collected 
only for the crystal from the second batch S2-5, while the magnetic moment 
was measured for the sample from the first batch S1. Although the crystal 
structures produced from the two batches were very similar (Table 5.3), the 
sample from the first batch seems to have one less lattice water molecule 
(Table 5.2). This difference should be investigated further, and the magnetic 
moment of [Fe(L20)2][Fe(L20)2(H2O)2][BF4]4·MeNO2·2H2O should also be 
measured, if possible. In the literature there examples of a dramatic of the 
lattice solvent content on the magnetic properties. For example, Gutlich et al. 
obtained a series of SCO compounds (Fig. 5.19),4 one of which was 
crystallized with three, half, and no lattice water molecules. Each of these 
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has a different magnetic behaviour (Fig. 5.19), where Ak = C16H33 and A- = 
Cl- in all three cases, and S = 1 for A, S = 2 for B, and S = 0 for C. 
 
 
Fig. 5.19 Some of the long alkyl chain SCO complexes, obtained by Gutlich 
et al. and their magnetic behaviour4 
[Fe(L21)2][BF4]2 
A symmetrical compound, 2,6-di(4-(ethylcarboxy)pyrazol-1-yl)-pyridine, 
similar to this asymmetric iron complex [Fe(L21)2][BF4]2, has been reported 
by Halcrow et al. It stayed LS in solid state, and switched quite abruptly in 
solution, with T1/2 at ca 250 K.6 The asymmetric iron complex 
[Fe(L21)2][BF4]2 hasn’t been reported before.5 It shown a gradual SCO, with 
T1/2 at ca 200 K. Around 36% of the sample was trapped in HS, as the 
magnetic moment didn’t go below ca 1.25 cm3·K/mol (Fig. 5.20). Therefore 
the T1/2 should match the xT = (3.5 - 1.25) + 1.25 = 2.375 cm3·K/mol, which 
gives a temperature of ca 200 K. 
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Fig. 5.20 SQUID magnetic susceptibility measurements for [Fe(L21)2][BF4]2 
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5.7 Conclusions 
In this chapter a series of novel asymmetric ligands, based on 2,6-
bis(pyrazol-1-yl)pyridine was obtained and analysed. One of these ligands 
formed an interesting coordination polymer with Fe2+, and five variable 
temperature crystal structures were collected for it. There are two different 
metal centres in the repeating chain of the coordination polymer, one of 
which undergoes a gradual SCO, and the other remains HS between 150 
and 290 K. This structure can be crystallized with either one or two lattice 
water molecules, the effect of which should be further investigated, as there 
are examples in the literature of strong effect of the solvent content on the 
magnetic behaviour.6,7,8 Certain 1,2,3-triazole derivatives can be selectively 
N-alkylated.3 It would be good to test the synthesis of asymmetric ligands 
with them in the future work. 
  
- 184 - 
List of References 
1. Chandrasekhar, N. and Chandrasekar, R. “Super hybrid tridentate 
ligands”: 4-substituted-2-(1-butyl-1H-1,2,3- triazol-4-yl)-6-(1H-pyrazol-1-
yl)pyridine ligands coordinated to Fe(II) ions display above room 
temperature spin transitions. Dalton Trans. 2010, 39, 9872-9878. 
2. Wang, X.-J.; Zhang, L.; Krishnamurthy, D.; Senanayake, C.H. and Wipf, 
P. General Solution to the Synthesis of N-2-Substituted 1,2,3-Triazoles. 
Org. Lett. 2010, 12, 20, 4632-4635. 
3. NMR prediction tool online. http://www.nmrdb.org 
4. Pritchard, R.; Kilner, C.A.; Barrett, S.A. and Halcrow, M.A. Two new 4’ 
,4’’-disubstituted dipyrazolylpyridine derivatives, and the structures and 
spin states of their iron(II) complexes. Inorganica Chim. Acta. 2009, 362, 
4365-4371. 
5. SciFinder. Chemical Abstracts Service, accessed 24/4/2019 
https://scifinder.cas.org 
6. Seredyuk, M.; Gaspar, A. B.; Ksenofontov, V.; Galyametdinov, Y.; Kusz, 
J.  and Gutlich, P. Does the Solid-Liquid Crystal Phase Transition Provoke 
the Spin-State Change in Spin-Crossover Metallomesogens? J. Am. 
Chem. Soc. 2008, 130, 1431-1439. 
7. Fumanal, M.; Jiménez-Grávalos, F.; Ribas-Arino, J. and Vela, S. Lattice-
Solvent Effects in the Spin-Crossover of an Fe(II)-Based Material. The 
Key Role of Intermolecular Interactions between Solvent Molecules. Inorg. 
Chem. 2017, 56(8), 4474-4483. 
8. Galadzhun, I.; Kulmaczewski, R.; Halcrow, M.A. Five 2,6-Di(pyrazol-1-
yl)pyridine-4-carboxylate Esters, and the Spin States of their Iron(II) 
Complexes. Magnetochem. 2019, 5, 9. 
 
 
 
 
 
 
- 185 - 
Chapter 6 
Experimental 
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6.1 General Experimental Considerations 
6.1.1 Analytical techniques used 
1H NMR spectra were recorded at either 300 MHz on a Bruker 
Ultrashield™ 300, or at 400 MHz on a Bruker Ascend™ 400 spectrometer at 
298 ± 5 K. Evans method NMR spectra were measured at different 
temperatures. Chemical shifts were quoted in parts per million with respect 
to TMS or the respective residual solvent resonances. 13C NMR spectra 
were run using broadband proton decoupling operating at 75 MHz, on a 
Bruker Ascend™ 400 spectrometer, and quoted in parts per million with 
respect to the respective solvent resonances.  
Electrospray ionization mass spectrometry (ESI-MS) spectra were 
obtained on an Agilent Technologies 1200 Series spectrometer, and on 
Thermo Scientific Dionex UltiMate 3000, from MeCN feed solution. CHN 
microanalyses were carried out either by the University of Leeds School of 
Chemistry microanalytical service, or by the London Metropolitan University 
microanalytical service. Infrared spectra IR were recorded on Bruker Alpha 
Platinum - ATR infrared spectrophotometer, with the samples being 
analyzed as solids. Melting points MP were determined on an Electrothermal 
digital melting point apparatus and on Stuart SMP3 Melting Point Apparatus.  
Differential Scanning Calorimetry DSC was run on a TA instruments 
DSC Q20 analyser, and thermogravimetric analyses TGA using a TA 
instruments TGA Q50 analyser. Both were performed at the University of 
Leeds by Dr A. Kazlauciunas. Magnetic susceptibility measurements were 
performed by either Dr R. Kulmaczewski, Namrah Shahid, or Izar Capel 
Berdiell, on a Quantum Design VSM SQUID magnetometer at the School of 
Physics, University of Leeds, in an applied field of 5 000 G. A diamagnetic 
correction for each sample was estimated from Pascal’s constants, and 
diamagnetic correction for the sample holder was measured and subtracted 
from the raw data. Variable temperature magnetic susceptibility 
measurements in solution were performed via Evans method NMR by Mr S. 
Barrett or Dr M. Howard on a Bruker DRX 500 spectrometer at a frequency 
of 500.13 MHz. And a correction for the solvent density change with 
temperature were applied to the obtained data. 
Powder X-ray Diffraction patterns PXRD were obtained at room 
temperature on a Bruker D2 Phaser machine, equipped with a LynxEye 
detector, using Long Fine Focused Cu radiation (λ = 0.71073). Data workup 
was done using Bruker DIFFRAC Suite software. X-ray Diffraction Crystal 
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Structures XRD were collected either on (i) Agilent SuperNova 
diffractometer, equipped with an Atlas CCD detector, and connected to an 
Oxford Cryosystem low temperature device, using monochromated Cu Kα 
radiation (λ = 1.54184 Å) or Mo Kα radiation (λ = 0.7107 Å), or (ii) Rigaku 
Saturn 724 CCD diffractometer, using synchrotron radiation from Diamond 
Light Source (λ = 0.6889 Å) and an Oxford Cryostream low temperature 
device. 
Unless otherwise stated, the analyses were performed by the author of 
this thesis. 
6.1.2 Obtaining single crystals for XRD crystallography 
Single crystals for XRD crystallography in this thesis were obtained either by 
slow evaporation of the solvent from an NMR tube with a cap on – this 
technique has worked predominantly for ligands, – or by slow antislovent 
diffusion, which works best for metal complexes. The obtained datasets 
were solved using the computer program ShelXT.1 
Growing single crystals by slow evaporation in an NMR tube 
In order to grow single crystals in an NMR tube, ca 10 mg of the compound 
were dissolved in appropriate solvent, usually deuterated chloroform, and 
left for about a month with the cap on in a quiet place with no vibrations. 
Growing single crystals by slow antisolvent diffusion 
To grow single crystals by slow antisolvent diffusion, the metal complex was 
dissolved in an appropriate solvent, which was usually MeCN for compounds 
with no long alkyl chains, and a DCE/acetone mixture for compounds with 
long alkyl chains. This was placed in a vial, which is then inserted in a bigger 
jar containming some antisolvent, and sealed inside the jar using parafilm. 
The level of antisolvent should be lower than the solution level inside the 
vial. The more volatile antisolvent slowly diffuses from the jar into the vial, 
causing the metal complex to crystallize from the solution. Diisopropyl ether 
was found to be a good antisolvent for compounds with no long alkyl chains, 
while pentane showed good results for compounds with long alkyl chains. 
6.1.3 Simulating powder patterns 
The simulated powder patterns were obtained from the .res files of solved 
crystal structures, using the X-Seed software.2  
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6.1.4 Calculating T1/2 from SQUID magnetic susceptibility graphs 
T1/2 is the temperature at which half of the molecules in the sample are HS, 
and half of them are LS. If spin crossover has a hysteresis, there going to be 
two T1/2 values – one upon heating, and another one upon cooling. Many 
samples in this thesis have T1/2 at the temperatures above the maximum 
temperature for the SQUID machine, which is ca 350K. In that case it is 
impossible to determine T1/2 from the SQUID curve, which shows  only 
beginning of the spin crossover. If switching on the SQUID curve goes from 
0 to at least 1.75 cm3K/mol, the T1/2 may be determined by plotting the 
derivative of the SQUID curve, dχT vs T. The maximum on this graph would 
be T1/2.  
In cases when a complete switching can be observed on the SQUID graph, 
T1/2 may be determined directly by recording the temperature at which χT = 
1.75 cm3K/mol,  or a half of 3.5 cm3K/mol - the magnetic susceptibility of fully 
HS iron(II).  
6.1.5 DSC measurements 
As was mentioned above, DSC analyses were run by Dr A. Kazlauciunas at 
the University of Leeds. Each analysis was run according to the following 
protocol: 
1: Equilibrate at Tmin, °C 
2: Ramp 10.00°C/min to Tmax, °C 
3: Mark end of cycle 1 
4: Ramp 5.00°C/min to Tmin, °C 
5: Mark end of cycle 2 
6: Ramp 10.00°C/min to Tmax, °C 
7: Mark end of cycle 3 
The Tmin and Tmax are the minimum and the maximum temperature, which 
depends on the sample, and may be seen on each individual DSC graph. As 
can be seen from the above protocol, the cooling cycle was performed at 
half the rate of the heating cycles. 
6.1.6 Labelling schemes for NMR assignment for each chapter 
For all the ligands in this thesis for 1H and 13C NMR assignment the atoms 
were consistently labelled as shown on the figures at the beginning of each 
section (Fig. 6.1 and 6.2). The labelling on the crystal structures is different, 
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as it is not possible to add long prefixes to atom numbering when processing 
the crystal structures in Olex. 
6.2 Chapter 2 - Bis(pyrazol-1-yl)pyridine derivatives with no 
long alkyl chains, and their iron(II) complexes 
The labelling scheme for this chapter is shown below, on the Fig. 6.1.  
  
Fig. 6.1. Labelling scheme for Chapters 2 and 3 
6.2.1 L1 - 2,6-dibromo pyridine-4-carboxylic acid 
Citrazinic acid (4.725 g, 30.5 mmol, 1 eq.) was mixed with 
POBr3 (26.250 g, 91.5 mmol, 3 eq.), and the flask was 
connected to a condenser, connected to a water bubbler, to 
absorb the emitted gases, and also to an empty safety 
bubbler, to prevent sucking water into the reaction mixture. 
This was heated at 140oC for 24 hrs. After cooling to room 
temperature, the dark-brown mixture was quenched with deion. water (25 
ml) (careful – strongly exothermic reaction), heated to reflux and cooled to rt 
again. The obtained precipitate was thoroughly washed with water. After 
desiccation 7.03 g (yield 82%) of the product was obtained as a cream-white 
powder.3  
Notes: 1. The reaction mixture should be heated quickly, and water should 
be added fast enough so the water starts boiling, otherwise an insoluble 
glass-like solid will form on the bottom of the flask, which is extremely hard 
to remove.  
Analyses: 1H NMR (DMSO-D6, 400.130 MHz, ppm): δ 7.99 (s, 2H, Py H3,5), 
13C NMR (100.613 MHz, DMSO): δ 126.74 (Py C3,5), 140.80 (Py C4), 
143.67 (Py C2,6), 163.52 (Py C7), MS (ESI) m/z: calc. for [C6H2Br2NO2-]: 
279.8, found: 280.2, MP: 177.5 - 178˚C (lit.1 173-175˚C), IR (cm-1): 1220 (Py 
C-H),  1236 (C-OH), 1730 (C=O), 2750-3100 broad (CO-H), CHN: calculated 
for C6H3Br2NO2: C 25.65, H 1.08, N 4.99%, found: C 25.40, H 1.00, N 
4.90%. 
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6.2.2 L2 - 2,6-di(1H-pyrazole-1’-yl)pyridine-4-carboxylic acid 
NaH, 60% dispersion in mineral oil (3.641 g, 
90.59 mmol, 3.3 eq.) was stirred in diglyme (110 
ml) for 30 mins, after which 1H-pyrazole (5.608 
g, 82.35 mmol, 3 eq.) was carefully added to the 
suspension. After the H2 has evolved completely 
and the reaction mixture become clear, 2,6-
dibromo pyridine-4-carboxylic acid (7.71 g, 27.45 
mmol, 1 eq.) was dropped into the flask, which then was connected to a 
condenser and heated at 130oC for 5 days.4  
The cooled contents were poured onto water (500 cm3), and a crude beige 
solid was obtained through acidification to pH 3 with 4M HCl, and washed on 
a glass frit with acidified to pH 3 water.  
After thorough desiccation the beige solid was triturated in hexane, collected 
on a glass frit, and recrystallized from 5 ml of acetone. The obtained white 
powder was dried in the vacuum oven at 90oC for 24h, which yielded a clean 
final product (5.68 g, 81%). 
Notes: It can be very hard to filter the water suspension of the product. It 
may be easier to filter the mixture before acidification, and then acidify the 
filtrate and filter it again. 
Analyses: 1H NMR (DMSO-D6, 400.130 MHz, ppm): δ 6.68 (dd, 2H, Pz H4), 
7.92 (d, 2H, Pz H3), 8.18 (s, 2H, Py H3,5), 9.00 (d, 2H, Pz H5), 13C NMR 
(100.613 MHz, DMSO, ppm): δ 108.06 (Py C3,5), 108.83 (Pz C4), 128.37 
(Pz C5), 143.16 (Pz C3), 144.45 (Py C4), 150.37 (Py C2,6), 164.91 (Py C7), 
MS (ESI) m/z: calc. for [C12H9N5O2 + H+]: 256.08, found: 255.5, calc. for 
[C12H9N5O2 + H+ + 2DMSO]: 412.1, found: 412.7, MP: 257˚C dec., IR (cm-1): 
1210 (Py C-H),  1232 (C-OH), 1728 (C=O), 2300-3150 broad (CO-H), 1574 
(Pz C=C and C=N), 1468,1445, 1399 (Pz ring). 
6.2.3 L3 - 3,4-dimethoxyphenyl (2,6-di-1H-pyrazole-1-yl)pyridine-4-
carboxylate 
3,4-Dimethoxyphenyl (2,6-di-1H-pyrazole-1-yl)pyridine-4-carboxylate was 
prepared using the following procedure:5 
L2 2,6-Di(1H-pyrazole-1’-yl)pyridine-4-
carboxylic acid (1.275 g, 5 mmol) was 
heated to reflux in thionyl chloride (10 ml) 
for 12 hrs. The coloured solution was 
dried in vacuo and the acid chloride was 
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redissolved in DMF (15 ml). 3,4-Dimethoxyphenol (0.77 g, 5 mmol) was 
dissolved in DMF (10 ml), and triethylamine (20 ml) was added into the 
solution, after which this mixture was added to the acid chloride at room 
temperature. The reaction mixture was stirred for 48 hrs, until a large 
quantity of precipitate formed. Then water (40 ml) was added to the stirring 
reaction mixture to remove the salts, which made the product to precipitate 
as a beige solid, which was then filtered off, washed with water, and 
desiccated, which yielded the product as a white powder (1.080 g, 55%). 
Analyses: 1H NMR (DMSO-D6, 400.130 MHz, ppm): δ 9.04 (d, 2H, Pz H5), 
8.31 (s, 2H, Py H3,5), 7.94 (d, 2H, Pz H3), 7.08 (d, 1H, Ph H2), 7.03 (d, 1H, 
Ph H5),  6.89 (dd, 1H, Ph H6), 6.70 (dd, 2H, Pz H4), 3.79 (s, 3H, Ph H8), 
3.77 (s, 3H, Ph H7), 13C NMR (100.613 MHz, DMSO, ppm): δ 162.69 (Py 
C7), 150.50 (Py C2,6), 149.27 (Ph C1), 147.01 (Ph C4), 143.77 (Py C4), 
143.40 (Pz C3), 142.72 (Ph C3), 128.52 (Pz C5), 112.89 (Ph C5), 111.81 
(Ph C6), 109.05 (Pz C4), 108.20 (Py C3,5), 106.29 (Ph C2), 55.85 (Ph C7), 
55.77 (Ph C8), MS (HR- ESI) m/z: calc. for [C20H17N5O4 + H+]: 392.1353, 
found: 392.1387, MP: 201-202˚C, IR (cm-1): 1188, 1179 (C-OR), 1748 
(C=O), 1506 (Ph C-H), 2838 (Ph O-CH3), 1574 (Pz C=C and C=N), 1462, 
1446, 1392 (Pz ring), 1219 (Py C-H), CHN: calculated for C20H17N5O4: C 
61.38, H 4.38, N 17.89%, found: C 61.80, H 4.20, N 18.80%. 
6.2.4 L4 - 4-methoxyphenyl (2,6-di-1H-pyrazole-1-yl)pyridine-4-
carboxylate 
4-Methoxyphenyl (2,6-di-1H-pyrazole-1-
yl)pyridine-4-carboxylate was prepared using 
the following procedure: L2 2,6-Di(1H-
pyrazole-1’-yl)pyridine-4-carboxylic acid 
(3.00 g, 11.75 mmol, 1 eq.) was heated to 
reflux in thionyl chloride (70 ml, 29.2 eq.) 
under nitrogen for 12 hrs. The obtained reddish-brown transparent solution 
was dried in vacuo, using an external liquid nitrogen trap to collect the 
thionyl chloride, and the obtained dark-brown solid was then heated for 
additional 15 mins at 70oC under vacuum, until the colour changed to light-
yellow. It is important to remove all the thionyl chloride completely, otherwise 
the yield will be low and the product will be dirty. The obtained acid chloride 
was dissolved in dry THF (70 ml). 4-Methoxyphenol (1.459 g, 11.75 mmol, 1 
eq.) was mixed with THF (10 ml) and triethylamine (9 ml), and the obtained 
transparent solution was added into the reaction mixture. The obtained pale-
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brown mixture was stirred for 48 hrs, until a large quantity of the cream 
precipitate had been formed.  
Water (40 ml) was added to the stirring reaction mixture to remove the salts, 
and the product was precipitated as a beige solid, filtered off and washed 
with water. After desiccation the pure product (3.618 g, 85%) was obtained 
as a white powder. 
Analyses: 1H NMR (DMSO-D6, 400.130 MHz, ppm): δ 9.06 (d, 2H, Pz H5),  
8.31 (s, 2H, Py H3,5), 7.95 (s, 2H, Pz H3), 7.33 (d, 2H, Ph H2,6), 7.05 (d, 
2H, Ph H3,5), 6.71 (t, 2H, Pz H4), 3.81 (s, 3H, Ph H7), 13C NMR (100.613 
MHz, DMSO, ppm): δ 162.7 (Py C7), 157.34 (Ph C4), 150.48 (Py C4), 
143.62 (Ph C1), 143.38 (Pz C3), 142.66 (Py C2,6), 128.52 (Pz C5), 122.54 
(Ph C2,6), 114.59 (Ph C3,5),  109.02 (Pz C4), 108.20 (Py C3,5), 55.47 (Ph 
C7), MS (HR- ESI) m/z: calc. for [C19H15N5O3 + Na+]: 384.1073, found: 
384.1085, MP: 196˚C, IR (cm-1): 1190, 1180 (C-OR), 1739 (C=O), 1507 (Ph 
C=C), 2835 (Ph O-CH3), 1577 (Pz C=C and C=N), 1466, 1449, 1396 (Pz 
ring), 1227 (Py C-H) ), CHN: Calculated for C19H15N5O3 + 0.5 H2O: C 61.62, 
H 4.35, N 18.91 %, found: C 61.80, H 4.20, N 18.80 %. 
6.2.5 L5 - 3,4-dihydroxyphenyl (2,6-di-1H-pyrazole-1-yl)pyridine-4-
carboxylate 
3,4-Dihydroxyphenyl (2,6-di-1H-pyrazole-1-
yl)pyridine-4-carboxylate was prepared using the 
following procedure:4 L3 3,4-Dimethoxyphenyl 
(2,6-di-1H-pyrazole-1-yl)pyridine-4-carboxylate 
(1.564 g, 4 mmol, 1 eq.) was dissolved in dry 
DCM (40 ml) under nitrogen. The solution was 
cooled in a mixture of cardice and acetone, and boron tribromide (4 ml, 
42.15 mmol, 10.5 eq.) was added dropwise. The reaction mixture was 
stirring for 4 hrs at reflux under nitrogen using subaseal. The obtained 
orange solution was cooled in ice water and water (20 ml) was added 
dropwise, and two precipitates, white and red, were filtered, washed with 
water, dried on the filter and then washed with DCM and recrystallized from 
acetone. After this purification both red and white precipitates turned into a 
greyish-white powders, which were confirmed to be the same compound by 
1H NMR. After desiccation, a greyish-white powder of the target product 
(1.009 g, 69%) was obtained. 
Analyses: 1H NMR (DMSO-D6, 400.130 MHz, ppm): δ 9.34 (s, 1H, Ph H7), 
9.04 (d, 2H, Pz H5), 8.29 (s, 2H, Py H3,5), 7.95 (d, 2H, Pz H3), 6.82 (d, 1H, 
Ph H5), 6.77 (d, 1H, Ph H2), 6.71 (t, 2H, Pz H4), 6.64 (dd, 1H, Ph H6), 13C 
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NMR (100.613 MHz, DMSO, ppm): δ 162.67 (Py C7), 150.46 (Py C2,6), 
145.76 (Ph C1), 143.75 (Py C4), 143.39 (Pz C3,5), 142.79 (Ph C4), 142.44 
(Ph C3), 128.52 (Pz C5), 115.32 (Ph C5), 111.61 (Ph C6), 109.29 (Ph C2), 
109.04 (Pz C4),  108.18 (Py C3,5), MS (HR- ESI) m/z: calc. for [C18H13N5O4 
+ H+]: 364.0991, found: 364.1041, calc. for [C18H13N5O4 + Na+]: 386.0860, 
found: 386.0865, MP: 258˚C, IR (cm-1): 1194, 1184 (C-OR), 1738 (C=O), 
2800-3300 broad (Ph O-H), 1517 (Ph C=C), 1575 (Pz C=C and C=N), 1463, 
1446, 1399 (Pz ring), 1207 (Py C-H), CHN: calculated for C18H13N5O4: C 
59.50, H 3.61, N 19.28%, found: C 59.37, H 3.75, N 19.11 %. 
6.2.6 L6 - 4-hydroxyphenyl (2,6-di-1H-pyrazole-1-yl)pyridine-4-
carboxylate 
L6 3,4-Dihydroxyphenyl (2,6-di-1H-pyrazole-1-
yl)pyridine-4-carboxylate was prepared from L4 
by the procedure, described above for the L5 
synthesis, using the following quantities: L4 4-
methoxyphenyl (2,6-di-1H-pyrazole-1-yl)pyridine-
4-carboxylate 3.379 g (9.35 mmol, 1 eq), boron tribromide (5.32 ml, 14 g, 
56.1 mmol, 6 eq), dry DCM (150 ml), which yielded the target product (2.025 
g, 62 %) as white flakes. 
Analyses: 1H NMR (DMSO-D6, 400.130 MHz, ppm): δ 9.60 (br s, 1H, Ph 
H7), 9.03 (d, Pz 5), 8.29 (s, 2H, Py H3,5), 7.94 (s, 2H, Pz H3), 7.17 (d, 2H, 
Ph H2,6), 6.86 (d, 2H, Ph H3,5), 6.69 (t, 2H, Pz H4), 13C NMR (100.613 
MHz, DMSO, ppm): δ 162.79 (Py C7), 155.57 (Ph C4), 150.49 (Py C4), 
143.39 (Ph C1), 142.42 (Pz C3), 142.74 (Py C2,6), 128.51 (Pz C5), 122.40 
(Ph C2,6), 115.77 (Ph C3,5), 109.04 (Pz C4), 108.20 (Py C3,5), MS (HR- 
ESI) m/z: calc. for [C18H13N5O3 + Na+]: 370.0916, found: 370.0910, MP: 233-
234˚C, IR (cm-1): 1188, 1180 (C-OR), 1750 (C=O), 3100-3300 broad (Ph O-
H), 1509 (Ph C=C), 1574 (Pz C=C and C=N), 1465, 1443, 1395 (Pz ring), 
1227 (Py C-H), CHN: calculated for C18H13N5O3: C 62.24, H 3.77, N 20.16%, 
found: C 62.14, H 3.58, N 19.95%. 
6.2.7 L7 - 1,4-di(2,6-di(1H-pyrazol-1’-yl)pyridine-4-
carboxy)benzene 
Attempts to attach a long alkyl chain to L6 led to 
formation of 1,4-di(2,6-di(1H-pyrazol-1’-yl)pyridine 
-4-carboxy)benzene. L5 4-hydroxy-phenyl(2,6-di-
1H-pyrazole-1-yl)pyridine-4-carboxylate (63.6 mg, 
0.18 mmol, 1 eq.) was dissolved in dry MeCN (15 
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ml), after which  anhydrous K2CO3 (38 mg, 0.27 mmol, 1.5 eq.), a catalytic 
amount of KI, and 1-bromododecane (51 mg, 0.18 mmol, 1 eq.) in dry MeCN 
(5 ml) were added into the solution. The reaction mixture was stirred under 
nitrogen at 40˚C for 16h, and then the cream coloured flakes were filtered off 
from the solution, washed with water and acetone, and dried. 
Analyses: MS (HR- ESI) m/z: calc. for [L6+ Na+]: 370.0916, found: 370.0909; 
calc. for [L7 + H+]: 585.1748, found: 858.1759, calc. for [L7 + Na+]: 607.1567, 
found: 607.1578, calc. for [L7 + K+]: 623.1301, found: 623.1320, where L6 - 
C18H13N5O3, L7 - C30H20N10O4, 1H NMR (DMSO-D6, 400.130 MHz, ppm): δ 
9.05 (d, 2H, Pz H5), 8.89 (d, 2H, Pz H5’), 8.30 (s, 2H, Py H3,5), 8.13 (s, 2H, 
Py H3,5’), 7.95 (s, 2H, Pz H3), 7.85 (s, 2H, Pz H3’), 7.16 (d, 2H, Ph H2,6), 
6.87 (d, 2H, Ph H3,5), 6.70 (t, 2H, Pz H4), 6.60 (t, 2H, Pz H4’). See Chapter 
2.2.5 for more information. 
6.2.8 L8 - 3,4-methoxybenzyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-
carboxylate 
L8 was obtained according to the procedure, 
reported by Marcelis et al.5 with some 
modifications. A mixture of L2 2,6-di(1H-
pyrazol-1’-yl)pyridine-4-carboxylic acid (1.100 g, 
4.31 mmol, 1 eq), N,N-dicyclohexyl 
carbodiimide (DCC) (1.956 g, 9.482 mmol, 2.2 
eq), 3,4-methoxybenzyl alcohol (0.725 g, 0.616 
ml, 4.31 mmol, 1 eq), and a catalytic amount of dimethyl-aminopyridine 
(DMAP) (caution - very toxic) in DCM was stirred for 2 days under a CaCl2 
tube, the precipitate was filtered off, and the obtained golden-yellow filtrate 
was either concentrated under vacuum and recrystallized from boiling MeCN 
(20 ml), filtered off, washed with hexane and desiccated, which yielded a 
pure product as a white crystalline powder (1.200 g, 69%). 
Analyses: 1H NMR (DMSO-D6, 400.130 MHz, ppm): δ 8.96 (d, 2H, Pz H5),  
8.13 (s, 2H, Py H3,5), 7.89 (d, 2H, Pz H3), 7.15 (d, 1H, Ph H2), 7.07 (dd, 1H, 
Ph H5), 7.01 (d, 1 H, Ph H6), 6.65 (dd, 2H, Pz H4), 5.35 (s, 2H, Ph H7), 3.79 
(s, 3H, Ph H9), 3.78 (s, 3H, Ph H8), 13C NMR (100.613 MHz, DMSO, ppm): 
δ 163.30 (Py C7), 150.35 (Ph C2,6), 149.11 (Ph C4), 148.70 (Ph C3), 
142.95 (Ph C1), 143.21 (Pz C3), 128.36 (Pz C5), 127.44 (Py C4), 121.56 
(Ph C5), 112.74 (Ph C2), 111.72 (Ph C6), 108.88 (Pz C4), 107.76 (Py C3,5), 
67.70 (Ph C7), 55.50 (Ph C8,9), MS (HR- ESI) m/z: calc. for [C21H19N5O4 + 
H+]: 406.1510, found: 406.1507, calc. for [C21H19N5O4 + Na+]: 428.1329, 
found: 428.1335, calc. for [2 C21H19N5O4 + Na+]: 833.2766, found: 833.2764, 
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MP: 130.2-130.4˚C,  IR (cm-1): 2826 (OCH3), 1721 (C=O), 1575 (Pz C=C), 
1459, 1446 (Ph OCHR-H), 1239, 1226, 1211 (C-OR), 1053, 1028 (RCH2-
OR), 757 (Py C-H). 
6.2.9 L9 - 4-methoxybenzyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-
carboxylate 
4-Methoxybenzyl (2,6-di-1H-pyrazol-1-yl) 
pyridine-4-carboxylate was prepared by the 
same procedure as for L8, using the 
following quantities: 2,6-di(1H-pyrazol-1’-
yl)pyridine-4-carboxylic acid 1 g (3.918 
mmol, 1 eq), 4-methoxybenzyl alcohol 
541.3 mg (3.918 mmol, 1 eq), DCC 1.778 g 
(8.620 mmol, 2.2 eq), and a pinch of DMAP as a catalyst. Recrystallization 
from MeCN didn’t yield a pure compound, therefore the crude product was 
separated by column chromatography (hexane: ethyl acetate, 1:1, 1st spot) 
as a white crystalline powder (220 mg, 15%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.55 (d, 2H, Pz H5), 8.38 
(s, 2H, Py H3,5), 7.78 (d, 2H, Pz H3), 7.42 (d, 1H, Ph H2,6), 6.93 (d, 2H, Ph 
H3,5), 6.51 (dd, 2H, Pz H4), 5.37 (s, 2H, Ph H7), 13C NMR (100.613 MHz, 
CDCl3, ppm): δ 164.13 (Py C7), 160.10 (Ph C4), 150.92 (Py C4), 143.63 (Py 
C2,6), 142.96 (Pz C3), 130.75 (Ph 2,6), 127.41 (Ph C1), 127.35 (Pz C5), 
114.24 (Ph C3,5), 109.40 (Py C3,5), 108.53 (Pz C4), 67.85 (Ph C7), 55.46 
(Ph C8), MS (HR- ESI) m/z: calc. for [C20H17N5O3 + H+]: 376.1404, found: 
376.1402, calc. for [C20H17N5O3 + Na+]: 398.1224, found: 398.1223, MP: 
150.6-152.5˚C, IR (cm-1): 2850 (OCH3), 1718 (C=O), 1575 (Pz C=C), 1463, 
1448 (Ph OCHR-H), 1237, 1207 (C-OR), 1052, 1042 (RCH2-OR), 753 (Py C-
H). 
6.2.10 L10 - benzyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate 
Benzyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-
carboxylate was prepared using the same 
procedure as for L8, with the following 
quantities: 2,6-di(1H-pyrazol-1’-yl)pyridine-4-
carboxylic acid (1.000 g, 3.918 mmol, 1 eq), 
benzyl alcohol (424 mg, 3.918 mmol, 1 eq), 
DCC (1.778 g, 8.620 mmol, 2.2 eq), and a 
pinch of DMAP as a catalyst. Recrystallization from MeCN and ethyl acetate 
yielded an almost pure compound, which was then purified by a short 
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column (hexane: ethyl acetate, 1:1, 1st spot) to yield white plate crystals (250 
mg, 19%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.56 (d, 2H, Pz H5),  8.41 
(s, 2H, Py H3,5), 7.79 (d, 2H, Pz H4), 7.48 (dd, 1H, Ph H4), 7.47 (d, 2H, Ph 
H2,6), 7.39 (dd, 2H, Ph H3,5), 6.51 (t, 2H, Pz H4), 5.44 (s, 2H, Ph H7), 13C 
NMR (100.613 MHz, CDCl3, ppm): δ 164.08 (Py C7), 150.96 (Ph C4), 
143.46 (Py C2,6), 142.99 (Pz C3), 135.26 (Ph C1), 128.86 (Ph C2,6), 128.81 
(Ph C3,5), 127.36 (Pz C5), 109.40 (Py C3,5), 108.56 (Pz C4), 67.98 (Ph 
C7), MS (HR- ESI) m/z: calc. for [C19H15N5O2 + H+]: 346.1299, found: 
346.1302, calc. for [C19H15N5O2 + Na+]: 368.1118, found: 368.1130, MP: 
119.9-120.2˚C, IR (cm-1): 1727 (C=O), 1572 (Pz C=C), 1456, 1445 (Ph 
OCHR-H), 1237, 1207 (C-OR), 1064, 1048 (RCH2-OR), 758 (Py C-H). 
6.2.11 Iron(II) complexes from chapter 2 
All the iron(II) complexes in Chapter 2 were obtained 
by this general procedure, adapted from the literature:4 
The ligand (1 eq.) was dissolved in the appropriate 
solvent – either nitromethane, acetonitrile or acetone, 
and iron(II) tetrafluoroborate hexahydrate (0.5 eq.) was 
dissolved in the same solvent, with a gentle heating, if 
necessary. The two solutions were mixed at room 
temperature, which lead to instant formation of an 
intensively coloured solution, which, if necessary, was 
filtered through a pipette filter, then concentrated in 
vacuo. The isolated by filtration complex solution was 
first tested by mixing a small amount of the solution with Et2O, and if it 
induced the precipitation, the vials with the complex solution were set for 
ether diffusion crystallization. Sometimes diluting the complex solution a little 
led to growth of better quality crystals. 
[Fe(L3)2][BF4]2  
3,4-Dimethoxyphenyl (2,6-di-1H-pyrazole-1-yl)pyridine-4-carboxylate iron(II) 
tetrafluoroborate was obtained according with the general procedure 
described above, using the following quantities: L3 3,4-dimethoxyphenyl 
(2,6-di-1H-pyrazole-1-yl)pyridine-4-carboxylate (39 mg, 0.100 mmol, 1eq), 
iron(II) tetrafluoroborate hexahydrate (17 mg, 0.050 mmol, 0.5 eq), MeNO2 
(7.5 ml), which yielded red crystals (32 mg, 63%), and a small quantity of 
yellow crystals, which were separated crystal-by-crystal using tweezers; 
single crystal XRD structures were collected for both red and yellow crystals, 
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which proved these two polymorphs to be have the same formula, but the 
red crystals to be LS at room temperature, and the yellow ones to be HS. 
Analyses: 1H NMR (MeCN-D3, 300.130 MHz, ppm): δ 40.41, 39.52, 26.36, 
23.32 (Pz H3, H4, H5, Py H3,5), MS (HR - ESI) m/z: calc. for 
[C20H17N5O4+H+]: 392.1353, found: 392.1387, IR (cm-1): 1186 (C-OR), 1744 
(C=O), 970-1180 (B-F stretch),  521 (B-F deformation), 1509 (Ph C=C), 
2831 (PhO-CH3), 1577 (Pz C=C and C=N), 1461, 1440, 1407 (Pz ring), 1225 
(Py C-H), CHN: calculated for C40H34N10O8Fe1B2F8: C 47.46, H 3.39, N 
13.84%, found: C 47.27, H 3.48, N 13.63%. 
[Fe(L4)2][BF4]2  
4-Methoxyphenyl (2,6-di-1H-pyrazole-1-yl)pyridine-4-carboxylate iron(II) 
tetrafluoroborate was obtained according with the general procedure 
described above, using the following quantities: L4 4-methoxyphenyl (2,6-di-
1H-pyrazole-1-yl)pyridine-4-carboxylate (65 mg, 0.180  mmol, 1eq), iron(II) 
tetrafluoroborate hexahydrate (30.36 mg, 0.090 mmol, 0.5 eq), Me2CO, 
which yielded dark-red needle crystals (23 mg, 27%). 
Analyses: 1H NMR (MeCN-D3, 300.130 MHz, ppm): δ 40.38, 39.77, 26.22, 
23.11 (Pz H3, H4, H5, Py H3,5), MS (HR- ESI) m/z: calc. for 
[C19H15N5O3+H+]: 362.1254, found: 362.1250, IR (cm-1): 1187, 1168 (C-OR), 
1744 (C=O), 960-1083(B-F stretch), 521 (B-F deformation), 1506 (Ph C=C), 
2843 (PhO-CH3), 1577 (Pz C=C and C=N), 1472, 1441, 1407 (Pz ring), 1223 
(Py C-H), CHN: calculated for C38H30N10O6Fe1B2F8: C 47.93, H 3.18, N 
14.71, found: C 47.50, H 3.10, N 14.80%. 
[Fe(L5)2][BF4]2  
3,4-Dihydroxyphenyl (2,6-di-1H-pyrazole-1-yl)pyridine-4-carboxylate iron(II) 
tetrafluoroborate was obtained according with the general procedure 
described above, using the following quantities: L5 3,4-Dihydroxyphenyl 
(2,6-di-1H-pyrazole-1-yl)pyridine-4-carboxylate (162 mg, 0.456 mmol, 1 eq), 
iron(II) tetrafluoroborate hexahydrate (75.3 mg, 0.223 mmol, 0.5 eq), 
Me2CO, which yielded a dark-red crystalline powder (42 mg, 20%). 
Analyses: 1H NMR (MeCN-D3, 300.130 MHz, ppm): δ 40.32, 39.77, 26.01, 
23.08 (Pz H3, H4, H5, Py H3,5), MS (HR-ESI) m/z: calc. for 
[C18H13N5O4+H+]: 364.1046, found: 364.1042, calc. for [C18H13N5O4+Na+]: 
386.0866, found: 364.0860, IR (cm-1): 1742 (C=O), 2800-3600 (PhO-H), 
954-1144 (B-F stretch), ca. 520 (B-F deformation), 1498 (Ph C=C), 1575 (Pz 
C=C and C=N), 1461, 1440, 1407 (Pz ring), 1217 (Py C-H), CHN: calculated 
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for C36H26N10O8Fe1B2F8: C 45.22, H 2.74, N 14.65%, found: C 45.19, H 2.52, 
N 14.72%. 
[Fe(L6)2][BF4]2  
3,4-Dihydroxyphenyl (2,6-di-1H-pyrazole-1-yl)pyridine-4-carboxylate iron(II) 
tetrafluoroborate was obtained according with the general procedure 
described above, using the following quantities: L6 3,4-Dihydroxyphenyl 
(2,6-di-1H-pyrazole-1-yl)pyridine-4-carboxylate (150 mg, 0.431 mmol, 1 eq), 
iron(II) tetrafluoroborate hexahydrate (72.9 mg, 0.216 mmol, 0.5 eq), 
Me2CO, which yielded thin red needle crystals (97 mg, 49%). 
Analyses: 1H NMR (MeCN-D3, 300.130 MHz, ppm): δ 40.74, 39.60, 26.39, 
23.06 (Pz H3, H4, H5, Py H3,5), MS (HR-ESI) m/z: calc. for 
[C18H13N5O3+Na+]: 370.0911, found: 370.0925, IR (cm-1): 1184, 1165 (C-
OR), 1749 (C=O), 3100-3500 (PhO-H), 1050 very broad (B-F stretch), 517 
(B-F deformation), 1509 (Ph C=C), 1574 (Pz C=C and C=N), 1472, 1442, 
1409 (Pz ring), 1221 (Py C-H), CHN: calculated for C36H26N10O6Fe1B2F8: C 
46.79, H 2.84, N 15.16%, found: C 46.72, H 3.00, N 15.26%. 
[Fe(L8)2][BF4]2  
3,4-Methoxybenzyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate iron(II) 
tetrafluoroborate was obtained according with the general procedure 
described above, using the following quantities: L8 3,4-methoxybenzyl (2,6-
di-1H-pyrazol-1-yl)pyridine-4-carboxylate (200 mg, 0.493 mmol, 1eq), iron(II) 
tetrafluoroborate hexahydrate (93.1 mg, 0.247 mmol, 0.5 eq), acetone (ca 
5.5 ml), ), and Et2O as antisolvent, which yielded the product as small red 
needle crystals (102 mg, 40%). 
Analyses: 1H NMR (MeCN-D3, 300.130 MHz, ppm): δ 37.24 ((Pz H3), 37.02 
(Pz H4), 24.73 (Pz H5), 21.32 (Py H3,5), MS (HR- ESI) m/z: calc. for 
[C21H19N5O4 + H+]: 406.1510, found: 406.1514, calc. for [C21H19N5O4 + Na+]: 
428.1329, found: 428.1332, calc. for [2 C21H19N5O4 + Na+]: 833.2766, found: 
833.2767, IR (cm-1): 2839 (OCH3), 1731 (C=O), 1573 (Pz C=C), 1472, 1462 
(Ph OCHR-H), 1247 (CO-R), 1052, 764 (B-F), CHN: calculated for 
C42H38N10O8Fe1B2F8: C 48.49, H 3.68, N 13.46 %, found: C 48.36, H 3.72, N 
13.33 %. 
[Fe(L9)2][BF4]2  
4-Methoxybenzyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate iron(II) tetra-
fluoroborate was obtained according with the general procedure described 
above, using the following quantities: L9 4-methoxybenzyl (2,6-di-1H-
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pyrazol-1-yl)pyridine-4-carboxylate (100 mg, 0.266 mmol, 1eq), iron(II) 
tetrafluoroborate hexahydrate (50.3 mg, 0.1332 mmol, 0.5 eq), acetone (ca 
7.5 ml), and Et2O as antisolvent, which yielded the product as big red scale-
like crystals (104 mg, 40%). 
Analyses: 1H NMR (MeCN-D3, 600.2563 MHz, ppm): δ 40.11 (Pz H3), 38.26 
(Pz H3), 24.89 (Pz H5), 21.38 (Py H3,5), MS (HR- ESI) m/z: calc. for 
[C20H17N5O3 + H+]: 376.1404, found: 376.1403, calc. for [C20H17N5O3 + Na+]: 
398.1224, found: 398.1228, calc. for [2 C20H17N5O3 + Na+]: 773.2561, found: 
773.2553, IR (cm-1): 2937 (OCH3), 1730 (C=O), 1573 (Pz C=C), 1472 (Ph 
OCHR-H), 1242 (CO-R), 1051, 764 (B-F), CHN: calculated for 
C40H34N10O6Fe1B2F8: C 49.01, H 3.50, N 14.29 %, found: C 48.89, H 3.61, N 
14.05 %. 
[Fe(L10)2][BF4]2  
Benzyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate iron(II) tetrafluoro-
borate was obtained according with the general procedure described above, 
using the following quantities: L10 benzyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-
carboxylate (100 mg, 0.266 mmol, 1eq), iron(II) tetrafluoroborate 
hexahydrate (54.7 mg, 0.145 mmol, 0.5 eq), acetone (ca 5.5 ml), and Et2O 
as antisolvent, which yielded the iron complex as thick red plate crystals 
(96.5 mg, 36%). 
Analyses: 1H NMR (MeCN-D3, 600.2563 MHz, ppm): δ 36.85 (Pz H3), 35.41 
(Pz H4), 23.66 (Pz H5), 20.20 (Py H3,5), MS (HR- ESI) m/z: calc. for 
[C19H15N5O2 + H+]: 346.1299, found: 346.1294, calc. for [C19H15N5O2 + Na+]: 
368.1118, found: 368.1119, calc. for [2 C19H15N5O2 + Na+]: 713.2344, found: 
713.2336, IR (cm-1): 1729 (C=O), 1572 (Pz C=C), 1471 (Ph OCHR-H), 1243 
(CO-R), 1050, 762 (B-F), CHN: calculated for C38H30N10O4Fe1B2F8: C 49.60, 
H 3.29, N 15.22 %, found: C 49.45, H 3.17, N 15.08 %. 
6.3 Chapter 3 - Pyridine-substituted bis(pyrazol-1-
yl)pyridine derivatives with long alkyl chains, and their 
iron(II) complexes 
The labelling scheme for this chapter is shown on the Fig. 6.1 
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6.3.1 L11Cx - alkyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylates   
Alkyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-
carboxylates were obtained using the 
procedure, described in literature,5 with some 
modifications. A mixture of L2 2,6-di(1H-
pyrazol-1’-yl)pyridine-4-carboxylic acid (1 eq), 
N,N-dicyclohexyl carbodiimide (DCC) (2.2 eq), 
a long alkyl chain alcohol (1eq), and a catalytic 
amount of dimethylaminopyridine (DMAP) 
/caution - very toxic/ in DCM was stirred for 2 days under a CaCl2 tube, the 
precipitate was filtered of, and the obtained golden-yellow filtrate was either 
(i) concentrated under vacuum and separated by column chromatography 
(0.3% MeOH in DCM), the target product came out at rf = 0.5, or (ii) 
recrystallized from boiling MeCN, washed with hexane and dessicated. 
L11C6 - hexyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate 
Hexyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate was prepared using the 
general procedure described above, using the following quantities: 2,6-
di(1H-pyrazol-1’-yl)pyridine-4-carboxylic acid 2.036 g (7.97 mmol, 1 eq), 
hexanol 0.814 g (7.97 mmol, 1 eq), DCC 3.616 g (17.53 mmol, 2.2 eq), and 
a pinch of DMAP. The product was purified column chromatography 
(hexane: ethyl acetate, 4:1), and obtained as a white solid (1.249 g, 46%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.56 (d, 2 H, Pz H5), 8.38 
(s, 2 H, Py H3,5), 7.79 (d, 2 H, Pz H3), 6.51 (dd, 2 H, Pz H4), 4.39 (t, 2 H Ak 
H1), 1.81 (p, 2H, Ak H2), 1.44 (p, 2 H, Ak H3), 1.35 (s, 4 H, Ak H4,5), 0.91 (t, 
3H, Ak H6), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 164.24 (Py C7), 150.92 
(Py C2,6), 143.82 (Py C4), 142.95 (Pz C3), 127.35 (Pz C5), 109.32 (Py 
C3,5), 108.52 (Pz C4), 66.52 (Ak C1), 31.56 (Ak C4), 28.69 (Ak C2), 25.71 
(Ak C3), 22.66 (Ak C5), 14.13 (Ak C6), MS (HR-ESI) m/z: calc. for 
[C18H21N5O2+H+]:  340.1768, found: 340.1713, calc. for [C18H21N5O2+Na+]:  
362.1587, found: 362.1512, IR (cm-1): 2917, 2856 (CH3, CH2), 1724 (C=O), 
1571 (Pz C=C, C=N), 1457, 1392 (Pz ring), 1240 (C-OR), 1039 (Py C=C-H), 
MP: 77.6-78.0˚C, CHN: calculated for C18H21N5O2: C 63.70, H 6.24, N 
20.64%, found: C 63.84, H 6.33, N 20.58%. 
L11C12 - dodecyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate 
Dodecyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate was prepared using 
the general procedure described above, using the following quantities: 2,6-
di(1H-pyrazol-1’-yl)pyridine-4-carboxylic acid 0.26 g (1 mmol, 1 eq), 
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dodecanol 0.186 g (1 mmol, 1 eq), DCC 0.46 g (2.2 mmol, 2.2 eq), and a 
pinch of DMAP. The product was purified by recrystallization from MeCN, 
and collected as a white solid (0.228 g, 16%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.58 (d, 2 H, Pz H5), 8.39 
(s, 2 H, Py H3,5), 7.80 (d, 2 H, Pz H3), 6.53 (dd, 2 H, Pz H4), 4.40 (t, 2 H Ak 
H1), 1.81 (p, 2H, Ak H2), 1.44 (p, 2 H, Ak H3), 1.26 (s, 16 H, Ak H4-11), 0.87 
(t, 3H, Ak H12), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 164.26 (Py C7), 
150.94 (Py C2,6), 143.84 (Py C4), 142.96 (Pz C3), 127.36 (Pz C5), 109.35 
(Py C3,5), 108.53 (Pz C4), 66.54 (Ak C1), 28.73 (Ak C2), 26.04 (Ak C3), 
29.78, 29.76, 29.71, 29.63, 29.48, 29.39 (Ak C4-9), 32.05 (C10), 22.82 (Ak 
C11), 14.25 (Ak C12), MS (HR-ESI) m/z: calc. for [C24H33N5O2+H+]: 
424.2707, found: 424.2722, calc. for [C24H33N5O2+Na+]: 446.2526, found: 
446.2531, IR (cm-1): 2912, 2848 (CH3, CH2), 1728 (C=O), 1575 (Pz C=C, 
C=N), 1464. 1395 (Pz ring), 1243 (C-OR), 1039 (Py C=C-H), MP: 79.9˚C, 
CHN: calculated for C24H33N5O2: C 68.06, H 7.85, N 16.53%, found: C 
67.94, H 7.96, N 16.44%. 
L11C14 - tetradecyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate 
Tetradecyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate was prepared 
using the general procedure described above, using the following quantities: 
2,6-di(1H-pyrazol-1’-yl)pyridine-4-carboxylic acid 0.800 g (3.1 mmol, 1 eq), 
tetradecanol 0.665 g (3.1 mmol, 1 eq), DCC 1.424 g (6.9 mmol, 2.2 eq), and 
a pinch of DMAP. The product was purified by recrystallization from MeCN, 
and collected as a white solid (0.225 g, 14%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.57 (d, 2 H, Pz H5), 8.38 
(s, 2 H, Py H3,5), 7.80 (d, 2 H, Pz H3), 6.52 (dd, 2 H, Pz H4), 4.39 (t, 2 H Ak 
H1), 1.81 (p, 2H, Ak H2), 1.44 (p, 2 H, Ak H3), 1.26 (s, 20 H, Ak H4-13), 0.87 
(t, 3H, Ak H14), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 164.26 (Py C7), 
150.94 (Py C2,6), 143.85 (Py C4), 142.96 (Pz C3), 127.36 (Pz C5), 109.35 
(Py C3,5), 108.53 (Pz C4), 66.55 (Ak C1), 28.73 (Ak C2), 25.76 (Ak C3), 
32.07, 29.83, 29.79, 29.72, 29.64, 29.50, 29.40 (Ak C4-13), 14.25 (Ak C14), 
MS (HR-ESI) m/z: calc. for [C26H37N5O2+H+]: 452.3020, found: 452.3028, 
calc. for [C26H37N5O2+Na+]: 474.2839, found: 474.2841, IR (cm-1): 2914, 
2849 (CH3, CH2), 1728 (C=O), 1576 (Pz C=C, C=N), 1463. 1396 (Pz ring), 
1241 (C-OR), 1039 (Py C=C-H), MP: 81.6˚C, CHN: calculated for 
C26H37N5O2: C 69.15, H 8.26, N 15.51%, found: C 69.08, H 8.13, N 15.41%. 
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L11C16 - hexadecyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate 
Hexadecyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate was prepared 
using the general procedure described above, using the following quantities: 
2,6-di(1H-pyrazol-1’-yl)pyridine-4-carboxylic acid 0.831  g (3.1 mmol, 1 eq), 
hexadecanol 0.665 g (3.1 mmol, 1 eq), DCC 1.424 g (6.9 mmol, 2.2 eq), and 
a pinch of DMAP. The product was purified by recrystallization from MeCN, 
and collected as a white solid (0.810 g, 52%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.57 (d, 2 H, Pz H5), 8.38 
(s, 2 H, Py H3,5), 7.80 (d, 2 H, Pz H3), 6.52 (dd, 2 H, Pz H4), 4.39 (t, 2 H Ak 
H1), 1.81 (p, 2 H, Ak H2), 1.44 (p, 2 H, Ak H3), 1.26 (s, 24 H, Ak H4-15), 
0.87 (t, 3 H, Ak H16), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 164.26 (Py 
C7), 150.94 (Py C2,6), 143.85 (Py C4), 142.96 (Pz C3), 127.36 (Pz C5), 
109.35 (Py C3,5), 108.53 (Pz C4), 66.55 (Ak C1), 28.74 (Ak C2), 26.05 (Ak 
C3), 32.07, 29.84, 29.81, 29.72, 29.64, 29.50, 29.40, 22.84 (Ak C4-15), 
14.26 (Ak C16), MS (HR-ESI) m/z: calc. for [C28H41N5O2+H+]: 480.3333, 
found: 480.3337, calc. for [C28H41N5O2+Na+]: 502.3152, found: 502.3152, IR 
(cm-1): 2912, 2848 (CH3, CH2), 1728 (C=O), 1575 (Pz C=C, C=N), 1464. 
1395 (Pz ring), 1243 (C-OR), 1039 (Py C=C-H), ), MP: 86.7˚C, CHN: 
calculated for C28H41N5O2: C 70.11, H 8.62, N 14.60, found: C 69.95, H 8.57, 
N 14.48%. 
L11C18 - octadecyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate 
Octadecyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate was prepared using 
the general procedure described above, using the following quantities: 2,6-
di(1H-pyrazol-1’-yl)pyridine-4-carboxylic acid 0.800  g (3.1 mmol, 1 eq), 
octadecanol 0.839 g (3.1 mmol, 1 eq), DCC 1.424 g (6.9 mmol, 2.2 eq), and 
a pinch of DMAP. The product was purified by recrystallization from MeCN, 
and collected as a white solid (0.800 g, 50%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.57 (d, 2 H, Pz H5), 8.39 
(s, 2 H, Py H3,5), 7.80 (d, 2 H, Pz H3), 6.52 (dd, 2 H, Pz H4), 4.39 (t, 2 H Ak 
H1), 1.81 (p, 2 H, Ak H2), 1.44 (p, 2 H, Ak H3), 1.26 (s, 28 H, Ak H4-17), 
0.88 (t, 3 H, Ak H18), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 164.26 (Py 
C7), 150.94 (Py C2,6), 143.85 (Py C4), 142.96 (Pz C3), 127.36 (Pz C5), 
109.35 (Py C3,5), 108.53 (Pz C4), 66.55 (Ak C1), 28.74 (Ak C2), 26.05 (Ak 
C3), 32.07, 29.84, 29.72, 29.64, 29.51, 29.40, 22.84 (Ak C4-17), 14.26 (Ak 
C18), MS (HR-ESI) m/z: calc. for [C30H45N5O2+H+]: 508.3646, found: 
508.3651, calc. for [C30H45N5O2+Na+]: 530.3465, found: 530.3463, IR (cm-1): 
2912, 2848 (CH3, CH2), 1728 (C=O), 1575 (Pz C=C, C=N), 1464. 1395 (Pz 
- 203 - 
ring), 1243 (C-OR), 1039 (Py C=C-H), MP: 90.3-90.6˚C, CHN: calculated for 
C30H45N5O2 + 3 H2O: C 55.48, H 7.45, N 10.78%, found: C 55.19, H 7.64, N 
10.86%. 
6.3.2 L12CxM and L12CxD - 4-alkyloxyphenols and 1,4-bis 
(alkyloxy)benzenes 
4-Alkyloxyphenols and 1,4-bis(alkyloxy)benzenes 
were obtained using the procedure, described in 
literature6 with some modifications. A solution of 
the alkyl bromide (1 eq) and hydroquinone (5 eq) 
in DMF was flushed with nitrogen, after which 
K2CO3 (3 eq) was added, and the mixture was 
refluxed for 4 hours under an inert atmosphere.  
After cooling to room temperature, the reaction mixture was poured into 350 
mL of a 5% KOH solution. The precipitate was filtered off, washed with water 
until colourless filtrate starts coming out, then washed with 30 mL of 5% 
aqueous HCl and with water until pH 7. 
The obtained white solid was washed with acetone, and the precipitate was 
dried, which resulted in a white powder of corresponding 1,4-bis 
(alkyloxy)benzene; while removing the solvent from the filtrate resulted in a 
white powder of 4-alkyloxyphenol. 
L12C6 
4-hexyloxyphenol L12C6M and 1,4-bis (hexyloxy)benzene L12C6D were 
prepared using the general procedure described above, using the following 
quantities: hydroquinone (10.2 g, 92.63 mmol, 5 eq), 1-bromohexane (3.058 
g, 18.53 mmol, 1 eq), DMF 40 ml, and K2CO3 (7.683 g, 55.6 mmol, 3 eq). As 
the product mixture didn’t precipitate from KOH solution, it was mixed with 
15% HCl until the precipitate was formed, which then was filtered off, and 
separated by column chromatography (hexane: ethyl acetate, 4: 1), which 
yielded 1,4-bis(hexyloxy)benzene L12C6D (0.181 g, 7%), and 4-
alkyloxyphenol L12C6M (1.641 g, 45.6%), both as white waxy solids. 
Analyses: L12C6M 1H NMR (CDCl3, 400.130 MHz, ppm): δ 6.78 (d, 2 H, Ph 
H2,6), 6.76 (d, 2 H, Ph H3,5), 4.82 (s, 1 H, Ph OH), 3.90 (t, 2 H, Ak H1), 1.75 
(p, 2 H, Ak H2), 1.45 (p, 2 H, Ak H3), 1.34 (s, 4 H, Ak H4,5), 0.91 (t, 3 H, Ak 
H6), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 153.41 (Ph C1), 149.51 (Ph 
C4), 116.16 (Ph C2,6), 115.83 (Ph C3,5), 68.98 (Ak C1), 31.74 (Ak C4), 
29.46 (Ak C2), 25.85 (Ak C3), 22.74 (Ak C5), 14.16 (Ak C6), IR (cm-1): 
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3410.3 (PhO-H), 2931.2, 2869.7 (CH3), 1511 (Ph C=C), 1231, (C-O stretch), 
1034 (C-O), 822 (PhH-H), MP: 45.3-45.5˚C. 
L12C6D 1H NMR (CDCl3, 400.130 MHz, ppm): δ 6.83 (s, 4 H, Ph H2,3,5,6), 
3.90 (t, 4 H, Ak H1), 1.75 (p, 4 H, Ak H2), 1.45 (p, 4 H, Ak H3), 1.34 (p, 8 H, 
Ak H4,5), 0.89 (t, 6 H, Ak H6), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 
153.36 (Ph C1,4), 115.56 (Ph C2,3,5,6), 68.83 (Ak C1), 31.77 (Ak C4), 29.53 
(Ak C2), 22.85 (Ak C5), 14.18 (Ak C6), MS (HR-ESI) m/z: calc. for 
[C18H30O2+H+]: 279.2319, found: 279.2314, IR (cm-1): 2916, 2848 (CH3), 
1513 (Ph C=C), 1241, 1230 (C-O stretch), 1036, 1028 (C-O), 825 (PhH-H), 
MP: 43.8-44.3˚C. 
L12C12 
4-Dodecyloxyphenol L12C12M and 1,4-bis (dodecyloxy)benzene L12C12D 
were prepared following the general procedure described above, using the 
following quantities: hydroquinone 11.045 g (100.3 mmols, 5 eq), 1-
bromododecane 5 g (20.06 mmols, 1 eq), DMF 50 ml, and K2CO3 8.32 g 
(60.18 mmols, 3 eq). The yield was 3.285 g (59%) for 4-dodecyloxyphenol 
and 0.654 g (15%) for 1,4-bis (dodecyloxy)benzene. 
Analyses: L12C12M 1H NMR (CDCl3, 400.130 MHz, ppm): δ 6.78 (d, 2 H, 
Ph H2,6), 6.76 (d, 2 H, Ph H3,5), 4.76 (s, 1 H, Ph OH), 3.90 (t, 2 H, Ak H1), 
1.75 (p, 2 H, Ak H2), 1.31 (p, 2 H, Ak H3), 1.27 (s, 16 H, Ak H4-11), 0.89 (t, 
3 H, Ak H12), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 153.44 (Ph C1), 
149.50 (Ph C4), 116.15 (Ph C2,6), 115.82 (Ph C3,5), 68.96 (Ak C1), 32.06 
(Ak C4), 29.75 (Ak C2), 26.19 (Ak C3), 29.80, 29.78, 29.74, 29.56, 29.51, 
29.49 (Ak C5-10), 22.83 (Ak C11), 14.23 (Ak C12), MS (HR-ESI) m/z: calc. 
for [C18H30O2+H+]: 279.2319, found: 297.2317, IR (cm-1): 3426 (PhO-H), 
2915, 2850 (CH3), 1514 (Ph C=C), 1237, 1038 (C-O stretch), 1038, 1047 (C-
O), 820 (PhH-H), MP: 78.1˚C, CHN: calculated for C18H30O2: C 77.65, H 
10.86%, found: C 77.58, H 10.79%. 
L12C12D 1H NMR (CDCl3, 400.130 MHz, ppm): δ 6.82 (s, 4 H, Ph H2,3,5,6), 
3.90 (t, 4 H, Ak H1), 1.76 (p, 4 H, Ak H2), 1.45 (p, 4 H, Ak H3), 1.31 (p, 4 H, 
Ak H11), 1.28 (s, 28 H, Ak H4-10), 0.89 (t, 6 H, Ak H12), 13C NMR (CDCl3, 
100.613 MHz, ppm): δ 153.36 (Ph C1,4), 115.54 (Ph C2,3,5,6), 68.81 (Ak 
C1), 32.08 (Ak C4), 29.52 (Ak C2), 26.22 (Ak C3), 29.82, 29.79, 29.76, 
29.58, 29.51 (Ak C4-10), 22.84 (Ak C11), 14.26 (Ak C12), MS (HR-ESI) m/z: 
calc. for [C30H54O2+H+]: 447.4197, found: 447.4192, IR (cm-1): 2916, 2848 
(CH3), 1513 (Ph C=C), 1241, 1230 (C-O stretch), 1036, 1029 (C-O), 825 
(PhH-H), MP: 74.7˚C. 
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L12C14 
4-Tetradecyloxyphenol and 1,4-bis (tetradecyloxy)benzene were prepared 
using the general procedure described above, using the following quantities: 
hydroquinone 9.91 g (90 mmols, 5 eq), 1-bromotetradecane 5 g (18 mmols, 
1 eq), DMF 50 ml, and K2CO3 7.463 g (54 mmols, 3 eq).The yield was 2.274 
g (41%) for 4-tetradecyloxyphenol and 0.632 g (14%) for 1,4-bis 
(tetradecyloxy)benzene. 
Analyses: L12C14M 1H NMR (CDCl3, 400.130 MHz, ppm): δ 6.78 (d, 2 H, 
Ph H2,6), 6.76 (d, 2 H, Ph H3,5), 4.81 (s, 1 H, Ph OH), 3.90 (t, 2 H, Ak H1), 
1.75 (p, 2 H, Ak H2), 1.44 (p, 2 H, Ak H3), 1.31 (p, 2 H, Ak H13), 1.27 (s, 20 
H, Ak H4-12), 0.89 (t, 3H, Ak H14), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 
153.42 (Ph C1), 149.51 (Ph C4), 116.16 (Ph C2,6), 115.82 (Ph C3,5), 68.97 
(Ak C1), 29.75 (Ak C2), 26.19 (Ak C3), 32.07, 29.81, 29.80, 29.74, 29.73, 
29.56, 29.51 (Ak C4-12), 22.83 (Ak C13), 14.25 (Ak C14), MS (HR-ESI) m/z: 
calc. for [C20H34O2+H+]: 307.2632, found: 307.2631, calc. for [2 
C20H34O2+H+]: 613.5190, found: 613.5194, IR (cm-1): 3435 (PhO-H), 2915, 
2848 (CH3), 1515 (Ph C=C), 1370 (CH3 C-H), 1241, 1230 (C-O stretch), 
1036, 1029 (C-O), 820 (PhH-H), MP: 84.0 ˚C, CHN: calculated for C20H34O2: 
C 78.38, H 11.18%, found: C 78.29, H 11.05%. 
L12C14D 1H NMR (CDCl3, 400.130 MHz, ppm): δ 6.82 (s, 4 H, Ph H2,3,5,6), 
3.90 (t, 4 H, Ak H1), 1.75 (p, 4 H, Ak H2), 1.44 (p, 4 H, Ak H3), 1.31 (p, 4 H, 
Ak H13), 1.27 (s, 36 H, Ak H4-12), 0.89 (t, 6 H, Ak H14), 13C NMR (CDCl3, 
100.613 MHz, ppm): δ 153.36 (Ph C1,4), 115.55 (Ph C2,3,5,6), 68.33 (Ak 
C1), 29.52 (Ak C2), 26.22 (Ak C3), 32.08 (Ak C4), 29.81, 29.76, 29.75, 
29.57, 29.52 (Ak C5-12), 22.85 (Ak C13), 14.26 (Ak C14), IR (cm-1): 2916, 
2848 (CH3), 1513 (Ph C=C), 1240, 1240 (C-O stretch), 1040, 1027 (C-O), 
825 (PhH-H), MP: 80.1˚C. 
L12C16 
4-hexadecyloxyphenol and 1,4-bis (hexadecyloxy)benzene were prepared 
using the general procedure described above, using the following quantities: 
hydroquinone 9.015 g (81.9 mmols, 5 eq), 1-bromododecane 5 g (16.4 
mmols, 1 eq), DMF 50 ml, and K2CO3 6.79 g (49.1 mmols, 3 eq). The yield 
was 3.729 g (68%) for 4-dodecyloxyphenol and 0.853 g (19%) for 1,4-bis 
(dodecyloxy)benzene. 
Analyses: L12C16M 1H NMR (CDCl3, 400.130 MHz, ppm): δ 6.80 (d, 2 H, 
Ph H2,6), 6.79 (d, 2 H, Ph H3,5), 4.59 (s, 1 H, Ph OH), 3.90 (t, 2 H, Ak H1), 
1.77 (p, 2 H, Ak H2), 1.44 (p, 2 H, Ak H3), 1.27 (s, 24 H, Ak H4-15), 0.89 (t, 
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3 H, Ak H16), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 153.42 (Ph C1), 
149.51 (Ph C4), 116.16 (Ph C2,6), 115.82 (Ph C3,5), 68.97 (Ak C1), 29.56 
(Ak C2), 26.19 (Ak C3), 32.07, 29.81, 29.80, 29.74, 29.73, 29.56, 29.51 (Ak 
C4-14), 22.83 (Ak C15), 14.25 (Ak C16), MS (HR-ESI) m/z: calc. for 
[C22H38O2 - H+]:333.2794, found: 333.2797, calc. for [2 C22H38O2 - H+]: 
667.5665, found: 667.5668, IR (cm-1): 3426 (PhO-H), 2915, 2850 (CH3), 
1514 (Ph C=C), 1370 (CH3 C-H), 1241, 1230 (C-O stretch), 1036, 1029 (C-
O), 820 (PhH-H), MP: 88.6˚C, CHN: calculated for C22H38O2: C 78.99, H 
11.45%, found: C 79.01, H 11.49%. 
L12C16D 1H NMR (CDCl3, 400.130 MHz, ppm): δ 6.82 (s, 4 H, Ph H2,3,5,6), 
3.90 (t, 4 H, Ak H1), 1.75 (p, 4 H, Ak H2), 1.44 (p, 4 H, Ak H3), 1.31 (p, 4 H, 
Ak H15), 1.27 (s, 44 H, Ak H4-14), 0.89 (t, 6 H, Ak H16), 13C NMR (CDCl3, 
100.613 MHz, ppm): δ 153.36 (Ph C1,4), 115.55 (Ph C2,3,5,6), 68.33 (Ak 
C1), 29.52 (Ak C2), 26.22 (Ak C3), 32.08, 29.81, 29.76, 29.57 (Ak C4-14), 
22.85 (Ak C15), 14.26 (Ak C16), IR (cm-1): 2916, 2848 (CH3), 1515 (Ph 
C=C), 1243, 1231 (C-O strch.), 1039, 1030 (C-O), 824 (PhH-H), MP: 85.7˚C. 
L12C18 
4-Octadecyloxyphenol and 1,4-bis (octadecyloxy)benzene were prepared 
using the general procedure described above, using the following quantities: 
hydroquinone 8.26 g (75 mmols, 5 eq), 1-bromododecane 5 g (15 mmols, 1 
eq), DMF 50 ml, and K2CO3 6.22 g (45 mmols, 3 eq). The yield was 3.569 g 
(65%) for 4-dodecyloxyphenol and 0.680 g (14%) for 1,4-bis 
(dodecyloxy)benzene. 
Analyses: L12C18M 1H NMR (CDCl3, 400.130 MHz, ppm): δ 6.77 (d, 2 H, 
Ph H2,6), 6.76 (d, 2 H, Ph H3,5), 4.49 (s, 1 H, Ph OH), 3.89 (t, 2 H, Ak H1), 
1.75 (p, 2 H, Ak H2), 1.44 (p, 2 H, Ak H3), 1.26 (s, 28 H, Ak H4-17), 0.88 (t, 
3 H, Ak H18), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 153.52 (Ph C1), 
149.46 (Ph C4), 116.13 (Ph C2,6), 115.78 (Ph C3,5), 68.91 (Ak C1), 32.08 
(Ak C4), 29.57 (Ak C2), 26.20 (Ak C3), 29.85, 29.82, 29.75, 29.74, 29.57, 
29.53, 29.52 (Ak C5-16), 22.84 (Ak C17), 14.26 (Ak C18), MS (HR-ESI) m/z: 
calc. for [C24H42O2 - H+]: 361.3101, found: 361.3102, calc. for [2 C24H42O2 - 
H+]: 723.6292, found: 723.6282, IR (cm-1): 3432 (PhO-H), 2915, 2849 (CH3), 
1515 (Ph C=C), 1370 (CH3 C-H), 1237, 1038 (C-O), 818 (PhH-H, MP: 92.4˚
C, CHN: calculated for C24H42O2: C 79.50, H 11.68%, found: C 79.39, H 
11.65%. 
L12C18D 1H NMR (CDCl3, 400.130 MHz, ppm): δ 6.81 (s, 4 H, Ph H2,3,5,6), 
3.89 (t, 4 H, Ak H1), 1.75 (p, 4 H, Ak H2), 1.44 (p, 4 H, Ak H3), 1.26 (s, 52 H, 
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Ak H4-17), 0.88 (t, 6 H, Ak H18), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 
153.36 (Ph C1,4), 115.55 (Ph C2,3,5,6), 68.33 (Ak C1), 32.08 (Ak C4), 29.52 
(Ak C2), 26.22 (Ak C3), 29.85, 29.76, 29.58, 29.52 (Ak C5-16), 22.85 (Ak 
C17), 14.26 (Ak C18), IR (cm-1): 2915, 2847 (CH3), 1516 (Ph C=C), 1241 (C-
O stretch), 1038, 1026 (C-O), 823 (PhH-H), MP: 90.7˚C. 
6.3.3 L13Cx - 4-(alkyl)phenyl 2,6-di-1H-pyrazol-1-ylisonicotinates   
4-(Alkyl)phenyl 2,6-di-1H-pyrazol-1-ylisonicoti-
nates were obtained using the same protocol 
as for L3 syntheses, described in literature,5 
with some modifications. A mixture of L2 2,6-
di(1H-pyrazol-1’-yl)pyridine-4-carboxylic acid (1 
eq), N,N-dicyclohexyl carbodiimide (DCC) (2.2 
eq), a long alkyl chain alcohol (1eq), and a 
catalytic amount of dimethylaminopyridine 
(DMAP) /caution - very toxic/ in DCM was stirred for 2 days under a CaCl2 
tube, the precipitate was filtered of, and the solvent was removed under 
reduced pressure from the filtrate. After the obtained light-yellow oil 
crystallized, it was recrystallized from MeOH and desiccated. 
L13C6 
4-Hexyloxyphenyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate was 
prepared using the general procedure described above, using the following 
quantities: 2,6-di(1H-pyrazol-1’-yl)pyridine-4-carboxylic acid 1.839 g (7.21 
mmol, 1 eq), 4-hexyloxyphenol 1.400 g (7.21 mmol, 1 eq), DCC 3.271 g 
(15.85 mmol, 2.2 eq), and a pinch of DMAP. Unlike other ligands in L9 
series, L9C6 was hard to purify by recrystallization, so it was purified by 
column chromatography (hexane: ethyl acetate, 4:1) and additionally 
recrystallized from MeCN, which yielded clean product as a white crystalline 
solid (0.972 g, 31%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.59 (d, 2 H, Pz H5), 8.53 
(s, 2 H, Py H3,5), 7.81 (d, 2 H, Pz H3), 7.14 (Ph H2,6), 6.95 (Ph H3,5), 6.54 
(dd, 2 H, Pz H4), 3.97 (t, 2 H Ak H1), 1.80 (p, 2 H, Ak H2), 1.47 (p, 2 H, Ak 
H3), 1.35 (s, 4 H, Ak H4,5), 0.92 (t, 3 H, Ak H6), 13C NMR (CDCl3, 100.613 
MHz, ppm): δ 163.14 (Py C7), 157.40 (Ph C1,4), 151.09 (Py C2,6), 143.09 
(Py C4), 143.09 (Pz C3), 127.40 (Pz C5), 122.23 (Ph C2,6), 115.33 (Ph3,5), 
109.64 (Py C3,5), 108.66 (Pz C4), 68.59 (Ak C1), 31.72 (Ak C4), 29.37 (Ak 
C2), 25.86 (Ak C3), 25.75 (Ak C5), 14.17 (Ak C6), MS (HR-ESI) m/z: calc. 
for [C24H25N5O3 + H+]: 432.2030, found: 432.1951, calc. for [C24H25N5O3 + 
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Na+]: 454.1850, found: 454.1758, IR (cm-1): 2940, 2847 (CH3, CH2), 
1742(C=O), 1575 (Pz C=C, C=N), 1507 (Ph C=C), 1462, 1397 (Pz ring), 
1227, 1201 (Ph-O-R), 1042 (Py C=C-H), 827 (PhH-H), 758 (Pz-Py N-C), 
MP: 108.3-108.5˚C, CHN: calculated for C24H25N5O3: C 66.81, H 5.84, N 
16.23, found: C 67.01, H 5.73, N 16.41%. 
L13C12 
4-(Dodecyl)phenyl 2,6-di-1H-pyrazol-1-ylisonicotinate was prepared using 
the general procedure described above, using the following quantities: 2,6-
di(1H-pyrazol-1’-yl)pyridine-4-carboxylic acid 1.5 g (5.88 mmol, 1 eq), 4-
dodecyloxyphenol 1.640 g (5.88 mmol, 1 eq), DCC 2.670 g (12.93 mmol, 2.2 
eq), and a pinch of DMAP. The product was collected as a white crystalline 
solid (1.722 g, 57%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.59 (d, 2 H, Pz H5), 8.53 
(s, 2 H, Py H3,5), 7.81 (d, 2 H, Pz H3), 7.14 (Ph H2,6), 6.95 (Ph H3,5), 6.54 
(dd, 2 H, Pz H4), 3.96 (t, 2 H Ak H1), 1.79 (p, 2 H, Ak H2), 1.47 (p, 2 H, Ak 
H3), 1.28 (s, 16 H, Ak H4-11), 0.89 (t, 3 H, Ak H12), 13C NMR (CDCl3, 
100.613 MHz, ppm): δ 163.14 (Py C7), 157.40 (Ph C1,4), 151.08 (Py C2,6), 
143.89 (Py C4), 143.08 (Pz C3), 127.39 (Pz C5), 122.22 (Ph C2,6), 115.33 
(Ph3,5), 109.64 (Py C3,5), 108.66 (Pz C4), 68.59 (Ak C1), 29.40 (Ak C2), 
26.18 (Ak C3), 32.06, 29.80, 29.78, 29.74, 29.73, 29.49, 29.54, 22.83 (Ak 
C4-11), 14.26 (Ak C12), MS (HR-ESI) m/z: calc. for [C30H37N5O3+H+]: 
516.2969, found: 516.2971, IR (cm-1): 2911, 2849 (CH3, CH2), 1742(C=O), 
1575 (Pz C=C, C=N), 1506 (Ph C=C), 1464. 1395 (Pz ring), 1226, 1202 (Ph-
O-R), 1042 (Py C=C-H), 826 (PhH-H), MP: 112.4-112.7˚C, CHN: calculated 
for C30H37N5O3: C 69.88, H 7.23, N 13.58, found: C 69.69, H 7.35, N 
13.51%. 
L13C14 
4-(Tetradecyl)phenyl 2,6-di-1H-pyrazol-1-ylisonicotinate was prepared using 
the general procedure described above, using the following quantities: 2,6-
di(1H-pyrazol-1’-yl)pyridine-4-carboxylic acid 0.750 g (2.94 mmol, 1 eq), 4-
tetradecyloxyphenol 0.900 g (2.94 mmol, 1 eq), DCC 1.330 g (6.45 mmol, 
2.2 eq), and a pinch of DMAP. The product was collected as a white 
crystalline solid (0.979 g, 60%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.59 (d, 2 H, Pz H5), 8.53 
(s, 2 H, Py H3,5), 7.81 (d, 2 H, Pz H3), 7.14 (Ph H2,6), 6.95 (Ph H3,5), 6.54 
(dd, 2 H, Pz H4), 3.96 (t, 2 H Ak H1), 1.79 (p, 2 H, Ak H2), 1.47 (p, 2 H, Ak 
H3), 1.28 (s, 20 H, Ak H4-13), 0.89 (t, 3 H, Ak H14), 13C NMR (CDCl3, 
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100.613 MHz, ppm): δ 163.14 (Py C7), 157.40 (Ph C1,4), 151.08 (Py C2,6), 
143.89 (Py C4), 143.08 (Pz C3), 127.39 (Pz C5), 122.22 (Ph C2,6), 115.33 
(Ph3,5), 109.64 (Py C3,5), 108.66 (Pz C4), 68.59 (Ak C1), 29.40 (Ak C2), 
26.18 (Ak C3), 32.06, 29.80, 29.78, 29.74, 29.73, 29.49, 29.54, 22.83 (Ak 
C4-13), 14.26 (Ak C14), MS (HR-ESI) m/z: calc. for [C32H41N5O3+H+]: 
544.3282, found: 544.3438, IR (cm-1): 2911, 2849 (CH3, CH2), 1742(C=O), 
1575 (Pz C=C, C=N), 1506 (Ph C=C), 1464. 1395 (Pz ring), 1226, 1202 (Ph-
O-R), 1042 (Py C=C-H), 826 (PhH-H), MP: 112.6-114.8˚C, CHN: calculated 
for C32H41N5O3: C 70.69, H 7.60, N 12.88, found: C 70.75, H 7.66, N 
12.89%. 
L13C16 
4-(Hexadecyl)phenyl 2,6-di-1H-pyrazol-1-ylisonicotinate was prepared using 
the general procedure described above, using the following quantities: 2,6-
di(1H-pyrazol-1’-yl)pyridine-4-carboxylic acid 1.526 g (5.98 mmol, 1 eq), 4-
hexadecyloxyphenol 2 g (5.98 mmol, 1 eq), DCC 2.714 g (13.15 mmol, 2.2 
eq), and a pinch of DMAP. The product was collected as a white crystalline 
solid (0.477 g, 14%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.59 (d, 2 H, Pz H5), 8.54 
(s, 2 H, Py H3,5), 7.81 (d, 2 H, Pz H3), 7.14 (Ph H2,6), 6.95 (Ph H3,5), 6.54 
(dd, 2 H, Pz H4), 3.97 (t, 2 H Ak H1), 1.79 (p, 2 H, Ak H2), 1.47 (p, 2 H, Ak 
H3), 1.27 (s, 24 H, Ak H4-15), 0.89 (t, 3 H, Ak H16), 13C NMR (CDCl3, 
100.613 MHz, ppm): δ 163.14 (Py C7), 157.40 (Ph C1,4), 151.09 (Py C2,6), 
143.90 (Py C4), 143.09 (Pz C3), 127.40 (Pz C5), 122.23 (Ph C2,6), 115.34 
(Ph3,5), 109.65 (Py C3,5), 108.67 (Pz C4), 68.60 (Ak C1), 29.41 (Ak C2), 
26.19 (Ak C3), 32.07, 29.85, 29.76, 29.74, 29.56, 29.51, 22.83 (Ak C4-13), 
14.27 (Ak C14), MS (HR-ESI) m/z: calc. for [C34H45N5O3+H+]: 572.3595, 
found: 572.3583, IR (cm-1): 2911, 2849 (CH3, CH2), 1742(C=O), 1575 (Pz 
C=C, C=N), 1506 (Ph C=C), 1464. 1395 (Pz ring), 1226, 1202 (Ph-O-R), 
1042 (Py C=C-H), 826 (PhH-H), MP: 112.4 – 112.7˚C, CHN: calculated for 
C34H45N5O3: C 71.42, H 7.93, N 12.25, found: C 71.35, H 7.86, N 12.17%. 
L13C18 
4-(Octadecyl)phenyl 2,6-di-1H-pyrazol-1-ylisonicotinate was prepared using 
the general procedure described above, using the following quantities: 2,6-
di(1H-pyrazol-1’-yl)pyridine-4-carboxylic acid 0.584 g (2.29 mmol, 1 eq), 4-
octadecyloxyphenol 0.830 g (2.29 mmol, 1 eq), DCC 1.039  g (5.04 mmol, 
2.2 eq), and a pinch of DMAP. The product was collected as a white 
crystalline solid (0.300 g, 22%). 
- 210 - 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.60 (d, 2 H, Pz H5), 8.54 
(s, 2 H, Py H3,5), 7.81 (d, 2 H, Pz H3), 7.14 (Ph H2,6), 6.95 (Ph H3,5), 6.54 
(dd, 2 H, Pz H4), 3.97 (t, 2 H Ak H1), 1.79 (p, 2 H, Ak H2), 1.47 (p, 2 H, Ak 
H3), 1.27 (s, 28 H, Ak H4-17), 0.89 (t, 3 H, Ak H18), 13C NMR (CDCl3, 
100.613 MHz, ppm): δ 163.14 (Py C7), 157.40 (Ph C1,4), 151.09 (Py C2,6), 
143.90 (Py C4), 143.09 (Pz C3), 127.40 (Pz C5), 122.23 (Ph C2,6), 115.34 
(Ph3,5), 109.65 (Py C3,5), 108.67 (Pz C4), 68.60 (Ak C1), 29.41 (Ak C2), 
26.19 (Ak C3), 32.08, 29.85, 29.76, 29.74, 29.56, 29.51, 22.84 (Ak C4-17), 
14.27 (Ak C18), MS (HR-ESI) m/z: calc. for [C36H49N5O3+H+]: 600.3908, 
found: 600.3806, IR (cm-1): 2911, 2849 (CH3, CH2), 1742(C=O), 1575 (Pz 
C=C, C=N), 1506 (Ph C=C), 1464. 1395 (Pz ring), 1226, 1202 (Ph-O-R), 
1042 (Py C=C-H), 826 (PhH-H), MP: 115.7 – 116.1˚C, CHN: calculated for 
C36H49N5O3: C 72.09, H 8.23, N 11.68, found: C 71.99, H 8.17, N 11.56%. 
6.3.4 [Fe(L11Cx)2][BF4]2 
The [Fe(L11Cx)2][BF4] iron(II) complexes were obtained by this general 
procedure, adapted from the literature:5 The ligand 
(1 eq.) was dissolved in either dichloroethane 
(DCE) or in DCM, and iron(II) tetrafluoroborate 
hexahydrate (0.5 eq.) was dissolved in acetone, 
with a gentle heating, if necessary. The two 
solutions were mixed at room temperature, which 
lead to instant formation of an intensively coloured 
solution, which, if necessary, was filtered through a 
pipette filter. The obtained complex solution was 
set for pentane diffusion crystallization. 
[Fe(L11C6)2][BF4]2 
Hexyl(2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate iron(II)  tetrafluoroborate 
was obtained using the general procedure described above, using the 
following quantities: hexyl(2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate (200 
mg, 0.589 mmol, 1 eq), iron(II) tetrafluoroborate hexhydrate (111.2 mg, 
0.295 mmol, 0.5 eq), which yielded dark-red crystals (199 mg, 74%).  
Analyses: paramagnetic 1H NMR (MeCN-D3, 300 MHz, ppm): δ 39.56, 
38.54, 25.88, 22.47 (Pz H3,4,5, Py H3,5), MS (HR-ESI) m/z: calc. for 
[C18H21N5O2 + H+]: 340.1768, found: 340.1776, calc. for [C18H21N5O2 + Na+]: 
362.1587, found: 362.1595, IR (cm-1): 2920, 2851 (CH3, CH2), 1733 (C=O), 
1575 (Pz C=C, C=N), 1471, 1408 (Pz ring), 1254 (C-OR), 1034 broad (B-F), 
519.05 broad (B-F).  
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[Fe(L11C12)2][BF4]2 
Dodecyl(2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate iron(II)  tetrafluoro-
borate was obtained using the general procedure described above, using the 
following quantities: dodecyl(2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate 
(150 mg, 0.35 mmol, 2 eq), iron(II) tetrafluoroborate hexhydrate (63 mg, 0.17 
mmol, 1eq). The reagents were dissolved in DCM and Me2CO, and 
crystallized by Et2O diffusion, which yielded a dark-red powder (135 mg, 
70%). 
Analyses: paramagnetic 1H NMR (MeCN-D3, 300 MHz, ppm): δ 39.62, 
38.95, 26.03, 22.60 (Pz H3,4,5, Py H3,5), MS (HR-ESI) m/z: calc. for 
[C24H33N5O2 + H+]: 424.2707, found: 424.2706, calc. for [C24H33N5O2 + Na+]: 
446.2526, found: 446.2526, IR (cm-1): 2920, 2851 (CH3, CH2), 1733 (C=O), 
1575 (Pz C=C, C=N), 1471, 1408 (Pz ring), 1254 (C-OR), 1034 broad (B-F), 
519.05 broad (B-F), CHN: calculated for [(C24H33N5O2)2Fe][BF4]2: C 53.55, H 
6.18, N 13.01%, found: C 53.38, H 6.33, N 12.94%. 
[Fe(L11C14)2][BF4]2 
Tetradecyl(2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate iron(II)  tetrafluoro-
borate was obtained using the general procedure described above, using the 
following quantities: tetradecyl(2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate 
(150 mg, 0.33 mmol, 2 eq), iron(II) tetrafluoroborate hexhydrate (67 mg, 0.18 
mmol, 1eq). The reagents were dissolved in DCM and Me2CO, and 
crystallized by Et2O diffusion, which yielded a dark-red powder (107 mg, 
55%). 
Analyses: paramagnetic 1H NMR (MeCN-D3, 300 MHz, ppm): δ 39.60, 
38.70, 25.93, 22.60 (Pz H3,4,5, Py H3,5), MS (HR-ESI) m/z: calc. for 
[C26H37N5O2 + H+]: 452.3020, found: 452.3018, calc. for [C26H37N5O2 + Na+]: 
474.2839, found: 474.2840, IR (cm-1): 2920, 2851 (CH3, CH2), 1733 (C=O), 
1575 (Pz C=C, C=N), 1471, 1408 (Pz ring), 1254 (C-OR), 1034 broad (B-F), 
519.05 broad (B-F), CHN: calculated for [(C26H37N5O2)2Fe][BF4]2: C 55.14, H 
6.58, N 12.37%, found: C 54.89, H 6.46, N 12.24%. 
[Fe(L11C16)2][BF4]2 
Hexadecyl(2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate iron(II)  tetrafluoro-
borate was obtained using the general procedure described above, using the 
following quantities: hexadecyl(2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate 
(150 mg, 0.312 mmol, 2 eq), iron(II) tetrafluoroborate hexhydrate (59 mg, 
0.156 mmol, 1eq). The reagents were dissolved in DCM and Me2CO, and 
crystallized by Et2O diffusion, which yielded a dark red powder. 
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Analyses: paramagnetic 1H NMR (MeCN-D3, 300 MHz, ppm): δ 39.83, 
39.06, 26.11, 22.74 (Pz H3,4,5, Py H3,5), MS (HR-ESI) m/z: calc. for 
[C28H41N5O2 + H+]: 480.3333, found: 480.3333, calc. for [C28H41N5O2 + Na+]: 
502.3152, found: 502.3153, IR (cm-1): 2920, 2851 (CH3, CH2), 1733 (C=O), 
1575 (Pz C=C, C=N), 1471, 1408 (Pz ring), 1254 (C-OR), 1034 broad (B-F), 
519.05 broad (B-F), CHN: calculated for [(C28H41N5O2)2Fe][BF4]2: C 56.58, H 
6.95, N 11.78%, found: C 56.51, H 6.79, N 11.64%. 
[Fe(L11C18)2][BF4]2·2.5H2O 
Octadecyl(2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate iron(II)  tetrafluoro-
borate was obtained using the general procedure described above, using the 
following quantities: octadecyl(2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate 
(185 mg, 0.364 mmol, 1 eq), iron(II) tetrafluoroborate hexhydrate (68.8 mg, 
0.182 mmol, 0.5 eq). The reagents were dissolved in DCE and Me2CO, and 
crystallized by pentane diffusion, which yielded dark red crystals (91 mg, 
40%). 
Analyses: paramagnetic 1H NMR (MeCN-D3, 300 MHz, ppm): δ 39.79, 
39.06, 26.03, 22.67 (Pz H3,4,5, Py H3,5), MS (HR-ESI) m/z: calc. for 
[C30H45N5O2 + H+]: 508.3646, found: 508.3643, calc. for [C30H45N5O2 + Na+]: 
530.3465, found: 530.3463, IR (cm-1): 2920, 2851 (CH3, CH2), 1733 (C=O), 
1575 (Pz C=C, C=N), 1471, 1408 (Pz ring), 1254 (C-OR), 1034 broad (B-F), 
519.05 broad (B-F), CHN: calculated for [(C30H45N5O2)2Fe][BF4]2·2.5 H2O: C 
55.87, H 7.42, N  10.86%, found: C 55.89, H 7.71, N 10.85%. 
6.3.5 [Fe(L13Cx)2][BF4]2 
The [Fe(L13Cx)2][BF4] iron(II) complexes were 
obtained using this general procedure: the ligand (1 
eq.) was dissolved in dichloroethane (DCE), and 
iron(II) tetrafluoroborate hexahydrate (0.5 eq.) was 
dissolved in fresh, not moist acetone. The two 
solutions were mixed at room temperature, and the 
obtained deep red solution, if necessary, was 
filtered through a pipette filter. The solution was 
distributed into many vials and diluted to different 
concentrations by DCE-acetone mixture and set for 
a slow pentane diffusion crystallization. After many 
trials with the crystallization conditions single crystals were obtained. 
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[Fe(L13C6)2][BF4]2 
4-Hexyloxyphenyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate iron(II)  
tetrafluoroborate was obtained using the general procedure described 
above, using the following quantities: hexyloxyphenyl (2,6-di-1H-pyrazol-1-
yl)pyridine-4-carboxylate (200 mg, 0.464 mmol, 1 eq), iron(II) 
tetrafluoroborate hexhydrate (87.5 mg, 0.232 mmol, 0.5 eq), which yielded a 
light red powder (139.5 mg, 55%).  
Analyses: paramagnetic 1H NMR (MeCN-D3:CDCl3 mixture, 300 MHz, 
ppm): δ 42.35, 41.25, 27.20, 24.13 (Pz H3,4,5, Py H3,5), MS (HR-ESI) m/z: 
calc. for [C24H25N5O3 + H+]: 432.2030, found: 432.2032, calc. for 
[C24H25N5O3 + Na+]: 454.1850, found: 454.1848, IR (cm-1): 2922, 2850 (CH3, 
CH2), 1749, 1731 (C=O), 1571 (Pz C=C, C=N), 1504 (Ph C=C), 1470, 1408 
(Pz ring), 1237, 1185 (Ph-O-R), 826 (PhH-H), 756 (Pz-Py N-C), 1030, 520 
broad (B-F), CHN: calculated for [(C24H25N5O3)2Fe][BF4]2·1DCE: C 50.40, H 
4.57, N 11.76%, found: C 50.16, H 4.15, N 12.14%. 
[Fe(L13C12)2][BF4]2 
4-Dodecyloxyphenyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate iron(II)  
tetrafluoroborate was obtained using the general procedure described 
above, using the following quantities: dodecyloxyphenyl (2,6-di-1H-pyrazol-
1-yl)pyridine-4-carboxylate (200 mg, 0.400 mmol, 1 eq), iron(II) 
tetrafluoroborate hexhydrate (75.6 mg, 0.200 mmol, 0.5 eq), which yielded a 
dark red powder (131 mg, 53%). 
Analyses: paramagnetic 1H NMR (MeCN-D3:CDCl3 mixture, 300 MHz, 
ppm): δ 40.14, 39.43, 26.22, 22.98 (Pz H3,4,5, Py H3,5), MS (HR-ESI) m/z: 
calc. for [C30H37N5O3 + H+]: 516.2969, found: 516.2970, calc. for 
[C30H37N5O3 + Na+]: 538.2789, found: 538.2783, IR (cm-1): 2922, 2852 (CH3, 
CH2), 1746(C=O), 1575 (Pz C=C, C=N), 1506 (Ph C=C), 1472, 1408 (Pz 
ring), 1235, 1186 (Ph-O-R), 826 (PhH-H), 756 (Pz-Py N-C), 1030, 520 broad 
(B-F), CHN: calculated for [(C30H37N5O3)2Fe][BF4]2·0.5 DCE: C 55.92, H 
5.85, N 10.69%, found: C 55.92, H 5.75, N 11.01%. 
[Fe(L13C14)2][BF4]2 
4-Tetradecyloxyphenyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate iron(II)  
tetrafluoroborate was obtained using the general procedure described 
above, using the following quantities: tetradecyloxyphenyl (2,6-di-1H-
pyrazol-1-yl)pyridine-4-carboxylate (200 mg, 0.379 mmol, 1 eq), iron(II) 
tetrafluoroborate hexhydrate (71.5 mg, 0.190 mmol, 0.5 eq), which yielded a 
light red powder (71 mg, 29%). 
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Analyses: paramagnetic 1H NMR (MeCN-D3:CDCl3 mixture, 300 MHz, 
ppm): δ 42.55, 41.26, 27.17, 24.27 (Pz H3,4,5, Py H3,5), MS (HR-ESI) m/z: 
calc. for [C32H41N5O3 + H+]: 544.3282, found: 544.3284, calc. for 
[C32H41N5O3 + Na+]: 566.3102, found: 566.1442, IR (cm-1): 2922, 2850 (CH3, 
CH2), 1749, 1731 (C=O), 1571 (Pz C=C, C=N), 1504 (Ph C=C), 1470, 1408 
(Pz ring), 1237, 1185 (Ph-O-R), 826 (PhH-H), 756 (Pz-Py N-C), 1030, 520 
broad (B-F), CHN: calculated for [(C32H41N5O3)2Fe][BF4]2: C 58.37, H 6.28, 
N 10.64%, found: C 58.19, H 6.19, N 10.68%. 
[Fe(L13C16)2][BF4]2 
4-Hexadecyloxyphenyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate iron(II)  
tetrafluoroborate was obtained using the general procedure described 
above, using the following quantities: hexadecyloxyphenyl (2,6-di-1H-
pyrazol-1-yl)pyridine-4-carboxylate (188.3 mg, 0.339 mmol, 1 eq), iron(II) 
tetrafluoroborate hexhydrate (63.9 mg, 0.169 mmol, 0.5 eq), which yielded a 
dark red powder (141 mg, 50%). 
Analyses: paramagnetic 1H NMR (MeCN-D3:CDCl3 mixture, 300 MHz, 
ppm): δ 42.54, 41.39, 27.18, 24.58 (Pz H3,4,5, Py H3,5), MS (HR-ESI) m/z: 
calc. for [C34H45N5O3 + H+]: 572.3595, found: 572.3595, calc. for 
[C34H45N5O3+ Na+]: 594.3415, found: 592.1604, IR (cm-1): 2922, 2850 (CH3, 
CH2), 1749, 1731 (C=O), 1571 (Pz C=C, C=N), 1504 (Ph C=C), 1470, 1408 
(Pz ring), 1237, 1185 (Ph-O-R), 826 (PhH-H), 756 (Pz-Py N-C), 1030, 520 
broad (B-F), CHN: calculated for [(C34H45N5O3)2Fe][BF4]2: C 59.49, H 6.61, 
N 10.20%, found: C 59.33, H 6.67, N 10.06%. 
[Fe(L13C18)2][BF4]2 
4-Octadecyloxyphenyl (2,6-di-1H-pyrazol-1-yl)pyridine-4-carboxylate iron(II)  
tetrafluoroborate was obtained using the general procedure described 
above, using the following quantities: octadecyloxyphenyl (2,6-di-1H-pyrazol-
1-yl)pyridine-4-carboxylate (187.4 mg, 0.320 mmol, 1 eq), iron(II) 
tetrafluoroborate hexhydrate (60.6 mg, 0.160 mmol, 0.5 eq), which yielded a 
light red powder (133 mg, 59%). 
Analyses: paramagnetic 1H NMR (MeCN-D3:CDCl3 mixture, 300 MHz, 
ppm): δ 42.87, 41.28, 27.09, 24.67 (Pz H3,4,5, Py H3,5), MS (HR-ESI) m/z: 
calc. for [C36H49N5O3 + H+]: 600.3908, found: 600.3909, calc. for 
[C36H49N5O3 + Na+]: 622.3728, found: 622.3726, IR (cm-1): 2922, 2850 (CH3, 
CH2), 1749, 1731 (C=O), 1571 (Pz C=C, C=N), 1504 (Ph C=C), 1470, 1408 
(Pz ring), 1237, 1185 (Ph-O-R), 826 (PhH-H), 756 (Pz-Py N-C), 1030, 520 
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broad (B-F), CHN: calculated for [(C36H49N5O3)2Fe][BF4]2: C 60.51, H 6.91, 
N 9.80%, found: C 60.51, H 6.99, N 9.83%.  
6.4 Pyrazole-substituted bis(pyrazol-1-yl)pyridine 
derivatives with long alkyl chains, and their iron(II) 
complexes 
The labelling scheme for this chapter is shown on the Fig. 6.2.  
 
Fig. 6.2 Labelling Scheme for the ligands in the Chapters 4 and 5 
6.4.1 L14, L15, L16 – the precursors 
L14 - 2-Fluoro-6-(1H-pyrazol-1-yl)pyridine 
2-Fluoro-6-(1H-pyrazol-1-yl)pyridine was obtained using 
the procedure, described in literature,7 with some 
modifications: 1H-pyrazole 1.4 g (20 mmol, 1 eq) was 
dissolved in a DMF (20 ml) / THF (6 ml) solvent mixture, 
after which NaH 60% dispersion in mineral oil 0.8 g (20 
mmols, 1 eq) was slowly added, and the reaction mixture was stirred for 10 
minutes until hydrogen emission ceased. Then 2,6-difluoropyridine 1.9 ml 
(2.417 g, 21 mmol, 1.05 eq) was added in in one go, after which the reaction 
mixture was stirred  for 20 h at room temperature, while being monitored by 
TLC. Water (250 ml) was then poured into the reaction mixture, which was 
extracted with Et2O (50 ml x 5). The organic layer was washed with water, 
brine, dried with MgSO4, after which the solvent was removed under reduced 
pressure, and the obtained yellowish oil was separated by column 
chromatography (1% MeOH in DCM, 2nd spot, rf = 0.7). That yielded the 
target product as a slightly yellowish oil which crystallize very slowly into 
transparent prismatic crystals (1.135g, 34%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.46 (d, 1 H, Pz H5), 7.87 
(p, 1 H, Py H4), 7.84 (ddd, 1 H, Py H3) 7.72 (d, 1 H, Pz H3), 6.79 (ddd, 1 H, 
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Py H5), 6.45 (dd, 1 H, Pz H4), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 
163.55, 161.15 (Py C7), 150.12, 149.98 (Py C2), 143.49, 143.41  (Py C4), 
142.76 (Pz C3), 127.55 (Pz C5), 109.00, 108.96 (Pz C4), 108.31 (Py C3), 
106.24, 105.89 (Py C5), 19F NMR (CDCl3, 400.130 MHz, ppm): δ 68.27 (Py 
F6), MS (HR-ESI) m/z: calc. for [C8H6F+H+]: 164.0619, found: 164.0610, 
calc. for [C8H6F+Na+]: 186.0438, found: 186.0429, IR (cm-1): 1606, 1586 (Py 
C=C in plane vibr.), 1461 (Py ring), 1237 (Ar-F), 754 (Py C-H), MP: ca  20oC. 
L15 - 2,6-Bis(4-iodo-1H-pyrazol-1-yl)pyridine 
2,6-Bis(4-iodo-1H-pyrazol-1-yl)pyridine was 
obtained using the following procedure: 4-
iodopyrazole 1 g (5.16 mmol, 2 eq) was 
dissolved in DMF (15 ml) and THF (5 ml) 
solvent mixture, after which NaH 60% dispersion in mineral oil 0.258 g (6.45 
mmols, 2.5 eq) was slowly added. The reaction mixture, was stirred for 1.5 h 
until clear solution formed, then 2,6-difluoro pyridine (0.23 ml, 0.297 g, 2.58 
mmol, 1 eq) was added, after which the reaction mixture was stirred  for 16 h 
at room temperature, while being monitored by TLC. Then water (180 ml) 
was slowly added into the reaction mixture, and the precipitate was filtered 
off, dried, and washed with hexane and desiccated. That yielded the target 
product as a white powder (0.807 g, 68%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.61 (s, 2 H, Pz H5), 7.96 
(dd, 1 H, Py H4), 7.84 (d, 2 H, Py H3,5), 7.74 (s, 2 H, Pz H3), 13C NMR 
(CDCl3, 100.613 MHz, ppm): δ 149.30 (Py C2,6), 147.33 (Pz C3), 141.97 
(Py C4), 131.70 (Pz C5), 109.66 (Py C3), 60.46 (Pz C4), MS (HR-ESI) m/z: 
calc. for [C11H7I2N5+H+]: 463.8864, found: 463.8857, calc. for 
[C11H7I2N5+Na+]: 485.8683, found: 485.8688, IR (cm-1): 1609, 1585 (Py C=C 
in plane vibr.), 1466 (Py ring), 797 (Py 2,6-subs. C-H, 752 (Py C-H), 600 (C-
I), MP: 177.8–178.5oC. 
L16 - 2-(4-iodo-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine 
2-(4-Iodo-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)py-
ridine was obtained using the following 
procedure, similar to the one for L14. 4-
Iodopyrazole (3.24 g, 16.7 mmol, 1 eq) was 
dissolved in DMF (17 ml) and THF (5 ml) solvent mixture, after which NaH 
60% dispersion in mineral oil (0.703 g, 17.5 mmols, 1.05 eq) was slowly 
added. The reaction mixture was stirred until hydrogen emission ceased and 
a clear solution was formed. Then 2-fluoro-6-(1H-pyrazol-1-yl)pyridine (2.723 
g, 16.7 mmol, 1 eq) was added, after which the reaction mixture was stirred  
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for 16 h at room temperature. Then water (200 ml) was poured into the 
reaction mixture, the precipitate was filtered off, dried, and washed with 
hexane and desiccated, which yielded the target product as a white powder 
(4.832g, 86%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.61 (s, 1 H, PzA H5), 
8.55 (d, 1 H, PzB H5), 7.94 (dd, 1 H, Py H4), 7.89 (dd, 1 H, Py H5), 7.79 (dd, 
1 H, Py H3), 7.76 (d, 1 H, PzB H3), 7.73 (s, 1 H, PzA H3), 6.50 (dd, 1 H, PzB 
H4), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 150.20 (Py C6), 149.28 (Py 
C2), 147.16 (PzA C3), 142.69 (PzB C3), 141.74 (Py C4), 131.68 (PzA C5), 
127.19 (PzB C5), 110.13 (Py C5), 109.02 (Py C3), 108.29 (PzB C4), 66.22 
(PzA C4), MS (HR-ESI) m/z: calc. for [C11H8IN5+H+]: 337.9897, found: 
337.9892, calc. for [C11H8IN5+Na+]: 359.9717, found: 359.9712, IR (cm-1): 
1608, 1585 (Py C=C in plane vibr.), 1468 (Py ring), 800 (Py 2,6-subs. C-H, 
752 (Py C-H), 603 (C-I), MP: 141.9oC, CHN: calculated for C11H8N5I: C 
39.19, H 2.39, N 20.77 %, found: C 39.33, H 2.35, N 20.66 %. 
6.4.2 L17CxM - 2-(4-alkyl-1-yn-1-yl-1H-pyrazol-1-yl)-6-(1H-pyrazol-
1-yl)pyridines 
L17C12M 
2-(4-Dodec-1-yn-1-yl-1H-pyrazol-1-
yl)-6-(1H-pyrazol-1-yl)pyridine was 
obtained using the  procedure 
described in the literature,8 with 
some modifications. A mixture of 2-
(4-iodo-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine L16 (1.2 g, 3.56 mmol, 1 
eq),  tetrakis(triphenylphosphine)-palladium(0) (0.123 g, 0.1 mmols, 0.03 
eq), triphenylphosphine (0.149 g, 0.56 mmol, 0.16 eq), CuI (0.149 g, 0.78 
mmol, 0.22 eq), Et3N (15 ml), and anhydrous dioxane (7 ml) was placed in a 
Schlenk tube and degassed by bubbling nitrogen through for 2 h. 1-
Dodecyne (1.141 ml, 0.887 g, 5.34 mmol, 1.5 eq) was then added, the 
reaction mixture was heated to 80˚C and kept stirring at that temperature for 
2 days, while being monitored by TLC. Later the reaction mixture was 
filtered, the solvent was removed from the filtrate, and recrystallization from 
MeCN resulted in a white powder of the target product (0.639 g, 48%).  
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.59 (s, 1 H, PzA H5), 
8.55 (d, 1 H, PzB H5), 7.92 (t, 1 H, Py H4), 7.87 (dd, 1 H, Py H3), 7.82 (dd, 1 
H, Py H5), 7.76 (d, 1 H, PzB H3), 7.75 (s, 1 H, PzA H3), 6.50 (dd, 1 H, PzB 
H4), 2.41 (t, 2 H, Ak H3), 1.61 (p, 2 H, Ak H4), 1.45 (s, 2 H, Ak H5), 1.28 (s, 
12 H, Ak H6-11), 0.88 (t, 3 H, Ak H 12), 13C NMR (CDCl3, 100.613 MHz, 
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ppm): δ 150.23 (Py C2), 149.65 (Py C6), 144.72 (PzA C3), 142.61 (PzB C3), 
141.59 (Py C4), 129.12 (PzA C5), 127.14 (PzB C5), 109.78 (Py C3), 109.49 
(Py C5), 108.20 (PzB C4), 106.61 (Ak C1), 92.78 (Ak C2), 70.85 (PzA C4), 
28.88 (Ak C4), 19.66 (Ak C3), 32.05, 29.74, 29.69, 29.47, 29.32, 29.12, 
22.83 (Ak C5-11), 14.25 (Ak C12), MS (HR-ESI) m/z: calc. for 
[C23H29N5+H+]: 376.2496, found: 376.2493, calc. for [C23H29N5+Na+]: 
398.2315, found: 398.2319, calc. for [2 C23H29N5+Na+]: 773.4738, found: 
773.4737, IR (cm-1): 2915, 2847 (CH3, CH2), 1602, 1582 (Pz C=N), 1465 (Py 
ring), 795 (Py C-H), MP: 58.1–58.5oC, CHN: calculated for C23H29N5: C 
73.57, H 7.78, N 18.65, found: C 73.60, H 7.75, N 18.47 %. 
L17C14M 
2-(4-Tetradec-1-yn-1-yl-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine was 
prepared using the same  procedure as for L17C12M, using the following 
quantities: 2-(4-iodo-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine L16 (1.448 
g, 4.3 mmol, 1 eq),  tetrakis(triphenylphosphine)palladium(0) (0.149 g, 0.13 
mmols, 0.03 eq), triphenylphosphine (0.180 g, 0.69 mmol, 0.16 eq), CuI 
(0.180 g, 0.95 mmol, 0.22 eq), Et3N (18 ml), and anhydrous dioxane (9 ml), 
and  1-tetradecyne (1.580 ml, 1.252 g, 6.4 mmol, 1.5 eq), which yielded 
white crystals of 2-(4-tetradec-1-yn-1-yl-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-
yl)pyridine (0.759 g, 44 %). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.59 (s, 1 H, PzA H5), 
8.55 (dd, 1 H, PzB H5), 7.92 (t, 1 H, Py H4), 7.87 (dd, 1 H, Py H3), 7.82 (dd, 
1 H, Py H5), 7.76 (d, 1 H, PzB H3), 7.75 (s, 1 H, PzA H3), 6.49 (dd, 1 H, PzB 
H4), 2.41 (t, 2 H, Ak H3), 1.61 (p, 2 H, Ak H4), 1.45 (s, 2 H, Ak H5), 1.26 (s, 
16 H, Ak H6-13), 0.87 (t, 3 H, Ak H14), 13C NMR (CDCl3, 100.613 MHz, 
ppm): δ 150.23 (Py C2), 149.64 (Py C6), 144.71 (PzA C3), 142.60 (PzB C3), 
141.58 (Py C4), 129.11 (PzA C5), 127.13 (PzB C5), 109.77 (Py C3), 109.48 
(Py C5), 108.19 (PzB C4), 106.60 (Ak C1), 92.78 (Ak C2), 70.85 (PzA C4), 
28.88 (Ak C4), 19.66 (Ak C3), 32.06, 29.82, 29.79, 29.69, 29.50, 29.33, 
29.12, 22.83 (Ak C5-13), 14.25 (Ak C14), MS (HR-ESI) m/z: calc. for 
[C25H33N5+H+]: 404.2809, found: 408.2803, calc. for [C25H33N5+Na+]: 
426.2628, found: 426.2628, calc. for [2 C25H33N5+Na+]: 829.5364, found: 
829.5364, IR (cm-1): 2914, 2847 (CH3, CH2), 1602, 1582 (Pz C=N), 1467 (Py 
ring), 795 (Py C-H), MP: 66.1–66.3, CHN: calculated for C25H33N5: C 74.40, 
H 8.24, N 17.35, found: C 74.11, H 7.92, N 17.02 %. 
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L17C16M 
2-(4-Hexadec-1-yn-1-yl-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine was 
prepared using the same  procedure as for L17C12M, using the following 
quantities: 2-(4-iodo-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine L16 (1.448 
g, 4.3 mmol, 1 eq),  tetrakis(triphenylphosphine)palladium(0) (0.149 g, 0.13 
mmols, 0.03 eq), triphenylphosphine (0.180 g, 0.69 mmol, 0.16 eq), CuI 
(0.180 g, 0.95 mmol, 0.22 eq), Et3N (18 ml), and anhydrous dioxane (9 ml), 
and  1-hexadecyne (1.80 ml, 1.433 g, 6.44 mmol, 1.5 eq), ), which yielded 
white crystals of 2-(4-hexadec-1-yn-1-yl-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-
yl)pyridine (0.780 g, 42 %). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.59 (s, 1 H, PzA H5), 
8.55 (d, 1 H, PzB H5), 7.93 (t, 1 H, Py H4), 7.87 (dd, 1 H, Py H3), 7.82 (dd, 1 
H, Py H5), 7.77 (d, 1 H, PzB H3), 7.75 (s, 1 H, PzA H3), 6.50 (dd, 1 H, PzB 
H4), 2.41 (t, 2 H, Ak H3), 1.61 (p, 2 H, Ak H4), 1.45 (s, 2 H, Ak H5), 1.28 (s, 
20 H, Ak H6-15), 0.88 (t, 3 H, Ak H 16), 13C NMR (CDCl3, 100.613 MHz, 
ppm): δ 150.23 (Py C2), 149.65 (Py C6), 144.72 (PzA C3), 142.61 (PzB C3), 
141.59 (Py C4), 129.12 (PzA C5), 127.14 (PzB C5), 109.78 (Py C3), 109.49 
(Py C5), 108.20 (PzB C4), 106.61 (Ak C1), 92.78 (Ak C2), 70.85 (PzA C4), 
28.88 (Ak C4), 19.66 (Ak C3), 32.05, 29.74, 29.69, 29.47, 29.32, 29.12, 
22.83 (Ak C5-15), 14.25 (Ak C16), MS (HR-ESI) m/z: calc. for 
[C27H37N5+H+]: 432.3122, found: 432.3122, calc. for [C27H37N5+Na+]: 
454.2941, found: 454.2936, calc. for [2 C27H37N5+Na+]: 885.5990, found: 
885.5986, IR (cm-1): 2914, 2847 (CH3, CH2), 1602, 1583 (Pz C=N), 1469 (Py 
ring), 795 (Py C-H), MP: 68.8–71.0oC, CHN: calculated for C27H37N5: C 
75.13, H 8.64, N 16.23, found: C 75.08, H 8.83, N 15.97 %. 
L17C18M 
2-(4-Octadec-1-yn-1-yl-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine was 
prepared using the same  procedure as for L17C12M, using the following 
quantities: 2-(4-iodo-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine L16 (1.022 
g, 3.032 mmol, 1 eq),  tetrakis(triphenylphosphine)palladium(0) (0.105 g, 
0.091 mmol, 0.03 eq), triphenylphosphine (0.127 g, 0.484 mmol, 0.16 eq), 
CuI (0.127 g, 0.667 mmol, 0.22 eq), Et3N dried with KOH pellets (12 ml), 
anhydrous dioxane (6 ml), and  1-octadecyne (solid, 759 g, 3.032 mmol, 1 
eq), ), which yielded white crystals of 2-(4-octadec-1-yn-1-yl-1H-pyrazol-1-
yl)-6-(1H-pyrazol-1-yl)pyridine (0.574 g, 34%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.60 (s, 1 H, PzA H5), 
8.56 (d, 1 H, PzB H5), 7.93 (t, 1 H, Py H4), 7.87 (dd, 1 H, Py H3), 7.82 (dd, 1 
- 220 - 
H, Py H5), 7.76 (d, 1 H, PzB H3), 7.75 (s, 1 H, PzA H3), 6.50 (dd, 1 H, PzB 
H4), 2.41 (t, 2 H, Ak H3), 1.61 (p, 2 H, Ak H4), 1.45 (s, 2 H, Ak H5), 1.25 (s, 
24 H, Ak H6-15), 0.88 (t, 3 H, Ak H 16), 13C NMR (CDCl3, 100.613 MHz, 
ppm): δ 150.23 (Py C2), 149.64 (Py C6), 144.72 (PzA C3), 142.62 (PzB C3), 
141.60(Py C4), 129.12 (PzA C5), 127.14 (PzB C5), 109.78 (Py C3), 109.49 
(Py C5), 108.21 (PzB C4), 106.59 (Ak C1), 92.78 (Ak C2), 70.83 (PzA C4), 
28.88 (Ak C4), 19.66 (Ak C3), 32.07, 29.84, 29.69, 29.69, 29.51, 29.33, 
29.13, 22.88 (Ak C5-15), 14.26 (Ak C16), IR (cm-1): 2914, 2847 (CH3, CH2), 
1602, 1583 (Pz C=N), 1469 (Py ring), 795 (Py C-H), MP: 75.3 – 75.6oC, 
CHN: calculated for C29H41N5: C 75.77, H 8.99, N 15.24, found: C 75.49, H 
8.86, N 15.06 %. 
6.4.3 L17CxD - 2,6-bis(4-alk-1-yn-1-yl-1H-pyrazol-1-yl)pyridines 
L17C12D 
2,6-Bis(4-dodec-1-yn-1-yl-1H-
pyrazol-1-yl)pyridine was obtained 
using the  procedure described in 
the literature,8 with some 
modifications.  A mixture of 2,6-
bis(4-iodo-1H-pyrazol-1-yl)pyridine L15 (2 g, 4.3 mmol, 1 eq),  tetra-
kis(triphenylphosphine)palladium(0) (0.250 g, 0.22 mmols, 0.05 eq), 
triphenylphosphine (0.1812 g, 6.9 mmol, 0.16 eq), CuI (0.181 g, 0.10 mmol, 
0.22 eq), Et3N (18 ml), and anhydrous dioxane (9 ml) was placed in a 
Schlenk tube and degassed by bubbling nitrogen through for 2 h. 1-
Dodecyne (2.78 ml, 2.161 g, 13.0 mmol, 3 eq) was then added, the reaction 
mixture was heated to 80˚C and kept stirring at that temperature for 2 days, 
while being monitored by TLC. The reaction mixture was filtered, the solvent 
was removed from the filtrate under reduced pressure, the crude mixture 
was separated by column chromatography (Hx/EtOAc, 12/1), and the 
obtained products were additionally recrystallized from EtOAc to remove the 
orange admixture of the palladium catalyst that passed through the column. 
This yielded the disubstituted product IG17C12D (spot #3, rf = 0.42, 1.454 g, 
62 %), and monosubstituted product IG17C12M (spot #4, rf = 0.26, 0.147 g, 
9 %), both as white powders.  
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.56 (s, 2 H, Pz H5), 7.90 
(t, 1 H, Py H4), 7.81 (d, 2 H, Py H3,5) 7.73 (s, 2 H, Pz H3), 2.40 (t, 4 H, Ak 
H3), 1.61 (p, 4 H, Ak H4), 1.45 (s, 4 H, Ak H5), 1.28 (s, 24 H, Ak H6-11), 
0.88 (t, 6 H, Ak H 12), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 149.64 (Py 
C4), 144.73 (Pz C5), 141.56 (Py C4), 129.10 (Pz C3), 109.68 (Py C3,5), 
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106.73 (Ak C1), 92.78 (Ak C2), 70.77 (Pz C4), 28.88 (Ak C4), 19.64 (Ak C3), 
32.05, 29.75, 29.68, 29.47, 29.33, 29.12, 22.82 (Ak C5-11), 14.24 (Ak C12), 
MS (HR-ESI) m/z: calc. for [C35H49N5+H+]: 540.4061, found: 540.4058, calc. 
for [C35H49N5+Na+]: 562.3880, found: 562.3876, IR (cm-1): 2915, 2847 (CH3, 
CH2), 1598, 1587 (Pz C=N), 1463 (Py ring), 800 (Py C-H), MP: 80.9oC, 
CHN: calculated for C35H49N5: C 77.88, H 9.15, N 12.97, found: C 77.66, H 
9.26, N 13.11 %. 
L17C14D 
2,6-Bis(4-tetradec-1-yn-1-yl-1H-pyrazol-1-yl)pyridine was prepared using the 
same  procedure as for L13C12D, using the following quantities: 2,6-bis(4-
iodo-1H-pyrazol-1-yl)pyridine L12 (2 g, 4.32 mmol, 1 eq),  
tetrakis(triphenylphosphine)palladium(0) (0.250 g, 0.22 mmols, 0.05 eq), 
triphenylphosphine (0.181 g, 6.9 mmol, 0.16 eq), CuI (0.181 g, 0.95 mmol, 
0.22 eq), Et3N (18 ml), and anhydrous dioxane (9 ml), and tetradecyne (3.19 
ml, 2.519 g, 12.96 mmol, 3 eq). The product was purified by multiple 
recrystallizations from EtOAc. During the purification a spillage occured, so 
the yield was lower than expected (0.589 g, 23%), and the product was 
obtained as white plate crystals. 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.56 (s, 2 H, Pz H5), 7.90 
(t, 1 H, Py H4), 7.81 (d, 2 H, Py H3,5) 7.73 (s, 2 H, Pz H3), 2.40 (t, 4 H, Ak 
H3), 1.61 (p, 4 H, Ak H4), 1.45 (s, 4 H, Ak H5), 1.28 (s, 32 H, Ak H6-13), 
0.88 (t, 6 H, Ak H14), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 148.64 (Py 
C4), 143.73 (Pz C5), 140.56 (Py C4), 128.10 (Pz C3), 108.68 (Py C3,5), 
105.73 (Ak C1), 91.78 (Ak C2), 69.77 (Pz C4), 27.88 (Ak C4), 18.64 (Ak C3), 
31.05, 28.75, 28.68, 28.47, 28.33, 28.12, 21.82 (Ak C5-13), 13.24 (Ak C14), 
IR (cm-1): 2915, 2847 (CH3, CH2), 1598, 1582 (Pz C=N), 1463 (Py ring), 800 
(Py C-H), MP: 84.9–85.5oC, CHN: calculated for C39H57N5: C 78.61, H 9.64, 
N 11.75, found: C 78.70, H 9.52, N 11.82 %. 
L17C16D 
2,6-Bis(4-hexadec-1-yn-1-yl-1H-pyrazol-1-yl)pyridine was prepared using the 
same  procedure as for L13C12D, using the following quantities: 2,6-bis(4-
iodo-1H-pyrazol-1-yl)pyridine L12 (2 g, 4.3 mmol, 1 eq),  tetrakis(triphenyl-
phosphine)palladium(0) (0.250 g, 0.22 mmols, 0.05 eq), triphenylphosphine 
(0.181 g, 6.9 mmol, 0.16 eq), CuI (0.181 g, 0.95 mmol, 0.22 eq), Et3N (18 
ml), and anhydrous dioxane (9 ml), and hexadecyne (3.63 ml, 2.891 g, 13.0 
mmol, 3 eq). The product was purified by recrystallization from EtOAc, 
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instead of by column chromatography, which yielded the target product as a 
white crystalline powder (1.119 g, 40 %). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.56 (s, 2 H, Pz H5), 7.90 
(t, 1 H, Py H4), 7.81 (d, 2 H, Py H3,5) 7.73 (s, 2 H, Pz H3), 2.40 (t, 4 H, Ak 
H3), 1.61 (p, 4 H, Ak H4), 1.45 (s, 4 H, Ak H5), 1.28 (s, 40 H, Ak H6-15), 
0.88 (t, 6 H, Ak H16), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 148.64 (Py 
C4), 143.73 (Pz C5), 140.56 (Py C4), 128.10 (Pz C3), 108.68 (Py C3,5), 
105.73 (Ak C1), 91.78 (Ak C2), 69.77 (Pz C4), 27.88 (Ak C4), 18.64 (Ak C3), 
31.05, 28.75, 28.68, 28.47, 28.33, 28.12, 21.82 (Ak C5-15), 13.24 (Ak C16), 
IR (cm-1): 2915, 2847 (CH3, CH2), 1599, 1582 (Pz C=N), 1481, 1463 (Py 
ring), 800 (Py C-H), MP: 89.4–89.7oC, CHN: calculated for C43H65N5: C 
79.21, H 10.05, N 10.74, found: C 79.07, H 9.96, N 10.84 %. 
6.4.4 L18CxM - 2-(4-alk-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-
yl)pyridines 
L18C12M 
2-(4-Dodec-1H-pyrazol-1-yl)-6-(1H-pyrazol-
1-yl)pyridine was obtained using the same 
procedure as for L14C12D, using the 
following quantities: 2-(4-dodec-1-yn-1-yl-
1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine 
L13C12M (0.350 g, 0.93 mmol, 1 eq), EtOAc 
(152 ml), 10% Pd on activated carbon (0.272 g, 0.23 mmol, 0.25 eq), which 
yielded 2-(4-dodec-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine (0.320 g, 
91%) as a white crystalline powder. 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.59 (d, 1 H, PzB H5), 
8.32 (s, 1 H, PzA H5), 7.90 (t, 1 H, Py H4), 7.82 (d, 1 H, Py H5), 7.80 (dd, 1 
H, Py H3), 7.76 (d, 1 H, PzB H3), 7.59 (dd, 1 H, PzA H3), 6.49 (dd, 1H, PzB 
H4), 2.55 (t, 2 H, Ak H1), 1.64 (p, 2 H, Ak H2), 1.35 (p, 2 H, Ak H3), 1.28 (s, 
16 H, Ak H4-11), 0.88 (t, 3 H, Ak H 12), 13C NMR (CDCl3, 100.613 MHz, 
ppm): δ 150.30 (Py C6), 150.11 (Py C2), 142.73 (PzA C3), 142.42 (PzB C3), 
141.36 (Py C4), 127.14 (PzB C5), 124.84 (PzA C5), 124.61 (PzA C4), 
109.13 (Py C5), 108.94 (Py C3), 107.97 (PzB C4), 30.81 (Ak C2), 29.75 (Ak 
C3), 24.38 (Ak C1), 32.06, 29.58, 29.49, 29.43, 22.82 (Ak C4-11), 14.24 (Ak 
C12), IR (cm-1): 2918, 2848 (CH3, CH2), 1604, 1582 (Pz C=N), 1469 (Py 
ring), 799, 722 (Py C-H), MP: 66.3–66.7oC, CHN: calculated for C23H33N5: C 
72.78, H 8.76, N 18.45, found: C 72.72, H 8.87, N 18.33 %. 
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L18C14M 
2-(4-Tetra-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine was obtained using 
the same procedure as for L14C12D, using the following quantities: 2-(4-
tetradec-1-yn-1-yl-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine L13C14M 
(0.4 g, 0.99 mmol, 1 eq), EtOAc (162 ml), 10% Pd on activated carbon 
(0.288 g, 0.25 mmol, 0.25 eq), which yielded 2-(4-tetradec-1H-pyrazol-1-yl)-
6-(1H-pyrazol-1-yl)pyridine (0.216 g, 54%) as a white powder. 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.59 (d, 1 H, PzB H5), 
8.32 (s, 1 H, PzA H5), 7.90 (t, 1 H, Py H4), 7.82 (d, 1 H, Py H5), 7.80 (dd, 1 
H, Py H3), 7.76 (d, 1 H, PzB H3), 7.59 (dd, 1 H, PzA H3), 6.49 (dd, 1H, PzB 
H4), 2.55 (t, 2 H, Ak H1), 1.64 (p, 2 H, Ak H2), 1.35 (p, 2 H, Ak H3), 1.26 (s, 
20 H, Ak H4-13), 0.88 (t, 3 H, Ak H 14), 13C NMR (CDCl3, 100.613 MHz, 
ppm): δ 150.33 (Py C2), 150.14 (Py C6), 142.76 (PzA C3), 142.45 (PzB C3), 
141.39 (Py C4), 127.17 (PzB C5), 124.88 (PzA C5), 124.64 (PzA C4), 
109.15 (Py C5), 108.97 (Py C3), 108.00 (PzB C4), 30.83 (Ak C2), 29.50 (Ak 
C3), 24.40 (Ak C1), 32.07, 29.76, 29.59, 29.44, 22.83 (Ak C4-13), 14.26 (Ak 
C14), IR (cm-1): 2916, 2848 (CH3, CH2), 1604, 1582 (Pz C=N), 1470 (Py 
ring), 798, 772 (Py C-H), MP: 72.4–72.7oC, CHN: calculated for C25H37N5: C 
73.67, H 9.15, N 17.18, found: C 73.78, H 9.27, N 17.05 %. 
L18C16M 
2-(4-Hexadec-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine was obtained 
using the same procedure as for L14C12D, using the following quantities: 2-
(4-hexadec-1-yn-1-yl-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine L13C16M 
(0.400 g, 0.93 mmol, 1 eq), EtOAc (151 ml), 10% Pd on activated carbon 
(0.270 g, 0.23 mmol, 0.25 eq), which yielded 2-(4-tetradec-1H-pyrazol-1-yl)-
6-(1H-pyrazol-1-yl)pyridine (0.380 g, 94%) as a white powder. 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.59 (d, 1 H, PzB H5), 
8.32 (s, 1 H, PzA H5), 7.90 (t, 1 H, Py H4), 7.82 (d, 1 H, Py H5), 7.80 (dd, 1 
H, Py H3), 7.76 (d, 1 H, PzB H3), 7.59 (dd, 1 H, PzA H3), 6.49 (dd, 1H, PzB 
H4), 2.55 (t, 2 H, Ak H1), 1.66 (p, 2 H, Ak H2), 1.35 (p, 2 H, Ak H3), 1.28 (s, 
24 H, Ak H4-15), 0.88 (t, 3 H, Ak H 16), 13C NMR (CDCl3, 100.613 MHz, 
ppm): δ 150.30 (Py C6), 150.11 (Py C2), 142.73 (PzA C3), 142.42 (PzB C3), 
141.36 (Py C4), 127.14 (PzB C5), 124.84 (PzA C5), 124.61 (PzA C4), 
109.13 (Py C5), 108.94 (Py C3), 107.97 (PzB C4), 30.81 (Ak C2), 29.75 (Ak 
C3), 24.38 (Ak C1), 32.06, 29.58, 29.49, 29.43, 22.82 (Ak C4-15), 14.24 (Ak 
C16), IR (cm-1): 2914, 2847 (CH3, CH2), 1609, 1582 (Pz C=N), 1474 (Py 
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ring), 798, 778 (Py C-H), MP: 78.6–78.9oC, CHN: calculated for C27H41N5: C 
74.44, H 9.49, N 16.08, found: C 74.52, H 9.57, N 15.87 %. 
L18C18M 
2-(4-Octadec-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine was obtained 
using the same procedure as for L14C12D, using the following quantities: 2-
(4-octadec-1-yn-1-yl-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine L13C18M 
(0.200 g, 0.435 mmol, 1 eq), EtOAc (70 ml), 10% Pd on activated carbon 
(0.127 g, 0.1088 mmol, 0.25 eq), which yielded 2-(4-tetradec-1H-pyrazol-1-
yl)-6-(1H-pyrazol-1-yl)pyridine (0.185 g, 92%) as a white powder. 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.59 (d, 1 H, PzB H5), 
8.32 (s, 1 H, PzA H5), 7.91 (t, 1 H, Py H4), 7.91 (dd, 1 H, Py H3), 7.82 (d, 1 
H, Py H5), 7.80 (dd, 1 H, Py H3), 7.76 (d, 1 H, PzB H3), 7.59 (dd, 1 H, PzA 
H3), 6.50 (dd, 1H, PzB H4), 2.55 (t, 2 H, Ak H1), 1.63 (p, 2 H, Ak H2), 1.34 
(p, 2 H, Ak H3), 1.25 (s, 28 H, Ak H4-15), 0.88 (t, 3 H, Ak H 16), 13C NMR 
(CDCl3, 100.613 MHz, ppm): δ 150.28 (Py C6), 150.10 (Py C2), 142.76 (PzA 
C3), 142.45 (PzB C3), 141.41 (Py C4), 127.17 (PzB C5), 124.88 (PzA C5), 
124.63 (PzA C4), 109.13 (Py C5), 108.95 (Py C3), 108.01 (PzB C4), 30.83 
(Ak C2), 29.77 (Ak C3), 24.39 (Ak C1), 32.08, 29.85, 29.77, 29.60, 29.51, 
29.47, 22.85 (Ak C4-15), 14.28 (Ak C16), IR (cm-1): 2914, 2847 (CH3, CH2), 
1609, 1582 (Pz C=N), 1474 (Py ring), 798, 778 (Py C-H), MP: 81.4 – 81.9oC, 
CHN: calculated for C29H45N5: C 75.12, H 9.78, N 15.10, found: C 75.06, H 
9.56, N 14.93 %. 
6.4.5 L18CxD - 2-(4-alk-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-
yl)pyridines 
L18C12D 
2-(4-dodec-1H-pyrazol-1-yl)-6-(1H-
pyrazol-1-yl)pyridine was obtained 
using the  procedure described in the 
literature,8 with some modifications. 
2-(4-Dodec-1-yn-1-yl-1H-pyrazol-1-yl)-
6-(1H-pyrazol-1-yl)pyridine L13C12D (0.243 g, 0.45 mmol, 1 eq) was 
dissolved in EtOAc (75 ml), degassed in a Schlenk tube by bubbling N2 
through the solution, after which 10% Pd on activated carbon (0.131 g, 0.11 
mmol, 0.25 eq) was added in. Then the gas was thoroughly extracted from 
the Schlenk tube, until high vacuum was achieved and the solvent started 
boiling. H2 gas was then added from a bladder via subaseal and a needle, 
and the extraction and filling with H2 was repeated once more. The reaction 
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mixture was stirred for 4 days at room temperature, while being monitored 
by TLC, after which it was vacuum filtered through a Celite plug, the plug 
was washed with 120 ml of EtOAc. Solvent was removed under vacuum 
from the obtained filtrate, which afforded 2,6-bis(4-dodec-1H-pyrazol-1-
yl)pyridine as a  white crystalline powder (0.224 g, 91%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.32 (s, 2 H, Pz H5), 7.87 
(dd, 1 H, Py H4), 7.77 (dd, 2 H, Py H3,5), 7.59 (s, 2 H, Pz H3), 2.55 (t, 4 H, 
Ak H1), 1.64 (p, 4 H, Ak H2), 1.35 (p, 4 H, Ak H3), 1.26 (s, 32 H, Ak H4-11), 
0.88 (t, 6 H, Ak H12), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 150.25 (Py 
C2,6), 142.66 (Pz C5), 141.27 (Py C4), 124.94 (Pz C4), 124.56 (Pz C3), 
108.66 (Py C5,6), 30.91 (Ak C2), 29.46 (Ak C3), 24.42 (Ak C1), 32.06, 
29.82, 29.79, 29.77, 29.60, 29.50, 29.46 (Ak C4-11), 14.25 (Ak C12), MS 
(HR-ESI) m/z: calc. for [C35H57N5+H+]: 548.4687, found: 548.4677, calc. for 
[C35H57N5+Na+]: 570.4506, found: 570.4490, IR (cm-1): 2916, 2849 (CH3, 
CH2), 1613, 1586 (Pz C=N), 1466 (Py ring), 800 (Py C-H), MP: 64.7–65.4oC, 
CHN: calculated for C35H57N5: C 76.73, H 10.49, N 12.78, found: C 76.83, H 
10.33, N 12.78 %. 
L18C14D 
2,6-Bis(4-tetradec-1H-pyrazol-1-yl)pyridine was prepared using the same 
procedure as for L14C12D, using the following quantities: 2-(4-tetradec-1-
yn-1-yl-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine L13C14D (0.265 g, 0.45 
mmol, 1 eq), EtOAc (75 ml + 100 ml for washing the Celite plug), 10% Pd on 
activated carbon (0.129 g, 0.11 mmol, 0.25 eq), which yielded 2,6-bis(4-
tetradec-1H-pyrazol-1-yl)pyridine (0.189 g, 70%) as a white powder. 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.32 (s, 2 H, Pz H5), 7.87 
(dd, 1 H, Py H4), 7.77 (dd, 2 H, Py H3,5), 7.58 (s, 2 H, Pz H3), 2.55 (t, 4 H, 
Ak H1), 1.64 (p, 4 H, Ak H2), 1.35 (p, 4 H, Ak H3), 1.26 (s, 40 H, Ak H4-13), 
0.88 (t, 6 H, Ak H14), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 150.25 (Py 
C2,6), 142.66 (Pz C5), 141.27 (Py C4), 124.94 (Pz C4), 124.56 (Pz C3), 
108.66 (Py C5,6), 30.91 (Ak C2), 29.46 (Ak C3), 24.42 (Ak C1), 32.06, 
29.82, 29.79, 29.77, 29.60, 29.50, 29.46 (Ak C4-13), 14.25 (Ak C14), IR (cm-
1): 2916, 2849 (CH3, CH2), 1613, 1584 (Pz C=N), 1466 (Py ring), 800 (Py C-
H), MP: 72.8–73.2oC, CHN: calculated for C39H65N5: C 77.56, H 10.85, N 
11.60, found: C 77.31, H 11.17, N 11.56 %. 
L18C16D 
2,6-bis(4-hexadec-1H-pyrazol-1-yl)pyridine was prepared using the same 
procedure as for L14C12D, using the following quantities: 2-(4-hexadec-1-
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yn-1-yl-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine L13C16D (0.5 g, 0.84 
mmol, 1 eq), EtOAc (137 ml + 200 ml for washing the Celite plug), 10% Pd 
on activated carbon (0.245 g, 0.21 mmol, 0.25 eq), which yielded 2,6-bis(4-
tetradec-1H-pyrazol-1-yl)pyridine (0.339 g, 61%) as a white powder. 
1H NMR (CDCl3, 400.130 MHz, ppm): δ 8.32 (s, 2 H, Pz H5), 7.87 (dd, 1 H, 
Py H4), 7.77 (dd, 2 H, Py H3,5), 7.59 (s, 2 H, Pz H3), 2.55 (t, 4 H, Ak H1), 
1.64 (p, 4 H, Ak H2), 1.35 (p, 4 H, Ak H3), 1.26 (s, 48 H, Ak H4-15), 0.88 (t, 
6 H, Ak H16), 13C NMR (CDCl3, 100.613 MHz, ppm): δ 150.25 (Py C2,6), 
142.66 (Pz C5), 141.27 (Py C4), 124.94 (Pz C4), 124.56 (Pz C3), 108.66 (Py 
C5,6), 30.91 (Ak C2), 29.46 (Ak C3), 24.42 (Ak C1), 32.06, 29.82, 29.79, 
29.77, 29.60, 29.50, 29.46 (Ak C4-15), 14.25 (Ak C16), IR (cm-1): 2915, 
2848 (CH3, CH2), 1613, 1586 (Pz C=N), 1466 (Py ring), 799 (Py C-H), MP: 
75.2–75.9oC, CHN: calculated for C43H73N5: C 78.24, H 11.15, N 10.61, 
found: C 78.15, H 11.26, N 10.44 %. 
6.4.6 Iron(II) complexes 
The [Fe(L17Cx)2][BF4]2 iron(II) complexes were obtained by this general 
procedure, adapted from the literature:4 The ligand (1 eq.) was dissolved in 
either dichloroethane (DCE) or in DCM, and iron(II) tetrafluoroborate 
hexahydrate (0.5 eq.) was dissolved in acetone, with a gentle heating, if 
necessary. The two solutions were mixed at room temperature, which lead 
to instant formation of an intensively coloured solution, which, if necessary, 
was filtered through a pipette filter. The obtained complex solution was set 
for pentane diffusion crystallization. 
[Fe(L16)2][BF4]2 
2-(4-Iodo-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl) 
pyridine iron(II) tetrafluoro-borate was obtained 
by dissolving 2-(4-iodo-1H-pyrazol-1-yl)-6-(1H-
pyrazol-1-yl)pyridine (133 mg, 0.390 mmol, 2 
eq) and iron(II) tetrafluoroborate hexhydrate 
(74.5 mg, 0.20 mmol, 1eq) in MeCN. The two 
solutions were mixed, and the product was 
crystallized by slow iPr2O diffusion, which yielded a brown-orange powder 
(110 mg, 62%). 
Analyses: paramagnetic NMR (MeCN-D3, 300 MHz, ppm): δ 66.04, 60.45 
(1 H PzA H3 and 1 H PzB H3), 57.81 (1 H, PzB H4), 47.16, 41.99 (1 H PzA 
H5 and 1H PzB H5), 38.55, 28.53 (1 H, Py H3 and 1 H, Py H5), 1.05 (Py 
H4), IR (cm-1): 3128 (Py N-Fe), 1621, 1588 (Py C=C), 1472 (Py ring 
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substituted), 1032, 782 (B-F), 596 (C-I), CHN: calculated for 
[(C11H8I1N5)2Fe][BF4]2: C 29.24, H 1.78, N 15.50%, found: C 29.18, H 1.86 , 
N 15.35%. 
[Fe(L17CxM)2][BF4]2 
[Fe(L17C12M)2][BF4]2 
2-(4-Dodec-1-yn-1-yl-1H-pyrazol-1-yl)-6-
(1H-pyrazol-1-yl)pyridine iron(II) tetrafluoro-
borate was obtained using the general 
procedure described above, using the 
following quantities: 2-(4-dodec-1-yn-1-yl-
1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine 
(150 mg, 0.40 mmol, 2 eq), iron(II) tetrafluoroborate hexhydrate (75.4 mg, 
0.20 mmol, 1eq). The reactants were dissolved in DCM, mixed, and the 
product was crystallized by iPr2O diffusion, which yielded a brown-orange 
powder (107 mg, 54%). 
Analyses: paramagnetic NMR (CDCl3, 300 MHz, ppm): δ 67.75, 60.78 (1 H, 
PzA H3 and 1 H, PzB H3), 58.78 (1 H, PzB H4), 51.01, 41.07 (1 H, PzA H5 
and 1 H, PzB H5), 37.20, 28.87 (1 H, Py H3 and 1H, Py H5), -1.66 (1 H, py 
H4), IR (cm-1): 3129 (Py N-Fe), 2923, 2853 (CH3, CH2), 2242 (C≡C), 1621, 
1588 (Py C=C), 1476 (Py ring substituted), 1055, 784 (B-F), CHN: calculated 
for [(C23H29N5)2Fe][BF4]2: C 56.35, H 5.96, N 14.29%, found: C 56.18, H 
6.12, N 14.16%. 
[Fe(L17C14M)2][BF4]2 
2-(4-Tetra-1-yn-1-yl-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine iron(II) 
tetrafluoroborate was obtained using the general procedure described 
above, using the following quantities: 2-(4-tetradec-1-yn-1-yl-1H-pyrazol-1-
yl)-6-(1H-pyrazol-1-yl)pyridine (150 mg, 0.37 mmol, 2 eq), iron(II) 
tetrafluoroborate hexhydrate (70.2 mg, 0.19 mmol, 1eq). The reactants were 
dissolved in DCM, mixed, and the product was crystallized by iPr2O 
diffusion, which yielded a brown-orange powder (94 mg, 48%). 
Analyses: paramagnetic NMR (CDCl3, 300 MHz, ppm): δ 67.72, 60.72 (1 H, 
PzA H3 and 1 H, PzB H3), 58.60 (1 H, PzB H4), 51.17, 41.01 (1 H, PzA H5 
and 1 H, PzB H5), 37.13, 28.94 (1 H, Py H3 and 1H, Py H5), -1.82 (1 H, py 
H4), IR (cm-1): 3129 (Py N-Fe), 2922, 2852 (CH3, CH2), 2244 (C≡C), 1621, 
1588 (Py C=C), 1476 (Py ring substituted), 1056, 784 (B-F), CHN: calculated 
for [(C25H33N5)2Fe][BF4]2·2H2O: C 55.99, H 6.58, N 13.06%, found: C 56.08, 
H 6.28, N 13.19 %. 
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[Fe(L17C16M)2][BF4]2 
2-(4-Hexa-1-yn-1-yl-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine iron(II) 
tetrafluoroborate was obtained using the general procedure described 
above, using the following quantities: 2-(4-hexadec-1-yn-1-yl-1H-pyrazol-1-
yl)-6-(1H-pyrazol-1-yl)pyridine (150 mg, 0.348 mmol, 2 eq), iron(II) 
tetrafluoroborate hexhydrate (65.6 mg, 0.174 mmol, 1eq). The reactants 
were dissolved in DCM, mixed, and the product was crystallized by iPr2O 
diffusion, which yielded a yellow powder (63 mg, 37%). 
Analyses: paramagnetic NMR (CDCl3, 300 MHz, ppm): δ 67.69, 60.76 (1 H, 
PzA H3 and 1 H, PzB H3), 58.65 (1 H, PzB H4), 50.86, 40.99 (1 H, PzA H5 
and 1 H, PzB H5), 37.10, 29.20 (1 H, Py H3 and 1H, Py H5), -1.74 (1 H, py 
H4), IR (cm-1): 3130 (Py N-Fe), 2916, 2850 (CH3, CH2), 2237 (C≡C), 1624, 
1588 (Py C=C), 1480 (Py ring substituted), 1048, 784 (B-F), CHN: calculated 
for [(C27H37N5)2Fe][BF4]2: C 59.36, H 6.83, N 12.82%, found: C59.21 , H 
6.75, N 12.73%. 
[Fe(L17C18M)2][BF4]2 
2-(4-Octa-1-yn-1-yl-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine iron(II) 
tetrafluoroborate was obtained using the general procedure described 
above, using the following quantities: 2-(4-octadec-1-yn-1-yl-1H-pyrazol-1-
yl)-6-(1H-pyrazol-1-yl)pyridine (75.5 mg, 0.163 mmol, 2 eq), iron(II) 
tetrafluoroborate hexhydrate (31 mg, 0.082 mmol, 1eq). The ligand was 
dissolved in DCE, and the iron salt was dissolved in acetone, the two 
solutions were mixed, and the obtained yellow solution was slowly 
precipitated by pentane diffusion, which yielded product as small yellow 
plate crystals (58 mg, 62%). 
Analyses: IR (cm-1): 3127 (Py N-Fe), 2916, 2849 (CH3, CH2), 2167 (C≡C), 
1623, 1588 (Py C=C), 1479 (Py ring substituted), 1061, 784 (B-F). 
[Fe(L17CxD)2][BF4]2 
[Fe(L17C12D)2][BF4]2 
2,6-Bis(4-dodec-1-yn-1-yl-1H-pyrazol-1-
yl)py-ridine iron(II) tetrafluoroborate was 
obtained using the general procedure 
described above, using the following 
quantities: 2,6-bis(4-dodec-1-yn-1-yl-1H-
pyrazol-1-yl)pyri-dine (142 mg, 0.26 mmol, 2 eq), iron(II) tetrafluoroborate 
hexhydrate (49.6 mg, 0.13 mmol, 1eq). The reagents were dissolved in 
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DCM, and crystallized by iPr2O diffusion, which yielded a yellow powder (66 
mg, 43%). 
Analyses: paramagnetic NMR (CDCl3 + MeCN-D3, 300 MHz, ppm): δ 59.42 
(2 H, Pz H3), 43.25 (2 H, Pz H5), 41.09 (2 H, Py H3,5), -3.77 (1 H, py H4), 
IR (cm-1): 3203 (Py N-Fe), 2916, 2848 (CH3, CH2), 2260 (C≡C), 1599, 1587 
(Py C=C), 1479 (Py ring substituted), 1069, 779 (B-F), 800 (Py  C-H). 
 [Fe(L17C14D)2][BF4]2 
2,6-Bis(4-tetradec-1-yn-1-yl-1H-pyrazol-1-yl)pyridine iron(II) tetrafluoroborate 
was obtained using the general procedure described above, using the 
following quantities: 2,6-bis(4-tetradec-1-yn-1-yl-1H-pyrazol-1-yl)pyridine 
(150 mg, 0.25 mmol, 2 eq), iron(II) tetrafluoroborate hexhydrate (47.5 mg, 
0.126 mmol, 1eq). The reagents were dissolved in DCM, and crystallized by 
iPr2O diffusion, which yielded a yellow powder (38 mg, 21%). 
Analyses: paramagnetic NMR (CDCl3 + MeCN-D3, 300 MHz, ppm): δ 59.07 
(2 H, Pz H3), 42.92 (2 H, Pz H5), 40.96 (2 H, Py H3,5), 7.79 (1 H, py H4), IR 
(cm-1): 3146 (Py N-Fe), 2915, 2848 (CH3, CH2), 2251 (C≡C), 1599, 1564 (Py 
C=C), 1477 (Py ring substituted), 1060, 779 (B-F), 800 (Py C-H), CHN: 
calculated for [(C39H57N5)2Fe][BF4]2·0.5 DCE: C 64.51, H 7.95, N 9.52%, 
found: C 64.59 , H 7.66 , N 9.48%. 
[Fe(L17C16D)2][BF4]2 
2,6-Bis(4-hexadec-1-yn-1-yl-1H-pyrazol-1-yl)pyridine iron(II) tetrafluoro-
borate was obtained using the general procedure described above, using the 
following quantities: 2,6-bis(4-hexadec-1-yn-1-yl-1H-pyrazol-1-yl)pyridine 
(150 mg, 0.23 mmol, 2 eq), iron(II) tetrafluoroborate hexhydrate (43.4 mg, 
0.120 mmol, 1eq). The reagents were dissolved in DCM, and crystallized by 
iPr2O diffusion, which yielded a brown-orange powder (114 mg, 62%). 
Analyses: paramagnetic NMR (CDCl3 + MeCN-D3, 300 MHz, ppm): δ 59.41 
(2 H, Pz H3), 43.29 (2 H, Pz H5), 41.06 (2 H, Py H3,5), -3.66 (1 H, py H4), 
IR (cm-1): 3125 (Py N-Fe), 2916, 2849 (CH3, CH2), 2242 (C≡C), 1591, 1566 
(Py C=C), 1477 (Py ring substituted), 1056, 791 (B-F), 800 (Py C-H), CHN: 
calculated for [(C43H65N5)2Fe][BF4]2 : C 67.36, H 8.54, N 9.13%, found: C 
67.43, H 8.50, N 9.05%. 
[Fe(L18CxM)2][BF4]2 
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[Fe(L18C12M)2][BF4]2 
2-(4-Dodec-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-
yl)pyridine iron(II) tetrafluoroborate was obtained 
using the general procedure described above, 
using the following quantities: 2-(4-dodec-1H-
pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine (90.7 
mg, 0.239 mmol, 2 eq), iron(II) tetrafluoroborate 
hexhydrate (45.1 mg, 0.119 mmol, 1eq). The ligand was dissolved in DCE, 
and the iron salt was dissolved in acetone. The two solutions were mixed, 
and the bright red solution was slowly precipitated by pentane diffusion, 
which yielded the product as yellow plate crystals (82 mg, 69%). 
Analyses: paramagnetic NMR (MeCN-D3, 300 MHz, ppm): δ 58.81, 54.65 
(3 H, PzA H3, PzB H3, PzB H4), 35.94, 35.47, 33.00 (4H, PzA H5, PzB H5, 
Py 3,5), 3.45 (Py H4), MS (HR-ESI) m/z: calc. for [C23H33N5+H+]: 380.2809, 
found: 380.2809, calc. for [C23H33N5+Na+]: 402.2628, found: 402.2631, calc. 
for [2 C23H33N5+Na+]: 781.5364, found: 781.5367, IR (cm-1): 3122 (Py N-Fe), 
2917, 2850 (CH3, CH2), 1622, 1591 (Py C=C), 1481 (Py ring substituted), 
1034, 789 (B-F), 801 (Py C-H). 
[Fe(L18C14M)2][BF4]2 
2-(4-Tetradec-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine iron(II) tetrafluoro-
borate was obtained using the general procedure described above, using the 
following quantities: 2-(4-tetradec-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)py-
ridine (147 mg, 0.361 mmol, 2 eq), iron(II) tetrafluoroborate hexhydrate (68.1 
mg, 0.180 mmol, 1eq). The ligand was dissolved in DCE, and the iron salt 
was dissolved in acetone. The two solutions were mixed, and the bright red 
solution was slowly precipitated by pentane diffusion, which yielded product 
as yellow plate crystals (155 mg, 82%). 
Analyses: paramagnetic NMR (MeCN-D3, 300 MHz, ppm): δ 58.65, 54.56 
(3 H, PzA H3, PzB H3, PzB H4), 35.89, 35.43, 32.98 (4H, PzA H5, PzB H5, 
Py 3,5), 3.44 (Py H4), MS (HR-ESI) m/z: calc. for [C25H37N5+H+]: 408.3122, 
found: 408.3124, calc. for [C25H37N5+Na+]: 430.2941, found: 430.2940, calc. 
for [2 C25H37N5+Na+]: 837.5990, found: 837.5991, IR (cm-1): 3122 (Py N-Fe), 
2916, 2850 (CH3, CH2), 1623, 1591 (Py C=C), 1481 (Py ring substituted), 
1035, 789 (B-F), 801 (Py C-H). 
[Fe(L18C16M)2][BF4]2 
2-(4-Hexadec-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine iron(II) tetrafluoro-
borate was obtained using the general procedure described above, using the 
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following quantities: 2-(4-hexadec-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)py-
ridine (186 mg, 0.427 mmol, 2 eq), iron(II) tetrafluoroborate hexhydrate (80.6 
mg, 0.214 mmol, 1eq). The ligand was dissolved in DCE, and the iron salt 
was dissolved in acetone. The two solutions were mixed, and the obtained 
bright red solution was slowly precipitated by pentane diffusion, which 
yielded product as yellow plate crystals (194 mg, 83%). 
Analyses: paramagnetic NMR (MeCN-D3, 300 MHz, ppm): δ 58.64, 54.51 
(3 H, PzA H3, PzB H3, PzB H4), 35.89, 35.43, 33.03 (4H, PzA H5, PzB H5, 
Py 3,5), 3.43 (Py H4), MS (HR-ESI) m/z: calc. for [C27H41N5+H+]: 436.3435, 
found: 436.3435, calc. for [C27H41N5+Na+]: 458.3254, found: 458.3258, calc. 
for [2 C27H41N5 + Na+]: 893.6616, found: 893.6620, IR (cm-1): 3122 (Py N-
Fe), 2916, 2849 (CH3, CH2), 1622, 1591 (Py C=C), 1481 (Py ring 
substituted), 1035, 789 (B-F), 801 (Py C-H), CHN: calculated for 
[(C37H41N5)2Fe][BF4]2: C 58.92, H 7.51, N 12.72%, found: C 58.84, H 7.37, N 
12.64%. 
[Fe(L18C18M)2][BF4]2 
2-(4-Octadec-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)pyridine iron(II) tetrafluoro-
borate was obtained using the general procedure described above, using the 
following quantities: 2-(4-octadec-1H-pyrazol-1-yl)-6-(1H-pyrazol-1-yl)py-
ridine (77.5 mg, 0.167 mmol, 2 eq), iron(II) tetrafluoroborate hexhydrate 
(31.6 mg, 0.084 mmol, 1eq). The ligand was dissolved in DCE, and the iron 
salt was dissolved in acetone. The two solutions were mixed, and the 
obtained yellow solution was slowly precipitated by pentane diffusion, which 
yielded product as yellow plate crystals (71 mg, 73%). 
Analyses: IR (cm-1): 3122 (Py N-Fe), 2916, 2849 (CH3, CH2), 1623, 1590 (Py 
C=C), 1482 (Py ring substituted), 1047, 789 (B-F), 801 (Py C-H), CHN: 
calculated for [(C29H45N5)2Fe][BF4]2: C 60.22, H 7.84, N 12.11%, found: C 
60.01, H 7.60, N 12.95 %. 
[Fe(L18CxD)2][BF4]2 
[Fe(L18C12D)2][BF4]2 
2-(4-Dodec-1H-pyrazol-1-yl)-6-(1H-pyrazol-
1-yl)pyridine iron(II) tetrafluoroborate was 
obtained using the general procedure 
described above, using the following 
quantities: 2-(4-dodec-1H-pyrazol-1-yl)-6-
(1H-pyrazol-1-yl)pyridine (47.7 mg, 0.087 
mmol, 2 eq), iron(II) tetrafluoroborate 
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hexhydrate (16.4 mg, 0.044 mmol, 1eq). The ligand was dissolved in DCE, 
and the iron salt was dissolved in acetone. The two solutions were mixed, 
and the obtained bright red solution was slowly precipitated by pentane 
diffusion, which yielded product as brown-red powder (30 mg, 52%). 
Analyses: paramagnetic NMR (MeCN-D3, 300 MHz, ppm): δ 50.98 (2H, Pz 
H3), 33.60 (2H Pz H5), 32.68 (2H, Py H3,5), 3.94 (Py H4), MS (HR-ESI) 
m/z: calc. for [C35H57N5+H+]: 548.4687, found: 548.4685, calc. for 
[C35H57N5+Na+]: 570.4506, found: 570.4505, IR (cm-1): 3119 (Py N-Fe), 
2917, 2850 (CH3, CH2), 1623, 1589 (Py C=C), 1489 (Py ring substituted), 
1033, 787 (B-F), 804 (Py C-H), CHN: calculated for [(C35H57N5)2Fe][BF4]2: C 
63.44, H 8.67, N 10.57%, found: C 63.29, H 8.53 , N 10.47 %. 
[Fe(L18C14D)2][BF4]2 
2,6-Bis(4-tetradec-1H-pyrazol-1-yl)pyridine iron(II) tetrafluoroborate was 
obtained using the general procedure described above, using the following 
quantities: 2,6-bis(4-tetradec-1H-pyrazol-1-yl)pyridine (100 mg, 0.166 mmol, 
2 eq), iron(II) tetrafluoroborate hexhydrate (31.3 mg, 0.083 mmol, 1eq). The 
reagents were dissolved in DCM, and crystallized by pentane diffusion, 
which yielded a dark-yellow powder (63.5 mg, 53%). 
Analyses: paramagnetic NMR (MeCN-D3, 300 MHz, ppm): δ 51.82 (2H, Pz 
H3), 34.06 (2H Pz H5), 33.32 (2H, Py H3,5), 3.79 (Py H4), IR (cm-1): 3117 
(Py N-Fe), 2917, 2849 (CH3, CH2), 1623, 1588 (Py C=C), 1490 (Py ring 
substituted), 1032, 787 (B-F), 801 (Py C-H), CHN: calculated for 
[(C39H65N5)2Fe][BF4]2: C 65.18, H 9.12, N 9.74%, found: C 65.37 , H 8.97, N 
9.81%. 
[Fe(L18C16D)2][BF4]2 
2,6-Bis(4-hexadec-1H-pyrazol-1-yl)pyridine iron(II) tetrafluoroborate was 
obtained using the general procedure described above, using the following 
quantities: 2,6-bis(4-hexadec-1H-pyrazol-1-yl)pyridine (100 mg, 0.151 mmol, 
2 eq), iron(II) tetrafluoroborate hexhydrate (28.6 mg, 0.076 mmol, 1eq). The 
reagents were dissolved in DCM, and crystallized by pentane diffusion, 
which yielded a dark-yellow powder (71 mg, 60%). 
Analyses: paramagnetic NMR (MeCN-D3, 300 MHz, ppm): δ 51.87 (2H, Pz 
H3), 34.06 (2H Pz H5), 33.22 (2H, Py H3,5), 3.78 (Py H4), IR (cm-1): 3117 
(Py N-Fe), 2916, 2849 (CH3, CH2), 1623, 1588 (Py C=C), 1490 (Py ring 
substituted), 1055, 785 (B-F), 808 (Py C-H), CHN: calculated for 
[(C43H73N5)2Fe][BF4]2: C 66.66, H 9.50, N 9.04%, found: C 66.71, H 9.38, N 
9.05%. 
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6.5 Asymmetric ligands with no long alkyl chains, and 
iron(II) complexes 
6.5.1 L19 - 2-(1H-pyrazol-1-yl)-6-(1H -1,2,3-triazol-1-yl)pyridine 
2-(1H-pyrazol-1-yl)-6-(1H-1,2,3-triazol-1-yl)pyri-
dine L19-A and 2-(1H-pyrazol-1-yl)-6-(2H-1,2,3-
triazol-1-yl) pyridine L19-B were obtained using 
the following procedure:6 NaH 60% dispersion in 
mineral oil (392 mg, 9.807 mmol, 1.6 eq) was 
added into a DMF (3 ml) / THF (6 ml) solvent 
mixture, after which 1,2,3-triazole (635 mg, 9.194 
mmol, 1.5 eq) was slowly added, and the reaction mixture was then stirred 
for 30 minutes. L14 2-fluoro-6-(1H-pyrazol-1-yl)pyridine (1 g, 6.129 mmol, 1 
eq) was then added. The reaction mixture was stirred at 80oC for 3 days 
under a CaCl2 tube, and monitored by TLC. After cooling to room 
temperature, the reaction mixture was slowly mixed with water, and the 
obtained white precipitated was filtered off. This was thoroughly dried in a 
vacuum oven, triturated in hexane, filtered off, and desiccated again, which 
allowed the a 1:1 mixture of two isomers as a white powder (1.118 g, 86%).  
The white powder turned out to be a mixture of two isomers, which have 
very small difference in rf on TLC (ethyl acetate:hexane, 2:1). After two 
recrystallizations from hexane:chloroform 1:1 mixture, a 1:3 mixture of 
isomers was obtained from the original 1:1 mixture. The proportions were 
monitored by NMR integrations. 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): L19-A: δ 8.72 (d, 1 H, Pz 
H5), 8.57 (s, 1 H, Trz H5), 8.01 (m, 2 H, Py H3,5), 7.93 (m, 1 H, Py H4), 7.76 
(d, 1 H, Pz H3), 6.48 (dd, 1 H, Pz H4); and L19-B: δ 8.53 (d, 1 H, Pz H5), 
8.06 (m, 1 H, Py H4), 8.02 (m, 2 H, Py H3,5), 7.92 (s, 1 H, Trz H4,5), 7.78 
(d, 1 H, Pz H3), 6.51 (dd, 1 H, Pz H4), MS (HR-ESI) m/z: calc. for 
[C10H8N6+H+]:  213.0883, found: 213.1011, calc. for [C10H8N6+Na+]:  
235.0703, found: 235.0846. 
6.5.2 L20 - 2-(1H-pyrazol-1-yl)-6-(1H-1,2,4-triazol-1-yl)pyridine 
2-(1H-pyrazol-1-yl)-6-(1H-1,2,4-triazol-1-
yl)pyridine  L20 was obtained using the same 
procedure as for L19, using the following 
quantities: NaH 60% dispersion in mineral oil (392 
mg, 9.807 mmol, 1.6 eq), in DMF (3 ml), THF (6 
ml), 1,2,4-triazole (635 mg, 9.194 mmol, 1.5 eq), and L14 2-fluoro-6-(1H-
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pyrazol-1-yl)pyridine (1 g, 6.129 mmol, 1 eq), which afforded the target 
product as white powder (1.237 g, 95%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 9.16 (s, 1 H, Trz H5), 8.55 
(d, 1 H, Pz H5), 8.12 (s, 1 H, Trz H3), 8.01 (d, 1 H, Py H5), 7.99 (d, 1 H, Py 
H3), 7.78 (dt, 1 H, Pz H3), 7.77 (m, 1 H, Py H4), 6.52 (t, 1 H, Pz H4), 13C 
NMR (CDCl3, 100.613 MHz, ppm): δ 153.20 (Trz C3), 150.46 (Py C6), 
147.90 (Py C2), 142.94 (Pz C3), 142.16 (Trz C5), 141.59 (Py C4), 127.23 
(Pz C5), 111.49 (Py C5), 110.05 (Py C3), 108.59 (Pz C4), MS (HR-ESI) m/z: 
calc. for [C10H8N6+H+]:  213.0883, found: 213.1019, calc. for [C10H8N6+Na+]:  
235.0703, found: 235.0852, IR (cm-1): 2922 (Py-H+), 1608, 1582 (Py C=C in 
plane vibr.), 1470 (Py ring 2-subs.), 1391 (C=N in-plane vibr.), MP: 163.3-
164.0, CHN: calculated for C10H8N6: C 56.60, H 3.80, N 39.60%, found: C 
56.78, H 3.85, N 39.41%. 
6.5.3 L21 - 2-(4-(ethylcarboxy)pyrazol-1-yl)-6-(1H-pyrazol-1-
yl)pyridine 
2-(4-(ethylcarboxy)pyrazol-1-yl)-6-(1H-pyrazol-
1-yl)pyridine L21 was obtained using the same 
procedure as for L19, with the following 
quantities: NaH 60% dispersion in mineral oil 
(219 mg, 5.463 mmol, 1.1 eq), in DMF (2 ml), THF (5 ml), 4-
(ethylcarboxy)pyrazole (731 mg, 5.215 mmol, 1.05 eq), and L14 2-fluoro-6-
(1H-pyrazol-1-yl)pyridine (810 mg, 4.966 mmol, 1 eq), which afforded the 
target product as white powder (752 mg, 53%). 
Analyses: 1H NMR (CDCl3, 400.130 MHz, ppm): δ 9.00 (s, 1 H, PzA H5), 
8.59 (d, 1 H, PzB H5), 8.11 (s, 1 H, PzA H3), 7.96 (dd, 1 H, Py H4), 7.93 (d, 
1 H, Py H3), 7.87 (d, 1 H, Py H5),  7.77 (s, 1 H, PzB H3), 6.51 (t, 1 H, Pz 
H4), 4.38 (dd, 2 H, Ak H1), 1.25 (t, 3 H, Ak H2), 13C NMR (CDCl3, 100.613 
MHz, ppm): δ 162.85 (PzA C6), 150.36 (Py C6), 149.36 (Py C2), 143.19 (Pz 
A3), 142.77 (PzB C3), 141.79 (Py C4), 130.18 (PzA C5), 127.28 (PzB C5), 
117.31 (PzA C4), 110.71 (Py C3), 109.88 (Py C5), 108.40 (PzB C4), 60.74 
(Ak C1), 14.55 (Ak C2), IR (cm-1): 2959, 2902 (CH2-H), 1709 (ArC=O) 1607, 
1584 (Py C=C in plane vibr.), 1472 (Py ring), 1247 (C-OC stretch), 762 (C-O-
C deform.), MP: 123.2-123.4. 
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6.5.4 [Fe(L20)2][Fe(L20)2(H2O)2][BF4]4·MeNO2·H2O 
The coordination polymer 
[Fe(L20)2][Fe(L20)2(H2O)2][BF4]
4·MeNO2·H2O was obtained 
using the same procedure as for 
other iron complexes in previous 
chapter. L20 2-(1H-pyrazol-1-
yl)-6-(1H-1,2,4-triazol-1-
yl)pyridine (125 mg, 0.58 mmol, 
2 eq) was dissolved in MeNO2 
and filtered through a cotton 
pipette filter. Fe(BF4)2·6H2O (99.5 mg, 0.295 mmol, 1 eq.) was also 
dissolved in MeNO2 and filtered. The two solutions were mixed and the 
resulted yellow solution was set to form crystals by slow diisopropyl ether 
diffusion. The target product was obtained as clusters of pale-yellow 
prismatic crystals. 
6.5.5 [Fe(L21)2][BF4]2 
2,6-di[4-(ethylcarboxy)pyrazol-1-yl]pyridine L20 
(200 mg, 0.706 mmol, 2 eq.) was dissolved in 
acetone (5 ml), and Fe(BF4)2·H2O (133.3 mg, 
0.353 mmol, 1 eq.) was also dissolved in 
acetone. The two solutions were mixed and left 
to form crystals under slow diethyl ether 
diffusion, and after three days clusters of dark-
yellow needle crystals (138 mg, 49%) were obtained.  
Analyses: paramagnetic NMR (MeCN-D3, 300 MHz, ppm): δ 64.31, 58.96 
(1 H PzA H3 and 1 H PzB H3), 56.53 (1 H, PzB H4), 46.98, 43.23 (1 H PzA 
H5 and 1H PzB H5), 37.36, 26.20 (1 H, Py H3 and 1 H, Py H5), 1.11 (Py 
H4), IR (cm-1): 3125 (Py N-Fe), 1715 (C=O), 1621, 1562 (Py C=C), 1478 (Py 
ring substituted), 1259 (COO-C), 1016, 763 (B-F). 
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Appendix A 
Crystallographic Tables 
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 L2 L3 L4 L6 
Empirical formula C12H9N5O2 C20H17N5O4 C19H15N5O3 C18H13N5O3 
Formula weight 255.24 391.39 361.36 347.33 
Temperature/K 275.56(10) 120.00(10) 119.99(10) 119.98(13) 
Crystal system orthorhombic monoclinic orthorhombic orthorhombic 
Space group Pna21 P21/c Pna21 Pbca 
a/Å 26.8599(13) 11.9677(2) 37.3393(10) 20.3048(5) 
b/Å 10.9972(5) 20.7834(4) 11.6145(3) 7.14047(18) 
c/Å 3.8386(2) 7.31376(14) 3.94390(10) 21.6604(5) 
α/° 90 90 90 90 
β/° 90 90.8996(17) 90 90 
γ/° 90 90 90 90 
Volume/Å3 1133.86(10) 1818.93(6) 1710.38(8) 3140.45(13) 
Z 4 4 4 8 
Dcalc/ gcm-3 1.495 1.429 1.403 1.469 
μ/mm-1 0.902 0.855 0.817 0.867 
F(000) 528.0 816.0 752.0 1440.0 
Crystal size/mm3 
0.5501 × 
0.0721 × 
0.0300 
0.475 × 
0.077 × 
0.06 
0.607 × 
0.101 × 
0.067 
0.744 ×  
0.131 × 
0.105 
Radiation λ/Å* 1.54184 1.54184 1.54184 1.54184 
2Θ range for data 
collection/° 
6.582 to 
134.052 
7.388 to 
147.696 
7.972 to 
147.96 
8.164 to 
148.12 
Index ranges 
-28 ≤ h ≤ 32, 
-13 ≤ k ≤ 13, 
-4 ≤ l ≤ 3 
-14 ≤ h ≤ 13, 
-25 ≤ k ≤ 25, 
-8 ≤ l ≤ 5 
-46 ≤ h ≤ 44, 
-14 ≤ k ≤ 10, 
-3 ≤ l ≤ 4 
-25 ≤ h ≤ 23, 
-8 ≤ k ≤ 5, -
26 ≤ l ≤ 25 
Reflections 
collected 
3505 7444 5988 11703 
Independent 
reflections 
1532 [Rint = 
0.0341, Rσ = 
0.0402] 
3524 [Rint = 
0.0256, Rσ = 
0.0317] 
2649 [Rint = 
0.0529, Rσ = 
0.0448] 
3164 [Rint = 
0.0342, Rσ = 
0.0261] 
Data/restrains/par
ameters 
1532/1/173 3524/0/264 2649/1/245 3164/0/236 
Goodness-of-fit 
on F2 
1.052 1.087 1.058 1.106 
Final R indexes 
[I>=2σ (I)] 
R1 = 
0.0387, 
wR2 = 
0.0909 
R1 = 
0.0439, 
wR2 = 
0.1373 
R1 = 0.0516, 
wR2 = 0.1391 
R1 = 0.0567, 
wR2 = 0.1717 
Final R indexes 
[all data] 
R1 = 
0.0461, 
wR2 = 
0.0948 
R1 = 
0.0519, 
wR2 = 
0.1464 
R1 = 0.0561, 
wR2 = 0.1427 
R1 = 0.0656, 
wR2 = 0.1815 
Largest diff. 
peak/hole / e Å-3 
0.18/-0.17 0.29/-0.20 0.33/-0.23 0.39/-0.40 
Flack parameter -0.6(4) - 0.0(4) - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
  
- 239 - 
 L8∙0.5MeCN L9 L10 L7 
Empirical formula C22H20.5N5.5O4 C20H17N5O3 C19H16N5O2 C30H22N10O4 
Formula weight 425.94 375.39 346.37 586.57 
Temperature/K 293(2) 293(2) 293(2) 293(2) 
Crystal system monoclinic orthorhombic monoclinic monoclinic 
Space group P21/c Pbca Pc P21/n 
a/Å 8.08190(10) 42.4145(3) 7.28330(10) 3.9643(4) 
b/Å 65.5476(5) 11.44430(10) 7.72900(10) 32.442(3) 
c/Å 7.60180(10) 7.20810(10) 29.9811(5) 10.7216(10) 
α/° 90 90 90 90 
β/° 91.0710(10) 90 92.9240(10) 92.221(8) 
γ/° 90 90 90 90 
Volume/Å3 4026.34(8) 3498.84(6) 1685.52(4) 1377.9(2) 
Z 8 8 4 2 
Dcalc/ gcm-3 1.405 1.425 1.365 1.414 
μ/mm-1 0.094 0.094 0.087 0.821 
F(000) 1784.0 1568.0 724.0 608.0 
Crystal size/mm3 300 × 20 × 180 
0.14 × 0.04 × 
0.02 
0.14 × 0.09 × 
0.01 
0.19 × 0.07 
× 0.02 
Radiation λ/Å*  0.6889 0.6889 0.6889 1.54184 
2Θ range for data 
collection/° 
1.204 to 
71.944 
1.862 to 
71.838 
2.636 to 
71.734 
8.692 to 
124.792 
Index ranges 
-13 ≤ h ≤ 13,  
-107 ≤ k ≤ 111, 
-12 ≤ l ≤ 12 
-68 ≤ h ≤ 71,  
-19 ≤ k ≤ 19,  
-12 ≤ l ≤ 12 
-12 ≤ h ≤ 11, 
 -13 ≤ k ≤ 13, 
 -49 ≤ l ≤ 49 
-4 ≤ h ≤ 3,  
-37 ≤ k ≤ 35,  
-12 ≤ l ≤ 11 
Reflections 
collected 
85158 69203 34739 8165 
Independent 
reflections 
19461  
[Rint = 0.0660, 
Rσ = 0.0645] 
8639 
[Rint = 
0.1162, Rσ = 
0.0591] 
15305 [Rint = 
0.0962, Rσ = 
0.1200] 
2168 [Rint = 
0.0812, 
Rσ = 
0.0758] 
Data/restraints/pa
rameters 
19461/0/573 8639/0/254 15305/2/469 2168/0/199 
Goodness-of-fit 
on F2 
1.019 1.008 1.012 1.372 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.0704, 
wR2 = 0.1800 
R1 = 0.0531, 
wR2 = 0.1544 
R1 = 0.0694, 
wR2 = 0.1729 
R1 = 0.1301, 
wR2 = 0.3628 
Final R indexes 
[all data] 
R1 = 0.0918, 
wR2 = 0.1864 
R1 = 0.0688, 
wR2 = 0.1614 
R1 = 0.1096, 
wR2 = 0.1895 
R1 = 0.1737, 
wR2 = 0.3939 
Largest diff. 
peak/hole / e Å-3 
0.61/-0.43 0.61/-0.30 0.47/-0.43 1.67/-0.51 
Flack parameter - - 0.1(7) - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
 
  
- 240 - 
 [Fe(L3)2][BF4]2∙2MeNO2 
Red polymorph 
[Fe(L3)2][BF4]2∙2MeNO
2 Yellow polymorph 
Empirical formula C42H40B2F8FeN12O12 C42H40B2F8FeN12O12 
Formula weight 1134.33 1106.89 1134.33 
Temperature/K 120.1(4) 290.00(10) 120.0(3) 
Crystal system triclinic triclinic triclinic 
Space group P-1 P-1 P-1 
a/Å 8.32214(15) 8.3954(3) 11.3589(9) 
b/Å 12.8301(2) 13.0340(3) 13.2662(13) 
c/Å 23.1768(6) 23.1820(6) 17.5527(14) 
α/° 88.1141(17) 88.817(2) 67.653(8) 
β/° 80.2771(19) 80.405(2) 80.169(7) 
γ/° 89.5667(14) 89.361(2) 78.448(8) 
Volume/Å3 2437.80(9) 2500.62(12) 2383.7(4) 
Z 2 2 2 
Dcalc/ gcm-3 1.545 1.470 1.580 
μ/mm-1 3.412 3.299 3.490 
F(000) 1160.0 1128.0 1160.0 
Crystal size/mm3 
0.2303 ×  
0.16 ×  
0.0973 
0.2608 × 
0.1415 × 
0.0806 
0.2429 × 0.1047 × 
0.0541 
Radiation λ/Å* 1.54184 1.54184 1.54184 
2Θ range for data 
collection/° 
7.744 to 148.714 
6.784 to 
147.558° 
7.286 to 148.958 
Index ranges 
-10 ≤ h ≤ 10, -16 ≤ 
k ≤ 15, -28 ≤ l ≤ 28 
-9 ≤ h ≤ 10, -
16 ≤ k ≤ 14, -
28 ≤ l ≤ 28 
-12 ≤ h ≤ 13, -13 ≤ k ≤ 
16, -12 ≤ l ≤ 21 
Reflections 
collected 
42425 22937 18103 
Independent 
reflections 
9493  
[Rint = 0.0340, Rσ = 
0.0273] 
9469 
[R(int) = 
0.0250] 
8979  
[Rint = 0.0672, Rσ = 
0.0885] 
Data/restraints 
/parameters 
9493/0/700 
9469/115/71
9 
8979/0/700 
Goodness-of-fit on 
F2 
1.079 1.033 1.039 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.0454, wR2 = 
0.1232 
R1 = 0.0492, 
wR2 = 0.1458 
R1 = 0.0701, wR2 = 
0.1689 
Final R indexes [all 
data] 
R1 = 0.0470, wR2 = 
0.1246 
R1 = 0.0537, 
wR2 = 0.1513 
R1 = 0.0964, wR2 = 
0.1897 
Largest diff. 
peak/hole / e Å-3 
1.03/-0.92 0.61/-0.39 0.75/-0.80 
Flack parameter - - - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
 
  
- 241 - 
 [Fe(L3)2][BF4]2 
∙2MeCN∙3H2O 
[Fe(L3)2][BF4]2 
∙2MeCN 
[Fe(L3)2][BF4]2 
∙Me2CO∙2Et2O 
Empirical formula C44H47B2F8FeN12O11 C44H41B2F8FeN12O8 C47H51B2F8FeN10O10 
Formula weight 1149.40 1074.83 1145.44 
Temperature/K 120.4(9) 300.01(10) 120.4(9) 
Crystal system triclinic triclinic triclinic 
Space group P-1 P-1 P-1 
a/Å 11.8763(5) 12.0097(11) 11.4869(3) 
b/Å 13.7050(6) 13.5397(8) 13.1875(4) 
c/Å 16.5211(7) 16.3744(14) 19.8174(8) 
α/° 81.690(4) 81.295(6) 103.178(3) 
β/° 86.566(4) 84.017(7) 99.818(3) 
γ/° 67.594(4) 70.585(7) 97.119(2) 
Volume/Å3 2459.9(2) 2478.1(4) 2838.37(17) 
Z 2 2 2 
Dcalc/ gcm-3 1.552 1.440 1.340 
μ/mm-1 3.372 3.259 2.896 
F(000) 1182.0 1100.0 1182.0 
Crystal size/mm3 
0.1081 × 0.0873 × 
0.0504 
0.183 × 0.0919 × 
0.0633 
0.639 × 0.199 × 
0.104 
Radiation λ/Å* 1.54184 1.54184 1.54184 
2Θ range for data 
collection/° 
7.038 to 147.484 6.976 to 112.332 7.352 to 147.934 
Index ranges 
-12 ≤ h ≤ 14, -15 ≤ 
k ≤ 17, -20 ≤ l ≤ 
20 
-10 ≤ h ≤ 12, -13 
≤ k ≤ 14, -15 ≤ l ≤ 
17 
-14 ≤ h ≤ 14, -12 
≤ k ≤ 15, -24 ≤ l ≤ 
24 
Reflections 
collected 
18471 12783 39100 
Independent 
reflections 
9264 [Rint = 
0.0409, Rσ = 
0.0524] 
6158 [Rint = 
0.0761, Rσ = 
0.0946] 
10915 [Rint = 
0.0364, Rσ = 
0.0305] 
Data/restraints 
/parameters 
9264/0/718 6158/0/682 10915/0/766 
Goodness-of-fit on 
F2 
1.034 1.019 1.073 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.0657, 
wR2 = 0.1757 
R1 = 0.0972, 
wR2 = 0.2603 
R1 = 0.0812, 
wR2 = 0.2435 
Final R indexes [all 
data] 
R1 = 0.0789, 
wR2 = 0.1902 
R1 = 0.1643, 
wR2 = 0.3193 
R1 = 0.0855, 
wR2 = 0.2476 
Largest diff. 
peak/hole / e Å-3 
1.00/-0.53 0.55/-0.45 1.44/-1.19 
Flack parameter - - - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
 
  
- 242 - 
 [Fe(L4)2][BF4]2 [Fe(L5)2][BF4]2 
Empirical formula C38H30B2F8FeN10O6 C38H30B2F8FeN10O6 C36H25B2F8FeN10O8 
Formula weight 952.19 952.19 955.13 
Temperature/K 120.0(3) 293(2) 120.1(4) 
Crystal system monoclinic monoclinic triclinic 
Space group I2/a I2/a P-1 
a/Å 27.5349(8) 35.3876(9) 8.6669(3) 
b/Å 8.3035(2) 8.3029(2) 16.8340(6) 
c/Å 35.3908(7) 27.5431(11) 27.0836(10) 
α/° 90 90 85.116(3) 
β/° 99.537(2) 99.546(3) 82.527(3) 
γ/° 90 90 87.474(3) 
Volume/Å3 7979.8(3) 7980.6(4) 3901.5(2) 
Z 8 8 4 
Dcalc/ gcm-3 1.585 1.585 1.626 
μ/mm-1 3.916 3.915 4.048 
F(000) 3872.0 3872.0 1932.0 
Crystal size/mm3 
0.295 × 0.026 × 
0.02 
0.291 × 0.089 × 
0.041 
0.25 × 0.028 × 
0.019 
Radiation λ/Å* 1.54184 1.54184 1.54184 
2Θ range for data 
collection/° 
6.51 to 147.628 6.508 to 147.606 5.992 to 149.102 
Index ranges 
-28 ≤ h ≤ 33, -10 ≤ 
k ≤ 9, -43 ≤ l ≤ 42 
-43 ≤ h ≤ 42, -9 ≤ 
k ≤ 10, -28 ≤ l ≤ 
33 
-10 ≤ h ≤ 10, -21 ≤ 
k ≤ 21, -29 ≤ l ≤ 33 
Reflections 
collected 
17646 17633 59588 
Independent 
reflections 
7630 [Rint = 
0.0349, Rσ = 
0.0462] 
7631 [Rint = 
0.0377, Rσ = 
0.0501] 
15162 [Rint = 
0.0738, Rσ = 
0.0609] 
Data/restraints 
/parameters 
7630/68/629 7631/0/626 15162/199/1261 
Goodness-of-fit on 
F2 
1.026 1.011 1.014 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.0560, 
wR2 = 0.1388 
R1 = 0.0479, 
wR2 = 0.1088 
R1 = 0.0726, wR2 = 
0.1938 
Final R indexes [all 
data] 
R1 = 0.0731, 
wR2 = 0.1509 
R1 = 0.0656, 
wR2 = 0.1196 
R1 = 0.1025, wR2 = 
0.2202 
Largest diff. 
peak/hole / e Å-3 
1.67/-1.34 0.86/-0.48 1.21/-0.51 
Flack parameter - - - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
 
  
- 243 - 
 [Fe(L6)2][BF4]2 
∙Me2CO 
[Fe(L6)2][BF4]2 
∙MeCN 
[Fe(L6)2][BF4]2 
Empirical formula C39H32B2F8FeN10O7 C38H29B2F8FeN11O6 C36H26B2F8FeN10O6 
Formula weight 982.21 965.19 924.14 
Temperature/K 120.00(13) 120.00(13) 121(1) 
Crystal system monoclinic triclinic triclinic 
Space group P21/c P-1 P-1 
a/Å 8.0143(5) 13.5568(3) 9.0387(6) 
b/Å 16.4857(9) 17.3525(5) 12.6099(7) 
c/Å 33.9358(12) 17.6675(6) 17.0032(6) 
α/° 90 84.906(3) 77.368(4) 
β/° 90.566(4) 82.515(2) 85.039(4) 
γ/° 90 78.283(2) 83.273(5) 
Volume/Å3 4483.4(4) 4026.6(2) 1874.34(18) 
Z 4 4 2 
Dcalc/ gcm-3 1.455 1.592 1.637 
μ/mm-1 3.520 3.897 4.148 
F(000) 2000.0 1960.0 936.0 
Crystal size/mm3 
0.128 × 0.052 × 
0.029 
0.83 × 0.69 × 
0.215 
0.14 × 0.08 × 0.05 
Radiation λ/Å* 1.54184 1.54184 1.54184 
2Θ range for data 
collection/° 
7.476 to 146.966 6.704 to 148.842 7.222 to 158.47° 
Index ranges 
-9 ≤ h ≤ 8, -20 ≤ k ≤ 
16, -40 ≤ l ≤ 42 
-16 ≤ h ≤ 16, -21 
≤ k ≤ 21, -21 ≤ l ≤ 
18 
-11 ≤ h ≤ 10, -15 ≤ 
k ≤ 14, -21 ≤ l ≤ 20 
Reflections 
collected 
20551 62738 13156 
Independent 
reflections 
8615 [Rint = 0.0823, 
Rσ = 0.1027] 
15485 [Rint = 
0.0993, Rσ = 
0.0726] 
7069[R(int) = 
0.0806] 
Data/restraints 
/parameters 
8615/0/608 15485/0/1195 7069/0/604 
Goodness-of-fit 
on F2 
1.633 1.033 1.478 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.1565, wR2 = 
0.4374 
R1 = 0.0726, 
wR2 = 0.1768 
R1 = 0.1171, wR2 = 
0.3451 
Final R indexes 
[all data] 
R1 = 0.1874, wR2 = 
0.4527 
R1 = 0.0965, 
wR2 = 0.1940 
R1 = 0.1660, wR2 = 
0.4190 
Largest diff. 
peak/hole / e Å-3 
1.58/-0.98 0.92/-1.01 1.23/-2.16 
Flack parameter - - - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
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 [Fe(L6)2][BF4]2∙0.5H2O 
Empirical formula 
C144H108B8F32Fe4N
39.5O28 
C36H27.5B2F8FeN10
O6.5 
C72H55B2F17Fe2N20
O12 
Formula weight 3757.57 933.65 1848.68 
Temperature/K 100 250 360 
Crystal system triclinic triclinic triclinic 
Space group P-1 P-1 P-1 
a/Å 11.9000(8) 11.9795(8) 11.950(3) 
b/Å 16.6124(11) 16.8209(12) 16.952(5) 
c/Å 20.8569(13) 21.0000(12) 21.191(5) 
α/° 99.288(6) 99.507(6) 100.78(2) 
β/° 99.125(6) 98.595(6) 97.96(2) 
γ/° 100.889(6) 100.802(6) 100.51(2) 
Volume/Å3 3919.0(5) 4027.8(5) 4079.6(18) 
Z 1 4 2 
Dcalc/ gcm-3 1.592 1.540 1.505 
μ/mm-1 0.450 0.437 0.432 
F(000) 1904.0 1894.0 1876.0 
Crystal size/mm3    
Radiation λ/Å* 0.6889 0.6889 0.6889 
2Θ range for data 
collection/° 
2.468 to 72.558° 2.438 to 72.456° 1.928 to 40.296 
Index ranges 
-20 ≤ h ≤ 19, -27 ≤ 
k ≤ 27, -35 ≤ l ≤ 
35 
-20 ≤ h ≤ 20, -27 
≤ k ≤ 28, -35 ≤ l ≤ 
35 
-11 ≤ h ≤ 11, -16 ≤ 
k ≤ 16, -21 ≤ l ≤ 21 
Reflections 
collected 
84122 85877 33743 
Independent 
reflections 
35855[R(int) = 
0.1366] 
36744[R(int) = 
0.1231] 
8519 [Rint = 0.0964, 
Rσ = 0.0728] 
Data/restraints/par
ameters 
35855/0/1163 36744/0/1151 8519/0/1130 
Goodness-of-fit on 
F2 
0.880 0.902 1.115 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.1199, 
wR2 = 0.2915 
R1 = 0.1219, 
wR2 = 0.3119 
R1 = 0.0991, wR2 = 
0.2757 
Final R indexes [all 
data] 
R1 = 0.2558, 
wR2 = 0.3795 
R1 = 0.2846, 
wR2 = 0.4116 
R1 = 0.1356, wR2 = 
0.3163 
Largest diff. 
peak/hole / e Å-3 
3.79/-0.80 2.73/-0.54 1.05/-0.30 
Flack parameter - - - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
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 [Fe(L8)2][BF4]2 
∙0.25MeCN 
[Fe(L8)2][BF4]2 
∙Me2CO∙0.25H2O 
[Fe(L9)2][BF4]2 
∙1.5MeCN 
[Fe(L9)2][BF4]2
∙0.5Me2CO 
Empirical formula 
C42H38.75B2F8
FeN10.25O8 
C45H44.5B2F8Fe
N10O9.25 
C43H38.75B2F8
FeN11.5O6 
C41.5H32.5B2F8
FeN10O6.5 
Formula weight 1044.55 1102.87 1042.07 1004.74 
Temperature/K 150.00(10) 119.99(13) 150.01(10) 120.2(5) 
Crystal system orthorhombic orthorhombic monoclinic orthorhombic 
Space group Pna21 Pna21 P21/c Pca21 
a/Å 16.1146(5) 16.1790(10) 27.4401(4) 20.7502(16) 
b/Å 21.2398(8) 21.1621(11) 16.5615(3) 15.444(3) 
c/Å 28.5755(10) 28.8196(8) 20.5281(2) 28.842(7) 
α/° 90 90 90 90 
β/° 90 90 100.2570(10) 90 
γ/° 90 90 90 90 
Volume/Å3 9780.6(6) 9867.3(8) 9179.9(2) 9243(3) 
Z 8 8 8 8 
Dcalc/ gcm-3 1.419 1.485 1.508 1.444 
μ/mm-1 0.399 3.298 3.466 3.421 
F(000) 4276.0 4532.0 4266.0 4092.0 
Crystal size/mm3 
0.453 × 
0.283 × 
0.198 
0.156 × 0.067 
× 0.065 
1.006 × 
0.316 × 
0.202 
 
Radiation λ/Å* 0.71073 1.54184 1.54184 1.54184 
2Θ range for data 
collection/° 
6.874 to 
59.436 
6.878 to 
147.934 
7.298 to 
149.53 
7.136 to 
150.934 
Index ranges 
-17 ≤ h ≤ 21, 
-20 ≤ k ≤ 29, 
-35 ≤ l ≤ 36 
-19 ≤ h ≤ 16, -
26 ≤ k ≤ 25, -
35 ≤ l ≤ 35 
-34 ≤ h ≤ 34, 
-18 ≤ k ≤ 15, 
-25 ≤ l ≤ 25 
-25 ≤ h ≤ 16, 
-18 ≤ k ≤ 12, 
-31 ≤ l ≤ 31 
Reflections 
collected 
39370 42450 77067 21769 
Independent 
reflections 
19974 [Rint = 
0.0316, Rσ = 
0.0537] 
16737 [Rint = 
0.1478, Rσ = 
0.1585] 
17912 [Rint = 
0.0514, Rσ = 
0.0428] 
12614[R(int) 
= 0.1603] 
Data/restraints/pa
rameters 
19974/1/131
5 
16737/1/1378 
17912/0/132
2 
12614/1/128
7 
Goodness-of-fit 
on F2 
1.074 1.018 1.043 1.003 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.0887, 
wR2 = 0.2313 
R1 = 0.0935, 
wR2 = 0.2141 
R1 = 0.0710, 
wR2 = 0.1901 
R1 = 0.1027, 
wR2 = 0.2232 
Final R indexes 
[all data] 
R1 = 0.1160, 
wR2 = 0.2524 
R1 = 0.1663, 
wR2 = 0.2677 
R1 = 0.0804, 
wR2 = 0.1977 
R1 = 0.2260, 
wR2 = 0.2906 
Largest diff. 
peak/hole / e Å-3 
0.76/-0.47 0.77/-0.76 0.96/-0.56 0.69/-0.51 
Flack parameter 0.284(6) 0.396(7) - 0.062(15) 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
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[Fe(L10)2][BF4]2∙1.5
MeCN 
[Fe(L10)2][BF4]2∙
2/3Me2CO 
DCC 
intermediate 
Empirical formula 
C41H34.5B2F8FeN11.5O
4 
B1.666667C38.166667
F6.666667FeN10O5.
333333H0.083333 
C22H28BrN5O2 
Formula weight 981.77 884.43 474.40 
Temperature/K 150.01(10) 120.3(7) 120.0(2) 
Crystal system triclinic monoclinic monoclinic 
Space group P-1 P21/c P21/n 
a/Å 13.8965(6) 14.6653(5) 11.7221(9) 
b/Å 17.0836(7) 46.894(2) 9.7208(7) 
c/Å 20.8001(7) 20.7067(6) 19.502(3) 
α/° 95.020(3) 90 90 
β/° 102.703(3) 105.985(3) 92.979(10) 
γ/° 113.133(4) 90 90 
Volume/Å3 4345.8(3) 13689.7(9) 2219.2(4) 
Z 4 12 4 
Dcalc/ gcm-3 1.501 1.287 1.420 
μ/mm-1 0.438 3.346 2.752 
F(000) 2004.0 5233.0 984.0 
Crystal size/mm3 
0.838 × 0.421 × 
0.298 
0.22 × 0.09 × 
0.05 
0.34 × 0.06 × 
0.04 
Radiation λ/Å* 0.71073 1.54184 1.54184 
2Θ range for data 
collection/° 
6.456 to 59.394 7.19 to 147.028° 8.608 to 146.98 
Index ranges 
-19 ≤ h ≤ 19, -17 ≤ k 
≤ 21, -27 ≤ l ≤ 27 
-13 ≤ h ≤ 18, -47 
≤ k ≤ 57, -25 ≤ l 
≤ 21 
-14 ≤ h ≤ 13, -11 
≤ k ≤ 8, -21 ≤ l ≤ 
23 
Reflections 
collected 
46531 56114 8398 
Independent 
reflections 
20799 [Rint = 0.0369, 
Rσ = 0.0658] 
26692[R(int) = 
0.1034] 
4326 [Rint = 
0.0944, Rσ = 
0.1249] 
Data/restraints/par
ameters 
20799/0/1219 26692/0/1701 4326/0/271 
Goodness-of-fit on 
F2 
1.037 1.655 1.109 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.0700, wR2 = 
0.1622 
R1 = 0.1490, 
wR2 = 0.3503 
R1 = 0.1041, 
wR2 = 0.2754 
Final R indexes [all 
data] 
R1 = 0.1101, wR2 = 
0.1865 
R1 = 0.2367, 
wR2 = 0.3924 
R1 = 0.1355, 
wR2 = 0.2956 
Largest diff. 
peak/hole / e Å-3 
1.02/-0.49 4.57/-0.68 2.17/-1.49 
Flack parameter - - - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
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L11C12 L11C14 L12C12 L12C14 
Empirical formula C24H34N5O2 C26H37N5O2 C18H30O2 C20H34O2 
Formula weight 424.56 451.60 278.42 172.20 
Temperature/K 119.97(17) 120.0(2) 120.00(11) 119.97(15) 
Crystal system orthorhombic orthorhombic triclinic triclinic 
Space group P212121 P212121 P-1 P-1 
a/Å 4.8145(2) 4.8622(4) 5.4266(2) 5.4604(11) 
b/Å 8.9592(9) 8.9415(12) 7.2027(2) 7.2025(14) 
c/Å 53.565(2) 57.636(6) 42.2414(14) 46.898(5) 
α/° 90 90 88.093(3) 91.733(14) 
β/° 90 90 86.332(3) 90.505(14) 
γ/° 90 90 89.637(3) 90.417(16) 
Volume/Å3 2310.5(3) 2505.8(5) 1646.75(9) 1843.5(6) 
Z 4 4 4 4 
Dcalc/ gcm-3 1.221 1.197 1.123 1.241 
μ/mm-1 0.632 0.612 0.071 0.639 
F(000) 916.0 976.0 616.0 728.0 
Crystal size/mm3 
0.0836 × 
0.0626 × 
0.0518 
0.25 × 0.07 × 
0.03 
0.467 × 
0.381 × 
0.113 
0.1312 × 
0.0618 × 
0.0482 
Radiation λ/Å* 1.54184 1.54184 0.71073 1.54184 
2Θ range for data 
collection/° 
6.6 to 
134.146 
6.134 to 
145.502 
6.75 to 
57.51 
7.544 to 
152.632 
Index ranges 
-5 ≤ h ≤ 4, -10 
≤ k ≤ 6, -63 ≤ 
l ≤ 55 
-5 ≤ h ≤ 5, -
10 ≤ k ≤ 11, -
68 ≤ l ≤ 71 
-7 ≤ h ≤ 4, -
8 ≤ k ≤ 9, -
35 ≤ l ≤ 57 
-5 ≤ h ≤ 6, -
8 ≤ k ≤ 8, -
58 ≤ l ≤ 56 
Reflections 
collected 
5413 8856 7545 13844 
Independent 
reflections 
3740 [Rint = 
0.0686, Rσ = 
0.1068] 
4508 [Rint = 
0.1396, Rσ = 
0.1440] 
6137 [Rint = 
0.0162, 
Rσ = 
0.0446] 
6108 [Rint = 
0.2165, 
Rσ = 
0.2060] 
Data/restraints/par
ameters 
3740/0/281 4508/0/299 6137/0/371 6108/0/177 
Goodness-of-fit on 
F2 
1.113 1.039 1.083 1.310 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.1069, 
wR2 = 0.2369 
R1 = 0.1082, 
wR2 = 0.2721 
R1 = 0.0794, 
wR2 = 0.1885 
R1 = 0.1960, 
wR2 = 0.4119 
Final R indexes [all 
data] 
R1 = 0.1461, 
wR2 = 0.2613 
R1 = 0.1624, 
wR2 = 0.3261 
R1 = 0.0955, 
wR2 = 0.1980 
R1 = 0.3419, 
wR2 = 0.5108 
Largest diff. 
peak/hole / e Å-3 
0.42/-0.39 0.67/-0.36 0.33/-0.29 0.70/-0.47 
Flack parameter -0.6(9) 0.5 - - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
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L13C12 L13C14 
[Fe(L11C6)2][BF4]  
·2H2O 
Empirical formula C30H37N5O3 C32H41N5O3 
C32.5H37B2F8FeN10
O6 
Formula weight 515.64 543.70 893.19 
Temperature/K 120.01(13) 293(2) 120.15 
Crystal system monoclinic monoclinic monoclinic 
Space group P21/n P21/n P21/c 
a/Å 4.09650(10) 4.12350(10) 17.925(3) 
b/Å 64.3183(13) 68.6353(8) 15.1997(15) 
c/Å 10.3525(2) 10.32150(10) 20.4944(16) 
α/° 90 90 90 
β/° 96.694(2) 96.8220(10) 101.974(12) 
γ/° 90 90 90 
Volume/Å3 2709.08(10) 2900.48(8) 5462.2(12) 
Z 4 4 4 
Dcalc/ gcm-3 1.264 1.245 1.086 
μ/mm-1 0.664 0.077 2.824 
F(000) 1104.0 1168.0 1832.0 
Crystal size/mm3 
0.573 × 0.095 × 
0.075 
0.14 × 0.01 × 
0.005 
0.56 × 0.37 × 0.16 
Radiation λ/Å* 1.54184 0.6889 1.54184 
2Θ range for data 
collection/° 
8.248 to 148.296 1.15 to 72.082 7.298 to 149.056 
Index ranges 
-4 ≤ h ≤ 4, -76 ≤ k ≤ 
80, -12 ≤ l ≤ 12 
-7 ≤ h ≤ 6, -115 
≤ k ≤ 116, -17 ≤ 
l ≤ 17 
-17 ≤ h ≤ 22, -15 ≤ 
k ≤ 18, -25 ≤ l ≤ 22 
Reflections 
collected 
17853 62461 21577 
Independent 
reflections 
5403 [Rint = 0.0701, 
Rσ = 0.0599] 
14043 [Rint = 
0.0936, Rσ = 
0.0965] 
10751 [Rint = 
0.1117, Rσ = 
0.1569] 
Data/restraints/par
ameters 
5403/0/344 14043/0/362 10751/31/279 
Goodness-of-fit on 
F2 
1.114 0.894 1.654 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.1194, wR2 = 
0.2678 
R1 = 0.0567, 
wR2 = 0.1374 
R1 = 0.2698, wR2 = 
0.5751 
Final R indexes [all 
data] 
R1 = 0.1284, wR2 = 
0.2714 
R1 = 0.1076, 
wR2 = 0.1542 
R1 = 0.3721, wR2 = 
0.6385 
Largest diff. 
peak/hole / e Å-3 
0.40/-0.39 0.39/-0.41 3.27/-1.70 
Flack parameter - - - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
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[Fe(L13C6)2][BF4]2
·H2O 
[Fe(L13C14)2][BF4]2
·2MeCN 
[Fe(L13C16)2][BF4]2
·H2O 
Empirical formula C48H52B2F8FeN10O7 C68H88B2F8FeN12O6 C68H92B2F8FeN10O7 
Formula weight 1110.46 1398.97 1390.98 
Temperature/K 119.99(14) 293(2) 120.01(10) 
Crystal system triclinic triclinic triclinic 
Space group P-1 P-1 P-1 
a/Å 10.3105(8) 14.31590(10) 13.2899(3) 
b/Å 15.1489(10) 15.21930(10) 13.6465(4) 
c/Å 16.7306(8) 16.7869(2) 19.4605(6) 
α/° 89.136(5) 84.0090(10) 98.865(2) 
β/° 77.066(6) 89.7180(10) 91.201(2) 
γ/° 82.387(6) 72.7220(10) 98.421(2) 
Volume/Å3 2524.2(3) 3472.07(6) 3446.19(17) 
Z 2 2 2 
Dcalc/ gcm-3 1.461 1.338 1.340 
μ/mm-1 3.191 0.294 0.301 
F(000) 1148.0 1472.0 1468.0 
Crystal size/mm3 
0.426 × 0.047 × 
0.028 
0.125 × 0.045 × 
0.02 
0.5509 × 0.3449 
× 0.2437 
Radiation λ/Å* 1.54184 0.6889 0.71073 
2Θ range for data 
collection/° 
7.944 to 147.374 2.732 to 71.914 5.384 to 59.242 
Index ranges 
-12 ≤ h ≤ 8, -18 ≤ 
k ≤ 18, -20 ≤ l ≤ 
20 
-23 ≤ h ≤ 23, -24 ≤ 
k ≤ 25, -27 ≤ l ≤ 27 
-18 ≤ h ≤ 18, -18 
≤ k ≤ 18, -27 ≤ l ≤ 
26 
Reflections 
collected 
21098 74716 51002 
Independent 
reflections 
9509 [Rint = 
0.0536, Rσ = 
0.0696] 
31297 [Rint = 
0.0507, Rσ = 
0.0722] 
16785 [Rint = 
0.0483, Rσ = 
0.0617] 
Data/restraints/par
ameters 
9509/0/699 31297/0/878 16785/0/879 
Goodness-of-fit on 
F2 
1.015 0.955 1.023 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.0753, 
wR2 = 0.1993 
R1 = 0.0506, wR2 = 
0.1313 
R1 = 0.0531, 
wR2 = 0.1115 
Final R indexes [all 
data] 
R1 = 0.0947, 
wR2 = 0.2176 
R1 = 0.0877, wR2 = 
0.1442 
R1 = 0.0790, 
wR2 = 0.1247 
Largest diff. 
peak/hole / e Å-3 
1.08/-0.58 0.95/-0.56 0.88/-0.53 
Flack parameter - - - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
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L14 L15 L16 
Empirical formula C8H6FN3 C11H7I2N5 C11H7IN5 
Formula weight 163.16 463.02 336.12 
Temperature/K 120.01(10) 119.98(14) 293(2) 
Crystal system orthorhombic monoclinic monoclinic 
Space group P212121 C2/c P21/n 
a/Å 4.03930(10) 33.3176(8) 16.2454(15) 
b/Å 11.2187(4) 4.63510(10) 4.3868(4) 
c/Å 16.2922(4) 17.8226(4) 17.3002(17) 
α/° 90 90 90 
β/° 90 101.956(2) 109.873(8) 
γ/° 90 90 90 
Volume/Å3 738.29(4) 2692.64(11) 1159.5(2) 
Z 4 8 4 
Dcalc/ gcm-3 1.468 2.284 1.925 
μ/mm-1 0.943 36.621 2.544 
F(000) 336.0 1712.0 644.0 
Crystal size/mm3 
0.465 × 0.201 × 
0.145 
0.404 × 0.079 × 
0.079 
0.34 x 0.12 x 0.08 
Radiation λ/Å* 1.54184 1.54184 0.6889 
2Θ range for data 
collection/° 
9.572 to 147.32 10.146 to 147.966 2.882 to 72.49 
Index ranges 
-2 ≤ h ≤ 4, -10 ≤ k 
≤ 13, -19 ≤ l ≤ 17 
-40 ≤ h ≤ 40, -4 ≤ k 
≤ 5, -20 ≤ l ≤ 22 
-27 ≤ h ≤ 20, -7 ≤ 
k ≤ 6, -27 ≤ l ≤ 20 
Reflections 
collected 
1712 9566 10728 
Independent 
reflections 
1212 [Rint = 
0.0130, Rσ = 
0.0191] 
2678 [Rint = 0.0280, 
Rσ = 0.0210] 
4721 [Rint = 
0.4031, Rσ = 
0.9116] 
Data/restraints/par
ameters 
1212/0/109 2678/0/181 4721/0/154 
Goodness-of-fit on 
F2 
1.092 1.064 0.741 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.0261, 
wR2 = 0.0708 
R1 = 0.0262, wR2 = 
0.0713 
R1 = 0.1170, 
wR2 = 0.2254 
Final R indexes [all 
data] 
R1 = 0.0275, 
wR2 = 0.0721 
R1 = 0.0297, wR2 = 
0.0745 
R1 = 0.4538, 
wR2 = 0.3605 
Largest diff. 
peak/hole / e Å-3 
0.14/-0.13 0.95/-0.89 1.93/-1.02 
Flack parameter 0.04(10) - - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
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L17C12D L17C16D L17C12M 
Empirical formula C35H49N5 C43H65N5 C23H29N5 
Formula weight 539.79 652.00 375.51 
Temperature/K 133.20(17) 150.00(10) 293(2) 
Crystal system monoclinic monoclinic monoclinic 
Space group Pc Pc P21 
a/Å 5.45900(10) 5.4576(3) 5.3944(2) 
b/Å 5.45440(10) 5.4477(3) 5.4384(2) 
c/Å 52.5779(10) 65.309(2) 35.4153(14) 
α/° 90 90 90 
β/° 91.576(2) 89.041(4) 90.989(3) 
γ/° 90 90 90 
Volume/Å3 1564.94(5) 1941.45(16) 1038.82(7) 
Z 2 2 2 
Dcalc/ gcm-3 1.146 1.115 1.200 
μ/mm-1 0.517 0.492 0.069 
F(000) 588.0 716.0 404.0 
Crystal size/mm3 
0.01 × 0.003 × 
0.003 
0.39 × 0.19 × 0.09 
0.06 × 0.03 × 
0.01 
Radiation λ/Å* 1.54184 1.54184 0.6889 
2Θ range for data 
collection/° 
6.728 to 148.496° 8.124 to 140.704 2.23 to 71.702 
Index ranges 
-6 ≤ h ≤ 5, -6 ≤ k ≤ 
6, -62 ≤ l ≤ 65 
-6 ≤ h ≤ 6, -6 ≤ k ≤ 
5, -79 ≤ l ≤ 73 
-9 ≤ h ≤ 9, -9 ≤ k 
≤ 9, -57 ≤ l ≤ 59 
Reflections 
collected 
6835 8193 22143 
Independent 
reflections 
4262[R(int) = 
0.0206] 
5116 [Rint = 0.0380, 
Rσ = 0.0415] 
9487 [Rint = 
0.0999, Rσ = 
0.1543] 
Data/restraints/par
ameters 
4262/2/363 5116/2/435 9487/1/254 
Goodness-of-fit on 
F2 
1.134 1.136 0.951 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.0452, 
wR2 = 0.1183 
R1 = 0.0893, wR2 = 
0.2239 
R1 = 0.0979, 
wR2 = 0.2415 
Final R indexes [all 
data] 
R1 = 0.0463, 
wR2 = 0.1190 
R1 = 0.0910, wR2 = 
0.2246 
R1 = 0.1787, 
wR2 = 0.2817 
Largest diff. 
peak/hole / e Å-3 
0.23/-0.20 0.43/-0.40 0.48/-0.30 
Flack parameter -0.1(4) 0.5 -0.7(10) 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
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L18C12M L18C14M [Fe(L17C18M)2][BF4]2 
Empirical formula C23H33N5 C25H37N5 C59H83B2F8FeN10 
Formula weight 379.54 407.59 1161.82 
Temperature/K 293(2) 119.97(15) 293(2) 
Crystal system triclinic triclinic triclinic 
Space group P-1 P-1 P-1 
a/Å 5.38900(10) 5.4094(4) 10.6801(2) 
b/Å 10.17380(10) 10.1832(6) 15.2720(2) 
c/Å 19.2473(3) 20.8390(15) 36.8778(5) 
α/° 95.5290(10) 87.346(5) 95.9150(10) 
β/° 94.4050(10) 83.903(6) 98.8820(10) 
γ/° 90.2580(10) 89.881(5) 89.9730(10) 
Volume/Å3 1047.18(3) 1140.19(14) 5910.51(16) 
Z 2 2 4 
Dcalc/ gcm-3 1.204 1.187 1.306 
μ/mm-1 0.069 0.550 0.304 
F(000) 412.0 444.0 2460.0 
Crystal size/mm3 
0.18 × 0.08 × 
0.01 
0.437 × 0.069 
× 0.047 
 
Radiation λ/Å* 0.6889 1.54184 0.6889 
2Θ range for data 
collection/° 
2.066 to 71.318 
8.544 to 
147.594 
1.09 to 72.56 
Index ranges 
-8 ≤ h ≤ 8, -12 ≤ k 
≤ 17, -32 ≤ l ≤ 32 
-6 ≤ h ≤ 4, -11 
≤ k ≤ 12, -25 ≤ 
l ≤ 23 
-16 ≤ h ≤ 17, -25 ≤ k ≤ 
25, -44 ≤ l ≤ 59 
Reflections 
collected 
15704 9977 96928 
Independent 
reflections 
8473 [Rint = 
0.0678, Rσ = 
0.1196] 
4286 [Rint = 
0.0373, Rσ = 
0.0409] 
50251 [Rint = 0.0848, 
Rσ = 0.2469] 
Data/restraints/par
ameters 
8473/0/254 4286/0/272 50251/0/1445 
Goodness-of-fit on 
F2 
0.976 1.054 0.827 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.0573, 
wR2 = 0.1643 
R1 = 0.0592, 
wR2 = 0.1664 
R1 = 0.0966, wR2 = 
0.2318 
Final R indexes [all 
data] 
R1 = 0.0875, 
wR2 = 0.2100 
R1 = 0.0721, 
wR2 = 0.1778 
R1 = 0.2592, wR2 = 
0.2844 
Largest diff. 
peak/hole / e Å-3 
0.53/-0.45 0.30/-0.36 1.56/-0.87 
Flack parameter - - - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
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 [Fe(L18C12M)2] 
[BF4]2 
[Fe(L18C16M)2]
[BF4]2 
[Fe(L18C16M)2][BF4]2 
Empirical formula C46H66B2F8FeN10 C54H87B2F8FeN10 C54H82B2F8FeN10 
Formula weight 988.55 1105.80 1100.76 
Temperature/K 293(2) 119.99(16) 150.00(10) 
Crystal system triclinic triclinic triclinic 
Space group P-1 P-1 P-1 
a/Å 10.8827(4) 10.8707(15) 10.9510(14) 
b/Å 15.2657(5) 15.1781(18) 15.0831(18) 
c/Å 30.1249(11) 34.644(4) 34.713(4) 
α/° 97.199(3) 83.813(10) 83.845(10) 
β/° 97.707(3) 82.791(10) 82.536(10) 
γ/° 90.123(3) 89.934(10) 89.868(10) 
Volume/Å3 4919.5(3) 5637.5(12) 5652.1(12) 
Z 4 4 4 
Dcalc/ gcm-3 1.335 1.303 1.294 
μ/mm-1 0.353 2.747 2.739 
F(000) 2080.0 2356.0 2336.0 
Crystal size/mm3 
0.07 × 0.02 × 
0.005 
0.374 × 0.076 × 
0.042 
0.36 × 0.074 × 0.038 
Radiation λ/Å* 0.6889 1.54184 1.54184 
2Θ range for data 
collection/° 
1.332 to 72.184 
7.762 to 
155.296° 
7.408 to 149.32 
Index ranges 
-18 ≤ h ≤ 17, -25 ≤ 
k ≤ 25, -49 ≤ l ≤ 
51 
-13 ≤ h ≤ 13, -18 
≤ k ≤ 13, -38 ≤ l 
≤ 42 
-13 ≤ h ≤ 9, -18 ≤ k ≤ 
18, -43 ≤ l ≤ 42 
Reflections 
collected 
108366 51522 49647 
Independent 
reflections 
44891 [Rint = 
0.2684, Rσ = 
0.4271] 
21509[R(int) = 
0.3165] 
21302 [Rint = 0.2087, 
Rσ = 0.2635] 
Data/restraints/par
ameters 
44891/0/1211 21509/0/1345 21302/0/1355 
Goodness-of-fit on 
F2 
0.736 0.956 1.017 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.0935, 
wR2 = 0.1971 
R1 = 0.2089, 
wR2 = 0.3894 
R1 = 0.1356, wR2 = 
0.2986 
Final R indexes [all 
data] 
R1 = 0.3426, 
wR2 = 0.2910 
R1 = 0.4108, 
wR2 = 0.5292 
R1 = 0.3040, wR2 = 
0.4196 
Largest diff. 
peak/hole / e Å-3 
0.97/-0.66 0.75/-0.90 0.68/-0.87 
Flack parameter - - - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
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 [Fe(L18C18M)2] 
[BF4]2 L19 
L20 
Empirical formula C59H91B2F8FeN10 C10H8N6 C10H8N6 
Formula weight 1169.88 212.22 212.22 
Temperature/K 293(2) 120.00(13) 150.01(10) 
Crystal system triclinic monoclinic monoclinic 
Space group P-1 Cc P21/c 
a/Å 10.9192(5) 4.54380(10) 12.5794(9) 
b/Å 15.1344(5) 25.9740(7) 3.8549(3) 
c/Å 36.7856(17) 8.5078(2) 20.4981(14) 
α/° 84.117(4) 90 90 
β/° 85.034(4) 99.788(3) 103.628(7) 
γ/° 89.951(3) 90 90 
Volume/Å3 6024.1(4) 989.48(4) 966.01(12) 
Z 4 4 4 
Dcalc/ gcm-3 1.290 1.425 1.459 
μ/mm-1 0.298 0.785 0.804 
F(000) 2492.0 440.0 440.0 
Crystal size/mm3  
0.483 × 0.122 
× 0.056 
0.37 × 0.074 × 
0.046 
Radiation λ/Å* 0.6889 1.54184 1.54184 
2Θ range for data 
collection/° 
2.166 to 71.964 
12.566 to 
147.176 
7.23 to 148.47 
Index ranges 
-18 ≤ h ≤ 17, -25 ≤ 
k ≤ 23, -60 ≤ l ≤ 45 
-5 ≤ h ≤ 4, -32 
≤ k ≤ 32, -7 ≤ l 
≤ 10 
-15 ≤ h ≤ 15, -4 ≤ k 
≤ 4, -25 ≤ l ≤ 25 
Reflections 
collected 
94542 3732 4625 
Independent 
reflections 
49978 [Rint = 
0.2155, Rσ = 
0.3853] 
1315 [Rint = 
0.0291, Rσ = 
0.0300] 
1948 [Rint = 0.0334, 
Rσ = 0.0388] 
Data/restraints/par
ameters 
49978/0/1435 1315/2/145 1948/0/145 
Goodness-of-fit on 
F2 
1.045 1.092 1.159 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.1969, wR2 = 
0.4609 
R1 = 0.0329, 
wR2 = 0.0865 
R1 = 0.0538, wR2 = 
0.1321 
Final R indexes [all 
data] 
R1 = 0.4213, wR2 = 
0.5521 
R1 = 0.0337, 
wR2 = 0.0870 
R1 = 0.0702, wR2 = 
0.1407 
Largest diff. 
peak/hole / e Å-3 
1.95/-1.09 0.16/-0.26 0.31/-0.18 
Flack parameter - 0.8(3) - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
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Code Batch Formula* Solvent content** 
S1 1 C41H41B4F16Fe2N25O5 [Fe1L2][Fe2L2(H2O)2][BF4]4·MeNO2·H2O 
 S2 2 C41H43B4F16Fe2N25O6 [Fe1L2][ Fe2L2(H2O)2][BF4]4·MeNO2·2H2O 
S3 2 C41H43B4F16Fe2N25O6 [Fe1L2][ Fe2L2(H2O)2][BF4]4·MeNO2·2H2O 
S4 2 C41H41B4F16Fe2N25O5 [Fe1L2][ Fe2L2(H2O)2][BF4]4·MeNO2·H2O 
S5 2 C41H41B4F16Fe2N25O5 [Fe1L2][ Fe2L2(H2O)2][BF4]4·MeNO2·H2O 
 
 
S1 S2 S3 
Empirical 
formula 
C41H41B4F16Fe2N25O5 C41H43B4F16Fe2N25O6 C41H43B4F16Fe2N25O6 
Formula weight 1422.93 1440.94 1440.94 
Temperature/K 150.00(10) 150.01(10) 200.00(10) 
Crystal system monoclinic monoclinic monoclinic 
Space group C2/c C2/c C2/c 
a/Å 19.9215(6) 19.9190(3) 19.9235(5) 
b/Å 15.5378(5) 15.3887(3) 15.5984(5) 
c/Å 18.5292(6) 18.5909(3) 18.6533(4) 
α/° 90 90 90 
β/° 101.222(3) 101.152(2) 100.512(2) 
γ/° 90 90 90 
Volume/Å3 5625.8(3) 5591.02(17) 5699.7(3) 
Z 4 4 4 
Dcalc/ gcm-3 1.680 1.712 1.679 
μ/mm-1 5.240 5.294 5.193 
F(000) 2872.0 2912.0 2912.0 
Crystal 
size/mm3 
0.656 × 0.589 × 
0.407 
1.045 × 0.384 × 
0.263 
0.895 × 0.326 × 
0.277 
Radiation λ/Å* 1.54184 1.54184 1.54184 
2Θ range for 
data collection/° 
7.268 to 148.018 7.312 to 148.16 7.244 to 147.44 
Index ranges 
-24 ≤ h ≤ 24, -19 ≤ 
k ≤ 18, -22 ≤ l ≤ 19 
-22 ≤ h ≤ 24, -18 ≤ 
k ≤ 18, -22 ≤ l ≤ 21 
-21 ≤ h ≤ 24, -19 ≤ 
k ≤ 14, -23 ≤ l ≤ 23 
Reflections 
collected 
17923 19986 19798 
Independent 
reflections 
5558 [Rint = 0.0604, 
Rσ = 0.0483] 
5616 [Rint = 0.0330, 
Rσ = 0.0284] 
5714 [Rint = 0.0412, 
Rσ = 0.0345] 
Data/restraints/p
arameters 
5558/0/450 5616/0/477 5714/0/450 
Goodness-of-fit 
on F2 
1.049 1.046 1.036 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.1006, wR2 = 
0.2697 
R1 = 0.0585, wR2 = 
0.1610 
R1 = 0.0869, wR2 = 
0.2467 
Final R indexes 
[all data] 
R1 = 0.1040, wR2 = 
0.2731 
R1 = 0.0604, wR2 = 
0.1627 
R1 = 0.0899, wR2 = 
0.2507 
Largest diff. 
peak/hole / e Å-3 
0.75/-0.92 0.69/-0.84 0.89/-0.77 
Flack parameter - - - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
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S4 S5 
Empirical formula C41H41B4F16Fe2N25O5 C41H41B4F16Fe2N25O5 
Formula weight 1422.93 1422.93 
Temperature/K 250.00(10) 289.97(10) 
Crystal system monoclinic monoclinic 
Space group C2/c C2/c 
a/Å 19.9189(6) 19.9010(5) 
b/Å 15.8603(5) 15.9683(4) 
c/Å 18.7484(4) 18.7282(6) 
α/° 90 90 
β/° 99.528(2) 99.397(3) 
γ/° 90 90 
Volume/Å3 5841.3(3) 5871.7(3) 
Z 4 4 
Dcalc/ gcm-3 1.618 1.610 
μ/mm-1 5.046 5.020 
F(000) 2872.0 2872.0 
Crystal size/mm3 0.918 × 0.389 × 0.232 0.888 × 0.38 × 0.309 
Radiation λ/Å* 1.54184 1.54184 
2Θ range for data 
collection/° 
8.19 to 147.2 8.174 to 147.738 
Index ranges 
-24 ≤ h ≤ 22, -17 ≤ k ≤ 19, -
23 ≤ l ≤ 22 
-24 ≤ h ≤ 24, -18 ≤ k ≤ 19, -23 
≤ l ≤ 20 
Reflections 
collected 
11206 19128 
Independent 
reflections 
5722 [Rint = 0.0521, Rσ = 
0.0651] 
5822 [Rint = 0.0451, Rσ = 
0.0429] 
Data/restraints/par
ameters 
5722/0/462 5822/0/450 
Goodness-of-fit on 
F2 
1.014 1.033 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.0820, wR2 = 0.2085 R1 = 0.0800, wR2 = 0.2247 
Final R indexes [all 
data] 
R1 = 0.1205, wR2 = 0.2362 R1 = 0.0867, wR2 = 0.2349 
Largest diff. 
peak/hole / e Å-3 
0.62/-0.46 0.70/-0.56 
Flack parameter - - 
* For Cu Kα, λ = 1.54184 Å; for Mo Kα, λ = 0.7107 Å; and for synchrotron 
radiation from Diamond Light Source λ = 0.6889 Å. 
